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ABSTRACT 
 
The focus of this thesis was to evaluate the mechanisms whereby myeloma cells 
develop intrinsic resistance with a focus on resistance in the context of bortezomib 
treatment. The aims of this thesis were to examine multidrug resistance pumps as a 
mechanism of resistance in MM, to investigate the contribution of p53 signalling 
perturbations in resistance mechanism in MM, to study the AMPK pathway as an 
alternative target to overcome MM resistance and finally to characterise myeloma 
resistance to bortezomib treatment using 2D-DIGE analysis.  
Focussing on bortezomib resistance models, we found that that overexpression of P-gp 
attenuates bortezomib activity. Bortezomib is a P-gp substrate and a combination of P-
gp inhibitor and bortezomib is able to overcome resistance. Bortezomib is also able to 
downregulate the expression and function of P-gp. Our findings therefore suggest that 
combination of a P-gp inhibitor and bortezomib in P-gp positive myeloma would be a 
reasonable treatment combination to extend use of the drug.  
We have shown that p53 apoptotic signalling pathways can be accentuated when 
bortezomib is combined with a Mdm2 inhibitor. In p53 WT cells, nutlin-3 in combination 
with bortezomib generates additive toxicity in MM cells but is highly synergistic in 
epithelial models and p53-mutated cell lines. This synergy persists in the presence of 
BMSCs. This observation has implications more so in epithelial cancers and p53 
mutated cancers where single agent bortezomib activity is mild. We have also shown 
that bortezomib-treated patients who had high expression of nutlin-3-suppressed 
genes had significantly shorter progression-free (p=0.001, log-rank test) and overall 
survival (p=0.002, log-rank test) compared to those with low expression levels. 
AMPK activation is promising as an anticancer pathway and may also be a 
chemoprevention target. Metformin and AICAR, which activate this pathway, both have 
demonstrated useful preclinical anticancer properties and have a good therapeutic 
index in patients. We explored mechanism of cell death and showed that AICAR was 
able to activate the apoptotic pathway. These agents also synergise with glycolysis 
inhibitors to further increase cytotoxicity in cancer cells. 
vii 
 
Identification of proteins whose expression is altered in differing states of sensitivity 
and resistance provides candidates for better understanding of resistance mechanisms 
so we also investigated bortezomib resistance in cellular models using proteomic 
techniques and isolated and identified several novel proteins which may play a role in 
this phenomenon. Our findings are mechanistically consistent since two of the 
identified proteins Hsp70 and caspase-3 are known in the literature to be affected by 
bortezomib treatment.  
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Chapter 1  
Introduction 
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1.1. Multiple Myeloma 
1.1.1. Pathogenesis 
Cancer is a major cause of human morbidity and mortality. It is caused by a group of 
cells demonstrating abnormal growth, invasion and metastasis. Cancers are caused by 
abnormalities in the genetic material of the abnormal cells. Genetic changes can occur 
at many levels, from gain or loss of entire chromosomes to a mutation affecting 
a single DNA nucleotide. There are two broad categories of genes which are affected 
by these changes. Oncogenes may be normal genes which are expressed at 
inappropriately high levels, or altered genes which have novel properties due to 
aberrant expression or mutation. In either case, expression of these genes promotes 
the malignant phenotype of cancer cells. Tumour suppressor genes are genes which 
inhibit cell division, survival, or other properties of cancer cells. Tumour suppressor 
genes are often disabled by cancer-promoting genetic changes. Typically, changes in 
several genes are required to transform a normal cell into a cancer cell [1]. Cancer can 
arise from virtually any tissue in the body and is typically referred to as a “solid” 
malignancy if originating from epithelial or connective tissue or haematological if 
originating from haematopoietic cells. Multiple Myeloma (MM) is one of a number of 
malignancies originating from haematological cells.  
MM is a plasma cell disorder that is characterized by an excess of plasma cells, 
monoclonal gammopathy (M-protein) and immunodeficiency. The diagnostic hallmarks 
of this disease are the development of hypercalcaemia, renal disease, anaemia and 
osteolytic bone disease (CRAB).  
A recent study by Landgren et al. [2], showed that monoclonal gammopathy of 
unknown significance (MGUS) precedes virtually all cases of MM. This is a key finding 
that helps to fill a gap in our understanding of myelomagenesis. The events that trigger 
progression of MGUS to MM is are currently still unknown. However, one has to keep 
in mind that the vast majority of MGUS cases will never develop MM or other 
lymphoproliferative disorders [2]. MGUS patients presenting with an abnormal serum 
kappa-lambda free light chain (FLC) -ratio, non-IgG MGUS, and a high serum M-
protein level (>1.5 g/dL) have been found to have a 58% absolute risk of developing 
MM over 20 years of follow up, whereas, in sharp contrast, MGUS cases with none of 
these risk factors have only a 5% absolute risk of MM progression (when accounting 
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for death as a competing risk, the corresponding absolute risk estimates were 27% and 
2%, respectively) [3]. These findings suggest that the well-documented 1% annual 
average risk of MM progression among MGUS patients [4] is highly heterogeneous and 
emphasize the fact that the risk of developing MM varies greatly among patients 
diagnosed with MGUS. 
Serum M-protein concentration may show a year by year increase prior to MM 
diagnosis or remain stable up to the diagnosis of MM [2]. As a result of this finding, the 
current recommendation for clinicians is to follow patients presenting with MGUS 
indefinitely as stable M-protein levels do not exclude the underlying development of 
MM. Until better molecular markers for progression to MM are available, clinicians will 
continue to use clinical measures in combination with routine blood test (including renal 
function, haemoglobin, and serum calcium) and serum and urine M-protein markers in 
their monitoring of MGUS cases to aid early detection of progression to MM. 
 
1.1.2. Epidemiology 
Globally, MM is a common haematological malignancy particularly increasing in 
prevalence as individuals’ age with a median age at diagnosis of 62 years for men and 
61 years for women (range 20–92); only 2% of patients are younger than 40 years. In 
the USA, MM is the second most frequent malignancy of the blood after non-Hodgkin’s 
lymphoma - the disease accounts for approximately 20 percent of deaths from 
haematological malignancy and two percent of deaths from all cancers [5]. About 
20,000 cases occur every year in the USA; the incidence adjusted for age and ethnic 
group is 7.1 per 100,000 in men and 4.6 per 100,000 in women. Occurrence of the 
disease is more common in men than women, and is twice as high in African American 
than in Caucasian American people [6, 7]. The reason for the uneven racial and gender 
distribution is unknown.  
The median survival for patients diagnosed with multiple myeloma ranges from about 3 
to 5 years, with variation largely dictated by genetic heterogeneity [8]. With the advent 
of autologous stem cell transplantation, the median survival has extended to 5 to 7 
years in patients eligible for this procedure [8]. The treatment landscape has changed 
in the last several years due to the introduction of novel therapies. These new 
approach to treatment have resulted in higher response rates and increases in both 
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progression-free survival and OS rates in the context of randomized, controlled trials 
[9].  
 
1.1.3. Genetics 
Conventional cytogenetics and fluorescent in-situ hybridization (FISH) have shown that 
numeric abnormalities occur in the genes of MM cells in both a non-hyperdiploid 
(NHRD; <48 or >75 chromosomes) and a hyperdiploid (HRD; 48–75 chromosomes) 
pattern. Non-hyperdiploid abnormalities are associated with reduced life-span because 
of high-risk translocations of immunoglobulin heavy chain variable region (IGHR) 
(t[4;14] or t[14;16]), partial (q14) or complete loss of chromosome 13, and partial loss 
of chromosome 17(p13). By comparison, hyperdiploid abnormalities caused by multiple 
trisomies, and low frequency of monosomy or deletion of chromosome 13 and 
translocation of IGHR (t[11;14]) are associated with improved survival statistics[10]. 
This difference in clinical outcome suggests that different molecular genetic pathways 
are involved in pathogenesis of the 2 subgroups. 
Primary early onset reciprocal choromosomal translocations occur at IGHR locus on 
chromosome 14q32 in about 50% to 70% of myeloma cases [11]. The most common 5 
translocations, accounting for 40% of all cases with IgH translocation are summarized 
in Table 1.1.3. The genes and their function are mostly related to cell cycle regulation. 
Numerical aberrations are also common in MM. Trisomy most frequently involves 
chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, whereas monosomy and partial deletions 
affect mainly chromosomes 6, 13, 16, and 22. Gains of 1q are the most common 
chromosomal aberrations in myeloma, detectable in up to 40% of those with an 
abnormal karyotype [11]. Monosomy 13 or interstitial deletion of 13 (q14) is detectable 
in 15% to 20% of newly diagnosed MM by conventional cytogenetics and 50% of cases 
by interphase FISH [11]. Deletion 13 can also be found in MGUS. 
Secondary late onset translocations and gene mutations that have been implicated in 
disease progression are MYC rearrangement, activation of N or K-RAS mutations, 
FGFR3 mutations, inactivation or mutation of TP53, RB1 and PTEN; and inactivation of 
cyclin-dependent kinase inhibitors CDKN2A and CDKN2C. Recent studies found that 
5 
 
mutations of the nuclear factor-kappa B (NF-kB) pathway components, such as 
TRAF3, cIAP1/2, CYLD, and NIK, also contribute to pathogenesis of myeloma [12, 13].          
 
Chromosome Gene Frequency (%) Functions 
11q13 CCND1 15 – 20 Cell cycle regulator 
4p16 FGFR-3 & 
MMSET 
 
15 Growth factor receptor tyrosine 
kinase 
Transcription factor 
16q23 C-MAF 5 Transcription factor 
6p21 CCND3 3 Cell cycle regulator 
20q11 MAFB 2 Transcription factor 
Table 1.1.3.  Most common partner genes involved in translocation of 
immunoglobulin heavy chain gene in MM [11] 
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1.2. Treatment options for Multiple Myeloma 
1.2.1. Conventional agents 
The conventional treatment agents employed in MM have historically been alkylating 
agents, anthracyclines and glucocorticoids. In 1962, the use of melphalan was first 
reported by Bergsagel et al. [14] to show a significant improvement in 8 out of 24 MM 
patients treated with the drug. Mass et al. [15] first tested corticosteroids and showed 
that in a placebo-controlled double-blind trial that prednisolone as a single agent 
produced haematological response and a reduction in serum globulin but no difference 
in survival. The classic regimen of melphalan plus prednisone (MP) was established in 
a randomized trial of 183 myeloma patients led by Alexanian et al., in which survival 
was 6 months longer with MP compared with melphalan alone [16]. This was the 
treatment for MM until the 1980’s when vincristine, doxorubicin, and dexamethasone 
(VAD) followed by autologous transplant (ASCT) became regarded as the standard of 
care for eligible patients [17, 18]. Patients ineligible for ASCT continue to receive MP. 
Although this approach possesses proven efficacy and robust experience, its 
cumbersome nature and ultimate inferiority in terms of response rates and OS in 
comparison to novel agents has resulted in the diminished utility of VAD. 
 
1.2.2. Stem cell transplantation 
Substantial improvement in progression-free and overall survival has been achieved by 
the introduction of high dose drug treatment followed by stem-cell transplantation. 
Barlogie et al. [19] established an intense treatment program using melphalan 
140mg/m2 followed by autologous transplantation that is still a protocol in current use. 
In 1996, a randomised trial by Intergroupe Francophone du Myelome showed that 
stem-cell transplantation resulted in significantly more disease-free individuals and 
better overall survival (OS) than did conventional chemotherapy (5-year OS 52% vs 
12%; mortality 3% for both treatments)[20]. This study group was the first to show 
better 7-year event-free survival (EFS) from tandem stem-cell transplantation (two 
sequential transplants) than from one transplantation, at least for patients who had not 
achieved complete response, broadly defined as no disease activity detectable, after 
the first transplantation [21]. Barlogie and colleagues [22] using a total therapy 
approach, in which all available methods of treatment were incorporated into front-line 
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treatment, showed similar results to the French study using tandem stem cell 
transplantation.  
The results for allogeneic transplantation have been controversial. Although this 
treatment is curative for 10 to 20% of patients with chemotherapy-resistant, refractory 
disease and is able to maintain a durable remission, there is a high transplant-related 
mortality of 25 to 50% that offsets the advantage with this approach. Much of the high 
response and curative potential of allografts is attributed to a ‘graft-versus tumour’ 
effect [23-25], which is not seen in autologous transplantation.  
A large European Bone Marrow Transplant (EBMT) registry trial found equivalent OS 
but inferior progression-free survival (PFS) when reduced-intensity allografts were 
compared with ablative allografts [26]. Reduced-intensity allogeneic transplant 
regimens result in reliable donor engraftment with a relatively low mortality compared 
with ablative regimens; however, the immunologic effect of the allograft treatment is 
modest, resulting in reduced rate of complete response and a higher rate of 
progression. Thus far, allogeniec transplant remains a tool used as a last line 
treatment. 
 
1.2.3. Novel agents 
In the last decade, there has been great advancement in the treatment options for MM. 
Three new therapies have been recently approved by the FDA for use in MM 
(thalidomide, bortezomib and lenalidomide). These agents have been able to 
overcome drug resistant disease in preclinical models and in clinical trials.  They have 
not only exhibited direct anti-MM affect but are also capable of overcoming the 
protective effects of the bone marrow microenvironment [27-29]. Each drug will be 
discussed separately. 
 
1.2.3.1. Thalidomide 
The antiangiogenic properties of thalidomide [30] initially led to the consideration of its 
use in MM based on the premise that myeloma is associated with both elevated levels 
of circulating angiogenic cytokines, such as vascular endothelial growth factor, and 
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small polypeptides. Inhibition of the proteasome causes endoplasmic reticulum stress 
leading to cellular apoptosis, with malignant, transformed, and proliferating cells being 
more susceptible [38, 39]. 
Two phase II trials, the Study of Uncontrolled Myeloma Management with proteasome 
Inhibition Therapy (SUMMIT) and Clinical Response and the Efficacy Study of 
bortezomib in the Treatment of refractory myeloma (CREST) trials demonstrated a 
response rate of 35% to 38% and a median survival of 16 months (SUMMIT). A subset 
analysis of SUMMIT and CREST underscored the ability of bortezomib to overcome 
poor prognosis conferred in MM by chromosome 13 deletion [40, 41]. These results 
were confirmed in the international, multicenter phase III Assessment of Proteasome 
Inhibition for EXtending remissions (APEX) trial, in the response rate among individuals 
in the bortezomib group was 38%, with a CR rate of 6%, whereas the OR and CR rates 
in the dexamethasone group were 18% and 1%, respectively. Superior median time to 
progression (TTP) (6.22 versus 3.49 months) and 1-year survival (80 versus 66%) 
were observed in the bortezomib as compared with dexamethasone-treated patients 
[42]. In an updated analysis, the OR and CR rates in the bortezomib arm were 43 and 
9%, respectively [43].  
Preclinical studies [44] have showed the potent sensitizing effect of bortezomib in 
combination with other classes of drugs including alkylating agents and anthracyclines 
and provided rationale for additional bortezomib-containing combinations in the 
treatment of relapsed and/or refractory MM. Trials evaluating bortezomib combination 
with liposomal doxorubicin demonstrated that 36% of patients achieved a response 
[45, 46]. The combination of bortezomib, doxorubicin and dexamethasone (PAD) has 
been evaluated in a study involving 64 patients with relapsed and/or refractory MM 
[47]. In this heavily pre-treated group, PAD produced a response in more than 67% of 
patients. 
 
1.2.3.3. Lenalidomide 
Several analogs of thalidomide were synthesized in an attempt to increase efficacy and 
minimize toxicity associated with the parental compound. Lenalidomide, a 4-amino 
substituted analog of thalidomide, formerly called CC-5013, belongs to a class of 
thalidomide analogs termed immunomodulatory drugs.  
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The MM-009 North American trial and the MM-010 European/Israeli/Australian trial 
showed a longer TTP in the lenalidomide/dexamethasone combination (MM-009: 11.1 
months; MM-010: 11.3 months) compared with placebo/dexamethasone (4.7 months in 
both trials) [48, 49].  The combination of lenalidomide, doxorubicin and dexamethasone 
was evaluated in a recently published study with relapsed and refractory MM [50]. This 
regimen produced an OR rate of 73%. The median TTP in the study was 45 weeks.  
 
1.2.3.4. Emerging therapies 
New therapies such as heat shock protein (HSP) 90 inhibitors, Akt inhibitors, histone 
deacytelase (HDAC) inhibitors, BCL2 inhibitors, pro-apoptotic peptides and other 
proteasome inhibitors are in preclinical studies to provide the framework for phase I 
and II clinical trials [51]. These new agents are tested singly or more commonly, in 
combination with other MM therapies.  
Microarray profiling showed that bortezomib induces HSP90 gene transcripts in MM 
cells[52]. The combination of Hsp90 inhibitor, 17AAG and bortezomib can block this 
stress response and increase cytotoxicity [53]. An ongoing clinical trial combining 
bortezomib and 17AAG is currently ongoing to see if the combination can overcome 
bortezomib resistance.  
Bortezomib downregulates ERK, Jak/STAT and PKC signalling pathways but activates 
the Akt survival pathway in vitro [27]. Hideshima et al. demonstrated that perifosine, an 
Akt inhibitor, when combined with bortezomib, is able to abrogate this response and 
induce synergistic MM cytotoxicity in vitro [51], A phase II clinical trial is currently 
evaluating this combination. 
Other important new combinations are the HDAC inhibitors SAHA or LBH589 with 
bortezomib. The HDAC inhibitors are able to block protein degradation through the 
aggresome autophagy pathway and upregulate proteasomal degradation; conversely, 
blockade of the proteasome with bortezomib upregulates aggresome activity [54, 55]. 
Preclinical studies have shown that combinations that block both pathways of protein 
degradation induce synergistic cytotoxicity in MM. A phase II trial of LBH589 is now 
ongoing in MM, with a combination LBH589 and bortezomib trial to follow. Richardson 
et al. [56] had reported modest single agent activity of SAHA in a phase I trial in 
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advanced MM patients and we are currently awaiting results of a combination trial 
involving SAHA and bortezomib.  
 
1.3. The impact of the bone marrow microenvironment on drug resistance 
in Multiple Myeloma 
The role of the local microenvironment in cancer cell growth, proliferation and survival 
has been recognized lately. Several studies in haematological malignancies and solid 
tumours [57-60] have provided evidence supporting the idea that the non-malignant 
cells that surround the neoplasia can affect the cancer cell growth, survival and drug 
resistance. 
In this context, MM is the prototypical disease model that best characterizes these 
tumour-microenvironmental interactions. Indeed, it is now well established that MM-
induced disruption of the bone marrow (BM) homeostasis between the highly 
organized cellular and extracellular compartments supports MM cell proliferation, 
survival, migration and drug resistance through activation of various signalling 
pathways (as reviewed in [60, 61]). For instance, it has been demonstrated that the 
response of MM to conventional therapies, such as glucocorticoids or cytotoxic 
chemotherapeutics is attenuated by the presence of bone marrow stromal cells 
(BMSCs) [27, 62-64]. As discussed above, the three novel agents that are FDA 
approved for use in MM (bortezomib, thalidomide and lenalidomide) not only exhibit 
direct anti-MM affect but are also capable of overcoming the protective effects of the 
BMSCs. This new understanding of the interplay between the microenvironment and 
malignant cells will serve as a model for identifying and validating new targeted 
therapeutics, not only in MM but also in other haematological malignancies and solid 
tumours. 
The BM milieu consists of two parts; organized cellular and non-cellular components 
which include the liquid component. The cellular component of the BM is composed of 
haematopoietic stem cells; progenitor and precursor cells; immune cells (including T 
cells, macrophages, and natural killer cells); erythrocytes; bone marrow stromal cells 
(BMSCs); BM endothelial cells (BMECs);  and cells involved in bone homeostasis 
(including osteoclasts and osteoblasts). The non-cellular component comprises 
extracellular matrix (ECM) proteins (fibronectin, collagen, laminin and osteopontin) and 
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the liquid component consists of growth factors and cytokines such as interleukins (IL)-
6, IL-1β, IL-3, IL-10, IL-15, IL-21, insulin-like growth factor-1 (IGF-1), vascular 
endothelial growth factor (VEGF), B-cell activating factor (BAFF), CD-40, transforming 
growth factor (TGF)-β, macrophage inflammatory protein (MIP)-1α, hepatocyte growth 
factor (HGF), fibroblast growth factors (FGFs), stromal cell–derived factor (SDF)–1a, 
tumour necrosis factor (TNF)–α and matrix metalloproteinases, for example, MMP-2 
and MMP-9. 
 
1.3.1. Role of growth factors/cytokines in drug resistance in Multiple 
Myeloma 
The liquid milieu of the BM microenvironment directly and indirectly plays a role in MM 
pathogenesis, MM cell growth, survival, migration and drug resistance. Cytokines and 
growth factors are produced and secreted by MM and other cells within the BM 
compartment and regulated by both autocrine and paracrine loops. The direct contact 
of MM cells to ECM proteins, BMSCs, BMECs, osteoclast, osteoblast and other cells in 
the BM milieu triggers in MM cells a pleiotropic spectrum of proliferative, antiapoptotic 
signalling pathways including PI3K/Akt/mTOR, IKK-α/NF-κB, Ras/Raf/MAPK, Wnt and 
JAK/STAT3 (as reviewed in [60, 61]). These signalling pathways can also be activated 
by binding of growth factors and cytokines to their receptors. Some of the more 
important growth factors/cytokines will be discussed in detail below.  
 
1.3.1.1. IL-6-induced signalling pathway 
IL-6 has historically been viewed as a major player in MM pathogenesis by inducing 
growth and survival. It is predominantly produced and secreted by BMSCs and 
osteoblasts [64, 65]. IL-6 also induces expression of Xbp-1 which is a transcription 
factor involved in plasma cell/MM cell differentiation [66-68]. 
Several prosurvival, antiapoptotic pathways are stimulated by IL-6. MEK/MAPK, 
JAK/STAT3 and PI3K/Alt/mTOR pathways are the major survival pathways in cancer 
stimulated by IL-6. Conversely, blockade of IL-6 induces upregulation of BH3-only 
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protein Bim coupled with Mcl-1 downregulation and activation of Bax, the sum of which 
induces MM cell apoptosis [69]. 
Besides MM cell proliferation, IL-6 also triggers drug resistance to dexamethasone and 
other conventional therapeutics by inducing PI-3K/Akt, MAPK, and JAK/STAT3 
cascades [70-72]. IL-6 also stimulates osteoclastogenesis [73], linking the increase in 
MM tumour burden in the BM with bone resorption.  
There have been anecdotal reports on the use of anti-IL-6 neutralising antibodies in 
MM [74, 75]. Based on the preclinical hypothesis and in vitro work, it was disappointing 
that major clinical responses were not observed. A likely explanation for the lack of 
response may be reasons related to the pharmacodynamics of the drug. It may not be 
possible to neutralise all the IL-6 present in a MM patient with a single anti-IL-6 Ab [76, 
77]. However, the more likely explanation is that IL-6 is crucial but not the sole factor in 
MM pathogenesis. It has been noted in vitro that only a subset of MM cell lines 
responds to IL-6 stimulation (and usually at a level many times higher than present in 
blood samples of MM patients) and even fewer cell lines depend on IL-6 for sustained 
growth.  
Several other compounds targeting IL-6 signalling pathways, including antibodies 
against IL-6 and IL-6 receptor, for example, CNTO328, IL-6 antisense oligonucleotides 
and IL-6 super antagonist Sant7, have been described. CNTO328 is the only anti-IL-6 
monoclonal antibody that is currently in clinical trials as a single agent or in 
combination with other anti-myeloma therapeutics (http://clinicaltrials.gov/).    
 
1.3.1.2. IGF-1-induced signalling pathway 
Another growth factor that plays a major role in MM growth, survival and migration is 
IGF-1. In solid tumours, IGFs and IGF-1R have been implicated in cancer 
pathogenesis and increased levels of circulating IGF-1 have been associated with 
higher risk of carcinogenesis [78-80]. A review by Mitsiades et al. [81] on IGF-1 
reported that many studies have reported increased proliferation of neoplastic cell 
lines, including MM cell lines with IGF-1 stimulation.  
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Although there is extensive preclinical data and strong epidemiological evidence for the 
inhibition of IGFs, there has been reluctance by myeloma clinicians and researches to 
utilize IGF-1 as a target for small molecule inhibitors. The extensive homology of the 
IGF-1 receptor (IGF-1R) to the insulin receptor and the fact that IGF-1R is expressed in 
normal tissues and at levels comparable to those present in their malignant 
counterparts, suggest perhaps that IGF-1R small molecule inhibitors might prove too 
toxic for clinical use [52]. These potential pitfalls were addressed in part by studies 
initially focused in MM models. NVP-AEW541, a selective IGF-1R kinase inhibitor, 
demonstrated in vitro antitumour activity against a broad spectrum of MM cell lines as 
well as primary MM cells and tumour cells from other neoplasias [82]. The same study 
reported anti-MM activity in vivo with no significant hyperglycaemia observed. An IGF-
1R monoclonal antibody, IMC-A12, and small molecule inhibitor, XL-228, (active 
against IGF-1R, Src, FGFR, and BCR-Abl) are currently in clinical trials to assess their 
safety and efficacy. 
IGF-1R functions as a key regulator of many pathways critical for the malignant 
phenotype. IGF-1R stimulates telomerase and proteasome activity, upregulates anti-
apoptotic caspase inhibitors, enhances the ability of MM cells to respond to other 
cytokines (e.g. IL-6) and stimulates the production of proangiogenic cytokines (e.g. 
VEGF) [52]. This translates into conferring resistance against conventional 
chemotherapeutics and in part, proteasome inhibitors. 
 
1.3.1.3. VEGF-induced signalling pathway  
Tumour-associated angiogenesis has been shown to be as important in MM as in solid 
tumours. A review by Rajkumar [83], reported there is increased BM microvascular 
density (MVD) in MM compared with MGUS or normal BM. The authors also 
highlighted the finding of higher MVD in advanced disease or plasma cell leukaemia as 
compared to early stage disease and there is a correlation of higher MVD with adverse 
clinical outcome. This neovascularization in MM contributes to increased proliferation, 
survival and drug resistance through paracrine and cell adhesion-mediated 
interactions.   
VEGF, one of the major growth factors associated with neoangiogenesis, is linked to 
tumour cell development, progression, metastatic osteolysis and drug resistance. The 
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role of VEGF in MM is exhibited by a high expression of VEGF receptor-1 (VEGFR-1) 
expressed on MM cells and it has been shown that several MM cell lines secrete VEGF 
and that VEGF is present in MM patient BM plasma [84]. The expression of VEGFR-1 
is consistent with autocrine signalling. Antiapoptotic and prosurvival pathways activated 
by VEGF include caveolin-1/PI3K/PKCα-dependent cascade mediating  MM migration 
on fibronectin, MEK/ERK pathways mediating MM cell proliferation and upregulation of 
Mcl-1 and survivin leading to increase survival [84, 85]. VEGF also affects other BM 
cellular components such as osteoblasts, NK cells, monocytes and endothelial 
progenitors [86]. 
In various solid tumours, a humanized monoclonal antibody against VEGF, 
bevacizumab (Avastin, Genentech Inc., CA, USA), has been used especially in 
combination with conventional chemotherapeutics with success. There are ongoing 
clinical trials in MM testing this agent in combination with other anti-MM novel agents. 
In addition to bevacizumab, there are other VEGF-targeting compounds under 
preclinical and clinical investigation in MM including pazopanib, sorafenib and sunitinib. 
Thalidomide, lenalidomide and bortezomib have been shown to indirectly target VEGF-
signalling sequelae.  
 
1.3.1.4. TNF-α superfamily-induced signalling pathway 
The TNF-α superfamily includes SDF-1α, CD40, BAFF and APRIL. SDF-1α and its G-
protein-linked cognate receptor CXCR4 are discussed in 1.3.2.1.  
CD40 is expressed by antigen-presenting cells, T cells and B cells. Its presence has 
been demonstrated on the majority of MM cell lines and MM patients’ cells, as well as 
BMSCs. CD40 is important in increasing MM growth via p53, PI3K/Akt/NF-κB 
dependent MM migration and triggers VEGF secretion [87]. CD40 activated MM cells 
adhere to fibronectin and are protected against apoptosis triggered by irradiation and 
doxorubicin [87]. A clinical phase 1 trial using SGN, the humanized anti-CD40 
monoclonal antibody, in patients with refractory and relapsed MM has now been 
completed [88] and based on preclinical work by Tai et al. [89], a combination trial with 
lenalidomide, which augments antibody-dependent cellular cytotoxicity, is ongoing. 
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Circulating TNF-α levels are higher in MM patients with overt bone disease, whose 
osteoblasts constitutively overexpress Fas, DR4/DR5 complex as receptors for TNF-
related apoptosis-inducing ligand, intercellular adhesion molecule-1 (ICAM-1), and 
monocyte chemotactic protein-1 (MCP-1) [90]. TNF-α, mainly secreted by 
macrophages and MM cells, does not induce significant growth or drug resistance in 
tumour cells. However, TNF-α is a more potent stimulus of IL-6 secretion (around 5 
fold) in BMSCs than VEGF or TGFβ, via nuclear factor-kappa B (NF-κB) activation [91]. 
Most MM cell lines and patient samples show evidence of constitutive NF-κB 
activation. NF-κB is a transcriptional factor that promotes transcription of a number of 
cytokines, chemokines, cell adhesion molecules, as well as anti-apoptotic and cellular 
growth control proteins [62]. After stimulation by TNF-α, κBα protein is phosphorylated 
by inhibition of kappaB kinase complex beta (IKKβ) and subsequently ubiquitinated and 
degraded by the 26S proteasome, thereby inducing p50/p65 NF-κB nuclear 
translocation to modulate gene transcription. NFκB also regulates expression of 
adhesion molecules (i.e. ICAM-1 and VCAM-1): TNFα further upregulates these 
adhesion molecules on both MM cells and BMSCs, thereby increasing binding of MM 
cells and the resultant induction of IL-6 transcription and secretion in BMSCs, as well 
as cell adhesion-mediated drug resistance (CAM-DR) [92]. Agents that target TNF-α, 
such as bortezomib, thalidomide and lenalidomide, in part abrogate the paracrine 
growth and survival advantage conferred by MM cell adhesion to the BM 
microenvironment. 
B-cell activation factor (BAFF) is normally expressed by monocytes, macrophages, 
dendritic cells, T cells and BMSCs. Osteoclasts produce both BAFF and a proliferation-
inducing ligand (APRIL), in high levels. This is also true of MM patients where both the 
tumour cells and their stromal counterparts express receptors and secrete high levels 
of BAFF and APRIL [93]. Functionally, BAFF and APRIL protect MM cells from 
apoptosis and promote growth by activating NF-κB, PI-3K/AKT, and MAPK pathways. 
Furthermore, BAFF and APRIL are able to upregulate antiapoptotic proteins such as 
Mcl-1 and Bcl-2, as well as regulate TACI and c-Maf-dependent expression of both 
cyclin D2 and integrin β7 [93, 94].  
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1.3.2. Bone marrow non-malignant accessory cells 
The interaction of MM cells with the BM microenvironment activates a pleiotropic 
cascade of proliferative/antiapoptotic signalling pathways. Importantly, this growth 
factor circuit between MM cells and BMSCs in the BM milieu promotes MM cell growth, 
survival, and migration, contributing to both MM progression and resistance to 
conventional drug treatment.  
 
1.3.2.1. Homing and adhesion of Multiple Myeloma cells to the bone 
marrow 
The homing of MM cells to the BM is mediated by certain chemokines, SDF-1α being 
one with a prominent role. SDF-1α interacts with its receptor CXCR4 on MM cells to 
trigger motility, internalization of CXCR4 and cytoskeletal rearrangement in MM cells 
[95]. SDF-1α is primarily produced by BMSCs but also by MM cells. Other factors that 
are known to stimulate MM cell migration in vitro and are considered to contribute to 
MM cell homing to the BM in vivo include VEGF [86, 96], HGF [97], MIP-1α [95], and 
IGF-1 [98, 99]. 
Both homotypic and heterotypic adhesion of MM cells to either ECM proteins or 
BMSCs are mediated through adhesion molecules. For instance, CD44, VLA-4 (very 
late antigen-4, CD49d), VLA-5 (CD49e), LFA-1 (leukocyte function-associated antigen-
1, CD11a), NCAM (neuronal adhesion molecule, CD56), ICAM-1 (intercellular 
adhesion molecule, CD54), syndecan-1 (CD138), and MPC-1 (CD49e) all contribute to 
MM cell adhesion to the ECM or BMSCs [60]. VLA-4 is expressed on MM cells and 
binds fibronectin and VCAM-1 (CD106) of ECM and BMSCs, respectively. The binding 
to fibronectin upregulates p27Kip1 and induces NF-κB activation in MM [92], which 
confers cell adhesion–mediated resistance to conventional chemotherapy [100, 101]. 
Furthermore, MM cell adhesion to BMSCs results in bone resorption and tumour 
invasion, triggered by release of MMP-1 resulting from the binding of syndecan-1 to 
type 1 collagen [102]. 
The CXCR4 inhibitor AMD3100 reversibly blocks SDF-1α binding to CXCR4 and 
inhibits stem cell homing. MM patients scheduled to undergo autologous stem cell 
transplantation have been treated with AMD3100 to facilitate stem cell mobilisation. It 
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has been shown that AMD3100 can be safely administered in these patients and can 
increase the number of mobilized CD34+ cells. This observation will facilitate prompt 
and durable engraftment of mobilized cells without mobilizing tumour cells from the BM 
[103].  
  
1.3.2.2. Bone marrow stromal cells and Multiple Myeloma 
Of all the cellular components in the BM microenvironment, BMSCs are considered to 
have a key role in localizing MM cells to the microenvironment via cell adhesion but 
also to have important additional functional sequelae. In the context of normal BM 
physiology, BMSCs are believed to function as an accessory cell population that 
supports the survival, cell division, and differentiation of normal hematopoietic stem 
cells and progenitors [104]. MM cell adhesion to BMSCs triggers the NF-κB-dependent 
transcription and secretion of cytokines such as IL-6 in BMSCs, which further stimulate 
MM growth, survival and drug resistance [62]. In turn, activation of NF-κB by cell 
adhesion and cytokines augments the binding of MM cells to BMSCs which further 
induces IL-6 secretion [91]. Furthermore, MM cells secrete other cytokines such as 
TNF-α, TGFβ and VEGF which further upregulate IL-6 secretion from BMSCs [84, 91, 
105]. Within the BM, interaction of CD40 on MM cells with its ligand CD40L on BMSCs 
upregulate adhesion molecules (such as VLA4 and LFA1) and augments MM cell 
adhesion, thereby increasing IL-6 and VEGF secretion in BMSCs [106].  
Besides integrins and CD40/CD40L, BMSC-MM interaction is also mediated through 
Notch. Upon Notch-notch ligand interaction, Notch signalling pathways are activated 
both in MM cells and BMSCs, with induction of IL-6, VEGF and IGF-1 secretion with 
associated MM proliferation and survival [107-109]. Activation of Notch-1, but not 
Notch-2, results in protection of tumour cells from alkylating agent-induced apoptosis 
[107]. The Notch ligand, Jagged2, was found to be overexpressed and is able to 
induce BMSCs to secrete IL-6, VEGF and IGF-1. Notch activation can interact with NF-
κB and C-myc to promote proliferation and inhibit apoptosis of MM cells, conferring 
drug resistance [110].    
Interactions of MM cell with the BM microenvironment – either directly through cell 
adhesion molecule-mediated interactions between MM cells and BMSCs, or indirectly 
by the effect of growth factors and cytokines released – activate a pleiotropic 
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proliferative and antiapoptotic cascade. In addition to NF-κB, other signalling pathways 
involved in this response are PI3K/Akt, Ras/Raf/MAPK and JAK/STAT3 pathway. 
Downstream sequelae of activation of this pathway include upregulation of cell cycle 
regulatory proteins and antiapoptotic proteins (such as Bcl-xl, Mcl-1 and caspase 
inhibitors). These events results in MM growth, survival, migration and contribute to 
drug resistance. 
An unanswered question about the role of BMSCs is whether there exists MM-specific 
abnormal BMSCs.  A recent study by Zdzisinka et al. [111], reported that MMP-1, 
MMP-2 and TIMP-2 is significantly increased in the BMSCs of MM patients versus 
healthy controls. Further studies are needed to verify this finding and to identify specific 
targets.   
 
1.3.2.3. Bone marrow endothelial cells and Multiple Myeloma  
Tumour associated angiogenesis has been shown to be as important in MM as in solid 
tumours.  Rajkumar et al. [83] reported an increase in BM MVD in MM, especially in 
advanced disease, compared with MGUS or normal BM. The authors also reported a 
correlation of higher MVD with adverse clinical outcome. This neovascularization in 
MM contributes to increased proliferation, survival and drug resistance through 
paracrine and cell adhesion mediated interactions.  
MM cells constitutively produce growth factors such as VEGF, bFGF and MMPs that 
stimulate BM angiogenesis. In the meantime, BMECs secrete VEGF, IL-6 and IGF-1, 
which promote MM cell growth in the BM milieu [84]. Importantly, VEGF and IL-8 allow 
MM cells to recruit new blood vessels in the BM [112]. The BMECs in these new MM 
associated vessels further support tumoural cell survival through cytokines and direct 
adhesion interactions. In addition to VEGF and bFGF, BMECs also express other pro-
angiogenic factors such as angiopontin 1, TGFβ, HGF and IL-1. MM progression is 
supported through these autocrine and/or paracrine loops present in the BM milieu 
The anti-MM activity exhibited by thalidomide [30] (a known antiangiogenic agent) is 
able to  inhibit BMECs-mediated secretion of VEGF, bFGF, and HGF, BMEC 
proliferation and capillarogenesis in patients who have MM [113]. Evidence is also 
accumulating of the antiangiogenic properties of bortezomib [114]. The antiangiogenic 
properties of these novel agents make them more effective in treating MM patients. 
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1.3.2.4. Osteoclast and Multiple Myeloma 
Normal bone is being continuously remodelled whereby osteoclasts (OCs) resorb old 
bone, which is replaced by deposition of new bone by osteoblasts (OBs). Bone 
remodelling should normally create no major net change in bone mass, because new 
bone deposition by OBs is regulated to equal the quantity of bone resorbed by OCs. In 
MM, bone resorption by OCs is uncoupled from new bone formation by OBs [115]. This 
uncoupling involves upregulated activity of OCs without corresponding increases in 
new bone deposition by OBs leading to the hallmark of MM; lytic lesions, also diffuse 
osteopenia, pathological fractures and bone pain. A variety of OC activating factors, 
produced by both tumour and BMSCs include MIP1α, MIP1β, RANKL (receptor 
activator of nuclear factor κB ligand), osteoprotegerin ligand, VEGF, TNFα, TNFβ, IL-
1α, IL-1β, IL-11, parathyroid hormone-related protein, HGF and IL-6. OC activity in turn 
modulates MM growth and survival [116, 117].  
One of the more important OC regulators is RANKL. RANKL expression is associated 
with differentiation and is induced from immature OB. RANKL stimulates osteoclast 
differentiation and activity whereas osteoprotegerin (OPG) functions as a decoy 
receptor by binding to RANKL and thereby inhibiting its ability to stimulate 
osteoclastogenesis [118]. It has been proposed that MM cells can trigger increased 
RANK signalling in OCs by stimulating RANKL expression by BMSCs and suppressing 
production (by BMSCs) of OPG thereby promoting lytic lesions [116]. 
Among these mediators of MM osteoclastogenesis, there has been considerable 
interest in MIP-1α, which potently stimulates OC formation independently of RANKL 
and increases RANKL- and IL-6–stimulated formation of OCs [119]. MIP-1α levels in 
plasma from BM aspirates of MM patients are higher compared with healthy controls 
and correlate with the degree of osteolytic lesions [120]. MIP-1α binds to CCR1 on 
OCs and CCR5 on MM cells. It has been shown that blocking CCR1 and CCR5 inhibits 
OC formation and MM cell adhesion to BMSCs respectively [121]. The functional 
significance of MIP-1α has been further demonstrated by studies in which antisense 
oligonucleotide against MIP-1α decreases bone destruction in vivo, and by MM cell 
adherence to BMSCs in vitro via decreased expression of the α5β1 integrin [119], 
suggesting a MIP-1α–mediated link between bone resorption and BMSC-mediated MM 
cell proliferation/survival. 
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Other cytokines involved in osteoclastogenesis include IL-6 which is secreted by 
BMSCs, and TGF-β. TGF-β produced by MM cells augments IL-6 secretion from 
BMSCs [105, 122], further triggering increased OC activity. p38MAPK in BMSCs 
upregulates the production of IL11, RANKL and MIP-1α, inducing OC formation and 
activity. Conversely, a p38MAPK inhibitor can suppress these cytokines resulting in 
decreased MM proliferation, adhesion and decreased osteoclastogenesis [123]. 
The main therapy for bone disease in MM is the amino bisphosphonates which inhibit 
osteoclastogenensis and thus reduce the bone resorption seen in MM. Newer agents, 
such as bortezomib, have been shown to increase OB activity [117] and lenalidomide 
has been shown to have inhibitory effects on osteoclastogenesis [124]. Moreover, in 
vivo studies have demonstrated both a decrease in osteolysis, as well as an indirect 
anti-MM effect using RANKL-Fc or OPG-Fc [65, 116, 117]. Based on signalling 
pathways in OCs and OBs, several additional compounds have been tested 
preclinically and shown to have antibone resorptive activity including: the MEK inhibitor 
AZD6244 [125], CCR1 inhibitor MLN3897 [126], the HDAC inhibitor PXD101 [127], 
Resveratrol [128] and cox inhibitor SDX-308 [129]. 
 
1.3.2.5. Osteoblast and Multiple Myeloma 
Lytic lesions in MM are not only caused by increased OC activity but also by decreased 
OB activity. The differentiation of mesenchymal stem cells to osteoblastic cells requires 
the activity and function of transcriptional factor Runx2/Cbfa1 [130]. The direct cell-to-
cell contact of osteoprogenitor cells with MM cells inhibits Runx2/Cbfa1 activity in 
osteoprogenitor cells via binding of VLA4 on MM cells to VCAM-1 on osteoblast 
progenitors [65]. Furthermore, soluble factors released by MM cells, such as Dickkopf 
1 (DKK1) and IL-3 also contribute to decreased Runx2/Cbfa1 activity and OB 
differentiation.  
DKK1 is an inhibitor of the Wnt pathway which is overexpressed at the transcriptional 
level in MM cells of approximately one third of patients (compared with normal plasma 
cells) and is detected in the serum of approximately one fourth of patients who have 
extensive osteolytic bone lesions [131]. As DKK1 inhibits the canonical Wnt pathway, 
which mediates differentiation of osteoblast progenitor cells, DKK1 expression by MM 
cells could inhibit osteoblastogenesis. Importantly, recombinant human DKK1 or serum 
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of BM aspirates containing high concentrations of DKK1 inhibited the in vitro 
differentiation of osteoblast precursor cells [131]. In addition, a subset of MM cell lines 
and primary MM tumour cells constitutively secrete a soluble Wnt inhibitor, Frizzled-
related protein 2 (sFRP-2), which also suppresses OB differentiation [132]. Conversely, 
DKK1 may have a key role in mediating osteolytic process as the expression of OPG 
and RANKL is also regulated by gWnt signalling [133].  
IL-3 has been shown to stimulate the activity of OCs, but recent reports indicate that it 
also inhibits bone morphogenic protein-2 (BMP-2)–stimulated osteoblast formation 
[134]. TGFβ from MM cells augments IL6 secretion from BMSCs [105] and OBs [122], 
thus further stimulating OC activity and bone resorption. HGF directly inhibits 
osteoblastogenesis in vitro and its serum levels in MM patients are increased and 
correlated inversely with bone-specific alkaline phosphatase, a marker of osteoblast 
activity [135]. The imbalance in the functional interaction of OCs versus OBs in MM is 
not mediated by a single cascade, and instead is due to multiple cytokine/growth factor 
networks.  
Unfortunately, reduction of tumour burden in MM does not lead to significant 
improvement in bone homeostasis; in many cases, patients who achieve complete 
remission after treatment with conventional therapies may still find that their pre-
existing osteolytic lesions not healed. This finding suggests that in MM, the relationship 
of disease activity in tumour cell burden versus bone homeostasis is complex and 
significant suppression of the MM cell population may not be sufficient to allow for 
resolution of bone lesions. From a therapeutic standpoint, identifying treatment 
strategies that not only abrogate bone resorption but also stimulate new bone 
formation will be useful toward improving the long-term outcome of patients who have 
MM. Bortezomib is an example of such an agent as it not only has anti-MM activity, but 
can also activate OB activity.  
23 
 
1.4. Intrinsic mechanisms conferring drug resistance in Multiple Myeloma 
1.4.1. Drug efflux pumps 
Clinical drug resistance has always been a major obstacle in the treatment of all types 
of cancer. There is primary (intrinsic) resistance where the drug insensitivity is present 
from first diagnosis and unresponsive to first line chemotherapy or secondary 
(acquired) resistance where tumour cells develop resistance during chemotherapy. 
There are myriad mechanisms of resistance described in cancer and all forms of 
resistance fall into one of two categories, pharmacokinetic resistance (PK), e.g. 
overexpression of drug efflux pumps and pharmacodynamic resistance, e.g. apoptosis 
resistance or altered survival pathways, where the agent reaches an appropriate 
concentration but this fails to propagate an appropriate cell death response. Both forms 
of resistance have been characterised as being important for MM cell survival.   
The cell membrane is the major determinant of cancer drug penetration to sub-cellular 
targets.  Cells have evolved complex chemical defence mechanisms to regulate the 
entry of foreign substances into and out of the cell. Of the known pump mechanisms, 
p-glycoprotein (P-gp; MDR-1; ABCB1), multidrug resistant protein-1 (MRP-1; ABCC1) 
and breast cancer resistance protein (BCRP; MXR; ABCG2), have the broadest 
substrate specificity and a strong correlation with drug resistance in vitro and in vivo in 
many models and forms of cancer [136]. Of all these drug efflux transporters, P-gp is 
the best studied, and considered to be the most important in contributing to drug 
resistance.  
 
1.4.1.1. P-glycoprotein (MDR-1; ABCB1) 
P-glycoprotein, called classical MDR, results from the overexpression of P-gp, a 
transmembrane protein with a mass of 170 kDa. P-gp is coded by the mdr-1 gene on 
chromosome 7q21 and belongs to the ATP binding cassette (ABC) transporter family. 
According to the human gene nomenclature proposed in 1999, P-gp is called ABCB1 
(http://www.gene.ucl.ac.uk/users/hester/abc.html). ABC transporters are a large 
superfamily of integral membrane proteins involved in ATP- dependent transport of 
chemotherapeutic drugs across biological membranes. Most ABC transporters consist 
of four domains, two membrane-spanning domains and two cytoplasmic domains. The 
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latter contain conserved nucleotide-binding motifs. Chemoresistance caused by the 
overexpression of P-gp exhibits a typical resistance pattern towards many drug classes 
(Table 1.4.1.1) [137]. 
Drug resistance resulting from ABC multidrug transporters can be prevented by 
another group of compounds, known variously as MDR modulators, reversers, 
inhibitors or chemosensitizers. In cellular models of resistance, the combination of a 
modulator with a drug to which cells are resistant will restore its cytotoxicity by shifting 
the LD50 to a much lower value. Modulators show the same diversity of chemical 
structure as substrates, and appear to act in several different ways. The mechanism of 
action of modulators has been explored in detail for P-gp. Some P-gp modulators 
compete with transport substrates for the drug-binding pocket of the transporter. Many 
of these compounds are transported by the efflux pump (e.g. cyclosporin A or 
verapamil) and can be viewed as competitive inhibitors. These first generation P-gp 
inhibitors, such as verapamil and cyclosporin A, have displayed useful MDR reversal 
activities in vitro and in murine models. The concentrations required, however, were 
high and often accompanied by increased side effects of toxicity [138]. Second 
generation inhibitors comprise newer analogues of the first generation agents like 
dexverapamil (less cardiotoxic r-enantiomer of verapamil) and PSC 833 (valspodar), 
the non-immunosuppressive analogue of cyclosporin A. These compounds were less 
cytotoxic and in some cases more potent P-gp modulators but still required micromolar 
concentrations to be effective. Third generation P-gp modulators have been developed 
based on structure-activity relationships that exhibit effective MDR reversal 
concentrations in the nanomolar range. These include GF120918 (Elacridar) [139], 
LY335979 (Zosuquidar) [140], XR9051 [141] and OC144-093-Ontogen (ONT-093) 
[142]. Other than competitive inhibition, there are other mechanisms of action of these 
modulators. The high-affinity modulator XR9576 (Tariquidar) [143] appears to interact 
with Pgp at a location distinct from the site of interaction of transport substrates, which 
may serve a modulatory function. Overall, the different mechanisms by which 
modulators exert their action at the molecular level are not well understood, making the 
rational design of new templates a challenging task.  
In normal physiology, P-gp is expressed at high levels in the apical membranes of 
epithelial cells lining the colon, small intestine, pancreatic and bile ductules, and the 
kidney proximal tubule. It is also found in the endothelial cells lining capillaries in the 
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brain, testis and inner ear. The pregnant endometrium, the placenta and the adrenal 
gland also express high levels of P-gp. The location of P-gp suggests that its primary 
physiological role is to protect sensitive organs and the fetus from toxic 
xenobiotics [144]. In the intestine, P-gp extrudes many drugs into the lumen, thus 
reducing their absorption and oral bioavailability. It may export endogenous steroid 
hormones from the adrenal gland. The presence of P-gp in hematopoietic progenitor 
cells protects the bone marrow from the toxicity of chemotherapeutic drugs [145]. 
The role of ABC transport proteins in drug-resistant cancers is still a topic that is being 
examined. A high incidence of P-gp overexpression has been observed prior to 
chemotherapy treatment in many different poorly responsive tumour types, including 
kidney, colon, liver, breast and ovarian cancers. In haematological malignancies, such 
as leukaemias, lymphomas and MMs, the low levels of P-gp expression observed 
initially are often markedly increased after chemotherapy treatment and relapse. 
Grogan et al. [146] have shown that previous treatments with anthracyclines and vinca 
alkaloids can induce expression of P-gp in MM patients.  However, clinical trials that 
used a combination of VAD with P-gp inhibitors such as cyclosporine [147], verapamil 
[148] or PS-833 [149] showed no clinical benefit in terms of increased OS or PFS. The 
failure of these trials can be related to poor inhibition of P-gp function by the P-gp 
inhibitors; additionally, generalized inhibition of P-gp can reduce the elimination of 
cytotoxic agents and in some trials this necessitated dose reduction to compensate for 
increases in toxicity evident in the P-gp treated patients. There are efforts under way to 
find more effective and less cytotoxic MDR modulators but another answer to the 
question may be to pair these modulators to drugs that are not chemotherapeutics in 
the traditional sense, such as bortezomib. 
Bortezomib, as described earlier, is a novel treatment for MM. The mechanism of 
resistance to bortezomib is multifactorial and while little is known about the interaction 
of bortezomib with P-gp, there are indications that overexpression of this pump may 
contribute to resistance to this agent. Rumpold et al .[150] showed that knockdown of 
P-gp resensitises P-gp-expressing cells to proteasome inhibitors. Another strategy to 
overcome P-gp-induced resistance is to prevent P-gp from reaching the cell surface 
after synthesis in the endoplasmic reticulum. Proteasome inhibitors, lactacystin and 
MG-132 have been shown to inhibit the maturation of P-gp [151]. Bortezomib may be 
able to do the same if this is a class effect. Hence, better characterization of the 
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interactions of this drug with classical resistance mechanisms should identify improved 
treatment applications.  
 
 
Anticancer drugs Vinca alkaloids (vinblastine and vincristine) 
  Anthracyclines (doxorubicin and daunorubicin) 
  Taxanes (paclitaxel and docetaxel) 
  Epipodophyllotoxins (etoposide and teniposide) 
  Camptothecins (topotecan) 
  Anthracenes (bisantrene and mitoxantrone) 
HIV protease inhibitors Ritonavir 
  Saquinavir 
  Nelfinavir 
Analgesics Morphine 
Antihistamines Terfenadine 
  Fexofenadine 
H2-receptor antagonists Cimetidine 
Immunosuppressive agents Cyclosporine A 
  Tacrolimus (FK506) 
Antiarrhythmics Quinidine 
  Amiodarone 
HMG-CoA reductase inhibitors 
Lovastatin 
Simvastatin 
Antiemetics Ondansetron 
Tyrosine kinase inhibitors Imatinib mesylate 
  Gefitinib 
Cardiac glycosides Digoxin 
Antihelminthics Ivermectin 
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Calcium-channel blockers Verapamil 
  Nifedipine 
  Azidopine 
Diltiazem 
Antihypertensives Reserpine 
  Propanolol 
Antibiotics Erythromycin 
  Gramicidin A 
Steroids Corticosterone 
  Dexamethasone 
  Aldosterone 
  Cortisol 
Table 1.4.1.1 Drugs and other compounds that interact with P-gp, taken from 
[137] 
 
1.4.1.2. Multidrug resistant protein-1 (MRP-1; ABCC1) 
MRP-1 is a drug transporter located in the plasma membrane, where it engages in 
active efflux of many drugs and drug conjugates. MRP-1 is a 190 kDa protein 
consisting of two NBDs and three transmembrane domains, a feature it shares with the 
MRP-2 (ABCC2), MRP-3 (ABCC3), MRP-6 (ABCC6) and MRP-7 (ABCC10). Other 
members of the MRP family (MRP-4, MRP-5, MRP-8 and MRP-9) contain two NBDs 
and two transmembrane domains similar to P-gp [152]. 
In contrast to P-gp and BCRP, MRP1 is expressed at the basolateral membrane of 
polarized epithelial cells. It protects tissues such as the bone marrow, kidney collecting 
tubules and oropharyngeal and intestinal mucosa from toxicants and is also involved in 
drug clearance from the cerebrospinal fluid, testicular tubules and peritoneum [153]. 
MRP1 plays a central role in glutathione homeostasis in vivo and exports LTC4 from 
mast cells. It may also be involved in protecting cells from the toxicity of bilirubin. 
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Less is known about the significance of MRP1 in tumours and its role in drug 
resistance remains controversial. MRP1 is expressed in many different tumour types, 
including solid tumours (non-small-cell lung cancer, gastrointestinal carcinoma, 
melanoma, neuroblastoma and cancers of the breast, ovary and prostate) and 
haematological malignancies including leukaemias [154]. Some studies have linked the 
presence of MRP1 to poor treatment outcome, but no comprehensive picture of its role 
in clinical MDR has emerged as yet. 
MRP1 transports a variety of endogenous molecules of physiological significance, 
including free glutathione, glutathione-conjugated leukotrienes and prostaglandins 
(LTC4, LTD4, LTE4, prostaglandin A2-SG, hydroxynonenal-SG), glucuronide conjugates 
(β-estradiol-β-D-glucuronide and glucuronosyl-bilirubin) and sulfate conjugates 
(dehydroepiandrosterone-3-sulfate and sulfatolithocholyl-taurine) (see Table 1.4.1.2) 
[137]. Similarly to P-gp, MRP1 also confers resistance to a variety of anti-cancer 
agents, although not taxanes.  
In contrast, only a few modulators have been described for MRP1 [155], including VX-
710 (biricodar), MK571 (a leukotriene D4-receptor antagonist), sulindac (an NSAID) 
flavonoids, raloxifene analogs, isoxazole-based compounds and glutathione 
derivatives.  
 
 
Anticancer drugs Vinca alkaloids (vinblastine and vincristine) 
  Anthracyclines (doxorubicin and daunorubicin) 
  Epipodophyllotoxins (etoposide and teniposide) 
  Camptothecins (topotecan and irinotecan) 
  Methotrexate 
Metalloids Sodium arsenate 
  Sodium arsenite 
  Potassium antimonite 
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Peptides Glutathione (GSH, GSSG) 
Glutathione conjugates Leukotrienes C4, D4 and E4 
  Prostaglandin A2-SG 
  Hydroxynonenal-SG 
  Aflatoxin B1-epoxide-SG 
  Melphalan-SG 
  Cyclophosphamide-SG 
  Doxorubicin-SG 
Sulfate conjugates Estrone-3-sulfate 
  Dehydroepiandrosterone-3-sulfate 
  Sulfatolithocholyl taurine 
Pesticides Fenitrothion 
  Methoxychlor 
 
Glucuronide conjugates 
 
Glucuronosylbilirubin 
  Estradiol-17-β-D-glucuronide 
  Etoposide-glucuronide 
  NS-38-glucuronide 
HIV protease inhibitors Ritonavir 
  Saquinavir 
Tyrosine kinase inhibitors Imatinib mesylate 
  Gefitinib 
Antibiotics Difloxacin 
  Grepafloxicin 
Table 1.4.1.2 Drugs and other compounds that interact with MRP-1, taken from 
[137]  
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1.4.1.3. Breast cancer resistance protein (BCRP; MXR; ABCG2) 
BCRP is a 72 kDa half-transporter, and likely functions as a homodimeric complex. It is 
also referred to as MXR (mitoxantrone resistance associated protein), ABCP 
(Placenta-specific ABC gene) and ABCG2. Identification of the molecule in the 
anthracycline-selected breast cancer cell line MCF-7/AdrVp led to it being named 
BCRP [156]. The BCRP gene has been mapped to chromosome 4q22 [157].  
BCRP is expressed in a variety of normal tissues, including intestine, kidney and 
placenta, as well as brain endothelial cells and hematopoietic stem cells. Its expression 
is strongly induced in the mammary gland during pregnancy and lactation. Similarly to 
P-gp, it is assumed to function in protecting tissues from toxicants and it likely plays a 
role in intestinal absorption, brain penetration and transplacental passage of drugs. 
The transporter is also expressed in certain stem cells, where it acts as a marker of 
pluripotent stem cells (the side population). In these cells, BCRP appears to interact 
with heme and prevent accumulation of porphyrins, enhancing cell survival under 
hypoxic conditions [158]. 
BCRP is a broad specificity drug transporter like P-gp; however, it appears to transport 
both positively and negatively charged drugs, including sulfate conjugates (Table 
1.4.1.3). BCRP cannot transport taxanes, cisplatin and verapamil (P-gp substrates), 
calcein (an MRP1 substrate) or Vinca alkaloids or anthracyclines (substrates for both 
P-gp and MRP1), indicating that its substrate specificity partially overlaps with that of 
the other two transporters.  
Since its discovery in 1998, high levels of BCRP expression have been found on a 
variety of drug-resistant cell lines that do not express either P-gp or MRP1. Since then, 
BCRP expression has been reported in many solid tumours [159], especially those 
from the GI tract, endometrium, lung and melanoma. However, a case has been made 
for the likely involvement of BCRP in resistance of both adult and childhood acute 
myeloid leukaemia to anticancer drugs [160] . 
BCRP inhibitors have only recently been investigated, and include VX-710, GF120918 
(elacridar), XR9576 (tariquidar), fumitremorgin C (a mycotoxin) and its derivative  
Ko143, pantoprazole, flavonoids, estrogens and antiestrogens [161].  
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Anticancer drugs Mitoxantrone 
  Bisantrene (R482T mutant form) 
  Epipodophyllotoxins (etoposide and teniposide) 
  Camptothecins (topotecan and irinotecan) 
  Anthracyclines (doxorubicin and daunorubicin; R482T mutant 
form) 
  Flavopiridol 
Antifolates Methotrexate 
Porphyrins Pheophorbide a 
  Protoporphyrin IX 
  Hematoporphyrin 
Flavanoids Genestein 
  Quercetin 
Carcinogens Aflatoxin B 
  PhiP 
Fungal toxins Fumitremorgin C 
  Ko143 
Antihypertensive Reserpine 
HMG CoA reductase inhibitors Rosuvastatin 
  Pravastatin 
  Cerivastatin 
Antiviral drugs Zidovudine 
  Lamivudine 
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Table 1.4.1.3 Drugs and other compounds that interact with BCRP, taken from 
[137] 
 
 
Drug & metabolite conjugates Acetominaphen sulfate 
  Estrone-3-sulfate 
  Dehydroepiandrosterone sulphate 
  Estradiol-17-β-D-glucuronide 
Tyrosine kinase inhibitors Imatinib mesylate 
  Gefitinib 
Antibiotics Ciprofloxacin 
  Norfloxacin 
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1.4.2. p53 signalling perturbations 
Mammalian p53 family proteins – p53, p63 and p73, are descendents of an 
evolutionarily ancient family of transcription factors. Of the three mammalian p53 family 
proteins, p53 is unique in its pre-eminence as a tumour suppressor. In fact, it is thought 
to be the ‘guardian of the genome’ and hailed as the ‘molecule of the year’ in 1993 
[162]. p53 is a transcription factor with multiple regulatory roles in stress and damage 
response such as DNA repair, cell cycle and apoptosis. It also plays a part in various 
physiological processes, including fertility, cell metabolism and mitochondrial 
respiration, autophagy, cell adhesion, stem cell maintenance and development [163]. 
In normal unstressed cells, p53 activity is maintained at a low level through a 
combination of p53 degradation and direct transcriptional repression, principally 
mediated by Mdm2 and Mdm4 (also known as MDMX in humans) [164]. 
p53 and Mdm2 interact with each other through an autoregulatory feedback loop. 
When p53 is activated, it transcribes the Mdm2 gene and in turn, the Mdm2 protein 
inhibits p53 activity by binding to the p53 transactivation domain and inhibiting its 
transcriptional activity [165]. Mdm2 is also responsible for exporting p53 out of the 
nucleus, promoting its degradation via the ubiquitin/proteasome pathway [166] and 
rendering it inaccessible to the target genes. The importance of the balance between 
Mdm2 and p53 protein is underscored by genetic studies, which have demonstrated 
that the genetic deletion of Mdm2 is embryonic lethal and that Mdm2 -/- mice can be 
successfully rescued only by a concomitant deletion of the TP53 gene [167, 168]. 
Another player in the regulation of p53 is Mdm4 which shows a high degree of 
homology to Mdm2. Mdm4 binds to p53 and inhibits its transactivation properties. The 
only difference between the two is that Mdm4 does not ubiquitinate and degrade p53 
[169, 170].   
As p53 has such an important role in tumour suppression, it is perhaps surprising that 
p53 is not functionally inactivated in more tumours – only about 50% of solid tumours 
have a mutation or deletion of the TP53 gene [171], while only about 15% of all 
haematological malignancies show deletion/mutation of p53, at least in the early stages 
of the disease [172]. In MM, this is the case as well with p53 mutation/deletion 
occurring at later stages of the disease. The significance of p53 mutation/deletion in 
MM was unknown in the context of novel therapies until a recent study by the IFM 
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group showed that bortezomib was able to overcome some poor prognostic markers 
[i.e. t(4;14)] but not Del 17p [173].   
It would seem that direct inactivation of p53 would be an effective means of inactivating 
the whole tumour suppressor pathway, however, tumours are seldom optimized for 
growth, as evident by their high apoptotic indices, necrotic cores, hypoxia and 
abundant cytopathologies [163]. There can be tumour growth even if p53-mediated 
apoptosis proceeds unchecked provided that cell proliferation is more rapid. There is a 
theory that partial loss-of-function p53 mutations that retain p53 attributes are 
advantageous to tumour cells: such mutant p53 forms would have gain-of-function 
properties when activated by upstream oncogenic and stress signals. Clearly, the 
inopportune shunting of rogue cells into repair and survival modes by such mutant 
forms of p53 has substantial potential to promote tumourigenesis [174, 175]. That 
might explain the paradox of why p53-inactivating mutations confer a selective 
advantage only relatively late in the oncogenicity of many tumour types. In the 
remaining human cancers, p53 retains wild-type (p53WT) status but its function is 
inhibited by Mdm2. Mdm2 was initially discovered as the product of an oncogene found 
overexpressed by amplification in a spontaneously transformed mouse cell line [176]. 
Mdm2 has been found to be overexpressed in many human tumours [172] as its 
deregulated expression provides growth advantage to cells. 
Small molecule inhibitors of Mdm2 have been developed as therapeutic anticancer 
agents. Compounds that bind to Mdm2 and inhibit its ability to bind to or regulate p53 
can stabilize p53, increase its protein levels, and activate the p53 apoptotic pathway in 
a nongenotoxic manner. Nutlins, benzodiazepines, spiro-oxindoles and quinolinols bind 
to Mdm2 and inhibit its p53 association. 
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1.4.2.1.1. Combination therapies with Nutlin 
Experiments in patient samples retaining wild-type p53 show that nutlin-3 synergizes 
with doxorubicin, chlorambucil and fludarabine in CLL [178, 185, 186]; with doxorubicin 
and 1-h-Darabinofuranosylcytosine (Ara-C) in acute myeloid leukemia [187, 188]; and 
with doxorubicin in Hodgkin and Reed-Sternberg cells [189] in inducing apoptosis. In 
these studies, nutlin-3 was non-toxic toward normal haematopoietic cells. Another 
strategy is to combine Mdm2 inhibitor with tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL). TRAIL is known to bind to TRAIL-R2, a cell surface receptor, 
and transduces an apoptosis signal. It was shown that in p53WT acute myeloid 
leukaemia cells, nutlin-3 induces p53-dependent production of TRAIL-R2, leading to 
synergistic cell death when used in combination with TRAIL [187]. 
Mitsiades et al., have previously reported the in vitro synergistic activity of the 
combination between bortezomib and DNA-damaging, p53-activating, 
chemotherapeutic agents, such as doxorubicin and melphalan [44]. This concept has 
been validated in the clinical setting by trials demonstrating the superiority of combined 
pegylated liposomal doxorubicin plus bortezomib compared with bortezomib 
monotherapy for the treatment of patients with relapsed or refractory MM [46], as well 
as the superiority of combined bortezomib plus melphalan and prednisolone compared 
with only melphalan plus prednisolone to treat newly diagnosed MM patients [190]. 
These findings support the role of combining p53-activating chemotherapeutics with 
proteasome inhibitors as a promising novel therapeutic approach in MM. 
The ubiquitin/proteasome pathway is responsible for the degradation of many tumour-
suppressing and pro-apoptotic proteins that are important for survival and proliferation 
of cancer cells, including p53. The hypothesis that nongenotoxic stabilization of p53, 
caused by nutlin-3 through suppression of Mdm2-mediated p53 ubiquitination, may 
synergize with accumulation of p53 caused by bortezomib through proteasome 
inhibition, thereby leading to increased antitumour activity.  
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 1.4.3. AMP-activated protein kinase pathway 
AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase and serves 
as an energy sensor in all eukaryotic cells. AMPK is a heterotrimeric complex 
comprising of a catalytic α subunit and regulatory β and γ subunits [191]. AMPK is 
activated under conditions that deplete cellular ATP and elevate AMP levels such as 
glucose deprivation, hypoxia, ischaemia and heat shock which are associated with an 
increased AMP/ATP ratio [192]. As a result of the activation, AMP binds to the γ 
subunit causing phosphorylation of threonine 172 in the activation loop of the α 
catalytic subunit by upstream kinases such as LKB1 and CaMKK. 
LKB1 is a serine/threonine protein kinase and is the product of the gene lkb1. In 
patients with Peutz-Jeghers syndrome (PJS), this gene is mutated. Mutations in PJS 
patients were shown to be loss of function mutations of LKB1 ([193, 194]. PJS is 
characterized by mucocutaneous melanin pigmentation, gastrointestinal polyposis and 
markedly increased risk of cancer. LKB1 mutants that are inactive failed to suppress 
cell growth indicating that LKB1 has antiproliferative function and hence anti-tumour 
effect. LKB1 also induce p53 and p21 upregulation resulting in cell cycle arrest in 
melanoma cells [195] providing further evidence that it can function as a tumour 
suppressor. Several studies from different groups have shown a clear connection 
between LKB1 and AMPK-induced cell cycle arrest [196, 197]. 
Several groups have reported that activation of AMPK suppresses mTOR signalling by 
growth factors and amino acids [198-200]. When AMPK is activated, TSC2 is 
phosphorylated at Thr-1227 and Ser-1345 and increases the activity of TSC1–TSC2 
complex to inhibit mammalian target of rapamycin (mTOR) [201]. In addition, AMPK 
reportedly phosphorylates mTOR at Thr-2446 to reduce S6K1 phosphorylation by 
insulin, suggesting the inhibition of mTOR action [202]. Thus, AMPK directly and 
indirectly (via TSC2) suppresses mTOR activity to limit protein synthesis through the 
inhibition of translation elongation factor 2 (EF2). Therefore, AMPK activation regulates 
cellular proliferation in response to energy status or nutrient availability by limiting cell 
growth and proliferation when there is a lack thereof. 
mTOR is an evolutionarily conserved serine/threonine kinase and a key regulator of 
protein translation/synthesis and cell growth [203, 204]. The mTOR pathway is 
activated by amino acids and by growth factors (e.g. PDGF, epidermal growth factor 
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(EGF) and insulin. This stimulates protein synthesis, cell growth and proliferation. 
mTOR increases translation initiation of 5′-terminal oligopyrimidine tract-containing 
mRNAs, which encode components of the protein synthesis machinery. The 
downstream effectors of mTOR ribosomal protein S6 kinase 1 (p70S6K1 or S6K1) and 
the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) 
stimulates the initiation step of translation [205]. 
Constitutive activation of PI3K-Akt signalling has been reported in many cancers 
including glioblastoma, melanoma, prostate cancer and haematological malignancies, 
including MM. Previous studies have demonstrated that IL-6 stimulates growth and 
survival of MM cells in part via the PI3K-Akt pathway [70]. Other studies have shown 
that IGF-1, another growth factor for MM also activates the PI3K pathway [206, 207]. 
One of the most important targets of PI3K is activation of Akt which mediates survival, 
proliferation and growth of tumour cells [208, 209]. Akt also regulates cell cycle by 
modulating cyclin D1. Through phosphorylation and inhibition of cyclin D1, Akt prevents 
its degradation and leads to its accumulation in the cell [210]. Hideshima et al. [211], 
has demonstrated that perifosine, an Akt inhibitor, has significant anti-MM activity and 
this drug is currently in clinical trials. mTOR, a downstream target of Akt has shown 
significant antiapoptotic activity in MM [212-214]. AMPK activation is a feasible 
therapeutic strategy for these cancers since AMPK inhibits mTOR signalling 
downstream of Akt, and inhibition of mTOR pathway has been reported to inhibit 
tumour growth and metastasis in experimental animal models as well as in cultured 
cells. 
Activation of AMPK by metformin, AICAR or thiazolidinediones or expression of 
constitutively active mutants have been shown to cause apoptosis or cell cycle arrest 
of various cancer cells (to be discussed below). On the other hand, activation of this 
pathway has been shown to be protective on non-neoplastic tissues such as injured 
cells in cardiac ischemia and reperfusion injury models [215, 216]. AMPK activation 
protects human umbilical vein endothelial cells from hyperglycaemia by inhibition of 
caspase 3 and Akt activation [217] and by a similar mechanism in thymocytes [218].  
These and other studies have suggested that AMPK activation confers protection 
against cell death. The underlying mechanism for these apparently opposing effects of 
AMPK activation is unknown at this time, but it can be postulated that in actively 
dividing cancer cells, the inhibition of ATP-consuming processes by AMPK may be less 
compatible
protective 
ATP-cons
[219]. 
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A pilot case-control study and a population-based cohort study have demonstrated 
decreased incidence of cancer and decreased cancer mortality in metformin users 
compared to controls, sulfonylurea monotherapy users, or subjects who used insulin 
[220, 221]. Furthermore, metformin use has been associated with a 44% risk reduction 
for prostate cancer diagnosis among Caucasian men [222] and a 56% risk reduction 
for breast cancer diagnosis among women long-term users [223]. Concurrent 
metformin use in diabetic women with breast cancer receiving neoadjuvant 
chemotherapy increased the rate of pathologic complete response, suggesting that 
metformin can enhance the cytotoxic activity of conventional chemotherapy [224].  It is 
possible that the anticancer activity of metformin is exerted indirectly via the beneficial 
effects of metformin on the endocrine and metabolic milieu, such as improvement of 
hyperinsulinemia and suppression of systemic IGF-I levels. Alternatively, there could 
be a direct effect of metformin on the cancer cell. Direct anticancer activity of metformin 
has recently been demonstrated in in vitro studies using breast, prostate, colon, 
pancreatic, endometrial and ovarian carcinoma cell lines [225-230]. Such a direct effect 
may be mediated via increased phosphorylation of AMPK, decreased mTOR, p70S6K, 
ribosomal protein S6 and eIF4E-binding protein 1 activation and phosphorylation, and 
inhibition of translation initiation. 
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Whether phosphorylation of Ser-15 on p53 is mediated by AMPK itself or by another 
protein kinase, which is co-immunoprecipitated with AMPK, has not been elucidated. 
AMPK activation by AICAR has also been recently reported to inhibit proliferation of 
various cancer cell lines in vitro and in vivo by causing cell cycle arrest with an 
increase in p21CIP, p27KIP and p53. The authors of this study also demonstrated that 
AICAR seems to affect the PI3K-Akt proliferation pathway, because AICAR inhibited 
PI3K activity and Akt phosphorylation [219]. AICAR has also been shown to have an 
anti-tumour role in myeloma [235] and to cause a proliferation block and cell death by 
inhibiting fatty acid and protein synthesis pathways and increasing p21 expression in 
prostate cells [236]. Other studies have shown that AMPK activation is able to cause 
apoptosis in gastric cancer cells [237] and pancreatic cells by inducing JNK pathway 
[238]. Similarly, AMPK induced JNK and caspase 3 activity resulting in apoptosis in 
liver cells [239]. AMPK activation was also demonstrated to enhance H2O2-mediated 
apoptosis in neuroblastoma cells by inducing NF-κB activation along with activation of 
p38 MAPK and c-Jun [240]. These studies suggest that AMPK is an efficient growth 
inhibitor and apoptosis inducer. Thus, AMPK can be considered as a negative 
regulator of proliferation and can modulate protein expression to this effect, classifying 
it as a tumour suppressor pathway system that can be exploited for attenuation of 
cancer growth. 
 
1.5. Use of proteomics to investigate drug resistance in Multiple Myeloma  
The success of the human genome project highlights how far science has advanced 
our understanding of the human body and cellular interactions. However, limitations of 
information on DNA sequence must be acknowledged. Although the DNA code 
provides the instructions for the amino-acid sequence, there are an estimated 1.5 
million proteins, or roughly 50 proteins for every gene [241]. As the human body is 
made up mostly of proteins, being able to assess protein-protein interaction is 
important in understanding normal physiology as well as disease states. 
The correlation between genotype and phenotype is low as many other processes 
affect protein synthesis such as chemical modification of amino acids (glycosylation, 
acetylation, glucuronidation, phosphorylation, deaminations and methylations). In 
addition, multiple products can arise from a single gene through alternate transcription 
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and post-transcriptional modification of the gene product through alternative splicing, 
translation of more than one polypeptide from a single mRNA, or modification of an 
amino acid before or after release from a polysome [242]. 
Proteomics is the study of proteins in a cell. Proteomics represents a powerful tool to 
discover protein locations, protein modifications, changes in protein abundance and to 
interrogate protein-protein interaction. Disease states arise when any part of this 
system is perturbed. 
 
1.5.1. 2D-DIGE MALDI-TOF MS 
The traditional method to measure protein expression is two-dimensional gel 
electrophoresis (2-DE) and it remains the gold standard to this day. 2-DE is a protein 
separation method that separates proteins in a first dimension by isoelectric focusing, 
which separates proteins by charge and then by molecular weight in the second 
dimension. Among proteomic techniques, differential in-gel electrophoresis (DIGE) 
circumvents many of the issues associated with traditional 2DE, such as reproducibility 
and limited dynamic range, and allows more accurate and sensitive quantitative 
proteomics studies. This innovative technology relies on pre-electrophoretic labelling of 
samples with one of three CyDye fluors (Cy2, Cy3, Cy5), each with a unique 
fluorescent wavelength, allowing for two experimental samples and an internal 
standard to be simultaneously separated on the same gel. The internal standard is a 
pool of an equal amount of all the experimental samples and facilitates accurate data 
normalization among gels, increasing statistical confidence in quantitative comparative 
analysis. Under optimal condition, several thousand proteins’ expression levels can be 
defined simultaneously on a single 2D gel. The proteins can then be compared using 
computer software, e.g. DeCyder biological variation analysis (BVA), to identify 
proteins that are differentially expressed.   
2D-DIGE is a descriptive technique and must be coupled with an analytical method 
such as mass spectrometry (MS) to identify the proteins. MS provides structural 
information, such as peptide mass and amino acid sequence, which is then used to 
identify the protein by searching against nucleotide and protein databases [243]. 
Proteins that are identified to be of interest are then picked from preparatory gels and 
subsequently digested using trypsin to extract the proteins. These specific 
44 
 
proteolytically-derived peptides are then characterized for protein identification. Mass 
spectrometers are capable of forming, separating, and detecting molecular ions on the 
basis of the mass-to charge ratio (m/z). This requires that the peptides are ionized. 
Ionization techniques transfer biomolecules from the solid or liquid phase to the gas 
phase, making them amenable to MS measurement. A method of peptide ionization for 
MS analysis is matrix-assisted laser desorption/ionization (MALDI). Ionization ensues 
as a result of the addition of 1 or more protons. Thus, a peptide of molecular weight 
1000 Da will have an m/z value of 1001 after ionization by the addition of a single 
proton and 501 with the addition of 2 protons (M+2H/2). The time-of-flight (TOF) 
analyser separates ions according to their m/z ratios by measuring the time it takes for 
ions to travel through a field free region known as the flight or drift tube. The smaller 
ions possess higher velocity relative to larger/heavier ions. Separated ion fractions 
arriving at the end of the drift tube are detected by an appropriate recorder that 
produces a signal upon impact of each ion group. The TOF mass spectrum is a 
recording of the detector signal as a function of time.  
After the unknown protein of interest is cleaved into smaller peptides and the absolute 
masses accurately measured with a mass spectrometer, these masses are then 
compared to either a database containing known protein sequences or even the 
genome. This is achieved by using computer programs that translate the known 
genome of the organism into proteins, then theoretically cut the proteins into peptides 
and calculate the absolute masses of the peptides from each protein. They then 
compare the masses of the peptides of the unknown protein to the theoretical peptide 
masses of each protein encoded in the genome. The results are statistically analyzed 
to find the best match. This method of protein analysis is also known as peptide mass 
fingerprint (PMF) [244, 245]. Unfortunately, a single peptide is rarely unique to 1 
protein, thus several peptides (>3) that are derived from the same protein are typically 
required for identification. Accurate identification can be problematic in some 
scenarios, for example a simple rearrangement of the constitutive amino acids can 
have the same mass or that the peptides from post-translationally-modified proteins will 
not match the masses of the peptides from the unmodified protein in the database. Any 
contamination by keratin and peptides from the autolysis of trypsin may also be 
problematic. Moreover, not all proteins are amenable to identification by PMF alone as 
a large percentage of human proteins are not represented in databases. In addition, 
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small proteins may not yield a sufficient number of peptides from the tryptic digest for 
unambiguous identification. However, 2-DIGE MALDI-TOF MS is still a robust method 
to measure protein expression and protein identification.  
 
1.5.2. Bioinformatics 
Bioinformatics is the application of information technology and computer science to the 
field of molecular biology. The term bioinformatics was coined by Paulien Hogeweg in 
1979 for the study of informatics processes in biological systems. Its primary use since 
at least the late 1980s has been in genomics and genetics, particularly in those areas 
of genomics involving large-scale DNA sequencing. In proteomics, bioinformatics can 
determine proteomic signatures responsible for the important clinico-pathological 
features and identify key proteins that may be candidates for disease markers and 
therapeutic targets. Bioinformatics now entails the creation and advancement of 
databases, algorithms, computational and statistical techniques and theory to solve 
formal and practical problems arising from the management and analysis of biological 
data. 
Information about proteins can be obtained using large international databases such as 
SWISS-PROT and NCBI, primarily. Secondary proteomic databases, such as 
Bioinfomatic harvester, Open proteomics and Pubmed, are also informative in 
searching all that is known about a protein’s interactions and its related gene. Software 
packages are available to analyse proteomic data e.g. PathwayStudio and Gene 
Ontology (GO STAT). PathwayStudio is a product aimed at the visualisation and 
analysis of biological pathways, gene regulation networks and protein interaction maps. 
It comes with a comprehensive database that gives a snapshot of all information 
available in PubMed, with the focus on pathways and cell signalling networks. This 
product allows visualisation of results in the context of automatically created pathways, 
gene regulation networks and protein interaction maps. The GO STAT consortium 
provides structural description of protein function that is used as a common language 
for gene annotation in many organisms. Large-scale techniques have generated many 
valuable protein-protein interaction datasets that are useful for the study of protein 
function [246]. 
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The combination between 2D-DIGE, mass spectrometry and bioinformatics gives us a 
powerful tool in understanding disease. The efforts to understand the overall features 
of the proteome by using a bioinformatics approach to analyse 2D-DIGE data, together 
with the integrated information of the individual proteins identified by 2D-DIGE, will 
enable us to probe further the action of any drug as well as resistance mechanisms 
that can arise.  
 
1.5.3. Proteomics and drug resistance biomarkers in Multiple Myeloma 
Gottesman and colleagues [247], were one of the first groups to study protein profiles 
in drug resistant human KB carcinoma cells. However, it was years later before the first 
systematic comparative proteomic profiling and analysis of the drug-selected cancer 
cell lines were performed with the advancement of MS technology [248]. Currently, 
advances in the use of proteomic technologies (specifically the comparative proteomic 
approach) provide a robust approach to study multiple signalling pathways 
simultaneously and mechanism of resistance to anticancer therapy (Table 1.5.5). The 
altered proteins identified by proteomic approach can be further characterized as 
potential drug targets and the global analysis of the protein alterations can result in 
valuable information to understand the drug resistance mechanisms [249-251].  
Proteomics has also been utilized to investigate mechanism of drug activity in MM. Ge 
et al., has shown that 14-3-3ζ may play a vital role in mediating arsenic trioxide-
induced apoptosis [252]. 14-3-3 proteins are a family of multifunctional phosphoserine 
binding molecules that can serve as effectors of survival signalling. They are involved 
in a variety of important cellular processes that include cell cycle progression, growth, 
differentiation as well as apoptosis. The authors also demonstrated that arsenic trioxide 
increased the expression levels of heat shock proteins (HSPs) but suppressed 
ubiquitin proteasome system (UPS) in myeloma cells. HSPs and UPS are participants 
in keeping proteins folded correctly and are essential for cellular functions and survival 
in many tissues. Another study demonstrating that proteomics is a valuable tool to 
examine resistance markers in MM implicated FKBP5, which was noted to be 
increased in MM cells following dexamethasone treatment [253]. The FKPB5 protein 
plays a role in immunoregulation and basic cellular processes involving protein folding 
and trafficking. It is also a member of the Hsp90 steroid receptor complex [254]. 
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Resistance to the novel agent bortezomib has been described in MM and other 
cancers. The mechanism of resistance is still unclear. One study by Weinkauf et al., 
has used 2-DE technology to investigate the proteins that are up- or downregulated 
with this drug to try to determine potential resistance mechanisms [255]. In colon 
cancer, aldo-keto reductase ARK1B10 has been shown to be upregulated after 
bortezomib treatment in HRT-18 cell line [256]. HRT-18 which was previously less 
sensitive to bortezomib, was sensitized when siRNA was used to knockdown this 
protein.          
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Tumour Drug Proteins Altered in Resistant Cells 
 
Reference 
    Up-regulated  Down-regulated   
Gastric cancer Daunorubicin Annexin I   [248] 
  Mitoxantrone  Annexin I    
    Thioredoxin    
Pancreatic   Daunorubicin  Cofilin    [257] 
Cancer Mitoxantrone  Cofilin     
    
Epidermal Fatty Acid Binding 
Protein    
    Stratifin (14-3-3-σ)    
Fibrosarcoma  Mitoxantrone  
Rho-Guanine Dinucleotide 
Phosphate (Rho-GDP) 
Dissociation Inhibitor   [258] 
Colon cancer  Mitoxantrone  
Adenine Phosphoribosyl 
Transferase    [258] 
    
Breast Cancer Specific Gene 1 
    
Colon cancer  5-fluorouracil  
Metabotropic Glutamate 
Receptor 4    [259] 
Colon cancer  5-fluorouracil    F1F0-ATP Synthase [260] 
Melanoma  Vindesine  
Translationally Controlled 
Tumour Protein    [261] 
  Cisplatin Human Elongation Factor 1-δ    
  Fotemustine 
Tetratricopeptide Repeat 
Protein    
  Etoposide  14-3-3-γ    
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Neuro- 
 
Etoposide 
 
Peroxiredoxin I 
 
dUTP 
 
[262] 
 blastoma   
β-Galactoside Soluble Lectin 
Binding Protein Pyrophosphatase   
    Vimentin     
    Heat Shock Protein 27    
    
Heterogeneous Nuclear 
Ribonucleoprotein K    
Gastric cancer  Cisplatin    Pyruvate Kinase M2 [263] 
Breast cancer  Melphalan  Retinoic Acid Binding Protein II  Calreticulin  [264] 
    
Macrophage Migration 
Inhibition Factor  Cyclophin A  
      
Heat Shock Protein 
27  
Breast cancer  Doxorubicin Annexin I Catechol-O- 
 
[265] 
    
Neuronal Ubiquitin Carboxyl 
Hydrolase  Methyltransferase  
    Isoenzyme L1    
    Glutathione-S-Transferase pi    
    
Nicotinamide N-
Methyltransferase    
    Interleukin-18 Precursor    
Table 1.5.5 Summary of studies using 2DE/MS to investigate chemotherapy 
resistance using cell lines [266]  
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1.6 Aims of the thesis 
The focus of this research project was to evaluate the mechanisms whereby myeloma 
cells develop intrinsic resistance with a focus on resistance in the context of 
bortezomib treatment. The aims of this thesis are as follows: 
 
• Examine multidrug resistance pumps as a mechanism of resistance in MM. 
• Characterise the interaction of bortezomib with multidrug resistance pumps. 
 
• Investigate the role of p53 signalling perturbations in resistance mechanism in 
MM using nutlin-3 (Mdm2 inhibitor) 
• Assess the activity of nutlin-3 in MM cell lines 
• Toxicologically characterise the effect of nutlin-3 combinations with bortezomib 
in MM cell models. 
 
• Examine the AMPK pathway as an alternative therapeutic target in drug-
resistant MM 
• Explore the activity of AICAR and Metformin on MM cell lines, patient samples 
and non-neoplastic cells. 
• Define the in vivo anti-cancer activity of AICAR and Metformin. 
 
• Examining myeloma resistance to bortezomib treatment using 2D-DIGE 
analysis.  
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Chapter 2 
Materials and Methods 
52 
 
2.1. Ultrapure Water 
Ultrapure water, (UHP) was used for the preparation of all media and solutions. This 
water was purified to a standard of 12-18 MΩ/cm resistance by a reverse osmosis 
system (Millipore Milli-RO 10 Plus, Elgastat UHP). A conductivity meter in the system 
continuously monitored the quality of the UHP. 
 
2.2. Glassware 
Some of the solutions utilized in the various stages of cell culture were stored in sterile 
glass bottles. These sterile bottles and other glassware required for cell culture-related 
applications were prepared as follows: glassware and lids were soaked in a 2% 
solution of RBS-25 (AGB Scientific) for 1 hour. After this time, they were cleaned and 
rinsed in tap water. The glassware was then washed in an industrial dishwasher, using 
Neodisher detergent and rinsed twice with UHP. The materials were finally sterilized by 
autoclaving as described in Section 2.3. 
 
2.3. Sterilisation Procedures 
All thermostable solutions, water and glassware were sterilized by autoclaving at 121oC 
for 20 minutes (mins) at 15 p.s.i.. Thermolabile solutions were filtered through 0.22µm 
sterile filters (Millipore, Millex-GV SLGV025BS).  
  
2.4. Preparation of Cell Culture Media 
Cell culture media Roswell Park Memorial Institute medium (RPMI)-1640, Dubelcco’s 
Modified Eagle Medium (DMEM) and Minimum Essential 
Medium Eagle, Alpha Modification (MEM Alpha) were purchased from Cellgro, 
Mediatech, Manassas, VA, USA. Complete media was prepared as follows: 5-10% 
foetal calf serum (FCS) (GIBCO/BRL, Gaithersburg, MD, USA), 100U/L of penicillin 
and 100ug/ml streptomycin were added to volumes of 50ml basal media as required. 
Complete media were maintained at 4oC for up to a maximum of 1 week.  
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2.5. Cells and Cell Culture 
All cell culture work was carried out in a class II laminar air-flow cabinet. Before and 
after use, the laminar air-flow cabinet was cleaned with 70% industrial methylated 
spirits (IMS). Any items brought into the cabinet were also cleaned with IMS. At any 
time, only one cell line was used in the laminar air-flow cabinet and upon completion of 
work with the cell line, the laminar air-flow cabinet was allowed to clear for at least 15 
mins so as to eliminate any possibility of cross-contamination between the various cell 
lines. Details pertaining to the cell lines used for the experiments in this thesis are 
provided in table 2.5.1. All cells are incubated at 37oC and in an atmosphere of 5% 
CO2. Cells were fed with fresh media or subcultured every 3 days in order to maintain 
active cell growth. 
 
2.5.1. Subculturing of cell lines 
For adherent cell lines 
1. The waste cell culture medium was removed from the tissue culture flask and 
discarded into a waste bottle containing bleach. The flask was then rinsed out with 
1ml of PBS to ensure the removal of any residual media. 
2. 5ml of trypsin (Cellgro) was then added to the flask, which was then incubated at 
37oC, 5% CO2 for approximately 5 mins, until all of the cells detached from the 
inside surface of the flask. 
3. The trypsin was deactivated by adding an equal volume of complete media to the 
flask. 
4. The cell suspension was removed from the flask and placed in a sterile tube 
(Falcon, BD, Franklin Lakes, NJ, USA) and centrifuged at 1000 xg for 5 minutes. 
5. The supernatant was then discarded from the tube and the pellet suspended in 5ml 
of complete medium. A cell count was performed and an aliquot of cells was used 
to reseed a new flask at the required density. 
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For suspension or semi-adherent cell lines 
1. A cell scraper (Corning, Lowell, MA, USA) was used to remove any attached cells 
on the inside surface of the flask. 
2. The cell suspension was removed from the flask and placed in a sterile tube 
(Falcon) and centrifuged at 1000 xg for 5 mins. 
3. The supernatant was then discarded from the tube and the pellet suspended in 5ml 
of complete medium. A cell count was performed and an aliquot of cells was used 
to reseed a new flask at the required density.  
 
 
 
Cell Line Media Source 
Myeloma Cell Line (MM)     
OCIMy5     
OPM2     
OPM1     
RPMI8226 and its sublines     
                               Dox40 RPMI-1640 with Dana Farber 
                                          MR20 
100 U/ml penicillin,  
Cancer 
Institute 
INA6 (plus IL-6 10ng.ml) 100 µg/ml streptomycin    
KMS11 and 10% FCS   
KMS34     
U266     
L363      
MM.1S and its subline     
                               MM.1R     
NCIH929     
SKMM1     
S6B45     
JJN3     
ARK   
  
ANBL6 and its subline (plus IL-6 
10ng/ml) 
                                        ANBL6-VR5 
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Thyroid Cancer cell line 
    
KAT18     
WRO DMEM with    
FRO 100 U/ml penicillin,  Dana Farber 
TT 
100 µg/ml streptomycin  Cancer 
Institute 
SW579 and 10% FCS   
DRO-81-1     
HRO-85-1     
Other Cancer Cell Line     
MDA-MB-231 (breast) 
DMEM with 100 U/ml penicillin, 
100 µg/ml Dana Farber 
PC3 (prostate) streptomycin and 10% FCS 
Cancer 
Institute 
DU145 (prostate)     
DLKP and its sublines (lung) DMEM with    
DLKP-A 10% FCS  NICB 
DLKP-SQ -Mitox     
A549 and its subline (lung) RPMI-1640 with  NICB 
A549-taxol 5% FCS   
NCI/Adr-res (ovarian) RPMI-1640 with 10% FCS NICB 
Non Malignant Cell Line     
HS-5 
DMEM with 100 U/ml penicillin, 
100 µg/ml Dana Farber 
THLE3 streptomycin and 10% FCS 
Cancer 
Institute 
Table 2.5.1 Source description and media requirements of cell lines used in 
experiments described in this thesis. 
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2.5.2. Assessment of cell number and viability 
1. Cells were trypsinised, pelleted and resuspended in 5ml media. An aliquot of the 
cell suspension was then added to trypan blue at a ratio of 1:10. 
2. The mixture was incubated for 3 mins at room temperature. A 10µl aliquot of the 
mixture was then applied to the chamber of a glass coverslip-enclosed 
haemocytometer. 
3. Cells in the 16 squares of the four grids of the chamber were counted. The average 
cell number per 16 squares was multiplied by 105 to determine the number of cells 
per ml in the original cell suspension. 
4. Non-viable cells stained blue, while viable cells excluded the trypan blue dye as 
their membrane remained intact and thus unstained. On this basis, % viability could 
be calculated and only viable cells were counted. 
 
2.5.3. Cryopreservation of cells 
1. Cells for cryopreservation were harvested in the log phase of growth and counted 
as described in Section 2.5.2. 
2. Cell pellets were resuspended in a suitable volume of serum. An equal volume of 
10% (final concentration) DMSO/serum solution was added dropwise to the cell 
suspension. This is done quickly to minimize the duration of exposure of the cells to 
DMSO toxicity. 
3. A total volume of 2ml (usually 2 x 105 to 5 x 106 cells/1 ml vial) of this suspension 
was then placed in cryovials (Nunc, Rochester, NY, USA). These vials were then 
placed in a isopropanol bath container (Nalgene, Cat#5100-0001, Rochester, NY, 
USA) that is subsequently cooled in a -80oC freezer. The container provided 
cooling at a rate of 1oC/minute. 
4. The next day, the frozen vials were then removed from the -80oC freezer and 
transferred to the liquid nitrogen-fill storage (-196oC). 
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2.5.4. Thawing of cryopreserved cells 
1. A volume of 9ml of fresh complete medium was added to a sterile 15ml tube 
(Falcon). The cryopreserved vials were removed from the liquid nitrogen and kept 
in dry ice until all of the apparatus for thawing cells were readied. The vials were 
then thawed rapidly in a water bath at 37oC. The cells were removed from the vials 
and transferred to the aliquoted media.  
2. The resulting cell suspension was centrifuged at 1000 xg for 5 mins. The 
supernatant was removed and the pellet resuspended in fresh culture medium.  
3. An assessment of cell viability on thawing was then carried out (Section 2.5.2). 
4. Thawed cells were then added to an appropriately sized tissue culture flask with a 
suitable volume of growth medium that contained twice the amount of FCS that the 
cells would normally need.  
 
2.5.5. Selection of primary myeloma cells using CD138 tagged micro-beads 
(Miltenyi Biotec; Bergisch Gladbach, Germany) as per manufacturer’s 
instructions. 
1. In brief, following consent, myeloma patient samples were collected in Lithium 
heparin tubes, the bone marrow sample was then Ficoll gradient separated. The 
bone marrow was layered over the Ficoll and centrifuged for 800 xg for 30 mins. 
The interface was removed and washed twice with PBS before resuspended in 
medium and cells counted.  
2. The cells were pelleted again and resuspended in buffer (PBS, 0.1%BSA, EDTA). 
There should be 107 cells/80µl Buffer. 20µl of beads/80µl buffer was added and 
incubated at 4oC for 20 minutes. 
3. After the incubation period, 5ml of buffer was added to the bead suspension and 
centrifuged at 1000 xg for 5 mins. Cells were resuspended in 1ml of buffer. 
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4. The columns were placed in the magnet and primed with 3ml of buffer. The cells 
were passed through each column and then washed with 3ml of buffer. The cells 
collected in the first pass were the CD138- cells. 
5. The columns were removed from the magnet and washed with 3ml of buffer. These 
cells collected were the CD138+ cells. The cells were then counted and plated at a 
density of 104 cells/well and cultured in RPMI-1640 U/ml penicillin, 100 μg/ml 
streptomycin, 10ng/ml IL6 (R&D systems, Minneapolis, MN) and 20% FBS.  
 
2.5.6. Mycoplasma analysis of cell lines using PlasmoTest Mycoplasma 
Detection test (InvivoGen, San Diego, CA, USA) as per manufacturer’s 
instructions.   
1. In brief, cells of interest were cultured without antibiotics two days prior to running 
the test. 500µL of cell culture was collected and transferred to a 1.5mL microtube. 
Sample was then heated at 100oC for 15 mins and allowed to cool to room 
temperature before addition to a 96 well plate. 
2. HEK-Blue 2 cells were prepared by removing the medium and washing the cells 
with PBS. The HEK-Blue 2 cells were removed from the flask by tapping it gently. 
The cells were diluted with HEK-Blue detection media to a concentration of 250,000 
cells/mL. 
3. 50µl of each sample and 200µl of HEK-Blue 2 cells were added to each well of a 96 
well plate. A 1X dilution of a positive and negative control were added. The plate 
was incubated overnight and read on a spectrophotometer at 620-655nm.  
4. All cell lines used in this thesis were screened for mycoplasma contamination as 
above and were determined to be mycoplasma-free. 
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2.5.7. Osteoclast differentiation as described by [125] 
In brief, peripheral blood mononuclear (PBMCs) were isolated as described in section 
2.5.5 using Ficoll gradient separation. The PBMCs were cultured in alpha-MEM media 
containing 10% FBS and Pen/Strep for 16 hrs to allow attachment. The non-adherent 
cells were removed, fresh media supplemented with macrophage colony stimulating 
factor (MCSF) (25 ng/mL; R&D Systems # 216-MC-005) and receptor activator of NF-
kappaB ligand (RANKL) (50 ng/mL; Peprotech #310-01), and cells were cultured for 3-
4 weeks to differentiate into mature osteoclasts. The culture medium was replaced 
twice weekly with alpha-MEM containing fresh MCSF and RANKL. At 3-4  weeks, cells 
were trypsinized, replated, and stained using the Acid Phosphatase, Leukocyte (TRAP) 
Kit (Sigma-Aldrich, St Louis, MO) to determine differentiation of osteoclasts.  
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2.6. Reagents 
Reagent 
MW 
(g/mol) Source Solubility 
2-deoxyglucose  164.16 Sigma-Aldrich Molecular grade H2O  
3-Bromopyruvate 166.96  Sigma-Aldrich Molecular grade H2O  
AICAR 258.23  
Toronto Research 
Chemicals Molecular grade H2O/ PBS* 
Bortezomib 384.24  
Millenium 
Pharmaceuticals  DMSO 
Compound C 399.5 Calbiochem/Merck DMSO 
Doxorubicin 543.52  Sigma-Aldrich PBS  
Elacridar  563.64 Sequoia Research DMSO  
Metformin  165.62 Sigma-Aldrich Molecular grade H2O  
Nutlin-3 581.5  
Cayman Chemical 
Company DMSO 
Phytohemagglutinin    Sigma-Aldrich PBS  
SN38 392.4   Sequoia Research DMSO  
Sulindac Sulphide 340.41 Sigma-Aldrich DMSO  
Verapamil  464.6  Sigma-Aldrich Molecular grade H2O  
ZVAD-FMK  467.5  Calbiochem DMSO  
Table 2.6 The reagents used in this thesis  
 
All reagents are kept at -20oC until use.  
* AICAR was reconstituted with molecular grade H2O for in vitro experiments and PBS 
for in vivo experiments 
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2.7. In vitro Toxicity Assays 
2.7.1. In vitro assay experimental procedure 
1. Cells in the exponential phase of growth were harvested as described in Section 
2.5.1. 
2. Cell suspension containing 1-x104 cells/ml was prepared in complete medium. 
Volumes of 100µl/well of this cell suspension were added to 96-well plates (Falcon) 
using a multichannel pipette. Plates were agitated gently in order to ensure even 
dispersion of cells over a given well. Cells were then incubated overnight at 37oC in 
5% CO2.  
3. Drug dilutions were prepared at 2X their final concentration for single agent 
treatment or 4X their final concentration for combination treatment in cell culture 
medium. Volumes of the drug dilutions (50µl or 100µl) were added to each well 
using a multichannel pipette. Plates were then mixed gently as above. 
4. Cells were incubated for a further 2 to 5 days (indicated in experiment) at 37oC in 
5% CO2. After this incubation period, control wells would have reached 
approximately 80-90% confluency. 
5. Assessment of cell survival in the presence of drug was determined by the acid 
phosphatase assay (Section 2.7.2), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrasodium bromide (MTT;Chemicon International, Temecula, CA) colorimetric 
survival assay (Section 2.7.3) or Cell Titre Glo assay (Promega, Madison, WI, USA) 
(Section 2.7.4). The concentration of the drug which caused 50% cell kill (IC50 of 
the drug) was determined from a plot of the % survival (relative to the control cells) 
versus cytotoxic drug concentration. 
 
2.7.2. Acid phosphatase assay as described by [267] 
1. Following the incubation period of 5 days, medium was removed from the plates. 
2. Each well on the plate was washed twice with 100µl of PBS. This was then 
removed and 100µl of freshly prepared phosphatase substrate (10mM p-
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nitrophenol phosphate (Sigma,104-0) in 0.1M sodium acetate (Sigma, S8625), 
0.1% triton X-100 (BDH, 30632), pH 5.5) was added to each well. 
3. The plates were then incubated in the dark at 37oC for 2 hours. 
4. The enzymatic reaction was stopped by the addition of 50µl of 1M NaOH.  
5. The plate was read in a dual beam plate reader at 405nm with a reference 
wavelength of 620nm. 
 
2.7.3. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) 
colorimetric survival assay 
1. Following the incubation period of 2-3 days, MTT 5mg/ml at a ratio of 1:10 to total 
volume in wells was added. The plate were then incubated the dark at 37oC for 4 
hours. After incubation period, the plates were centrifuged at 1000 xg for 5 mins 
and medium was removed from the plates. 
2. 100µl of DMSO was added to each well. The plates were then shaken to dissolve 
the crystals.   
3. The plate was read in a dual beam plate reader at 540nm with a reference 
wavelength of 690nm. 
 
2.7.4. Cell Titre Glo assay (Promega, Madison, WI, USA). 
The Cell Titer-Glo reagent was prepared as per manufacturer’s instructions. The 
prepared reagent was stored as aliquots in -20oC. CTG at a ratio of 1:10 to total 
volume in wells was added. The plates were then agitated briefly and incubated in the 
dark at 37oC for 30 mins. The plates were read using a Luminoskan luminometer 
(Labsystems, Franklin, MA). 
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2.7.5. Stromal cell and osteoclast coculture as described by [212] 
1. The luciferase (luc)-expressing cell line MM.1S-GFP/luc, NCI-H929-GFP/luc and 
JJN3-GFP/luc was generated by retroviral transduction with the pGC-gfp/luc vector 
(kind gift of C.G. Fathman, Stanford University). RPMI-Dox40-MCherry/luc was 
generated by retroviral transduction with the pFUW-Luc-Ch-puro vector. All these 
cell lines were used for co-culture experiments with the luc-negative human stromal 
line HS-5 and generated osteoclasts.  
2. Briefly, 50µl of 4x104/ml HS-5 stromal cells or 8x104/ml osteoclasts were plated in 
96-well plates and allowed to attach overnight. 50µl of 1x104/ml MM cells were then 
plated and treated for at the doses indicated.  
3. Following incubation, 2.5mg/ml of luciferin substrate (Xenogen Corp, Alameda, CA) 
at a ratio of 1:10 to total volume in wells was added.  The plates were then 
incubated in the dark at 37oC for 30 mins and the resulting bioluminescence signal 
was measured using a Luminoskan luminometer (Labsystems). 
 
2.8. Western Blotting 
2.8.1. Lysate preparation 
1. Cells were seeded at a density of 107 cells per 30mm tissue culture dish (Falcon). 
Treatment of cells and duration of exposure of cells to treatment were carried out 
as shown in the example below: 
All cells were plated at the same time using the same media. The longest time point 
was treated first and each subsequent treatment was carried out counting down to 
the shortest time point (see timeline). After the incubation period for the longest 
time point, all the cells were collected at the same time. This was to ensure that all 
the cells had the same environmental exposure for the same amount of time to 
reduce variability. 
 
Figure 2.8
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NP-40 lysis buffer 
50mM Tris-HCl pH=8.0 
120mM NaCl 
5mM EDTA 
1% Igepal (NP40) 
Complete TM Proteinase inhibitors (1 tablet in 50 ml) 
Phosphatase inhibitors from Calbiochem 
Table 2.8.1 NP-40 lysis buffer 
 
2.8.2. Protein quantification 
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 500-
0122) as follows: 
1. A 2mg/ml bovine serum albumin (BSA) solution (Bio-Rad, 500-0122) was prepared 
freshly in lysis buffer.  
2. A protein standard curve was prepared from the BSA stock with dilutions made in 
lysis buffer. 
3. The Bio-Rad reagent was diluted 1:5 in UHP water and filtered through Whatman 
paper before use. 
4. A 20µl volume of protein standard dilution or sample was added to 980µl of diluted 
dye reagent and the mixture vortexed. 
5. After 5 mins incubation, absorbance was assessed at 595nm. 
6. The concentration of the protein samples was determined from the plot of the 
absorbance at 595nm versus concentration of the protein standard. 
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2.8.3. Gel electrophoresis 
Proteins for analysis by Western blotting were resolved using precast 4-12% Bis Tris 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Invitrogen, Carlsbad, CA, USA).  
1. 20µg of protein was prepared for electrophoresis by mixing with high grade 
molecular water, sample buffer (Invitrogen) and reducing agent (Invitrogen) to a 
volume of 26µl. The samples were heated for 10 mins at 70oC and then loaded into 
the wells. 
2. 1X MOPS (Invitrogen, NuPage) running buffer and 500 µl of Antioxidant 
(Invitrogen) was added to gel apparatus.  
3. Gel was run at 200V until dye reached the bottom of the gel.  
  
2.8.4. Gel transfer 
1. PVDF membrane was activated with 100% methanol (MeOH) prior to transfer. Two 
pieces of thick blotting pads were soaked in transfer buffer (Boston Scientific, MA, 
USA) with 20% MeOH.  
2. A sandwich of blotting pad, membrane, gel and blotting pad was assembled on the 
semi-dry transfer apparatus. The gel was transferred at 0.4 amps for 1 hour. 
 
2.8.5. Membrane probing 
1. Membrane was blocked for 1 hour with 5% non fat milk in TBS-T. Primary antibody 
(Table 2.8) made at a dilution that had been optimally predetermined, was 
incubated with the membrane overnight at 4oC. 
2. The membrane was washed 3 times (5 mins each) with TBS-T and then incubated 
with the respective secondary horseradish peroxidase (HRP)-labelled antibody 
(Jackson ImmunoResearch (West Grove, PA) was added at 1:10,000 dilution for 1 
hour at room temperature. The membrane was then washed 5 times with TBS-T.  
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3. The protein was visualized using chemiluminescence (SuperSignal West Pico, 
Pierce, Rockford, IL). If enhanced signal was required, then SuperSignal West 
Femto IPierce, Rockford, IL) was used. The film used was from Kodak Scientific 
Imaging.  
 
2.8.6. Image acquisition 
The developed films with the protein bands were digitized using a flatbed scanner (HP 
scanjet 5500c, Hewlett-Packard, USA). The scanner operates in reflection mode and 
the films scanned at a resolution of 600 dpi (equals maximal physical, noninterpolated 
resolution). Adobe Photoshop software was used to crop the scanned films and all files 
were saved as TIFF files. 
 
2.8.7. Densitometry reading 
1. For analysis of the Western blot images, ImageJ 1.38 (Windows version of NIH 
Image, http://rsb.info.nih.gov/nih-image/), allows the measurement of density 
profiles and peak intensity (average OD of the band). Using ImageJ, the 
background correction was performed by measuring a rectangle (same size as the 
rectangle used to define the band) of developed film without any bands. To define 
the profiles, a rectangular box was defined in which the band was fitted as tight as 
possible. All bands were quantified using the same size rectangular box.  
2. The background OD was subtracted from all quantified bands. The bands of 
interest were expressed as a ratio to their individual loading control (usually 
GAPDH).  
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Table 2.8 List of primary antibodies used 
Antibody 
Molecular Weight 
(kDa) Company Name Catalogue Number 
10 Ab 
dilution 20 Antibody  
AMPKá  62 Cell Signaling 2793 1:1000 mouse 
AMPKá (phos Thr 172) 62 Cell Signaling 2535 1:1000 rabbit 
AMPKâ ½ 38, 34 Cell Signaling 4150 1:1000 rabbit 
Annexin A2 38 Abcam ab55771 1:5000 mouse 
A+U-rich element RNA binding factor 46 Abcam  1:2000 rabbit 
Caspase 3 17, 19, 35 Cell Signaling 9662 1:1000 rabbit 
cdc2 (cdk1) 34 Santa Cruz 8395 1:1000 mouse 
cdk4 30 Cell Signaling 2906 1:1000 mouse 
cdk6 36 Cell Signaling 3136 1:1000 mouse 
cyclin B1 60 Santa Cruz 245 1:1000 mouse 
cyclin D1 38 Santa Cruz 8396 1:500 mouse 
Endoplasmic reticulum protein 29 29 Abcam ab83073 1:1000 mouse 
FSCN1 55 Milipore MAB3582 1:1000 mouse 
Ferritin light chain 20 Abcam ab80617 1:10,000 mouse 
FUBP1 68 Abcam ab29732 1:1000 rabbit 
GAPDH - HRP conjugate 40 Abcam ab9482 1:10,000 none 
GSK3 (phos Ser21/9) 46, 51 Cell Signaling 9331S 1:1000 rabbit 
GSK3 á/â 47, 51 Santa Cruz 7291 1:1000 mouse 
hnRNP A1 39 Abcam ab4791 1:5000 rabbit 
hnRNP A2/B1 36 Cell Signaling 9304 1:1000 mouse 
hnRNP K 51 Abcam ab23644 1:1000 mouse 
Hsp70 72, 73 Cell Signaling 4872 1:1000 rabbit 
KHSRP 73 Abcam 83291 1:1000 rabbit 
MDM2 60, 90 Santa Cruz 965 1:1000 mouse 
Noxa 10 IMGENEX 349A 1:1000 mouse 
p53 53 Upstate Biotechnology 05-224 1:1000 mouse 
p70S6 Kinase 70, 85 Cell Signaling 9202 1:1000 rabbit 
p70S6K (phos Thr389) 70, 85 Cell Signaling 9205 1:1000 rabbit 
P-glycoprotein 170 Alexis Biochemicals 801-002  1:250 mouse 
PARP 24, 89, 116 Cell Signaling 9542 1:1000 rabbit 
Puma 18, 23 Cell Signaling 4976 1:1000 rabbit 
S6 ribosomal protein 32 Cell Signaling 2217 1:1000 rabbit 
S6 ribosomal protein  
(phos ser235/236) 32 Cell Signaling 2211 1:1000 rabbit 
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2.9. Two dimensional difference gel electrophoresis (2D-DIGE) 
2.9.1. Lysate preparation 
Lysate was prepared as detailed in Section 2.8.1. 
 
2.9.2. Sample preparation for 2-D Electrophoreses 
Cell lysates were subsequently precipitated prior to labelling using a 2-D Cleanup Kit 
(Biorad, Cat #163-2130) as per manufacturer’s instructions.  
1. In brief, 500µg of protein was mixed with 300µl of precipitating agent 1 in a 1.5ml 
eppendorf tube and incubated on ice for 15 mins. 300µl of precipitating agent 2 was 
then added, sample mixed well and centrifuged at (> 12,000 x g) for 5 minutes to 
form a pellet. The supernatant was discarded and 40 μl of wash reagent 1 was 
added on top of the pellet. 
2. The tube was centrifuged as before for 5 mins. After centrifugation, the wash was 
discarded and 25 μl of ultrapure water was added on top of the pellet.  
3. 1 ml of wash reagent 2 (which was prechilled at -20°C for at least 1 hr) and 5 μl of 
wash 2 additive was added to the tube. The tube was then incubated at -20°C for 
30 mins.  
4. After the incubation period, the tube was centrifuged at (> 12,000 x g) for 5 mins 
and the supernatant discarded. The pellet was air-dried briefly before being 
resuspended in ice-cold DIGE-lysis buffer. See Table 2.9.2 for recipe. 
5. Protein quantification was performed using the Quick Start Bradford Protein Assay 
as described in Section 2.8.3. 
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DIGE-lysis buffer   
20mM Tris 
7 M Urea 
2 M Thiourea 
4% CHAPS pH 8.5 
  
Table 2.9.2 DIGE-lysis buffer 
 
2.9.3. 2-D DIGE labelling: 
1. Samples were labelled with N-hydroxy succinimidyl ester-derivatives of the cyanine 
dyes Cy2, Cy3, and Cy5 following standard protocol.  
2. The CyDye DIGE Fluor minimal dye was reconstituted as follows. The dye was 
allowed to warm to room temperature before dimethylformamide (DMF) was added 
to give a stock concentration of 1 mM. 
3. Typically, 50 µg of lysate was minimally labelled with 200 pmol of either Cy3 or Cy5 
for comparison on the same 2D gel. Labelling reactions were performed on ice in 
the dark for 30 minutes and then quenched with a 50-fold molar excess of free 
lysine to dye for 10 minutes on ice. A pool of all samples was also prepared and 
labelled with Cy2 to be used as a standard on all gels to aid image matching and 
cross-gel statistical analysis. The Cy3 and Cy5 labelling reactions (50 µg of each) 
from each lysate were mixed and run on the same gels with an equal amount (50 
µg) of Cy2-labelled standard.  
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2.9.4. Casting 12.5% homogeneous polyacrylamide gels 
1. Low fluorescence glass plates without scratches were used to cast high quality 
gels. 
2. Displacing solution (see Table 2.9.4a) and acrylamide gel stock solution (see Table 
2.9.4b) was prepared. The gel caster was assembled as described in the Ettan 
DALT electrophoresis user manual.  
3. Gels were poured and allowed to set before use. They were then used on the same 
day for 2D gel electrophoresis. 
Reagents Final concentration 
1.5mM Tris pH 8.8 
Glycerol 
1% Bromophenol blue stock solution 
Make up to 100ml with distilled water 
375mM 
50% (v/v) 
0.002% (w/v) 
Table 2.9.4A Displacing solution 
 
Reagents Quantity for 900ml  
Acrylamide/PAGE 40% (w/v)  
PlusOne Methylenebisacrylamide 2% 
(w/v) 
Tris (1.5 M, pH 8.8) 
10% (w/v) SDS  
10% (v/v) TEMED  
10% (w/v) APS  
Make up to 900 ml with distilled water 
281.25ml 
150.3ml 
225ml 
9ml 
1.24ml 
9ml 
 
Table 2.9.4B Acrylamide gel stock solution (12.5%) 
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2.9.5. Protein separation by 2D gel electrophoresis  
1. Immobilized 24cm linear pH gradient (IPG) strips, pH 3-11NL, were rehydrated in 
rehydration buffer (see Table 2.9.5) overnight, according to the manufacturer’s 
guidelines.  
2. Isoelectric focusing was performed using an IPGphor apparatus (GE Healthcare) 
for a total of 40 kV/hs at 20°C, 50 mA. Strips were equilibrated for 20 minutes in 50 
mM Tris-HCl, pH 8.8, 6 M Urea, 30% (v/v) Glycerol, 1% (w/v) SDS containing 65 
mM DTT and then for 20 minutes in the same buffer containing 240 mM 
iodoacetamide.  
3. Equilibrated IPG strips were transferred onto 18x20-cm 12.5% uniform 
polyacrylamide gels (Section 2.9.4). Strips were overlaid with 0.5% (w/v) low 
melting point agarose in running buffer containing bromphenol blue.  
4. Gels were run using the Ettan Dalt 12 apparatus (GE Healthcare) at 2 Watt/gel for 
45 minutes, then 15W/gel at 10°C until the dye front had run off the bottom of the 
gels. 
 
2.9.6. Image acquisition and data analysis  
All of the gels were scanned using the Typhoon 9400 Variable Mode Imager (GE 
Healthcare) to generate gel images at the appropriate excitation and emission 
wavelengths from the Cy2-, Cy3- and Cy5-labeled samples. All gels were scanned at a 
100µm pixel resolution to generate a target maximum pixel value of 50,000 to 80,000. 
The resultant gel images were cropped using the Image Quant software tool and 
imported into Decyder 6.5 software. The biological variation analysis (BVA) module of 
Decyder 6.5 was used to compare the sensitive cells lines from the resistance cell lines 
before and after treatment to generate lists of differentially expressed proteins. 
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2.9.7. Spot digestion  
1 Preparative gels containing 400 μg of protein were fixed and then post stained 
with colloidal CBB stain (Sigma).  
2 The subsequent gels were scanned using the Typhoon 9400 Variable Mode 
Imager (GE Heatlhcare) to generate gel images at the appropriate excitation and 
emission wavelengths for the colloidal CBB stain. Preparative gel images were 
then matched to the Master gel image generated from the DIGE experiment. 
Spots of interest were selected and a pick list was generated and imported into 
the software of the Ettan Spot Picker robot (GE Healthcare).  
3 Gel plugs were placed into presiliconised microtitre plate and stored at 4°C until 
digestion. Tryptic digestions were performed using the Ettan Digestor robot (GE 
Healthcare).  
4 Excess liquid was removed from each plug, and washed for three cycles of 20 min 
using 50 mM NH4HCO3 in 50% methanol solution.  
5 The plugs were then washed for two cycles of 15 min using 70% ACN and left to 
air dry for 1 hour. Lyophilised sequencing grade trypsin (Promega) was 
reconstituted with 50 mM acetic acid as a stock solution and then diluted to a 
working solution with 40 mM NH4HCO3 in 10% ACN solution, to a concentration 
of 12.5 ng trypsin per mL.  
6 Samples were digested at 37°C overnight and were then extracted twice with 50% 
ACN and 0.1% TFA solution for 20 min each. All extracts were pooled and 
concentrated by SpeedVac (Thermo Scientific) for 50 min. Subsequently, dried 
peptides were resuspended in 20 μl of 0.1% TFA. 
 
 
 
 
 
 
74
2.9.8. Protein identification using MALDI ToF/ToF Mass spectrometry 
1 Dried peptides were resuspended in 10 μl of 0.1% TFA, desalted and 
concentrated using µ-C18 ZipTips. Samples were eluted form the µ-C18 ZipTips 
using 0.5 μl of 50% acetonitrile/0.1% TFA and supplemented with 0.5 μl of a 5 
mg/ml solution of recrystalised α-cyano-4-hydroxy-trans-cinnamic acid matrix 
(Laser Biolabs) in 50% acetonitrile/0.1% TFA prior to analysis.  
2 Samples were subsequently spotted onto a 384 spot MALDI sample plate (Applied 
Biosystems).  
3 MALDI mass spectra were generated using a 4800 TOF/TOF Proteomics Analyzer 
instrument (Applied Biosystems). An internal sample mix, Pep4 (Laser Biolabs) 
was also spotted onto target slides and used as an internal calibrant. All MS and 
MS/MS experiments were carried out in positive reflectron mode. Ten precursor 
ions for MS/MS were selected automatically on the basis of intensity from the MS 
spectra. The MS and MS/MS data were combined and searched against a number 
of databases using GPS Explorer software (Applied Biosystems) and a local 
MASCOT (Matrix Science) search engine for protein identification. A mass window 
of 20 ppm was set for database searching on all precursors.  
4 Full scan mass spectra were recorded in profile mode and tandem mass spectra in 
centroid mode. The peptides were identified using the information in the tandem 
mass spectra by searching against the SWISS PROT database using SEQUEST.  
 
2.9.9. Statistical analysis 
DIGE gels were exported into image analysis using BVA module of Decyder software 
(GE Healthcare) statistics and quantitation of protein expression was carried out. 
Following confirmation of appropriate spot detection, matching, normalisation and spot 
statistics were reviewed. Averages for each spot were compared by their normalised 
volume using one-way analysis of variance between groups (ANOVA) test. The 
normalised volume of a spot was compared in all the gels between each group. Spots 
that were found to be statistically significant (t-test ≤ 0.01) were isolated for further 
analysis. 
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2.10. Flow cytometry  
For all these assays, cells were passed through a flow cytometer (BD, FACS Canto II) 
and analyzed using FlowJo analysis software (Treestar; Ashland, OR). A minimum of 
10,000 events were collected for each sample for all flow cytometry experiments.  
 
2.10.1. Cell Cycle 
1x105 cells/ml was incubated in 12 well plates and treated for the time points indicated. 
After incubation, the cells were harvested and washed twice with PBS. The cells were 
incubated with 300µl of 0.2% Triton X-l00 and 1µl of 1mg/ml RNAse for 30 mins in the 
dark at 37oC to lyse the cells. Finally, the cells were stained with 20µl of 1mg/ml 
propodium iodide (PI) for 10 mins, according to published methods [268]. After staining 
period, the cells were place on ice and PI uptake was analyzed by flow cytometry. 
 
2.10.2. Annexin V-PI apoptosis assay 
For evaluation of apoptosis, cells were processed using an Annexin V-FITC / PI kit as 
per manufacturer’s instructions (Becton Dickinson Biosciences, San Jose, CA). Briefly, 
cell suspension of 1x105 cells/ml was treated at doses and time points indicated. After 
treatment period, cells were washed twice with ice-cold PBS and then resuspended in 
100µl 1X binding buffer. 5µl each of Annexin V and PI were added to the binding buffer 
and the mixture incubated for 15 mins in the dark at room temperature. After 
incubation, an additional 100µl of binding buffer was added to the mixture and 
analysed by flow cytometry as soon as possible. 
 
2.10.3. Mitochondrial membrane depolarization as described by [268] 
To evaluate the mitochondrial membrane potential (∆Ψ), JC-1 dye was used to 
measure red/green fluorescence ratio. Briefly, cell suspension of 1x105 cells/ml was 
treated at doses and time points indicated. After treatment period, cells were washed 
twice with PBS and incubated with 400µl of PBS/0.2% BSA containing a final 
concentration of 2µM JC-1 (Molecular Probes, Eugene, OR, USA) at 37oC for 30 min. 
After incubation period, cells were passed through a flow cytometer with 488nm 
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excitation using emission filters appropriate for Alexa Fluor 488 dye and R-
phycoerythrin. 
 
2.10.4. Cell Vue Claret for membrane labelling  
MM cell proliferation, both in the presence vs. absence of BMSCs, was evaluated using 
flow cytometry, by labelling MM cells with the CellVue® cell linker kit (Molecular 
Targeting Technologies, West Chester, PA, USA) as per manufacturer’s instructions.  
1. 2 X107/ml of cells in Diluent C was stained with 4µl/ml of CellVue® dye in a final 
staining volume of 2 ml. The cells were incubated for 2 minutes with periodic 
mixing.  
2. After incubation, an equal volume (2 ml) of serum was added to the sample 
followed by 1 min incubation.  
3. Cells were then washed three times in complete medium to ensure removal of 
unbound dye. MM cells were analysed for viability (>95%) before using in coculture 
experiment. 
4. Stained MM cells were plated on BMSCs (which were plated the day before) and 
treated at concentrations indicated.  
5. After incubation period, cells were analyzed on a flow cytometry at 655nm 
excitation. 
 
2.10.5. Functional drug accumulation assay 
1. The P-glycoprotein activity was determined by means of Rhodamine (Rho) 123 
(Sigma) efflux, as this fluorescent dye is a substrate for P-gp. HS-5 cells were 
seeded in 6-well plates at 1x104 cells and allowed to attach overnight. Then, RPMI-
Dox40 cells were seeded in the 6-well plates in the presence or absence of HS-5 
cells at a density of 1x104 cells and treated with various concentrations of 
bortezomib as described for 72 hours.  
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2. After the incubation period, the cells were washed and incubated with 200 ng/ml of 
Rho 123 dye in the presence or absence of the P-gp inhibitor, verapamil (VP) 
(Sigma) at a concentration of 10 μM for 30 min at 37˚C in 5% CO2.  
3. After washing, cells were incubated at 37˚C in 5% CO2 in a Rho 123-free medium 
supplemented with 10% FCS, in the presence or absence of VP. Aliquots were 
removed for analysis at 30, 60 and 90 min respectively.  
4. Prior to analysis, cells were centrifuged and washed twice in PBS before incubation 
for 20 mins at room temperature with P-gp monoclonal Ab (CD243/PE, Beckman 
Coulter, Cat# IM2370U) and 7AAD (Becton Dickinson, CA).  
5. Cells were used for the analysis of antigen expression and for studies of P-gp 
activity. Data acquisition and analysis were performed using a FACS Canto 
equipped with a 488-nm argon laser. To investigate dye efflux in RPMI-Dox40 cells, 
this cell subset was prelabelled with Cellvue dye (Section 2.10.4) to distinguish 
from stroma cells. The relative values were identified by dividing the median 
fluorescence intensity of each measurement by that of control cells. Rho 123 efflux 
was calculated based on the percentage of dye-effluxing cells in the VP-free 
experiment, compared with cells treated with VP. 
 
 
2.11. Relative quantification of selected transcripts in Multiple Myeloma 
cells  
MM1.S-GFP/luc cells were cultured for 24 hrs in the presence or absence of the BMSC 
line HS-5 and then sorted by FACS cell sorter (BD FACSAria™ cell sorter, Becton 
Dickinson, San Jose, CA). RNA was extracted with TRIZOL-LS (Invitrogen), further 
treated with DNase I, and purified with the RNeasy MinElute Cleanup Kit (Qiagen, 
Valencia, CA). Reverse transcription was accomplished with random hexamers and 
Superscript II, followed by incubation with RNase H (Invitrogen). Amplification reactions 
(25 μl, 100 ng cDNA/reaction) with Taqman FAM/MGB probes were performed in a 
7500 Real-Time PCR System (Applied Biosystems) for select p53-regulated 
transcripts. Relative quantification for each target vs a reference gene transcript 
(glucuronidase beta, GUSB) was assessed with the SDS v1.3 software (Applied 
Biosystems). For all assessments, the evaluation threshold was set at 0.3. The 
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treatment and FACS sorting of cells as well as the collection of RNA were done in 
Dana Farber Cancer Institute but the PCR and relative quantification of transctipts 
analysis were done in a collabotor laboratory in the Department of Pathology, 
School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.  
  
2.12. In vivo Study 
2.12.1. In vivo Study protocol 
1. The in vivo anti-MM activity of AICAR was evaluated in both subcutaneous 
xenograft model in which male (7-week old) SCID/CB17 mice (Jackson 
laboratories, Bar Harbor, ME) were housed and monitored in the Animal 
Research Facility of the Dana-Farber Cancer Institute.  
2. Mice were gamma-irradiated (150 rads) using Cs137 γ-irradiator source and 
(24 hrs post-irradiation) injected subcutaneously in between the shoulder 
blades with MM cells (1x106 / mouse) suspended in PBS. 
3. Subcutaneous MM tumours were documented within 7 days of injection by 
biphotonic imaging (Section 2.12.2). The reason to stratify the mice using 
biphotonic imaging rather than the traditional calliper measurement was 
because at this stage, the tumours were barely palpable and thus a more 
accurate measurement of tumour load could be made by biphotonic imaging 
rather than calliper measurement.  
4. Tumour bearing mice were then randomly assigned to two cohorts: group 1: 
control (PBS) administered by intraperitoneal (i.p.) injection; and group 2: 
(treatment) AICAR 600mg/kg i.p. The two groups started out with similar tumour 
burden (average).  Treatment was given every day.  
5. Tumour burden was monitored by calliper measurement. Tumour volume was 
calculated using this formula - 1/2(length × width2).  
6. Mice were also followed for changes in body weight, potential toxicity and signs 
of infection or paralysis. In accordance with institutional guidelines, mice were 
sacrificed by CO2 inhalation in the event of tumour size >2cm, paralysis or 
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major compromise in their quality of life. All experimental procedures and 
protocols had been approved by the Animal Care and Use Committee of the 
Dana-Farber Cancer Institute. OS (defined as time between initiation of 
treatment and sacrifice or death) was compared in control vs. AICAR-treated 
mice by Kaplan-Meier method. 
 
2.12.2. Biphotonic imaging 
Mice were injected with a ketamine (5mg/ml), xylazine (1.5mg/ml) and D-luciferin 
potassium salt (6mg/ml) mixture. The ketamine and xylazine acted as an anaesthetic 
for the mice. Mice were imaged using a Xenogen IVIS 100 series system. Briefly, each 
animal was serially imaged after i.p. injection of luciferin mixture (10 μl per 1g of mice). 
Photons were quantified using the software Living Image (Xenogen, Alameda, CA). 
 
2.13. Transcriptional signature of stroma-responsive genes and 
relationship with clinical outcome in bortezomib-treated Multiple Myeloma 
patients 
A transcriptional index of tumour cell response to nutlin-3 was identified, based on 
previously published studies of transcripts selectively downregulated by nutlin-3 
treatment in responsive but not in unresponsive, tumour lines [180]. The probes of that 
signature for U133plus2.0 oligonucleotide microarray chips were utilized to filter the 
log2-transformed and median centered gene expression dataset of tumour cells from 
bortezomib-treated MM patients enrolled in phase II and III clinical trials of this agent 
[40, 42, 269]. After the filtering, the transcriptional index of nutlin-3-suppressed genes 
was calculated as the average of the log2-transformed and median centered values for 
each probe of the signature. Patients were then classified as having low (bottom tertile 
of expression) vs. high (top 2 tertiles) expression of nutlin-3-suppressed genes and 
Kaplan-Meier survival analyses for progression-free and OS of bortezomib-treated 
patients were performed using SPSS 17.0. This analysis was kindly done by Dr 
Constantine Mitsiades, Dana Farber Cancer Institute. 
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2.14. Statistical Analysis 
In the cell viability assays, each experimental point was set up in triplicate wells and 
each assay was repeated identically and independently at least once. The final data 
were expressed as a percentage of the proliferation that took place in control wells 
where cells were not exposed to any drugs. IC50 values were determined for each 
experiment. To evaluate the differences across various experimental conditions, one-
way analysis of variance was performed, and post-hoc tests (Students t-test) served to 
evaluate differences between individual pairs of experimental conditions.  
The additive, synergistic or antagonistic nature of the interaction between two drug 
combinations was evaluated using the combination index method of Chou and Talalay 
[270, 271]. Calcusyn software (version 1.1, Biosoft, Cambridge, UK), which is based on 
this method and takes into account both potency [median dose (Dm) or IC50] and the 
shape of the dose-effect curve (the m value), was used to calculate the combination 
index (CI). With the use of the combination index, synergism is defined as a more-than-
expected additive effect and antagonism is defined as a less-than-expected additive 
effect. Thus, by this method, a combination index equal to 1 indicates an additive 
effect, a combination index less than 1 indicates synergy, and a combination index 
greater than 1 indicates antagonism. It has been proposed by the creators of CalcuSyn 
software that CIN values be interpreted as follows: antagonistic effect when CIN > 1.1, 
additive effect when CIN = 0.9–1.1, slight synergism when CIN = 0.7–0.9, synergism 
when CIN = 0.3–0.7, strong synergism when CIN = 0.1–0.3 and very strong synergism 
when CIN < 0.1. The combination index value can be calculated at different “effect 
levels” or “fraction affected” levels (e.g. at LC50 or LC99 [i.e. concentration lethal to 50% 
or 99% of the cells]) and may vary depending on the fractional effect level at which it is 
calculated. The mutually nonexclusive assumption was used in these analyses 
because agents tested in combinations were assumed to have different mechanisms of 
action. For combination index plots, the combination index is plotted as the log10 (CIN) 
versus fraction affected (defined as 1 − survival fraction), and the 95% confidence 
intervals (CIs) are shown where calculable, with the use of the algebraic approximation 
method of the CalcuSyn program. On these plots, additivity is defined as log10 (CIN) = 
0; very strong synergy is defined as log10 (CIN) = −1; and antagonism is defined as 
log10 (CIN) > 0. Although synergism and cytotoxicity may be related, a combination 
 
 
81
index that indicates strong synergy does not necessarily imply a high degree of 
absolute cytotoxicity (i.e. a small survival fraction); conversely, a combination index 
that indicates antagonism need not exclude a high degree of cytotoxicity. 
In the in vivo models, the OS of mice was evaluated with Kaplan-Meier survival 
analyses, and differences between the various cohorts of each experiment were 
assessed by log-rank tests. All values are expressed as mean plus or minus the 
standard deviation (SD) or standard error (SE) (where indicated). The statistical 
significance of differences between treatments was analyzed using the Student t test; 
differences were considered significant when P was less than or equal to .05. 
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3.1. MDR associated protein expression as a mechanism of resistance 
3.1.1. Introduction 
Chapter 3 
Results 
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MDR proteins, P-gp, BCRP and MRP-1 have been linked to resistance mechanism in 
MM and other cancers. Bortezomib is a novel agent in the arsenal of 
chemotherapeutics in MM and its interaction with the MDR proteins has not been well 
characterised. To study the effects of bortezomib on MDR transport effectively, we 
used several lung cancer cell lines that had been developed by our institute. These cell 
lines overexpress P-gp, MRP-1 and BCRP. The cell lines and the MDR proteins they 
express are outlined in Table 3.1.1.    
 
Cell Line   MDR proteins overexpressed References 
DLKP parental MRP-1 [272] 
DLKP-A subline P-gp [273] 
DLKP-
SQ/Mitox subline BCRP 
Created by Helena 
Joyce, NICB unpublished 
A549 parental MRP-1, BCRP [272], [274] 
A549-taxol subline P-gp [275] 
RPMI-8226 parental BCRP [274] 
RPMI-Dox40 subline P-gp [276] 
NCI-Adr/res parental P-gp [277] 
Table 3.1.1 The MDR protein expression in cell lines used. 
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We investigated the effect of bortezomib on P-gp-associated resistance. Using the lung 
cancer cell line, DLKP-A which overexpresses P-gp [273], we were able to 
demonstrate that bortezomib was a substrate of P-gp by showing synergistic 
cytotoxicity in the presence of a P-gp inhibitor; elacridar (Fig. 3.1.3.1). DLKP-A cells 
were incubated with 60nM of bortezomib alone or with elacridar, 0.25μM, for 24hours. 
This data suggests that bortezomib is a P-gp substrate.    
We wanted to demonstrate if this effect was sustained with a longer incubation period 
and if we were able to use lower drug doses. DLKP-A cells were incubated with 6nM 
and 12nM of bortezomib alone or with elacridar, 0.125μM, for 5 days. The single agent 
activity of bortezomib or elacridar alone was minimal and there was marked synergistic 
cytotoxicity seen (Fig. 3.1.3.2), indicating that bortezomib is likely a P-gp substrate.  
The dose of bortezomib used was 10 times lower in the longer incubation period and 
the synergistic cytotoxicity was just as marked, therefore, the decision was made to 
carry out further experiments using the longer incubation period.    
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As bortezomib is a P-gp substrate, we wanted to demonstrate if it has any inhibitory 
actions on P-gp activity. Using the same cell line that overexpresses P-gp, DLKP-A, we 
were able to demonstrate that bortezomib is not an effective P-gp inhibitor as 
synergistic cytotoxicity in the presence of a known P-gp substrate, doxorubicin, was 
only demonstrated at the highest dose of bortezomib, 12nM (Fig. 3.1.3.3). DLKP-A 
cells were incubated with 6nM and 12nM of bortezomib alone or with doxorubicin 
1μg/ml for 5 days.  
 
There have been reports that bortezomib and doxorubicin demonstrate synergistic 
cytotoxicity even in cell lines that are not known to express P-gp [44, 278]. Fig. 3.1.3.4 
showed that in MM1.S cell line which does not express P-gp, bortezomib and 
doxorubicin were mildly synergistic. This suggests that bortezomib and doxorubicin 
synergy may be due to other factors rather than through P-gp inhibition. 
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To investigate if the activity of bortezomib was affected by P-gp expression, we tested 
its single agent cytotoxicity in two cell lines that overexpress P-gp. DLKP-A, which 
expresses a high level of P-gp, and A549-taxol, which expresses a low level of P-gp. 
The activity of bortezomib was reduced in DLKP-A cell line compared to DLKP (Fig. 
3.1.3.5A) whereas there was no reduction in activity in A549-taxol cell line compared to 
its parental cell line (Fig 3.1.3.5B). The cells were incubated with a range of bortezomib 
concentration for 5 days. This data suggest that P-gp expression causes resistance to 
bortezomib treatment but a minimal level of overexpression may be necessary to see a 
bortezomib resistance effect. 
To determine that elacridar, as a single agent, had minimal single agent activity, we 
incubated DLKP-A cells with elacridar 0.25µM and 0.4µM for 5 days (Fig.3.1.3.6). After 
5 days incubation, the cell viability, as measured by alkaline phosphatase assay, 
revealed minimal single agent activity of elacridar. 
To ensure that the dose of elacridar used in this and subsequent experiments was 
adequate to inhibit the P-gp function. Fig. 3.1.3.7 demonstrates that 0.125µM of 
elacridar was adequate to inhibit P-gp activity as all doxorubicin doses showed 
synergistic activity with elacridar. The DLKP-A cell line was incubated with a range of 
doxorubicin doses alone or with elacridar 0.125μM for 5 days.  
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3.1.4. The effect of Bortezomib on MRP-1 associated resistance 
Sulindac was previously found to be an MRP-1 inhibitor by our group [272]. Sulindac 
sulphide is a more potent MRP-1 metabolite of sulindac. To explore any possible 
interactions between bortezomib and the other MDR proteins, we first investigated if 
bortezomib combined with sulindac had any synergistic cytotoxicity. We used the lung 
cancer cell line, DLKP which overexpresses MRP-1, and were able to demonstrate that 
bortezomib is not a MRP-1 substrate as synergistic cytotoxicity in the presence of 
sulindac sulphide was not demonstrated (Fig. 3.1.4). DLKP cells were incubated with 
2nM of bortezomib alone or with sulindac 1μM or 8 μM for 5 days. 
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3.1.5. The effect of Bortezomib on BCRP-associated resistance 
We next investigated the MDR protein, BCRP. Figure 3.1.5.1 demonstrates that 
bortezomib is not a BCRP substrate. DLKP-SQ/Mitox cells, which overexpresses 
BCRP [279], were incubated with 2nM and 4nM of bortezomib alone or in combination 
with elacridar, a known BCRP inhibitor, for 5 days. There was no demonstrable 
synergy seen.  
This conclusion is further supported by the lack of resistance seen in DLKP-SQ/Mitox 
cells compared to DLKP with treated with single agent bortezomib for 5 days (Fig. 
3.1.5.2). 
We also showed that bortezomib is not a BCRP inhibitor by using the same cell line 
DLKP-SQ/Mitox. Bortezomib 2nM and 4nM was combined with 10nM SN38  for 5 days. 
SN38 is a known BCRP substrate. Fig. 3.1.5.3 demonstrates that this combination 
yielded no synergistic cytotoxicity.     
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3.1.6. P-glycoprotein expression is associated with bortezomib’s efficacy 
as a P-glycoprotein substrate 
As seen in the Western blot analysis (Fig. 3.1.2), P-gp expression varies between the 
different cell lines. We have shown that the expression level of P-gp in each cell line 
corresponded to the degree of synergy seen when bortezomib was combined with 
elacridar, with cell lines that exhibited the highest levels of P-gp showing the most 
synergy when bortezomib was combined with elacridar (Fig. 3.1.6.1). Thus, DLKP-A 
and NCI-Adr/res had the most synergy when bortezomib was combined with elacridar, 
followed by RPMI-Dox40 and the least amount of synergy was seen with A549-taxol 
cells (Fig. 3.1.6.1). This synergy was confirmed by the calculated combination index 
(CIN) using Calcusyn software in Table 3.1.6.1. Synergy was indicated by a CIN value 
that <1. The lower the CIN value below 1, the higher the degree of synergism. The cell 
lines expression level of P-gp corresponds to the degree of synergy seen when 
bortezomib was combined with elacridar. 
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 Cell Lines 
Bortezomib 
(nM) 
Elacridar 
(ìM) 
Fraction 
affected CIN 
 
P-gp expression 
DLKP-A  12 0.125 0.888415 0.016 ++++ 
 A549-Taxol 4 0.4 0.0562078 1.369 + 
NCI-Adr/res 16 0.125 0.878684 0.356 +++ 
 RPMI-Dox40 2 0.125 0.140981 0.398 ++ 
Table 3.1.6.1 Combination index for the various cell lines when bortezomib is 
combined with elacridar demonstrating that the degree of synergy 
correspond to the P-gp expression levels. 
A representative combination dose for each cell line outlined in Figure 3.1.6.1 was 
calculated using Calcusyn software. CIN values were interpreted as follows: 
antagonistic effect when CIN > 1.1, additive effect when CIN = 0.9–1.1, slight 
synergism when CIN = 0.7–0.9, synergism when CIN = 0.3–0.7, strong synergism 
when CIN = 0.1–0.3, and very strong synergism when CIN < 0.1. The cell lines 
expression level of P-gp corresponds to the degree of synergy seen when bortezomib 
was combined with elacridar. 
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In the literature, P-gp mediated resistance can be induced after exposure to 
anthracyclines. We wanted to examine if this synergy between bortezomib and 
elacridar was preserved in the same cell line that had different P-gp levels. RPMI-
Dox40 was selected to be P-gp positive by exposure to doxorubicin. To ensure 
continued P-gp positivity, this cell line had to be cultured in the presence of low dose 
doxorubicin (400nM). In our cell line bank, we had a version of RPMI-Dox40 that was 
not cultured in doxorubicin and thus, the P-gp levels were lower. Using these two 
RPMI-Dox40s; RPMI-Dox40 with low P-gp (RPMI-Dox40 LP) and RPMI-Dox40 with 
high P-gp (RPMI-Dox40 HP), we wanted to address the question whether the level of 
P-gp affects synergy in the same cell line. As shown in Fig. 3.1.6.2., the RPMI-Dox40 
(HP) had an increase in resistance to both bortezomib and doxorubicin compared to 
the RPMI-Dox40 (LP). By using a phycoerythrin (PE) conjugated P-gp antibody, we 
demonstrated that RPMI-Dox40 (HP) has a higher expression of PE compared to 
RPMI-Dox40 (LP) as seen in Fig. 3.1.6.3 (A). This decrease in sensitivity to both drugs 
was associated with a higher P-gp expression in the RPMI-Dox40 (HP). The 
combination of elacridar and bortezomib demonstrated a stronger synergy in the RPMI-
Dox40 (HP) compared to RPMI-Dox40 (LP) (Fig. 3.1.6.3. B and C). The calculated CIN 
values were shown in Table 3.1.6.3. and showed similar results. Experiment was 
repeated in triplicate. 
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  Bortezomib (nM) Elacridar (ìM) Fraction affected CIN 
RPMI-Dox40 LP 8 0.125 0.67002 1.139 
  8 0.25 0.83151 0.965 
RPMI-Dox40 HP 8 0.125 0.85873 0.097 
  8 0.25 0.89529 0.082 
Table 3.1.6.3 Combination index for both RPMI-Dox40 versions when bortezomib 
is combined with elacridar demonstrating that the degree of 
synergy correspond to the P-gp expression levels. 
The combination dose for each cell line outlined in Figure 3.1.6.3 was calculated using 
Calcusyn software. CIN values were interpreted as follows: antagonistic effect when 
CIN > 1.1, additive effect when CIN = 0.9–1.1, slight synergism when CIN = 0.7–0.9, 
synergism when CIN = 0.3–0.7, strong synergism when CIN = 0.1–0.3, and very strong 
synergism when CIN < 0.1. RPMI-Dox40 HP which has a higher level of P-gp showed 
a greater degree of synergism when bortezomib was combined with elacridar. 
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3.1.7. Bortezomib and elacridar combination overcomes the stromal-
derived protection of Multiple Myeloma cells 
The role of the local microenvironment in MM growth, proliferation and survival is well 
established [60, 61]). For instance, it has been demonstrated that the response of MM 
to doxorubicin is attenuated by the presence of bone marrow stromal cells (BMSCs) 
[27, 62-64]. This is of clinical importance as P-gp expression also contributes to 
resistance to doxorubicin. On the other hand, bortezomib is known to be able to 
overcome the protective effects of the BMSCs. To ensure that the combination of 
bortezomib and elacridar might be useful clinically, we need to establish if the 
combination is able to have the same activity in the presence of BMSCs.  
Using the compartment-specific bioluminescence imaging (CS-BLI) approach, we were 
able to evaluate the MM cells when cocultured with another accessory cell. The MM 
cell line RPMI-Dox40-MCherry/luc was cultured in the presence of HS-5 stromal cells 
for 5 days, which triggered cell proliferation (Fig 3.1.7.1). Using the same technique, 
MM cells were treated with bortezomib and elacridar combination and cell viability 
measured at 5 days. Cell viability was normalized to each respective drug-free control 
and synergistic cytotoxicity was evident at all combination doses indicated (Fig. 
3.1.7.2). The presence of the stroma cells mildly attenuated the activity of the 
combination of bortezomib and elacridar but the synergistic cytotoxicity was still 
statistically significant.  
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3.1.8. Bortezomib affects P-glycoprotein expression and function 
 We next investigated the direct effect of bortezomib on P-gp expression. RPMI-Dox40 
cells and DLKP-A cells were treated with 4nM and 16nM of bortezomib respectively for 
0-72 h. P-gp expression was analyzed by Western blot and demonstrated a reduction 
in P-gp levels with bortezomib treatment by 24 h for both cell lines (Fig. 3.1.8.1).  
To determine if the P-gp function was similarly inhibited, we performed a rhodamine-
123 (Rh-123) efflux assay and analysed using flow cytometry. Verapamil was the P-gp 
inhibitor used in this study. Fig. 3.1.8.2 demonstrated that in this experiment, verapamil 
was able to inhibit P-gp function causing an accumulation of Rh-123 in the MM cells. 
RPMI-Dox40 cells were then treated with bortezomib 6, 10 and 15nM for 72 h. The 
cells were then washed and Rh-123 efflux assay performed. The results were 
expressed as the mean of the median Rh-123 fluorescence intensity as shown in Fig. 
3.1.8.3. RPMI-Dox40 cells treated with bortezomib demonstrated a reduction in Rh-123 
efflux indicating a reduction in P-gp function at all doses tested with maximal inhibition 
of Rh-123 efflux at 120 mins. We have shown that bortezomib treatment reduces the 
expression of P-gp and its function was also reduced as well.  
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3.1.9. P-glycoprotein expression and function is affected by the local 
microenvironment 
As the BM microenvironment confers protection to MM cells [280]  we hypothesized 
that P-gp expression might be upregulated when MM cells are cocultured with BMSCs, 
because doxorubicin  is known to be attenuated in the presence of BMSCs. We also 
wanted to examine if the reduction of P-gp expression and function when treated with 
bortezomib was affected by the BM microenvironment.  
To answer these two questions, we performed the next set of experiments. RPMI-
Dox40 cells were co-cultured with BMSCs and treated with bortezomib 4nM for up to 
48 h before collection of cell lysates. Contrary to our hypothesis, we saw a reduction in 
P-gp expression in the coculture setting when compared to MM cells alone in the 
control lysates (Fig 3.1.9.1). After treatment with bortezomib 4nM, the immunoblot 
demonstrated a reduction in P-gp levels in the MM cells that were cocultured, 
compared to MM cells alone, at each time point (Fig. 3.1.9.1). This data suggest that 
the attenuation of doxorubicin when cocultured with BMSCs is unrelated to P-gp 
expression in the MM cells, as the cocultured MM control cells did not show an 
increase in P-gp expression. Fig 3.1.9.1 further showed that with bortezomib treatment, 
the P-gp expression was reduced in the MM cells alone and further reduced when MM 
cells were cocultured with stroma. 
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Figure 3.1.9.1 P-gp expression is downregulated when MM cells are co-cultured 
with BMSCs 
RPMI-Dox40 cells were cocultured with BMSCs HS-5 and treated with bortezomib 4nM 
for up to 48 h. Immunoblot analysis demonstrated a reduction of P-gp expression in the 
MM cells that were co-cultured with BMSCs (see control cells). Upon treatment with 
bortezomib, as seen before, P-gp expression was reduced in the MM cells alone and 
further reduced in the MM cells cocultured with stroma. GAPDH levels were used as a 
loading control. 
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The finding that P-gp expression was reduced in MM cells when cocultured with stroma 
was unexpected. To determine if the P-gp mediated efflux, i.e. function was similarly 
reduced in MM cells when cocultured, a Rh-123 assay was performed. We used RPMI-
Dox40 cells and cocultured them with BMSCs HS-5. The RPMI-Dox40 cell population 
was distinguished from the stroma cells by prelabelling with CellVue claret dye. Fig. 
3.1.9.2 demonstrates clearly the two cell populations using flow cytometry. Fig. 3.1.9.3 
demonstrated that in this experiment, verapamil was able to inhibit P-gp function 
causing an accumulation of Rh-123 in the MM cells. 
RPMI-Dox40 cells were then cocultured with BMSCs HS-5 for 72 h. The cells were 
then washed and Rh-123 efflux assay performed. The results were expressed as the 
mean of the median Rh-123 fluorescence intensity as shown in Fig. 3.1.9.4. RPMI-
Dox40 cells cocultured with stroma demonstrated a reduction in Rh-123 efflux 
indicating a reduction in P-gp function at all doses tested with maximal inhibition of Rh-
123 efflux at 2 h.  
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To further probe the relationship between P-gp and the BM microenvironment, we 
looked at the BMSCs fraction after coculturing with P-gp-positive RPMI-Dox40 cells. 
BMSCs do not express P-gp (Fig. 3.1.9.5). A study by Levchenko et al. [281] showed 
that intercellular transfer of functional P-gp from P-gp-positive to P-gp-negative cells in 
vitro and in vivo was possible. The authors demonstrated that intercellular transfer of 
functional P-gp occurs between different tumour cell types and results in increased 
drug resistance both in vitro and in vivo. They also showed that P-gp transfer also 
occurs to putative components of tumour stroma, such as fibroblasts, raising the 
possibility that multidrug resistance could be conferred by resistant tumour cells to 
critical stromal elements within the tumour mass. Fig 3.1.9.6 demonstrated that the 
previously P-gp-negative BMSCs, became P-gp-positive after coculturing with RPMI-
Dox40 for 72 h. This suggests the transference of P-gp from the cancer cells to the 
normal tumour stroma as demonstrated by Levchenko [281]. However, this transferred 
P-gp does not appear to be functional as there was no extrusion of Rh-123 in the 
absence of verapamil (Fig. 3.1.9.7). The transference of P-gp from MM cells to BMSCs 
may account for the reduction in the P-gp expression in the MM cells after coculture.  
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3.2.  Investigation of p53 signalling perturbations in Multiple Myeloma 
resistance 
3.2.1. Introduction 
TP53 (the human gene that encodes p53) inactivating mutations affect 11 million 
cancer patients and another 11 million people have tumours in which the p53 pathway 
is partially abrogated through the inactivation of other signalling or effector components 
[282]. Therefore, the p53 pathway is a prime target to investigate resistance 
mechanisms and for new cancer drug development strategies, 
Bortezomib, a proteasome inhibitor, is known to stabilize and prevent the degradation 
of many tumour-suppressing and pro-apoptotic proteins, including p53. It has also 
been shown that DNA-damaging, p53-activating agents, such as doxorubicin and 
melphalan, can demonstrate synergistic toxicity with bortezomib [44]. In the meantime, 
nutlin-3, a Mdm2 inhibitor, can stabilise p53, increase its protein levels and activate the 
p53 apoptotic pathway. The added advantage of nutlin-3 is that it stabilises p53 levels 
without genotoxicity which would be of benefit to normal tissues.  
We hypothesized that nongenotoxic stabilisation of p53, caused by nutlin-3, through 
suppression of Mdm2-mediated p53 ubiquination, might synergise with accumulation of 
p53 caused by bortezomib through proteasome inhibition, leading to increased 
antitumour activity.   
 
3.2.2. Nutlin-3 activity in Multiple Myeloma and carcinoma cell lines  
A panel of MM and carcinoma cell lines were treated with nutlin-3. MM cell lines were 
sensitive to nutlin-3, with decreased cell viability upon treatment; representative results 
for MM1.S, MM1.R and OPM-2 are shown in Fig. 3.2.2A. Epithelial tumour cell lines 
such as thyroid carcinoma were also sensitive to nutlin-3, although typically to lesser 
extent than to MM cells (Fig. 3.2.2B).  
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  3.2.3. Nutlin-3 upregulates expression of p53-dependent targets 
As an Mdm2 inhibitor, nutlin-3 is able to upregulate expression of several p53-
dependent targets including Bax, PUMA, Noxa, p21, and Mdm2 itself (Table 3.2.3). 
Table 3.2.3 demonstrated the mRNA levels of p53-responsive transcripts after FRO 
cells were treated with bortezomib for 0, 24 and 48h.  
The cellular response to genotoxic stress that damages DNA includes cell cycle arrest, 
activation of DNA repair and, in the event of irreparable damage, induction of 
apoptosis. When cells encounter genotoxic stress, certain sensors for DNA lesions 
eventually stabilize and activate p53. p53 causes apoptotic cell death by induction of 
caspase-3 cleavage (Fig. 3.2.3A). However, the pro-apoptotic effect of nutlin-3 was 
partially attenuated by the pan-caspase inhibitor, ZVAD-FMK (Fig. 3.2.3B), suggesting 
that caspase activity is not the sole mechanism of nutlin-3-induced cell death. 
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2-∆∆CT  24h  48h  
BAK  4.2 2.2
BAX  5.5 2.7
PUMA (BBC3)  7.8  2.6 
BTG1  4.8 4.0 
CDKN1A (p21/CIP1/WAF1)  11.0 5.5 
CDKN1B (p27/KIP1)  10.8 3.3 
CDKN1C (p57/KIP2)  2.4 1.6
CDKN2B (p15/INK4B)  2.6 11.5 
GADD45B  4.3  1.9 
GADD45G  19.7 12.2
HSP90AA1  5.5 3.7 
HSP90B1 (GRP94)  7.0  5.7  
HSPCB (HSP90AB1)  4.0 2.9 
MDM2  7.5 2.6 
PMAIP1 (NOXA)  8.8  2.9  
VEGF  1.8 4.7
CD44, iso 1-4  0.6 0.6
Table 3.2.3  Nutlin-3 upregulated expression of several p53-dependent targets 
FRO cells were treated with nutlin-3 (30 μM) for 0, 24 and 48h. mRNAs levels for a 
panel of p53-responsive transcripts were then analyzed by qRT-PCR and expressed 
fold change relative to control cells (i.e., controls are assigned a value of 1 by 
definition). Experiment was performed with three technical replicates. 
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3.2.4. Differential effect of Nutlin-3 on activity of sublethal doses of 
bortezomib against Multiple Myeloma vs. epithelial tumour cells. 
We have previously reported that bortezomib increases p53 protein levels, at least in 
part due to inhibition of its proteasomal degradation, as well as upregulates p53 mRNA 
expression and induces p53 phosphorylation (Ser15) [278, 283]. We hypothesized that 
combined treatment with the Mdm2 ubiquitin ligase inhibitor nutlin-3 would enhance the 
p53-stabilizing activity and hence the pro-apoptotic effect of bortezomib. MM cell lines 
are highly sensitive to in vitro single-agent bortezomib, including MM.1S, MM.1R, KMS-
11, and NCI-H929 (Fig. 3.2.4.1); and combinations of sublethal concentrations of 
nutlin-3 and bortezomib demonstrated a lack of synergistic cytotoxicity. This is reflected 
in Table 3.2.4.1 which showed the calculated combination index of the combinations 
above; the CIN was >1 for all cell lines except for KMS11 showing a lack of synergy. 
Although according to Chou and Talalay [271], a CIN value of >1.1 is indicative of 
antagonism, it was obvious that in this combination tested there was no antagonism 
seen, more an additive effect. Thus, in this study, we have regarded a CIN >0.9, < 1.5 
as additive. For the KMS11 cell line, the two highest doses of nutlin-3 demonstrated 
synergy when combined with bortezomib (in italics).  
 
In contrast, in epithelial cancer cell lines with little single agent activity to bortezomib or 
nutlin-3 alone, there was synergistic cytotoxicity when bortezomib was combined with 
nutlin-3. Fig. 3.2.4.2 demonstrated the impressive synergy against epithelial tumour 
cell lines including thyroid, breast and prostate carcinomas with the corresponding CIN 
values in Table 3.2.4.2.  
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Fig. 3.2.4.1 Effect of combined Mdm2 and proteasome inhibition on Multiple 
Myeloma cells.  
Treatment of the MM cell lines MM1.S, MM1.R, KMS-11 and NCI-H929 with 
combinations of sublethal concentrations of nutlin-3 and bortezomib exhibited lack of 
synergistic cytotoxicity. Data from representative cell lines are shown: (A) MM1.S cells 
were treated for 48h with nutlin-3 (0-10 μM) in the absence (    ) or presence of 
bortezomib (    : 2 nM,     : 4 nM). ) (B) MM1.R cells were treated for 48h with nutlin-3 
(0-10 μM) in the absence (    ) or presence of bortezomib (    : 2 nM,   : 4 nM). (C) KMS-
11 cells were treated for 48h with nutlin-3 (0-16 μM) in the absence (    ) or presence of 
bortezomib (    : 2 nM,   : 4 nM). (D) NCI-H929 cells were treated for 48h with nutlin-3 
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(0-10 μM) in the absence (     ) or presence of bortezomib (    : 2 nM,   : 4 nM). Cell 
survival was quantified by MTT and expressed as a percentage (mean±SD) relative to 
vehicle-treated controls. 
 
Cell lines Nutlin (ìM) Bortezomib (nM) Fraction affected CIN 
  5 2 0.10489 2.402 
MM1.S 5 4 0.37611 1.307 
  10 2 0.279224 1.741 
  10 5 0.478134 1.618 
  5 2 0.542056 1.264 
MM1.R 5 4 0.786957 1.036 
  10 2 0.725317 1.072 
  10 4 0.850924 1.055 
  8 1 0.120185 1.726 
KMS11 8 2 0.23333 0.934 
  16 1 0.174699 0.885 
  16 2 0.490668 0.392 
  5 2 0.10489 2.376 
NCI-H929 5 4 0.37611 1.348 
  10 2 0.279224 1.75 
  10 4 0.478134 1.471 
Table 3.2.4.1 Combination index for Nutlin-3 plus Bortezomib in MM cells 
 
Using Calcusyn software, the combination index (CIN) for the combination of Nutlin-3 
and bortezomib was calculated. For the MM cells, the CIN was >1 for all cell lines 
except for KMS11 showing a lack of synergy. For the KMS11 cell line, the two highest 
doses of nutlin-3 demonstrated synergy when combined with bortezomib (in italics). 
(Synergy – CIN <0.9, additive effect - CIN >0.9, <1.5). 
 
 
133
 
Fig. 3.2.4.2 Effect of combined Mdm2 and proteasome inhibition on epithelial 
cancer cells.  
Nutlin-3 also potentiates the activity of sublethal concentrations of bortezomib against 
several types of epithelial tumours, including thyroid, breast and prostate carcinomas. 
(A). Anaplastic thyroid carcinoma FRO cells were treated for 48h with nutlin-3 (0-30 
μM) in the absence (    ) or presence (    ) of bortezomib (4 nM). (B) Follicular thyroid 
carcinoma WRO cells were treated for 48h with nutlin-3 (0-30 μM) in the absence (    ) 
or presence of bortezomib (    : 20 nM,    : 40 nM). (C) Prostate carcinoma DU145 cells 
were treated for 48h with nutlin-3 (0-30 μM) in the absence (    ) or presence (    ) of 
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bortezomib (5 nM). (D) Breast carcinoma MDA-MB-231met-LN cells were treated for 
48h with nutlin-3 (0-30 μM) in the absence (    ) or presence (    ) of bortezomib (5 nM). 
Cell survival was quantified by MTT and expressed as a percentage (mean±SD) 
relative to vehicle-treated controls. 
 
Cell lines Nutlin (ìM) Bortezomib (nM) Fraction affected CIN 
FRO 10 4 0.7004 0.549 
  20 4 0.8387 0.489 
  30 4 0.97456 0.179 
  20 20 0.47584 0.216 
WRO 20 40 0.50929 0.324 
  30 20 0.57572 0.091 
  30 40 0.79245 0.02 
DU145 20 5 0.44151 1.1 
  30 5 0.69336 0.92 
MDA-MB-231met-LN 20 5 0.30712 0.024 
  30 5 0.83598 0.001 
Table 3.2.4.2 Combination index for Nutlin-3 plus Bortezomib in epithelial cancer 
cells 
 
Using Calcusyn software, the combination index (CIN) for the combination of Nutlin-3 
and bortezomib was calculated. For the epithelial cancer cells, the CIN was <1 for all 
cell lines except for one dose in the DU145 cell line (in italics) demonstrating synergy. 
For the DU145 cell line, the combination of 20ìM Nutlin-3 and Bortezomib 5nM yielded 
an additive effect. (Synergy - CIN<0.9, additive effect - CIN >0.9, <1.5).   
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 3.2.5. Nutlin-3 enhances the activation of the p53 apoptotic pathway by 
sublethal concentrations of bortezomib in epithelial carcinoma cell lines, but 
not in bortezomib-sensitive Multiple Myeloma cells. 
We next investigated the mechanism for the differential sensitivity of MM vs. epithelial 
cell lines to the combination of bortezomib with nutlin-3. Western blot analysis of 
MM1.S cells treated with this combination for 8h or 24h demonstrated no evidence of 
synergistic activation of p53 pathway and apoptosis mediators (Fig. 3.2.5), consistent 
with the lack of enhanced killing effect. In contrast, FRO cells treated with sublethal 
concentrations of nutlin-3 and bortezomib for 8h or 24h revealed synergistic activation 
of p53 pathway and apoptosis, associated with upregulation in p53, Hdm2, Noxa, and 
PUMA expression, as well as enhanced cleavage of PARP and caspase-3 (Fig. 3.2.5), 
consistent with the synergistic activity of this drug combination.  
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with bortezomib (4nM) resulted in synergistic activation of p53 pathway and apoptosis 
in FRO cells. 
 
3.2.6. The impact of bone marrow stroma cells coculture on p53 activity 
and sensitivity to nutlin-3 in Multiple Myeloma cells. 
BMSCs confer a protective effect on MM cells against several conventional pro-
apoptotic agents, such as dexamethasone or cytotoxic chemotherapy [27]. We 
therefore next investigated the effect of co-culture with BMSCs to the activation of the 
p53 pathway in MM cells and to sensitivity to nutlin-3. Human MM1.S-GFP/luc cells 
were co-cultured with HS-5 BMSCs for 24 hours and separated using a FACS cell 
sorter. Quantitative RT-PCR of MM1S cells co-cultured with BMSCs demonstrated 
decreased expression of p53 and gene transcripts known to be induced by p53 
including Hdm2 [284], Bax [285], Noxa [286], PUMA [287], BTG1, DAPK1 [288], 
GADD45B, ID2, Jun, Plk1, and Plk2 [289] (Fig. 3.2.6.1). These results suggest that co-
culture with BMSCs triggers downregulation of the p53 pathway in MM cells, which can 
contribute to resistance to apoptosis.  
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Fig 3.2.6.1 Coculture with BMSCs suppress levels of p53 responsive transcripts 
 
MM.1S-GFP/luc cells were cultured for 24 h in the presence or absence of BMSCs line 
HS-5, and then sorted by FACS. Levels of mRNAs for a panel of p53-responsive 
transcripts were quantified by qRT-PCR and expressed relative to the respective levels 
in control cells. Co-culture with BMSCs suppressed levels of these p53-responsive 
transcripts. Experiment was performed with three technical replicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
139
We next assessed the impact of co-culture with BMSCs on MM cell sensitivity to nutlin-
3. Using the compartment-specific bioluminescence imaging (CS-BLI) approach, we 
found that MM1.SGFP/luc cells were less sensitive to the pro-apoptotic effect of nutlin-
3 in the presence of HS-5 BMSCs (Fig. 3.2.6.2). This may have implications in the 
single agent treatment of nutlin-3 in MM. 
We next wanted to assess if the downstream effectors of p53 would be upregulated 
upon nutlin-3 treatment in the presence of stroma, since its activity was attenuated. 
Importantly, however, treatment with nutlin-3 was able to induce the expression of 
Hdm2 (Fig. 3.2.6.3A) and PUMA (Fig. 3.2.6.3B) even in the presence of BMSCs. This 
implies that the drug is still having an effect although somewhat blunted. 
 
 
 
 
 
 
 
 
 
  
Fig. 3.2.6.
MM1.S-GF
BMSCs. 
biolumines
SD) relativ
pro-apopto
 
 
2 Nutlin
P/luc cells
MM cell 
cence ima
e to vehicl
tic effect o
-3 cocultur
 were treate
viability 
ging (CS-B
e-treated co
f nutlin-3 on
140
ed with BM
d with nutl
was asse
LI) approac
ntrols. Coc
 MM1S. Ex
SCs in MM
in-3 for 48 h
ssed usi
h and expr
ulture with 
periment w
 cells. 
, in the pre
ng the c
essed as a 
BMSCs pa
as performe
sence or a
ompartmen
percentage
rtially atten
d in triplica
 
bsence of 
t-specific 
 (mean ± 
uated the 
te. 
 
 
 
141
 
Fig. 3.2.6.3 Nutlin-3 is able to induce expression of Hdm2 and PUMA even in the 
presence of BMSCs in MM cells. 
The effect of nutlin-3, in the presence or absence of BMSC, on the expression of Hdm2 
(A) and PUMA (B) in MM cells. MM.1S-GFP/luc cells were treated with nutlin-3 (8 μM) 
for 0, 24 or 48 hours in the presence or absence of the BMSC line HS-5, and then 
sorted by FACS. Levels of Hdm2 and PUMA mRNA were quantified by qRT-PCR and 
expressed as a ratio relative to respective levels in control cells.  Experiment was 
performed with three technical replicates. 
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3.2.7. Impact of bone marrow stroma cells on p53 activity and sensitivity 
to nutlin-3 in epithelial carcinoma cells  
As noted above, the combination of nutlin-3 with bortezomib mediates additive 
cytotoxicity against MM cells, but triggers synergistic cytotoxicity against epithelial 
carcinoma cell lines. We investigated whether this latter effect persists in the presence 
of BMSC. This is important to evaluate as other cancer types also metastasise to the 
BM. Using the compartment-specific bioluminescence imaging (CS-BLI) approach, we 
evaluated the impact of BSMCs on the effect of the combination of nutlin-3 with 
bortezomib on MDA-MB-231 met-luc-neo cells stably transfected with a luciferase 
vector. Coculture with BSMCs did not protect against the synergistic pro-apoptotic 
effect of the combination of nutlin-3 with bortezomib in this epithelial carcinoma model 
(Fig. 3.2.7). These data suggest that the enhanced activity of nutlin-3 combined with 
bortezomib against epithelial models of cancer is unlikely to be inhibited by 
microenvironmental interactions.  
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Fig. 3.2.7 Impact of coculture with BMSCs on effect of combined Hdm2 and 
proteasome inhibition.  
MDA-MB-231met-LN cells stably expressing luciferase were treated with nutlin-3 (0, 20 
or 30 μM) and bortezomib (5 nM) for 48 hrs, in the presence or absence of HS-5 
stromal cells. MDA-MB-231met-LN viability was assessed using the compartment-
specific bioluminescence imaging (CS-BLI) approach. Synergistic cytotoxicity of the 
combination of nutlin-3 and bortezomib persisted despite coculture with BMSCs. 
Experiment was performed in triplicate. 
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  3.2.8. Transcriptional signature of nutlin-3 suppressed genes correlates 
with clinical outcome in bortezomib treated Multiple Myeloma patients. 
To probe the clinical relevance of molecular sequelae triggered by nutlin-3, we next 
evaluated whether the transcriptional signature of tumour cell response to nutlin-3 
treatment was enriched in genes which may correlate with clinical outcome. To test this 
hypothesis, a previously reported signature of genes suppressed in tumour cells by 
nutlin-3 treatment [180] was used to classify bortezomib-treated MM patients enrolled 
in phase II SUMMIT and phase III APEX trials into cohorts with high vs. low expression 
of nutlin-3-suppressed genes. Bortezomib-treated patients who had, at baseline, high 
expression of nutlin-3-suppressed genes had significantly shorter progression-free 
survival (panel A, p=0.001, log-rank test) and OS (panel B, p=0.002, log-rank test) 
compared to those with low expression levels (Fig 3.2.8). The clinical significance of 
this finding is discussed further in Section 4.2.7. 
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Fig. 3.2.8 A transcriptional signature of nutlin-responsive genes correlates with 
clinical outcome in bortezomib-treated MM patients.  
Gene expression data were analyzed from tumour cells of bortezomib-treated MM 
patients (relapsed and/or refractory) enrolled in the phase II SUMMIT and phase III 
APEX trials. A previously reported signature of genes suppressed in tumour cells by 
nutlin-3 treatment was used to classify bortezomib-treated patients having high vs. low 
expression of nutlin-3-suppressed genes. Bortezomib-treated patients who had 
baseline high expression of nutlin-3-suppressed genes had significantly shorter 
progression-free (panel A, p=0.001, log-rank test) and OS (panel B, p=0.002, log-rank 
test) compared to those with low expression levels. 
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3.2.9. Nutlin-3 and bortezomib activity is independent of p53 . 
There have been studies showing that nutlin-3 have activity in p53-deleted or p53-
mutated cells, Nutlins are able to activate alternative transcription factors, in particular 
E2F1 [181, 182]. E2F1 can induce proliferation or apoptosis depending on the cell 
context and depending on the simultaneous activation of the Akt-prosurvival pathway 
[183]. Another study has demonstrated that nutlin-3 is able to induce apoptosis in p53-
null cells through activation of p73 [184]. p73 is a homolog of p53 and is able to 
transactivate proapoptotic genes and induce cell death. It is also regulated by Mdm2. 
These two targets make nutlin a viable therapeutic option even when p53 is deleted or 
mutated. 
To demonstrate if the synergy between bortezomib and nutlin-3 persists if p53 is not 
involved, we utilised two p53 mutated cell lines; OPM2 and ANBL6. Fig. 3.2.9.1 
showed that in both these cell lines, there was synergistic cytotoxicity in the 
combination except for in the lower dose of bortezomib 2nM used in cell line OPM2. 
Calculated combination index using Calcusyn software showed in Table 3.2.9. Of note, 
these two cell lines are MM cell lines.  
We then wanted to study if the combination of bortezomib and nutlin-3 would persist in 
a bortezomib-resistant cell line. Using the subline of ANBL6 which developed 
bortezomib resistance in vitro with repeated exposure to bortezomib 5nM; ANBL6-VR5 
(courtesy of Dr Robert Orlowski, MD Anderson Cancer Center); we showed that the 
combination of bortezomib and nutlin-3 was effective in producing synergy as well (Fig. 
3.2.9.2A). Table 3.2.9 demonstrated the combination index of the nutlin/bortezomib 
calculated using Calcusyn. Fig 3.2.9.2B demonstrated the attenuation of bortezomib in 
the resistant cell line ANBL6-VR5 compared to its parental control. 
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Cell lines Nutlin (ìM) Bortezomib (nM) Fraction affected CIN 
  8 2 0.17389 1.362 
  8 5 0.78176 0.94 
OPM2 10 2 0.282 1.168 
  10 5 0.82063 0.897 
  12 2 0.323 1.177 
  12 5 0.83962 0.884 
  10 1.5 0.04951 0.971 
ANBL6 10 3 0.76244 0.904 
  20 1.5 0.44693 0.651 
  20 3 0.82083 0.896 
  10 6 0.04933 1.035 
ANBL6-VR5 10 12 0.2169 0.787 
  20 6 0.24912 0.807 
  20 12 0.58065 0.61 
 
Table 3.2.9 Combination index for Nutlin-3 plus Bortezomib in p53 mutated cell 
lines 
 
Using Calcusyn software, the combination index (CIN) for the combination of Nutlin-3 
and bortezomib was calculated. For the p53 mutated cell lines, the CIN was <1 for all 
cell lines except for the combination of nutlin with bortezomib 2nM in OPM2 cell line, 
demonstrating synergy. (Synergy - CIN<0.9, additive effect - CIN >0.9).   
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3.3.  Activation of AMP-kinase pathway as an alternative to overcome drug 
resistance in Multiple Myeloma 
3.3.1. Introduction 
Several groups have reported that activation of AMPK suppresses mTOR signalling by 
growth factors and amino acids [198-200]. Activation of AMPK by metformin, AICAR or 
thiazolidinediones or expression of constitutively active mutants has been shown to 
cause apoptosis or cell cycle arrest of various cancer cells.  
PI3K-Akt-mTOR signalling is important in MM. In fact, perifosine, an Akt inhibitor, is 
already in clinical trials after having good preclinical activity in MM [211]. AMPK 
activation as an anticancer strategy has only begun to be studied but current preclinical 
data is encouraging. We are interested in this pathway as a novel and perhaps 
alternative pathway to overcome drug resistance in MM.  
 
3.3.2. Activity of Metformin on cancer cell lines 
A panel of MM and solid tumour cell lines were treated with metformin (0.1-5mM) for a 
period of 96 h, and viability was assessed by MTT colorimetric survival assay (Fig. 
3.3.2.1). MM cell lines were sensitive to metformin, with comparable or decreased 
sensitivity seen in solid tumour cell lines. 
BM microenvironmental factors confer a protective effect on MM cells against several 
conventional anti-MM agents, such as dexamethasone or cytotoxic chemotherapy [44]. 
Therefore, we next investigated the effect of coculture with BMSCs and differentiated 
osteoclasts on the sensitivity of metformin. Three MM cell lines, NCI-H929-GFP/luc, 
JJN3-GFP/luc and MM.1S-GFP/luc cells were treated with metformin, in the presence 
or absence of HS-5 stromal cells or differentiated osteoclasts (Fig. 3.3.2.2), and the 
viability assessed by compartment-specific bioluminescence imaging (CS-BLI). 
Metformin was as or more active in the presence of stromal cells or osteoclasts across 
the range of concentrations tested.  
Fig. 3.3.2.3 demonstrated the signalling pathways that were activated by metformin 
treatment. RPMI8226 cells treated with metformin 10mM demonstrated activation of 
phospho-AMPK (Thr 172) and AMPK with subsequent downregulation of phospho-
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p70S6k (Thr 389), p70S6k, phospho-S6 ribosomal (Ser 235/236) and S6 ribosomal 
protein as early as 8hr after treatment (Fig. 3.3.2.3). Cell cycle proteins (Cyclin D1, 
Cdk4, Cyclin B1 and Cdc2) were also downregulated by metformin treatment (Fig. 
3.3.2.3). By 8 hrs of treatment, metformin was able to decrease the levels of Cyclin D1. 
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3.3.3. Activity of AICAR on cancer cell lines 
We next evaluated another AMPK activator, AICAR. A panel of MM and solid tumour 
cell lines were treated with AICAR (20-1000μM) for a period of 96 hrs, and viability was 
assessed by MTT colorimetric survival assay (Fig. 3.3.3.1). MM cell lines were 
sensitive to AICAR with decreased cell viability upon treatment. Solid tumour cell lines 
were also sensitive to AICAR, although typically to a lesser extent than MM cells.  
As metformin was able to overcome the BM microenvironmental effects, we wanted to 
investigate if AICAR was also able to overcome stromal and osteoclast-derived 
protection of MM cells. NCI-H929-GFP/luc, JJN3-GFP/luc and MM.1S-GFP/luc cells 
were treated with AICAR, in the presence or absence of HS-5 stromal cells or 
differentiated osteoclasts (Fig. 3.3.3.2), and the viability assessed by compartment-
specific bioluminescence imaging (CS-BLI). AICAR was more active in the presence of 
stromal cells or osteoclasts across the range of concentrations tested.  
The signalling pathway of AICAR was examined next. RPMI8226 cells treated with 
150μM AICAR was able to activated AMPK with an increase in phospho-AMPK (Thr 
172) as shown on Western blot (Fig. 3.3.3.3). There was also a corresponding 
decrease of phospho-GSK3α/β (Ser 21/9), GSK3α/β, phospho-p70S6k (Thr 389), 
phospho-S6 ribosomal (Ser 235/236) and S6 ribosomal protein (Fig. 3.3.3.3). Cell cycle 
proteins such as Cyclin D1, Cdk4, and Cdc2 were also downregulated by AICAR 
treatment. In fact, by 16 hrs, Cyclin D1 levels were no longer detectable. However, 
Cyclin B1 showed a late increase with AICAR treatment. 
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3.3.4. Activity of AICAR and Metformin on patient samples 
Bone marrow aspirates from MM patients were processed using Miltenyi anti-CD138 
microbeads for purification of MM cells. These patient tumour cells were treated with 
increasing doses of AICAR for 96h and viability assessed. AICAR induced cytotoxicity 
in 3 / 4 MM patient samples, with IC50 values <500 μM (Fig. 3.3.4A). Metformin activity 
on patient samples was also tested. Only 1 / 3 MM patient showed a response to 
metformin. This data suggest that AICAR may be the more potent and broadly active 
anti-MM agent of the two.  
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3.3.5. Activity of AICAR and Metformin on non-neoplastic cells 
We next evaluated the impact of AICAR on non-neoplastic tissues. Non-malignant cells 
were also treated with AICAR, and their viability was assessed by MTT assay. The 
BMSC line HS-5 and the immortalized hepatocyte cell line THLE-3 were shown to be 
insensitive to AICAR with calculated EC50 values >1000μM (Fig. 3.3.5.1). In addition, 
PBMCs from healthy donors were PHA-stimulated to induce their cycling and 
proliferation, which resulted in a 2.7-5.7 fold increase in the number of viable cells 
following 96 h of culture. Moreover, the percentage of viable PBMCs was >50% AICAR 
treatment, suggesting a favourable therapeutic index (Fig. 3.3.5.2). 
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  3.3.6 The AMPK inhibitor Compound C does not attenuate the direct 
anticancer activity of metformin 
Both metformin (indirect AMPK activator) and AICAR (direct AMPK activator) have 
demonstrated anticancer activity in our in vitro models. We wanted to examine the 
impact of AMPK inhibition on the anticancer activity of metformin. Compound C is 
known to function as an ATP-competitive inhibitor of AMPK. We found that the AMPK 
inhibitor compound C did not attenuate the anticancer activity of metformin against 
RPMI8226, MM1.S and FRO cells (Fig. 3.3.6.1). These results suggest that, while 
direct AMPK activation (by AICAR) can have anticancer activity, metformin itself can 
also promote AMPK-independent anticancer effects. 
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3.3.7. Analysis of effect of AICAR and Metformin on induction of 
apoptosis and mitochondrial membrane depolarization in Multiple Myeloma 
cells 
Western blot analysis of RPMI8226 cells treated with 150 μM AICAR revealed 
molecular signalling events consistent with initiation of cell death. By 24 hrs of AICAR 
treatment, apoptosis was associated with cleavage of caspase 3 and PARP (Fig. 
3.3.7.1).  
We next carried out Annexin V/PI staining on MM cells exposed to AICAR and 
metformin. RPMI8226 cells were exposed to 150 μM of AICAR and 2mM of metformin 
for 0-96 hrs. Cells were collected, washed, stained for Annexin V and propodium iodide 
(PI), and analyzed using flow cytometry. Annexin V detects apoptotic events whilst PI 
detects necrotic events. Exposure to AICAR resulted in time-dependent increases in 
only Annexin V positive events, with increased Annexin V+, PI+ events at later time 
points, indicating apoptotic cell death of RPMI8226 cells (Fig. 3.3.7.2). However, 
treatment with metformin 2mM showed mild increase in non-viable cells but not 
through apoptosis (Fig. 3.3.7.3). These data suggest that AICAR is more effective in 
killing MM cells as they have the added advantage of being able to cause cell death 
through the apoptosis mechanism, whereas metformin seem to act in a cytostatic 
manner as there is decrease in viability (Section 3.3.2) but little apoptosis or even 
necrosis seen in Annexin V/PI staining. The amount of necrotic cell death with Annexin 
V/PI staining was 26% (Fig. 3.3.7.3) vs. 54% calculated cell death seen with MTT (Fig. 
3.3.7.4). 
The JC-1 assay was utilised to study the mitochondrial membrane potential. JC-1 dye 
exhibits potential-dependent accumulation in the mitochondria, indicated by a 
fluorescence emission shift from green (~529nm) to red (~590nm). The green 
fluorescence measures JC-1 monomers and the red fluorescence measures JC-1 
aggregates. Consequently, mitochondrial depolarization is indicated by a decrease in 
the red/green fluorescence intensity ratio caused by accumulation of the monomers. 
RPMI8226 cells were exposed to 150 μM of AICAR (Fig. 3.3.7.5) and 2mM of 
metformin (Fig. 3.3.7.6), stained with JC-1 dye and analyzed using flow cytometry. 
AICAR, but not metformin, caused mitochondrial membrane depolarization by 24 hrs. 
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3.3.8.  AICAR-induced apoptosis is attenuated by overexpression of Bcl-2 
and enhanced by activation of the Akt pathway 
Akt and Bcl-2 overexpression are known hallmarks of cancer activation. The Akt 
pathway is of interest in this study as both metformin and AICAR are AMPK activators, 
which affect events upstream of Akt. We wanted to examine what effects both these 
agents had on cells overexpressing Akt. Meanwhile, Bcl-2 stabilizes mitochondrial 
membrane potential and inhibits mitochondrial-mediated apoptosis. Having 
demonstrated that AICAR can potently induce mitochondrial membrane depolarization 
and apoptosis, we next examined the impact of the modulation of apoptotic pathways 
by Bcl-2 on AICAR-induced apoptosis.  
Stable overexpression of Bcl-2 attenuated the anticancer effect of AICAR (Fig. 
3.3.8.1A). Constitutive activation of the Akt pathway (via overexpression of 
myristoylated Akt) led to enhanced sensitivity to AICAR (Fig. 3.3.8.1A). Bcl-2 and Akt 
overexpression did not substantially modulate the effect of metformin (Fig. 3.3.8.1B). 
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3.3.9. In vivo activity of AICAR  
In vivo testing of AICAR in a subcutaneous xenograft model was performed in 
NOD.CB17 SCID mice. These mice are homozygous for the severe combined immune 
deficiency spontaneous mutation Prkdscid and are characterised by an absence of 
functional T cells and B cells, lymphopaenia, hypogammaglobulinaemia but with a 
normal haematopoietic microenvironment. OPM2-GFP/luc cells (106 cells per mouse) 
were injected subcutaneously into the mice in between the shoulder blades. Following 
7 days of tumour engraftment, mice were randomly assigned to receive 600 mg/kg 
AICAR or vehicle (PBS) i.p. Tumour load (by calliper measurement), survival, and 
weights were assessed.  
There were 7 mice in the control group and 8 mice in the treatment group. AICAR 
treatment significantly decreased tumour burden compared to controls (Fig. 3.3.9.1; 
P=0.005; unpaired one-tailed T-test). In addition, the survival of the treated mice was 
statistically significant compared to controls (Fig. 3.3.9.2; P=0.003; log-rank test) on 
Kaplan-Meier method. Furthermore, there was no significant change in the weights of 
treated mice (Fig. 3.3.9.3) indicating that the mice tolerated the treatment well. There 
were also no potential toxicities observed during the course of treatment with AICAR. 
AICAR treated mice responded to the treatment in a rapid fashion. Due to the rapid 
disappearance of the tumours, there was development of ulcers in the central portion 
of the tumour. As a result of the ulcer formation, the Animal Care and Use Committee 
of the Dana-Farber Cancer Institute instructed us to sacrifice the mice, despite the 
shrinking tumour load. As a result, we had to censor the groups to get an accurate 
Kaplan-Meier calculation.     
 
 
 
 
 
 
  
 
Figure 3.3
1 million 
Following 
2.12.1 to 
intraperito
Mouse tum
Avg tumo
controls, n
 
 
.9.1  AICAR
OPM2-GFP
7 days of t
receive 6
neally. Tum
our burde
ur size ± S
= 8 in treat
 is able to
/luc cells w
umour engr
00 mg/kg 
our load (b
n was signi
EM; unpai
ment group
176
 reduce tu
ere injecte
aftment, m
AICAR (b
y calliper m
ficantly red
red one-tai
) 
mour burd
d subcuta
ice were ra
roken line)
easureme
uced in the
led T-test) 
en in treate
neously int
ndomly ass
 or vehicl
nt) was ass
 subcutane
compared 
d mice. 
o CB17 SC
igned as p
e (PBS- s
essed twic
ous model 
to controls
 
ID mice. 
er section 
olid line) 
e a week. 
(P=0.005; 
. (n= 7 in 
 
  
Figure 3.3
The surviv
rank test).
death and
groups as
and Use C
treatment 
.9.2  AICAR
al of the s
 Survival w
 calculated
 some mice
ommittee 
group) 
 treated m
ubcutaneou
as defined 
 using the 
 had to be
of the Dan
177
ice surviv
s model w
as time bet
Kaplan-Mei
 sacrificed 
a-Farber C
(
e longer th
as statistica
ween initiat
er method.
early upon 
ancer Insti
Days) 
an control
lly significa
ion of treat
 (There wa
instructions
tute) (n= 7
s 
nt (C; P=0
ment and s
s censorsh
 by the An
 in controls
 
.003; log-
acrifice or 
ip in both 
imal Care 
, n= 8 in 
 
 Figure 3.3
controls 
Mice in th
weights co
tolerated t
 
 
 
 
 
.9.3  AICAR
e treatment
mpared to 
he treatmen
 treated 
 group (AIC
mice in the
t well. (n= 
178
mice sho
AR 600mg
 control gro
7 in controls
w no cha
/kg – broke
up (solid lin
, n= 8 in tre
nge in we
n line) sho
e). This in
atment gro
ight com
wed no diff
dicated tha
up) 
 
pared to 
erence in 
t the mice 
 
 
179
3.3.10. Synergy of AICAR and Metformin with glycolysis inhibitors 
According to the Warburg hypothesis, tumour cell survival and proliferation critically 
depend on aerobic glycolysis rather than mitochondrial glucose oxidative metabolism 
[290]. Because metformin inhibits the mitochondrial respiratory chain and AICAR 
decreases mitochondrial membrane potential, we hypothesized that combined 
treatment of metformin or AICAR with a glycolysis inhibitor would significantly reduce 
the capacity of the cancer cell to generate energy, as it would target concurrently both 
key ATP-producing pathways. We treated MM1.S and FRO cells with 3-bromopyruvate 
(3BP), an inhibitor of hexokinase II, and 2-deoxyglucose (2DG), a stable glucose 
analogue that is actively taken up by the hexose transporters and inhibits 
phosphoglucose isomerase in a competitive, and hexokinase in a noncompetitive, 
manner [291], in combination with AICAR or metformin. 
The doses used for the combinations were in the range of IC70 to IC90  for single agent 
activity. 3BrPA dose of 7.5µM and 15µM for MM1.S and 15µM and 30µM for FRO cells 
were picked based on the dose response curve in Fig 3.3.10.1. As 2-DG had minimal 
single agent activity at doses <1000µM, the dose of 125µM and 250µM were picked to 
represent the lowest dose that will still yield synergy with AMPK activators. 
MM1.S and FRO cells were treated for 96h with a combination of AICAR or metformin 
plus 3BP or 2DG. This combination exhibited synergistic cytotoxicity in almost all 
doses, more with AICAR than metformin (Fig. 3.3.10.2 and 3.3.10.3). The Calcusyn 
software calculated the combination index (CIN) using the Chou and Talalay method 
[270, 271]. In Table 3.3.10.1 and 3.3.10.2, the CIN for both MM1.S and FRO cells 
treated with AICAR or metformin plus glycolysis inhibitors, 3BP or 2DG are shown. 
With the use of this method, a combination index < 0.9 indicates synergy, a 
combination index >0.9 indicates additive effect. All CIN values for MM1.S cells were 
<0.9 except for the combination of metformin 1.5 mM and 3BP 15 µM and metformin 
3mM and 3BP 15 µM which showed a calculated CIN of > 0.9. The combinations that 
were < 0.9 were synergistic, whereas the two combinations in italics  indicated that the 
combination of metformin with 3BP was additive. The same synergistic results were 
seen with the FRO cells except for two combinations which were highlighted in italic. 
The combination of AICAR 600 µM with 3BP 30 µM was slightly antagonistic and the 
combination of metformin 2mM with 2DG 250 µM was additive.  
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The combination of AMPK activators and glycolysis inhibitors demonstrated synergistic 
cytotoxicity by enhancing apoptotic activity. Fig. 3.3.10.4 showed that the combination 
of AICAR with glycolysis inhibitors led to enhanced cleavage of caspase 3 and PARP. 
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AICAR (µM) 3-Bromopyruvate (µM) Fraction affected CIN 
200 7.5 0.221805 0.426 
200 15 0.350624 0.638 
400 7.5 0.474641 0.256 
400 15 0.660006 0.361 
600 7.5 0.419226 0.285 
600 15 0.739868 0.305 
 
Metformin (mM) 3-Bromopyruvate (µM) Fraction affected CIN 
1.5 7.5 0.431177 0.805 
1.5 15 0.506741 0.901 
2 5 0.471601 0.797 
2 15 0.621679 0.784 
3 7.5 0.603879 0.831 
3 15 0.620715 0.986 
 
AICAR (µM) 2 deoxy-glucose (µM) Fraction affected CIN 
200 125 0.153206 0.344 
200 250 0.471292 0.099 
400 125 0.182012 0.267 
400 250 0.552601 0.066 
600 125 0.228841 0.188 
600 250 0.630215 0.045 
 
Metformin (mM) 2 deoxy-glucose (µM) Fraction affected CIN 
1.5 125 0.423288 0.612 
1.5 250 0.446638 0.619 
2 125 0.515034 0.576 
2 250 0.598452 0.456 
3 125 0.576538 0.682 
3 250 0.570363 0.728 
Table 3.3.10.1   Combination index (CIN) for AICAR/Metformin + Glycolysis 
inhibitors (3-Bromopyruvate or 2-deoxyglucose) for MM1S cells. 
Using Calcusyn software, the combination index (CIN) for the combination of 
AICAR/Metformin and glycolysis inhibitors was calculated. The CIN values were <0.9 
(except the combination in italics), indicating that the combination of AICAR or 
metformin with 2DG or 3BP were synergistic. The value in italics indicated that the 
combination was additive. 
 
 
 
185
AICAR (µM) 3-Bromopyruvate (µM) Fraction affected CIN 
200 30 0.494308 0.879 
400 30 0.711659 0.86 
600 30 0.645551 1.204 
 
Metformin (mM) 3-Bromopyruvate (µM) Fraction affected CIN 
0.5 30 0.508185 0.589 
1 30 0.519125 0.584 
 
AICAR (µM) 2 deoxy-glucose (µM) Fraction affected CIN 
200 125 0.137895 0.744 
200 250 0.394176 0.586 
400 125 0.288792 0.518 
400 250 0.749566 0.364 
600 125 0.427672 0.404 
600 250 0.737363 0.38 
 
Metformin (mM) 2 deoxy-glucose (µM) Fraction affected CIN 
0.5 250 0.2487 0.868 
1 250 0.36224 0.675 
2 250 0.3132 1.015 
 
Table 3.3.10.2 Combination index (CIN) for AICAR/Metformin + Glycolysis 
inhibitors (3-Bromopyruvate or 2-deoxyglucose) for FRO cells. 
Using Calcusyn software, the combination index (CIN) for the combination of 
AICAR/Metformin and glycolysis inhibitors was calculated. The CIN values were <0.9 
(except the combination in italics), indicating that the combination of AICAR or 
metformin with 2DG or 3BP were synergistic. The value in italics indicated that the 
combination was additive. 
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3.4. Proteomic analysis to examine bortezomib resistance 
3.4.1. Introduction 
To study further the resistance mechanisms in MM, specifically resistance to 
bortezomib treatment, we utilised proteomic technologies; the comparative proteomic 
approach which enabled us to study multiple signalling pathways simultaneously and 
mechanism of resistance to bortezomib.  
As most MM cell lines are exquisitely sensitive to bortezomib treatment, there was 
difficulty in locating a resistant cell line to act as a negative control. At this time, a 
paired isogenic bortezomib resistant MM cell line has not been generated. The MM cell 
lines used in this study were MM1.S (sensitive) and OPM2 (intermediate resistant cell 
line). Thus, the decision to use paired sensitive and resistant thyroid carcinoma cell 
lines (KAT18 and WRO) was twofold. One of the reasons was to have a totally 
resistant cell line to act as a negative control; the other reason was to account for any 
artefacts that may have arisen as non-isogenic cell lines were used. 
To determine expression differences between bortezomib sensitive and bortezomib 
resistant cell lines, proteomic analysis was carried out on sensitive (MM1.S and 
KAT18) and resistant (OPM2 and WRO) cell lines treated with bortezomib for 24 hrs 
(see Table 3.4.1 for dose of treatment). The dose used corresponded to the IC50 of 
each cell line. Investigations into differential protein expression between the responses 
of the cell lines to bortezomib treatment could potentially identify proteins that respond 
or do not respond to bortezomib and may be critical for understanding resistant 
mechanisms to this drug.  
 
Cell lines Bortezomib dose
MM1.S 4nM 
OPM2 10nM 
KAT18 20nM 
WRO 100nM 
Table 3.4.1 Samples used in proteomic experiment 
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3.4.2. Experimental outline for 2D-DIGE analysis of the samples 
2D-DIGE protein separation was performed by separating proteins first by isoelectric 
point and then by molecular weight. Protein spots in a gel were visualised using 
fluorescent markers. 2-D DIGE enables the incorporation of the same internal standard 
on every 2-D gel. The internal standard is a pool of all the samples within the 
experiment, and therefore contains every protein from every sample. Duplicate 
technical repeats were also carried out as well as reverse labelling. Once proteins were 
separated and quantified, they were identified by MALDI-TOF MS (Chapter 2.9.8). 
Identification of proteins enabled lists to be generated detailing differentially regulated 
proteins between samples. 
 
 
Gel Cy2 Cy3 Cy5 
1 pooled sample MM1S control MM1S treatment 
2 pooled sample MM1S treatment MM1S control 
3 pooled sample OPM2 control OPM2 treatment 
4 pooled sample OPM2 treatment OPM2 control 
5 pooled sample KAT18 control KAT18 treatment 
6 pooled sample KAT18 treatment KAT18 control 
7 pooled sample WRO control WRO treatment 
8 pooled sample WRO treatment WRO control 
Table 3.4.2  Labelling of samples for proteomic experiment 
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 3.4.2.1. Identification of differentially regulated proteins  
Differential protein expression between sensitive and resistant cell lines to bortezomib 
was examined using 2D-DIGE. DeCyderTM 6.5 software was used to identify 
differentially regulated proteins in each comparison.  
To evaluate the differentially expressed proteins after 24 hrs of exposure to bortezomib 
in the cell lines MM1S, OPM2, KAT18 and WRO, four comparative protein lists were 
generated. These four lists comprised of differentially expressed proteins between 
control and treated MM1.S (list 1), control and treated KAT18 (list 2), control and 
treated OPM2 (list 3) and control and treated WRO (list 4). The generated protein list 
and analysis was looking at the trend of change in the cell lines before (control) and 
after (24h) treatment with bortezomib. 
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3.4.2.2. Identification of unique proteins demonstrating the same trend in 
sensitive vs. resistance cell lines  
In order to further determine the significance of these differentially changed proteins, 
the design analysis was planned to specifically identify proteins that were altered in the 
same trend in both of the sensitive lines (MM1S, KAT18) vs. the resistant lines (OPM2, 
WRO), e.g. protein x upregulated in sensitive lines and downregulated in resistant 
lines. Biological variation analyses of these spots showing greater than 1.2-fold change 
in expression with a t-test score of less than 0.05 were identified. A total number of 50 
spots containing proteins of interest were identified as being significant (Table 3.4.2.1). 
Fig 3.4.2.1 showed the preparative gel where the 50 spots were located. 30 spots 
contained proteins that were downregulated in the sensitive cell lines, 16 spots 
contained proteins that were upregulated in the sensitive cell lines and 4 spots 
contained proteins that were unchanged in the sensitive cell lines but increased in the 
resistant cell line. 
Out of these 50 spots, only 39 spots were able to be identified and picked from the 
preparative gel (Fig 3.4.2.2). The other 11 spots contained proteins that were of too low 
abundance to be identified from the preparative gel. These 39 spots were then trypsin 
digested and further analysed on the mass spectrometer (Chapter 2.9.8). The peptides 
generated from the mass spectrometer was then analysed by the MASCOT software 
(Chapter 2.9.8). Of these 39 spots, 14 spots contained proteins that were identified 
with confidence by the software and 1 spot contained a protein that was identified with 
borderline confidence (Table 3.4.2.2A and B). Further details on the Mascot software 
identification using KHSRP protein and Heterogenous nuclear ribonuclearprotein 
A2/B1 isoform B were provided in Appendix A.  
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  Sensitive - MM1.S Resistant - OPM2 
Spot ID Fold change   Fold change   
155 -1.59 Decreased -1.04 Unchanged 
222 -1.59 Decreased -1.06 Unchanged 
228 -1.45 Decreased -1.01 Unchanged 
272 1.08 Unchanged 1.38 Increased 
280 -1.49 Decreased -1 Unchanged 
283 -1.87 Decreased -1.08 Unchanged 
297 1.74 Increased 1.08 Unchanged 
323 -1.56 Decreased 1.13 Unchanged 
329 -2.33 Decreased -1.07 Unchanged 
339 -1.93 Decreased 1.01 Unchanged 
387 -1.95 Decreased -1.05 Unchanged 
443 -2.07 Decreased 1.06 Unchanged 
447 3.45 Increased -1.19 Unchanged 
457 1.7 Increased -1.08 Unchanged 
505 -1.36 Decreased 1.25 Increased 
603 -1.61 Decreased 1.06 Unchanged 
605 -1.61 Decreased 1.08 Unchanged 
609 -1.48 Decreased -1.03 Unchanged 
610 -1.45 Decreased -1.03 Unchanged 
614 1.53 Increased -1.06 Unchanged 
636 1.06 Unchanged -1.11 Unchanged 
669 -1.41 Decreased 1.08 Unchanged 
670 -1.55 Decreased 1.08 Unchanged 
675 -1.18 Unchanged 1.79 Increased 
676 -1.82 Decreased 1.07 Unchanged 
718 -1.51 Decreased 1.03 Unchanged 
868 1.61 Increased 1.1 Unchanged 
914 1 Unchanged 1.5 Increased 
1088 2.29 Increased -1.49 Decreased 
1166 1.77 Increased 1.03 Unchanged 
1265 1.73 Increased 1.06 Unchanged 
1306 -1.08 Decreased 1.16 Unchanged 
1330 5.36 Increased 1.04 Unchanged 
1351 -1.31 Decreased 1.03 Unchanged 
1387 -1.84 Decreased 1.12 Unchanged 
1436 -1.45 Decreased 1 Unchanged 
1465 -2.03 Decreased 1.16 Unchanged 
1479 -1.62 Decreased -1.19 Unchanged 
1480 1.4 Increased -1.06 Unchanged 
1552 -1.98 Decreased 1.15 Unchanged 
1649 -1.39 Decreased -1.1 Unchanged 
1669 1.24 Increased 1.02 Unchanged 
Table 3.4.2.1    Proteins identified with a significant trend  
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  Sensitive - MM1.S Resistant  OPM2 
Protein ID Fold change   Fold change   
1729 1.24 Increased 1.02 Unchanged 
1732 1.87 Increased 1.09 Unchanged 
1788 1.34 Increased -1.06 Unchanged 
1844 1.03 Decreased 1.42 Increased 
1932 13.06 Increased 1.31 Increased 
2275 -1.3 Decreased 1.12 Unchanged 
2403 -1.77 Decreased 1.19 Unchanged 
2525 6.25 Increased 1.53 Increased 
Table 3.4.2.1   Spots containing proteins identified with a significant trend  
The spots containing proteins identified when comparing the sensitive vs. resistant cell 
lines showing a significant trend. The fold change and the trend of change (whether 
upregulated or downregulated) of the protein after treatment with bortezomib when 
compared to its respective untreated control is shown.  
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Fig. 3.4.2.1 – Spots identified on the preparative gel 
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Fig. 3.4.2.2 – Spots containing proteins identified by Mascot software 
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Protein ID Protein Name Sensitive - MM1.S Resistant - OPM2 
    Fold change   Fold change   
222 KHSRP protein  -1.59 Decreased -1.06 Unchanged 
297 Heat shock 70kDa protein 8 isoform 2 1.74 Increased 1.08 Unchanged 
443 Far upstream element binding protein 1  -2.07 Decreased 1.06 Unchanged 
457 FSCN1 protein  1.7 Increased -1.08 Unchanged 
605 Heterogeneous nuclear ribonucleoprotein K -1.61 Decreased 1.08 Unchanged 
675 26S protease (S4) regulatory subunit -1.18 Unchanged 1.79 Increased 
914 Proteasome 26S subunit, ATPase 2 1 Unchanged 1.5 Increased 
1088 Proteasome 26S subunit, ATPase 2 2.29 Increased -1.49 Decreased 
1265 Annexin A2, isoform 2 1.73 Increased 1.06 Unchanged 
1306 
Heterogeneous nuclear ribonucleoprotein 
A2/B1 isoform B1  -1.08 Decreased 1.16 Unchanged 
1351 A+U-rich element RNA binding factor  -1.31 Decreased 1.03 Unchanged 
1436 
Heterogenous nuclear ribonucleoprotein A1 
(Rbd1,2) -1.45 Decreased 1 Unchanged 
1465 Caspase-3 -2.03 Decreased 1.16 Unchanged 
1669 Endoplasmic reticulum protein 29  1.24 Increased 1.02 Unchanged 
1932 Ferritin, light polypeptide  13.06 Increased 1.31 Increased 
Table 3.4.2.2A – Proteins with a significant trend that are identified from the list generated (Table 3.4.2) 
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Protein 
ID Protein Name Ascension 
Mass 
(Dalton) 
Mascot 
Score 
Peptides 
match 
Sequence 
coverage 
222 KHSRP protein  gi|54648253 73307 149 22 26% 
297 Heat shock 70kDa protein 8 isoform 2 gi|24234686 53598 164 19 36% 
443 Far upstream element binding protein 1  gi|37078490 67603 112 16 23% 
457 FSCN1 protein   gi|14043107 55729 63* 13  25%  
605 Heterogeneous nuclear ribonucleoprotein K gi|55958544 47756 142 17 32% 
675 26S protease (S4) regulatory subunit gi|403456 49326 67 18 36% 
914 Proteasome 26S subunit, ATPase 2  gi|51095169 49002 130 14 23% 
1088 Proteasome 26S subunit, ATPase 2 gi|51095169 49002 207 24 49% 
1265 Annexin A2, isoform 2 gi|16306978 38822 116 17 43% 
1306 
Heterogeneous nuclear ribonucleoprotein A2/B1 
isoform B1  gi|14043072 37464 370 24 50% 
1351 A+U-rich element RNA binding factor  gi|2547076 30337 114 14 29% 
1436 
Heterogenous nuclear ribonucleoprotein A1 
(Rbd1,2) gi|2194069 21116 114 11 50% 
1465 Caspase-3   31587   3 21% 
1669 Endoplasmic reticulum protein 29 precursor  gi|5803013 29032 134 10 26% 
1932 Ferritin, light polypeptide   gi|18203882 20106 98 10 36% 
Table 3.4.2.2B – Proteins with a significant trend that are identified from the list generated (Table 3.4.2) 
The masses were calculated from the sequence of the protein in the database. The sequence coverage is the amount of the 
protein sequence covered by the matched peptides. For protein identification, all proteins were digested and identified at 
least twice from separate gels with MALDI-TOF MS. Mascot scores greater than 64 are significant (p<0.05). * is a protein 
that was identified with borderline confidence. 
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3.4.3. Proteins identified that are known to be affected by bortezomib 
treatment 
3.4.3.1. Heat shock protein 70kD 
One of the proteins identified was Heat shock protein 70 (Hsp70). This protein was 
induced by bortezomib treatment whereas in bortezomib resistant cells, there was 
no change in this protein after exposure to bortezomib (Fig. 3.4.3.1). We validated 
this result in the bortezomib sensitive cell line MM1.S by Western blot (Fig. 3.4.3.3) 
showing an increase in Hsp70 after treatment with bortezomib.   
 
 
Fig 3.4.3.1  Trend of change in Heat shock protein 70kD 
There was an increase in Hsp70 in sensitive cell lines (MM1.S and KAT18) and no 
change in resistant cell lines (OPM2 and WRO).  The abundance of the Hsp70 
protein for each cell line shown was calculated based on the intensity of the spot on 
the 2D-DIGE gel 
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3.4.3.2. Caspase-3 protein 
Another protein identified was caspase-3. This protein was downregulated in the 
sensitive cells that were treated with bortezomib and there was no change in the 
resistant cell lines (Fig. 3.4.3.2). We validated this result in the bortezomib sensitive 
cell line MM1.S by Western blot (Fig. 3.4.3.3) showing a decrease in total caspase-
3 and formation of cleaved products after treatment with bortezomib.   
 
 
Fig 3.4.3.2  Trend of change in caspase-3 protein 
There was a decrease in total caspase-3 in sensitive cell lines (MM1.S and KAT18) 
and no change in resistant cell lines (OPM2 and WRO). The abundance of the 
caspase-3 protein for each cell line shown was calculated based on the intensity of 
the spot on the 2D-DIGE gel 
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 3.4.4. Novel proteins identified 
Proteins shown in Table 3.4.4.1 were proteins with no previously known association 
with myeloma or bortezomib treatment. These proteins were identified (from Table 
3.4.2.2) showing a significant trend with the treatment and we plan to validate these 
proteins and further identify how bortezomib treatment affects or changes them. 
Heterogeneous nuclear ribonucleoprotein A2/B1 isoform B1 and KHSRP protein 
were picked from Table 3.4.4.1 to highlight the details of the Mascot software on 
obtaining the protein identification (Appendix A). 
2D-DIGE analysis was used to identify the proteins in this experiment. To validate 
the proteins in Table 3.4.4.1, Western blotting was done. Fig. 3.4.4 demonstrated 
that Western blotting revealed the same trend of change as our results with 2D-
DIGE (Table 3.4.4.1). Table 3.4.4.2 showed the densitometry readings analysed 
using Image J, of the protein bands in Fig. 3.4.4. 
3 proteins that were also identified as having a significant trend were 26S protease 
(S4) regulatory subunit (protein ID 675), proteasome 26S subunit, ATPase 2 
(protein ID 914) and proteasome 26S subunit, ATPase 2 (protein ID 1088). These 
proteins were not further studied as bortezomib is a proteasome inhibitor and would 
be expected to affect proteins such as these.  
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  MM1.S OPM2 
  Control Bortezomib 4nM Control Bortezomib 10nM 
KHSRP 1.0 0.7 1.0 1.0 
FUBP1 1.0 0.4 1.0 1.0 
FSCN1 1.0 20.7 1.0 1.0 
HnRNP K 1.0 0.5 1.0 1.0 
Annexin A2 1.0 1.4 NA NA 
HnRNP A2/B1 1.0 0.7 1.0 1.0 
A + U rich element RNA binding 
factor 1.0 0.5 1.0 1.0 
HnRNP A1 1.0 0.6 1.0 1.0 
ERp 29 1.0 1.2 1.0 1.0 
Ferritin 1.0 1.4 1.0 1.1 
GAPDH 1.0 1.0 1.0 1.0 
 
Table 3.4.4.2  Densitometry readings of the Western blot analysis in Fig. 3.4.4 
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4.  Investigation of the intrinsic mechanism of resistance 
With the advent of novel therapies, patients with MM are enjoying a longer survival. 
With more patients surviving longer, genetic mutations that were rarely seen in MM, 
such as p53 mutation/deletion are now more commonplace. P-gp expression is also 
another resistance mechanism that has the potential to increase in 
relapse/refractory MM. Although bortezomib is an effective drug, more and more 
patients are relapsing when treated as a single therapy. The trend is to combine 
bortezomib with other conventional agents, such as dexamethasone, doxorubicin 
and melphalan and novel agents, such as lenalidomide. There are other clinical 
trials looking at the combination of bortezomib with other investigational agents 
such as perifosine and histone deacetylase inhibitors. The reason that bortezomib 
is used in so many different combinations is that it is a very effective agent in MM. 
Thus, being able to prolong its use in relapse/refractory patients is imperative. The 
aim of this thesis was to investigate resistant mechanisms in MM with regard to 
bortezomib treatment. Development of resistance to bortezomib via the 
overexpression of p-gp or through perturbations of the p53 pathway is overcome by 
using a p-gp modulator or Mdm2 inhibitor respectively. Using AMPK activators, we 
can overcome bortezomib-resistant MM by activating an alternative pathway to 
killing MM cells. Finally, using 2D-DIGE analysis, we have identified proteins that 
are potential targets in causing bortezomib resistance.  
 
4.1 MDR associated protein expression as a mechanism of resistance  
4.1.1. The relationship between Multiple Myeloma and MDR proteins 
MM is an incurable plasma cell disorder which generally responds to treatment but 
inevitably relapses, even with the advent of newer more targeted therapies. As 
mentioned in the introduction, there exist primary (intrinsic) resistance where the 
drug insensitivity is present from first diagnosis and unresponsive to first line 
chemotherapy or secondary (acquired) resistance where tumour cells develop 
resistance during chemotherapy. One of the underlying causes of drug resistance is 
the acquisition of multidrug transporters in the cancer cells; these transporters are 
energy-dependent transmembrane proteins which can efflux a broad range of 
anticancer drugs, and thereby play a role in resistance to the actions of substrate 
agents. P-glycoprotein (P-gp; MDR-1; ABCB1), multidrug resistant protein-1 (MRP-
1; ABCC1) and breast cancer resistance protein (BCRP; MXR; ABCG2) are thought 
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to play the most important roles in transporter-mediated resistance. That is the 
reason that these three MDR proteins were chosen to be studied in this thesis.  
The incidence of MDR proteins in MM is not well characterised. P-gp does not 
seem to be overexpressed de novo in MM cells obtained from patients before they 
receive chemotherapy. In most P-gp related studies of MM, the collection and 
analysis of P-gp expression and function was limited due to technical difficulties. A 
study by Schwarzenbach [292] demonstrates the incidence of the three genes 
associated with multidrug resistance (MDR) in multiple myeloma in relation to 
treatment status. MDR1 mRNA/Pgp (P-glycoprotein) expression was detected in 
41% of 93 myeloma samples. Generally, the incidence of MDR1/Pgp expression 
was higher in pretreated samples, and treatments with doxorubicin and/or 
vincristine were more effective in inducing MDR1/Pgp expression than with 
alkylating agents. Two other studies [146, 293] showed that P-gp expression does 
increase in approximately 75% of patients treated with vincristine, doxorubicin and 
dexamethasone (VAD). The likelihood of P-gp expression in MM correlated with the 
cumulative dose of doxorubicin and vincristine the patient received. As most 
previous and current MM regimens contain one or both of these drugs, MM patients 
who have been previously treated may have developed P-gp related resistance. 
The same study by Schwarzenbach [292] showed that taking MRP mRNA and 
protein expression together, MRP was detected in 20.5% of 88 myeloma samples. 
LRP (lung-resistance protein) protein expression by immunohistochemistry was 
observed in 12.5% of 72 myeloma samples. MRP and LRP expression was similar 
in samples with and without prior therapy.  
BCRP is a more recently identified multidrug resistance protein. Similar to the other 
members of the ATP-binding cassette family of membrane transporters, such as P-
gp and MRP1, BCRP is expressed in a variety of malignancies, where it may 
produce resistance to chemotherapeutic agents [294]. Cell lines that express high 
levels of BCRP are fibrosarcoma, ovarian cancer, breast cancer, and myeloma cell 
lines [295]. Haematological malignancies such as acute myeloid leukaemia [296] 
and acute lymphoblastic leukemia [297] have been shown to express BCRP as a 
resistance mechanism. It has also been found to be expressed in the mitoxantrone-
selected human MM cell line 8226[295]; however, the clinical relevance of this 
transporter in MM patients remains to be validated.  
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In the mid-1990s, there was a lot of interest in P-gp-mediated resistance and using 
P-gp inhibitors to overcome drug resistance in an attempt to improve treatment 
outcome of patients with MM. A phase I/II study was conducted using the MDR 
modulator verapamil, in combination with VAD, to treat patients with refractory MM 
[298]. An approximately 50% partial response was found in the study, but this 
combined therapeutic strategy resulted in significant cardiac toxicity. An attempt to 
minimise this side effect by using lower doses of verapamil in combination with VAD 
to treat patients with MM in a randomized phase III trial yielded no therapeutic 
benefit as a result of the suboptimal dose of verapamil[148]. Quinine was another 
P-gp modulator that was utilised in combination with VAD and prednisone in a 
phase III Southwestern Oncology Group trial [299]. Progression-free and OS rates 
were similar between the two arms. Sonneveld et al. [147] used cyclosporine, 
another MDR modulator, has been used with the VAD regimen in treating refractory 
or progressive MM patients. They reported more toxicity in the treatment arm 
containing cyclosporine with similar overall response rate, progression-free and OS 
rates in the two arms. Valspdar (also called PSC833) is an oral form of a 
cyclosporine D derivative and is approximately five-fold more potent than 
cyclosporine in inhibiting P-gp. Unlike the early generation of MDR modulators that 
are the substrates and competitive inhibitors of P-gp, valspodar is a non-
competitive inhibitor of P-gp. There is a strong interaction between valspodar and 
other P-gp substrates. Valspodar can inhibit P-gp in the liver and kidneys, which is 
required for serum drug excretion. Concomitant use of valspodar was shown to 
increase the therapeutic efficacy of doxorubicin and reduce the total dose needed 
by 50% to 75%.In MM, valspodar had been tested in 22 patients with refractory MM 
in a phase I trial in which oral valspodar was used with VAD [300]. It seems to be 
less toxic than cyclosporine, however, recent data from phase III trials of other 
haematological malignancies, including AML, have failed to demonstrate the benefit 
of adding valspodar to the chemotherapy regiment in treating relapsed disease 
[301]. A phase III trial conducted by the Cancer and Leukemia Group B showed 
excessive toxicity and death from valspodar treatment in previously untreated 
elderly patients with AML, resulting in the premature closure of the study [302]. 
Newer generation P-gp modulators include GF120918 (also called elacridar), 
LY335979 (also called zosuquidar) and VX-710 (also called biricodar). Elacridar, a 
substituted isoquinolinyl acridonecarboxamide, is a multispecific third-generation 
MDR modulator [139]. In vitro studies indicate that elacridar fully reversed 
resistance to etoposide, doxorubicin, vinblastine, docetaxel, and paclitaxel in MDR 
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sarcoma cells [303] and enhanced doxorubicin tumour cell kill in Pgp–mediated 
resistant leukeamia and myeloma cells [304]. Recent publications also demonstrate 
complete reversal of mitoxantrone resistance due to the ATP-binding cassette half-
transporter, BRCP, with the use of elacridar [305, 306]. Unlike valspodar, elacridar 
appears to have minimal interactions with MDR substrates. Clinical phase I trial 
combining elacridar with doxorubicin indicate that unlike valspodar, doxorubicin 
pharmacokinetics were not affected by the modulator [307]. Another phase I trial 
examining the above combination in solid tumours demonstrated that the 
doxorubicin dose was marginally influenced by elacridar but only at the highest 
dose levels. These patients however, had significant increase in the area under the 
curve of doxorucibin especially in later cycles, resulting in neutropenia [308]. 
Zosuquidar, a difluorocyclopropyl dibenzosuberane, is one of the most potent, 
highly selective P-gp modulators to date [140]. As such, it has been combined with 
various chemotherapy regimens in different malignancies. Zosuquidar has a high 
affinity to, but is not a substrate of, P-gp. Preclinical studies demonstrated that this 
compound sensitizes various MDR cell lines and enhances survival of nude mice 
engrafted with the Pgp–expressing leukaemia cell line, P388/ADR. A number of 
phase I trials combining oral zosuquidar with docetaxel in metastatic breast cancer 
and other solid tumours have been performed. An earlier trial [309] reported a 
minimal increase in docetaxel peak plasma concentration and area under the curve 
whereas a later trial [310] deemed the combination safe. The evidence on whether 
the pharmacokinetics of doxorubicin is similarly affected is controversial. One phase 
I trial [311] reported that zosuquidar at doses that exceed 500mg generated a 
modest decrease in doxorubicin clearance with haematological toxicity whereas 
another phase I/II trial [312] stated that the pharmacokinetics of doxorubicin was not 
affected. Zosuquidar also affects the pharmacokinetics of vincristine and vinorelbine 
[312, 313]..  
Biricodar, an amido-keto-pipecolinate derivative, is a potent modulator of P-gp and 
also inhibits MRP1-related drug transport, thus overcoming two of the most 
prevalent resistance phenotypes [314]. biricodar reversed resistance to doxorubicin, 
etoposide, and vincristine in both Pgp– and MRP-expressing MDR cell lines. 
Rowinsky et al. [315] reported minimal toxicity when biricodar was used alone in 
patients with solid malignancies.  
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Thus far, the clinical trials using first and second generation P-gp modulators did 
not show clinical benefit or there was unacceptable toxicity. The newer modulators 
show some toxicity with but it was minimal compared to the older P-gp modulators. 
However, there was no clinical benefit seen when P-gp modulators were added to 
chemotherapeutics in metastatic breast cancer or elderly acute myeloid leukaemia 
[310, 316]. At the present time, clinical trial evidence indicates that P-gp modulation 
in combination with chemotherapeutics is still not a feasible strategy for improving 
overall treatment efficacy.  
 
4.1.2. The rationale for proteasome inhibition as an anticancer therapy 
As part of the ubiquitin–proteasome pathway, the proteasome is the final common 
endpoint of the vast majority of regulated intracellular proteolysis. Proteins destined 
for destruction and turnover are tagged with polyubiquitin chains by the ubiquitin 
conjugation system. In the first reaction, the E1 ubiquitin enzyme activates ubiquitin 
and attaches it to the ubiquitin-conjugating enzyme E2 in an ATP-dependent 
manner. The E3 ubiquitin ligase then links the ubiquitin molecule to the target 
protein and which is shuttled to the 20S and 26S proteasomes for digestion and 
turnover [317, 318]. By inhibiting proteasome activity, bortezomib affects this 
proteolytic process leading to an accumulation of intracellular ubiquitinated proteins. 
NF-κB is composed of a family of homo- and heterodimeric transcription factors that 
bind to a common sequence motif called the κB site. Inhibition of κB (IκB) protein 
contain an N-terminal regulatory domain followed by multiple ankyrin repeats that 
interact with the Rel homology domain of NF-κB through protein-protein interaction. 
The various IκBs bind to NF-κB proteins, covering the nuclear localisation signal of 
NF-κB proteins, and thereby preventing their translocation from the cytoplasm to 
the nucleus.  
NF-κB-I-κB complexes are mostly located in the cytoplasm and remain 
transcriptionally inactive until the cells receive extracellular stimuli, such as 
proinflammatory cytokines TNF-α and IL-1 [136]. In response to these stimuli, the 
IκB kinase complex (IKK) is activated and it phosphorylates NF-κB-bound IκB 
proteins on two conserved serine residues within the NH2-terminal regulatory 
domain. Phosphorylated IκB proteins are then recognised by the TrCP-containing 
Skp1/Cullin/F-box protein ubiquitin ligase complex, resulting in its ubiquitination 
followed by proteolytic degradation through the function of 26S proteasome. 
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Removal of IκB proteins by proteasome-dependent degradation unmasks the 
nuclear localisation signals of NF-κB causing an activation of gene transcription that 
leads to the expression of anti-apoptotic proteins. 
NF-κB has been to shown to promote myelomagenesis by inducing growth and 
angiogenesis factors such as interleukin-6 and vascular endothelial growth factor, 
by activating important cell-cycle regulators such as c-Myc and cyclin-D1, by 
promoting an antiapoptotic state through intermediates such as Bcl-2 and Bcl-xL, 
and by enhancing myeloma cell adherence to the surrounding stroma, such as 
through effects on fibronectin and vascular cell adhesion molecule-1 [27]. Activation 
of apoptosis in cancer cells resulting from NF-κB inhibition is the basis that NF-κB 
inhibition could be used as a mechanism to treat cancers. Bortezomib is a drug that 
was specifically developed to block the signal transduction pathways activated by 
NF-κB [38]. The destruction of IκBα proteins after their phosphorylation by IKK and 
subsequent ubiquination is primarily mediated by proteasome degradation. 
Bortezomib suppresses NF-κB activity by inhibiting this degradation and stabilising 
IκBα, which binds NF-κB and prevents its nuclear translocation; thereby 
downregulating levels of its targets and producing a potent antimyeloma effect [27]. 
 A number of studies have shown the inhibitory effect of proteasome inhibitors on 
tumour cell growth and proliferation [27, 44, 278, 319]. Hideshima et al. [27] have 
demonstrated in vitro that bortezomib can inhibit proliferation through induction of 
apoptosis of several human MM cell lines, as well as MM cells isolated from 
patients. In animal studies, bortezomib has been shown to have a therapeutic role 
by inhibiting tumour growth in mice treated with the drug [320]. On the basis of 
positive preclinical studies, several human trials with bortezomib were conducted. 
After phase I trials demonstrated the safety of bortezomib among patients with a 
variety of advanced malignancies [321], phase II trials (SUMMIT) and (CREST) 
were conducted to treat patients with relapsed of refractory MM. There was a 
response rate of 35% to 38% and a median survival of 16 months (SUMMIT) [40, 
41]. These results were confirmed in the international, multicenter phase III 
Assessment of Proteasome Inhibition for EXtending remissions (APEX) trial, in the 
response rate among individuals in the bortezomib group was 38%, with a CR rate 
of 6%, whereas the OR and CR rates in the dexamethasone group were 18% and 
1%, respectively. Superior median time to progression (TTP) (6.22 versus 3.49 
months) and 1-year survival (80 versus 66%) were observed in the bortezomib as 
compared with dexamethasone-treated patients [42]. In an updated analysis, the 
OR and CR rates in the bortezomib arm were 43 and 9%, respectively [43]. 
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However, patients who have been previously treated with bortezomib are now 
demonstrating resistance to proteasome inhibition. 
 
4.1.3. Bortezomib’s relationship with MDR ptoteins 
As described earlier, bortezomib is a novel treatment for MM. Resistance to this 
drug is multifactorial and there is now emerging evidence that proteasome inhibitors 
interact with MDR proteins. Of all the MDR proteins, P-gp appears to be the most 
studied in relation to bortezomib but the nature of interactions between this agent 
and this efflux protein is controversial. There are indications that overexpression of 
this pump may contribute to resistance to bortezomib. Rumpold et al .[150] showed 
that knockdown of P-gp resensitises P-gp-expressing cells to proteasome inhibitors. 
The authors also showed that bortezomib was a P-gp substrate. In Ewing’s 
sarcoma, Nakamura et al. [322] demonstrated that P-gp and MRP-1-expressing 
clones of Ewing’s tumours, which have shown resistance to substrates of P-gp and 
MRP-1 (e.g. adriamycin, vincristine, etoposide, and actinomycin D), also possess a 
cross resistance to bortezomib. This suggests that bortezomib is not only a P-gp 
substrate but also a MRP-1 substrate. The authors proceeded to show that 
combination treatment with bortezomib and a P-gp or MRP-1 inhibitor reduced the 
resistance seen with single agent bortezomib treatment. This finding is further 
supported by Iijima et al. [323] who showed that the proteasome inhibitor class of 
agents are substrates of P-gp. With MDR-interacting agents, substrates are not 
necessarily inhibitors and vice versa and other studies have demonstrated that 
proteasome inhibitors are also P-gp inhibitors [324]. Finally, there are some studies 
which have demonstrated that bortezomib is not an MDR substrate at all. Such 
studies points to the fact that there is little cross resistance to bortezomib in cells 
that are known to be P-gp or MRP-1-overexpressors [325, 326]. Thus far, there is 
no conclusive evidence one way or the other about the interaction of bortezomib 
with MDR proteins.  
In our findings, we wanted to clarify the interaction of bortezomib with MDR 
proteins. In the present study, we characterized the interaction of bortezomib with 
multidrug transporters; P-gp, BCRP and MRP1 and explored the potential for this 
interaction to play a role in resistance. To establish if bortezomib interacts with the 
MDR protein P-gp, we utilised cell lines that have different and defined levels of 
overexpression of P-gp; DLKP-A, RPMI-Dox40, A549-taxol and NCI-Adr/res (Table 
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3.3.1.) All but one of the cells lines that were used to determine MDR expression 
and function were different isogenic lines that were developed in the NICB, Dublin. 
It was important to use an isogenic line (i.e. to compare parent and resistant 
daughter line) to ensure that any comparison between the cell lines would be 
related to the MDR proteins and not a cell line-specific effect. In these lines, P-gp 
overexpression ranges from low (A549-taxol) to high (DLKP-A) (Fig. 3.1.5). This 
was necessary to be able to study the mechanism of bortezomib interaction with P-
gp in detail.   
Elacridar, a P-gp inhibitor was combined with bortezomib in a series of 
experiments. We first determined a dose of bortezomib for each cell line used that 
gave an IC70-90. . Elacridar was also tested on the cell lines and it was non- toxic in 
all cell lines at the concentrations employed (Fig 3.1.2.5). Nonetheless, the dose 
used in the experiments was the lowest possible dose that still yielded an adequate 
P-gp inhibition (Fig. 3.1.2.6) 
Using the DLKP-A cell line, we compared the response of bortezomib to its parental 
line, DLKP. There was a marked increase in resistance in the DLKP-A cell line 
(Fig.3.1.2.5). This suggests that P-gp is responsible for resistance to bortezomib 
but to better examine this hypothesis, bortezomib was combined with the P-gp 
inhibitor, elacridar and there was marked toxicological synergy in this combination 
(Fig. 3.1.2.1 and 3.1.2.2.) The synergy was most obvious when the two drugs were 
allowed to interact for a longer period of time. This means that not only cell death is 
involved but cell proliferation was inhibited by this combination as well.  
To see if this synergistic cytotoxicity was maintained across different cancer types, 
we tested the bortezomib and elacridar combination in several different P-gp-
overexpressing cancer cell lines; DLKP-A (lung cancer) NCI-Adr/res (ovarian 
cancer) and RPMI-Dox40 (MM), results of which confirmed that there was 
synergistic cytotoxicity when elacridar and bortezomib were combined (Fig. 3.1.6). 
These experiments demonstrate that bortezomib is a substrate of P-gp as it was 
able to reverse the resistance seen when P-gp was inhibited by elacridar. This 
finding that bortezomib is a P-gp substrate confirms the results of other recent 
studies [150, 322, 323]. 
In the literature, there is a study on a breast cancer cell line that suggested 
bortezomib is a P-gp inhibitor [324]. Two other studies undertaken using leukemia 
cell lines suggested that bortezomib is not an inhibitor as it does not synergise with 
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daunorubicin (an anthracycline) [327, 328]. In our data, we tested the P-gp 
overexpressing cell line DLKP-A  and concluded that bortezomib is at best a weak 
inhibitor. When doxorubin, a P-gp substrate, was combined with bortezomib, we 
found only an additive effect except at the highest dose of bortezomib tested, where 
there was mild synergistic killing (Fig. 3.1.2.3). Collectively, these inconsistent 
reports suggest that findings with regard to interactions between bortezomib and 
anthracyclines might depend on the choice of drug used in combination, the cell line 
studied and the method used to assess the drug interactions. 
 Another reason that bortezomib synergises with doxorubicin may be related to 
other apoptotic mechanisms and is not P-gp related. In the treatment of MM, 
Mitsiades et al. investigated the mechanism of the chemosensitising activity of 
bortezomib with oligonucleotide gene microarray analysis [44]. The authors 
demonstrated that bortezomib could downregulate the transcripts for several 
effectors of the protective cellular response to genotoxic stress: topoisomerase II 
beta, which relaxes DNA torsion on replication, transcription, and cell division and is 
inhibited by doxorubicin. They concluded that this was the reason for synergy 
between bortezomib and doxorucibin. In support of this, we demonstrated that 
bortezomib and doxorubicin mildly synergises in a P-gp negative cell line (Fig. 
3.1.2.4) implying that P-gp status has no bearing on bortezomib and doxorubicin 
synergy and consistent with the findings of Mitsiades et al..[44] 
Although P-gp is not usually overexpressed in early MM disease, with exposure to 
natural products such as anthracyclines and vinca alkaloids, and a longer disease 
period, there is increased expression of the transporter [146, 292]. Previous 
clinicals trial carried out with the premise that inhibition of overexpressed P-gp 
would lead to increased anti-cancer activity have failed to show a survival or 
progression free benefit in the P-gp positive patients [147-149]. One of the reasons 
for the failure of these trials was the increased general toxicity from anthracyclines.  
P-gp expression in normal body tissues, especially the liver, is important for 
eliminating such agents from the body, thereby abrogating the toxic actions of 
anthracyclines (and other P-gp substrate chemotherapeutics) and hence body-wide 
P-gp inhibition increases the incidence and severity of side effects. In our current 
study, we have shown that bortezomib is a good P-gp substrate and a weak 
inhibitor. The cross resistance to bortezomib seen in P-gp-overexpressing cells may 
be overcome by combining a P-gp inhibitor, such as elacridar, to bortezomib. 
Bortezomib is a very efficacious agent in MM, if we can extend the life of this agent 
in patients who have developed resistance to the drug by adding in a P-gp inhibitor, 
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we expect to see efficacy of this drug in the P-gp positive patient population. MM 
cells are exquisitely sensitive to bortezomib and if a P-gp inhibitor is functioning to 
increase the intracellular dose of bortezomib, it seems likely that we can use 
standard or even a lower dose of bortezomib to treat P-gp-induced resistance in 
MM patients. Thus we may be able to overcome toxicity issues associated with 
having to use elevated doses of bortezomib in such patients. 
 
MRP overexpression is not a common phenomenon in MM. It was only detected in 
about 20.5% of 88 myeloma samples [292], with overexpression being more 
common in other haematological malignancies such as acute myeloid leukaemia 
[329]. However, MRP-1 is a known multidrug resistance protein and we wanted to 
investigate its interaction with bortezomib. 
We used the DLKP cell line. DLKP is known to have MRP-1 overexpression.  While 
the level of overexpression of this transporter is small, it still contributes to this cell 
line being resistant to MRP-1 substrate agents and inhibition of MRP-1 increases 
the efficacy of MRP-1 substrate drugs [272]. We combined bortezomib with 
sulindac sulphide, a MRP-1 inhibitor and failed to demonstrate any synergy (Fig. 
3.1.3). Even though MRP-1 is only expressed in a small majority of MM resistance, 
our findings suggest that there is little evidence that MRP-1 resistance would affect 
bortezomib treatment although we have not specifically shown this in MM cells. This 
has also been seen in an MRP-1 overexpressing leukaemia cell line where there 
was no cross resistance to bortezomib [328]. 
BCRP is a relatively newly identified multidrug resistant protein. Similar to the other 
members of the ATP-binding cassette family of membrane transporters, such as 
MDR1 and MRP1, BCRP is expressed in a variety of malignancies, where it may 
produce resistance to chemotherapeutic agents [294]. Turner et al. [294] reported 
that BCRP mRNA and protein expression in myeloma cell lines increased after 
exposure to topotecan and doxorubicin, and was greater in log growth phase cells 
when compared with quiescent cells. Therefore, as with P-gp, BCRP can be 
induced in MM after exposure to chemotherapeutics. 
We wanted to further characterise the role of BCRP in bortezomib resistance in 
MM. Treatment of DLKP-SQ/Mitox (which overexpresses BCRP) [279] did not show 
any synergistic cytotoxicity when bortezomib was combined with elacridar (which 
can also act as a BCRP inhibitor) (Fig. 3.1.4.1). We wanted to investigate this 
further and treated DLKP and DLKP-SQ/Mitox with bortezomib. The two cell lines 
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responded to bortezomib in a similar fashion without any resistance seen in the 
BCRP-overexpressing cell line (Fig. 3.1.4.2). This is unlike Fig. 3.1.2.5A where the 
P-gp expressing cell line DLKP-A, demonstrated significant resistance to 
bortezomib. This finding suggests that bortezomib is not a substrate for BCRP. The 
interaction of bortezomib with BCRP was further analysed. SN38 is an irinotecan 
metabolite which is a known substrate for BCRP. Bortezomib was combined with 
SN38 and DLKP-SQ/Mitox cells were treated with this combination. There was no 
synergistic killing evident demonstrating that bortezomib is not a BCRP inhibitor 
(Fig 3.1.4.3). These findings are in agreement with another study using leukaemia 
cells which also demonstrated that bortezomib is not a BCRP substrate [328].   
 
4.1.4. P-gp expression correlates to bortezomib’s efficacy as a 
substrate 
As mentioned in section 4.1.1, clinical trials that used a combination of VAD with P-
gp inhibitors such as cyclosporine [147], verapamil [148] or PS-833 [149] showed 
no clinical benefit in terms of increased OS or progression-free survival in the arm 
with VAD + P-gp inhibitor. Poor inhibition of tumour P-gp function by the P-gp 
inhibitors and requisite dose reduction of chemotherapeutics as a result of 
increased general toxicity are some of the postulated reasons for failure. Another 
potential reason is that patients in these trials were not stratified by tumour P-gp 
overexpression, so any potential benefit that may be seen in inhibition of tumour P-
gp function was not taken into account. In all these trials [146-149], there was a 
slight benefit in the P-gp positive patients to VAD + P-gp inhibitors, but the numbers 
of patients that was evaluated was too small to show any statistical significance. 
The quantity of the P-gp expression was also not evaluated in these trials and we 
can show in our study that it has a bearing on how efficacious bortezomib is able to 
act as a P-gp substrate. 
In our study, we first quantified the P-gp expression in different cell lines by 
densitometry (Fig. 3.1.5). Fig. 3.1.2.5. suggested that P-gp expression levels play a 
part in bortezomib resistance. We showed that a cell line with a higher level of P-gp 
overexpression (DLKP-A) demonstrated reduced sensitivity to bortezomib 
compared to its parental cell line but A549-taxol, which overexpresses a much 
lower P-gp level, had minimal attenuation of bortezomib activity. This suggested 
that the level of P-gp overexpression plays a part in bortezomib resistance. We then 
demonstrated that a cell’s P-gp expression correlates with how effective bortezomib 
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is able to function as a substrate for P-gp (Fig. 3.1.6.1). DLKP-A which expresses 
the highest level of P-gp demonstrated the most synergy in the bortezomib and 
elacridar combination, whereas A549-taxol which had the lowest level of P-gp had 
mainly additive effect. In the clinical trials with P-gp inhibitor, the expression level of 
P-gp was not quantified. There is a possibility that doxorubicin has a similar effect 
as bortezomib in that the expression levels of P-gp will dictate the ability of 
doxorubicin to synergise with P-gp inhibitors. There are currently no studies 
addressing this specific question in the literature. 
It was important to determine if this synergy correlation definitely related to P-gp 
levels and was not a tumour origin or cell line specific event. To address this, we 
examined RPMI-Dox40, a MM cell line which overexpresses P-gp. Its P-gp 
expression arose from in vitro selection by doxorubicin from the parental line 
RPMI8226. To maintain the P-gp expression, a low dose doxorubicin has to be in 
the culture medium to maintain the selection pressure. In our laboratory, we had a 
variant of this cell line RPMI-Dox40 LP that has not been cultured in doxorubicin, 
therefore, the P-gp expression was reduced (Fig. 3.1.6.3A).  The RPMI-Dox40 
which have been cultured in doxorubicin (RPMI-Dox40 HP) was more resistant to 
both doxorubicin and bortezomib (Fig. 3.1.6.2) and had a higher level of synergy 
with bortezomib and elacridar compared to RPMI-Dox40 LP (Fig. 3.1.6.3). This 
result suggests that the better synergy between bortezomib and elacridar is 
dependent upon P-gp and not  the origin of the cancer or the cell line employed. For 
patients who subsequently develop P-gp expression or an increase in P-gp 
expression, we have shown that by combining a P-gp inhibitor and bortezomib, we 
should be able to overcome any P-gp-related resistance to bortezomib.    
All the clinical studies conducted to date have a common weakness (where such 
data has even been analysed) that is the small numbers of P-gp positive patients 
enrolled. These studies were done in the era before the advent of novel treatments 
and thus the patient population was relatively early in their disease, despite there 
being cases of relapse patients. With the advent of novel therapies, MM patients 
are enjoying a longer survival. However, this increased survival benefit comes with 
a price. These patients would have been exposed to more lines of treatment 
including vinca alkaloids or anthracyclines and have lived with the disease longer 
for any potential P-gp resistance to emerge or be selected for. Therefore, P-gp-
mediated resistance may yet be a potential resistance mechanism and impact 
treatment options for MM patients. It is also unclear if bortezomib-refractory patients 
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will give rise to P-gp expression such as seen with patients treated with vinca 
alkaloids and anthracyclines. If P-gp-mediated resistance were to arise in this 
treatment group, continuing with bortezomib treatment would be a viable treatment 
option if a P-gp inhibitor were included in the regime as a P-gp inhibitor could 
negate the effect of this form of resistance. Our findings indicate that the higher the 
manifested P-gp expression, the better the synergy seen when bortezomib is 
combined with a P-gp inhibitor. Thus, we have the ability to continue treating 
patients with a valuable drug for longer periods of time. 
In line with the clinical theme of this thesis, we wanted to examine if the bone 
marrow microenvironment might affect the synergistic cytotoxicity seen with 
elacridar and bortezomib. Fig. 3.1.7.2 demonstrated that although there was a slight 
attenuation of the combination in the presence of BMSCs, the synergy seen in the 
absence of BMSCs persists.  This indicates that the increased activity of 
bortezomib in combination with elacridar that might be seen in resistant MM would 
not be abrogated by the presence of other accessory stromal cells.  
 
4.1.5. Bortezomib can affect P-gp expression and function 
Previous studies have demonstrated that MDR1 overexpression occurs through 
NF-κB activation that requires a NF-κB binding site located distal to the MDR1 
promoter [330, 331].  Further publications have implicated NF-kB in upregulation of 
P-gp expression, which controls drug efflux in cancer cells [332]. Therefore, it is 
likely that increased P-gp expression participates in NF-kB-related cancer cell 
resistance to treatment. As bortezomib inhibits NF-kB, we wanted to investigate if 
bortezomib is able to affect the expression and function of P-gp.  
In this study, we demonstrated that in RPMI-Dox40 and DLKP-A cells, P-gp 
expression levels were downregulated with bortezomib treatment (Fig. 3.1.8.1). 
These results were also reported by Fujita and colleagues [324] who demonstrated 
that proteasome inhibitors decreased the expression of mdr1 at both mRNA and 
protein levels in the breast cancer cell line MCF7. Similar findings were reported 
using MG132 in gastric cancer by Zhang et al. [333].  
Although interesting to note that bortezomib can affect the expression of P-gp, what 
we wanted to probe further as to whether the P-gp function was also similarly 
affected by bortezomib treatment (since P-gp expression may not correlate with 
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function/resistance). To demonstrate P-gp function, we utilised the Rh-123 efflux 
assay. Rhodamine 123 is a P-gp substrate and is pumped out in cells containing P-
gp. The rate of efflux is dependent on the amount of P-gp present in the plasma 
membrane of the cell tested. We have demonstrated that bortezomib treatment of 
RPMI-Dox40 cells caused a reduction in P-gp function by showing an accumulation 
of Rh-123 in bortezomib-treated cells (Fig. 3.1.8.3).  This reduction in function was 
seen at all doses of bortezomib tested and maximal inhibition of function was seen 
at 2 h. 
As mentioned, NF-kB activation is thought to upregulate P-gp. When NF-kB is 
downregulated by proteasome inhibitors, P-gp expression may be downregulated 
as well.  NF-kB activation is attributed to various signalling pathways, including drug 
resistance and anti-apoptosis [334]. Bentires-Alj et al. [335] showed a role for NF-
kB in the regulation of the mdr1 gene expression in cancer cells and drug 
resistance by demonstrating that inhibition of NF-kB, through transfection of a 
plasmid coding for a mutated IkBα inhibitor, increased cellular daunomycin uptake 
and reduced mdr1 mRNA and P-gp expression in P-gp-overexpressing colon 
cancer cells. As outlined in section 4.1.2., one of the main mechanisms of action of 
bortezomib is to block the proteasomal degradation of IκB proteins which then 
prevents the activation of NF-κB. Therefore, inhibiting the NF-kB pathway with 
bortezomib might be expected to downregulate MDR1activation and P-gp 
expression. 
The ubiquitination-proteasome system is known to be involved in the degradation of 
short-lived, mutant or misfolded proteins. P-gp is a relatively stable protein with a 
half-life of 14 to 17 h [336]. It has been shown that inhibition of N-glycosylation 
increases the ubiquitination, decreases the stability and reduces the function of P-
gp [336]. Immature, core-glycosylated P-gp has a shorter half-life of approximately 
3 h [151]. In addition, Loo and Clarke [337] demonstrated that mutant forms of P-gp 
which are unable to fold into the mature forms are rapidly degraded. Schinkel et 
al.[338] proposed that N-glycosylation contributes to proper routing or stability of P-
gp. Furthermore, inhibiting N-glycosylation of P-gp has been shown to decrease 
drug resistance in cancer cells overexpressing the transporter [339]. These data 
suggest that the core-glycosylated, immature or glycosylation-deficient P-gp are the 
targets of ubiquitination-proteasome system. As mentioned in section 4.1.2, 
bortezomib is able to increase ubiquitination of cellular proteins by preventing their 
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proteasomal degradation. Thus, by increasing ubiquitination and proteasome 
mediated degradation, bortezomib is able to decrease P-gp expression. 
Another explanation for the downregulation of P-gp expression with bortezomib 
treatment may be a block in the maturation of the P-gp protein by bortezomib. Loo 
and Clarke [151] have demonstrated that MG-132, a proteasome inhibitor is able to 
inhibit the maturation of P-gp by preventing P-gp from reaching the cell surface 
after synthesis in the endoplasmic reticulum. Whether this is caused by NF-kB 
inhibition is as yet unknown. Thus, the proteasome could play a dual role in the 
folding of ABC transporter; it could promote folding of the proteins as well as 
mediate degradation of incorrectly folded proteins, inhibition of this function would 
therefore reduce the activity of the protein. 
 
4.1.6. P-gp transference between cancer and its microenvironment 
It is well established that MM-induced disruption of the BM homeostasis between 
the highly organized cellular and extracellular compartments supports MM cell 
proliferation, survival, migration and drug resistance through activation of various 
signalling pathways. Conventional chemotherapeutics such as dexamethasone and 
doxorubicin have been shown to be attenuated in the presence of BMSCs [62-64, 
280]. We know that growth factors such as cytokines and chemokines are 
responsible for MM proliferation and resistance to conventional chemotherapeutics. 
The other BM accessory cells also play a role in promoting MM growth and survival 
[61, 72]. Thus far, the literature has few clues as to whether P-gp plays a role in 
mediating resistance to chemotherapeutics in this setting. We had hypothesized 
that P-gp expression in MM cells would be upregulated when co-cultured with 
BMSCs. In fact, a recent paper by Perez et al. [340] showed that stroma-released 
factor(s) induced NF-kB activation. If NF-kB is able to upregulate P-gp [332, 335, 
341], then coculture with stroma should induce P-gp expression in MM cells. We 
investigated the expression of P-gp when MM cells were cocultured with BMSCs 
and the findings were contrary to such a hypothesis. We found that P-gp expression 
was downregulated when RPMI-Dox40 cells were coculture with BMSCs (Fig. 
3.1.9.1). This finding may be explained by transference of P-gp protein to the 
BMSCs so when the P-gp expression of the MM cells was measured, there was 
less measurable P-gp in the MM cells.  It has been reported that intercellular 
transfer of functional P-gp from P-gp-positive to P-gp-negative cells in vitro and in 
vivo can occur and causes increased drug resistance in the recipient cells [281]. 
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Most importantly, such transfer-acquired resistance permits tumour cells to survive 
potentially toxic drug concentrations long enough to develop intrinsic P-gp-mediated 
resistance. P-gp transfer also occurs to putative components of tumour stroma, 
such as fibroblasts, raising the possibility that multidrug resistance could be 
conferred by resistant tumour cells to critical stromal elements within the tumour 
mass [281].  
In this present study, we demonstrated that BMSCs cocultured with MM cells 
acquired P-gp from them. As far as we know, this is the first study to evaluate this 
phenomenon in MM. Whether this observation of P-gp transference is the 
explanation that the activity of anthracyclines against MM is reduced in the 
presence of the BMSCs requires further study. P-gp transference has also been 
suggested to occur in solid tumours where it was observed that an increase in the 
proportion of cells expressing P-gp is evident after exposure to a combination 
chemotherapy program containing drugs known to select for P-gp expression in 
vitro. It is a common observation that there is an increase in P-gp expression in the 
endothelial cells within the tumour mass at these sites. The observation of 
increased immunoreactive endothelial cells suggests transactivation of the MDR1 in 
these cells and subsequent drug resistance [342]. Although bortezomib is also a 
substrate of P-gp, the reason that its activity is not attenuated by BMSCs is most 
likely because bortezomib works via a different mechanism from anthracyclines.  
What is yet unknown, is whether this downregulation or upregulation of P-gp 
expression in both MM and stromal cells in a coculture is correlated with changes in 
P-gp function. In this present study, we showed that in MM cells a downregulation 
of P-gp expression was associated with a reduction in P-gp function (Fig. 3.1.9.4). 
At each time point time tested, there was an increase in median fluorescence 
intensity of Rh-123 in the MM cells that were cocultured with BMSCs compared to 
the MM cells that were not cocultured. However, the transferred P-gp (from RPMI-
Dox40 to BMSCs) was shown to be non-functional (Fig. 3.1.9.7). When the stromal 
fraction of the coculture was analysed, the transferred P-gp was not functional as 
evidenced by the lack of Rh-123 extrusion in the absence of verapamil. This finding 
is different from that reported by Levchenko et al. [281]. Using P-gp labelling and 
dye extrusion assays, these authors demonstrated cell co-incubation results in a 
functional P-gp transfer from P-gp-positive to P-gp-negative cells.  
The reason for the difference seen between our findings and Levchenko’s is 
unclear. It may be that the P-gp transfer to BMSCs seen in our coculture system 
 
 
222
was minimal whereas there was a much greater transfer of P-gp in their study. This 
could be related to the longer co-incubation time used in Levchenko’s study (8 days 
vs. 3 days). The P-gp that was transferred may be detectable but not of a quantity 
to be able to confer a phenotype in the stromal cells. It may also be related to 
different cell lines used in the study, Levchenko’s study utilised neuroblastoma cells 
and its P-gp positive derivative whereas we used two different cell lines (RPMI-
Dox40 and BMSCs, HS-5), one malignant and one non-malignant. Further 
experiments will have to be done to investigate this further. 
 
 
223
4.2 Investigation of p53 signalling perturbations in Multiple Myeloma 
resistance  
4.2.1. The relationship between Mdm2 and p53 
p53 activity in transcription, translation and protein stability is tightly controlled. The 
main stimuli of p53 expression include DNA damage (caused by UV, ionizing 
radiation, or genotoxic drugs), oxidative stress, osmotic shock, ribonucleotide 
depletion, and deregulated oncogene activation. Genotoxic stress activates PI3 
kinase-like-kinases including DNA-PKc, Atm, and Atr at the DNA break sites, which 
in turn phosphorylate p53, Mdm2 and other proteins, leading to p53 
stabilization/activation [343]. 
In normal unstressed cells, p53 activity is maintained at a low level through a 
combination of p53 degradation and direct transcriptional repression, principally 
mediated by Mdm2 and Mdm4 (also known as MDMX in humans) [164]. p53 and 
Mdm2 interact with each other through an autoregulatory feedback loop. When p53 
is activated, it transcribes the Mdm2 gene and in turn, the Mdm2 protein inhibits 
p53 activity by binding to the p53 transactivation domain and inhibiting its 
transcriptional activity [165]. Mdm2 also ubiquitinates p53 in the nucleus and is 
responsible for exporting p53 out of the nucleus, promoting its degradation via the 
ubiquitin/proteasome pathway [166] and rendering it inaccessible to the target 
genes (Fig. 4.2.2). On the other hand, Mdm2 is a direct target of p53. Therefore, 
elevation of p53 upregulates Mdm2, which in turn downregulates p53 [164]. The 
significance of this regulatory loop is manifested by the genetic studies of Mdm2–/– 
and Mdm2–/–p53–/– mice. Knockout mice of Mdm2 show embryonic lethality, 
accompanied by an elevation of p53. Deletion of p53 in Mdm2–/– mice rescued the 
embryonic lethality phenotype, suggesting that p53 mediates the effects of Mdm2 
deficiency on mouse development and survival [167, 168].  
Mdm2 negatively regulates the stability of p53. Ubiquitination by Mdm2 is 
necessary for p53 nuclear export and degradation. The ubiquitination is dependent 
on the association between these two proteins [344]. Mdm2 binding-deficient p53 
mutant could not be ubiquitinated by Mdm2 [345]. Furthermore, ubiquitination 
depends on p53 oligomerization as Mdm2 could not target oligomerization-deficient 
p53 for ubiquitination [346]. Ubiquitinated p53 exists in two forms, 
monoubiquitination, which might elicit nuclear export of p53, and polyubiquitination, 
which promotes proteasomal degradation of p53 [347]. In addition, it is reported that 
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phosphorylation of p53 at Ser46 renders p53 resistant to Mdm2-mediated 
ubiquitination [348]. 
Besides mediating p53 turnover, Mdm2 could also affect the activity of p53 through 
various mechanisms. First, Mdm2 binds to the transactivation domain of p53 and 
inhibits its transcriptional activity possibly through blocking its access to target 
genes [165]. Secondly, Mdm2 inhibits the translation of p53 by targeting ribosomal 
protein L26 (RPL26) that would otherwise enhance p53 mRNA translation [349].  
 
4.2.2. The role of p53 in apoptosis  
Apoptosis occurs through either one of two major pathways described as either the 
intrinsic mitochondrial or extrinsic death receptor pathway (Fig. 4.2.2). In the 
intrinsic pathway, nuclear p53 induces Puma expression, which in turn releases 
cytosolic p53 held inactive in the cytoplasm through binding to Bcl-XL. Then, 
cytosolic p53 induces Bax oligomerization and mitochondrial translocation. 
Accumulation of p53 in the cytosol as a consequence of normal intracellular 
transport or stable monoubiquitination is the major source for mitochondrial p53. In 
the mitochondria, p53 induces Bax and Bak oligomerization, antagonizes the Bcl-2 
and Bcl-XL antiapoptotic effect, and forms a complex with cyclophilin D in the 
mitochondrial inner membrane. These changes result in marked disruption of 
mitochondrial membranes and subsequent release of both soluble and insoluble 
apoptogenic factors ultimately leading to caspase activation and apoptosis.  
Cells committed to die via p53-dependent apoptosis typically follow the 
mitochondrial pathway, although p53 can also modulate cell death through death 
receptors. Furthermore, most evidence suggests that the key contribution of p53 to 
apoptosis is primarily dependent on transcriptional activity. p53 has the ability to 
activate transcription of various proapoptotic genes, including those encoding 
members of the Bcl-2 family, such as the BH-3 only proteins Bax, Noxa, and Puma.  
Alternatively, p53 can also trigger apoptosis by repression of antiapoptotic genes, 
such as survivin, thus promoting caspase activation [350]. 
Acting on the death receptor pathway of apoptosis, p53 overexpression enhances 
cell surface levels of Fas by promoting its trafficking from Golgi complex [351]. In 
addition, p53 activates DR5, the death domain-containing receptor for TRAIL; DR5 
is induced in response to DNA damage and in turn, promotes cell death through 
caspase-8 [352]. Genes for proapoptotic proteins that may link apoptotic pathways, 
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such as bid and the p53-induced protein with a death domain (PIDD), were also 
described as transcriptional targets of p53. Importantly, p53 is also involved in the 
activation of the apoptosome via induction of Apaf-1 expression [353]. 
p53 apoptotic function is not limited to transcriptional dependent activities, there is 
now emerging evidence that the proapoptotic functions of p53 are transcription-
independent. Activation of p53 in enucleated cytoplasts is sufficient to directly or 
indirectly trigger apoptosis by inducing proapoptotic Bcl-2 family members [354]. A 
stress-stabilized cytoplasmic pool of p53 is probably the major source for p53 
mitochondrial translocation; however, it is still a matter of debate on how the pool is 
generated. Some authors contend that unstressed cytoplasm contains a mixture of 
unstable polyubiquitinated p53 that is almost immediately targeted for proteasomal 
degradation, and functional monoubiquitinated p53 that serves as a source for p53 
translocation to mitochondria. In the mitochondrion, p53 induces Bax and Bak 
oligomerization, physically interacts with protective Bcl-XL and Bcl-2, antagonizing 
their antiapoptotic effects, and also forms a complex with cyclophilin D leading to 
disruption of mitochondrial structure [355]. 
In addition to mitochondrial-targeted p53 actions, an alternative cytosolic p53 death 
pathway was recently reported that directly activates cytosolic Bax in UV-treated 
transformed mouse embryonic fibroblasts [356]. After stress, nuclear p53 induces 
transcription of puma, which in turn, liberates p53 from an inactive pre-existing 
soluble p53-Bcl-XL complex, via binding to Bcl-XL. The cytosolic p53 then induces 
homo-oligomerization of Bax, followed by Bax mitochondrial translocation. Cytosolic 
p53 may also modulate other mechanisms apart from apoptosis. As an example, 
cytosolic p53 operates at the mitochondria to repress autophagy [357]. 
p53 driven apoptosis is very complex and we are only now starting to understand all 
facets of this interesting protein. 
 
 
226
 
Figure 4.2.2  Regulation of p53 and Mdm2 and the outcomes of p53 
activation.  
(A) Mdm2 inhibits p53 through an autoregulatory loop. Mdm2 directly binds to the 
transactivation domain of p53 and inhibits its transcriptional activity, causes the 
ubiquitination and proteasomal degradation of p53, and exports p53 out of the 
nucleus which promotes p53 degradation and inhibits its activity. MDMX, a 
homologue of Mdm2, also directly binds to the transactivation domain of p53 and 
inhibits p53 activity, but does not induce p53 degradation. ARF binds to Mdm2 and 
sequesters Mdm2 into the nucleolus, leading to the stabilization of p53.  
(B) Activation of p53 can also lead to induction of apoptosis via intrinsic 
(mitochondrial) and extrinsic (death receptor) apoptosis pathways. Apoptosis can 
be transcriptional-dependent or -independent because p53 itself can participate in 
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mitochondrial mediated apoptosis through interaction with proapoptotic and 
antiapoptotic members of the Bcl-2 family.  
(C) Activation of p53 can halt cell cycle progression in the G1-S and G2-M 
boundaries of cell cycle through the up-regulation of the p21, Gadd45, and 14-3-3-j 
proteins. Transition into the S-phase requires cyclin-dependent kinases (CDK), 
such as CDK2, which phosphorylates and inactivates Rb, rendering E2F free and 
transcriptionally active, leading to cell cycle progression. However, p53 activation 
induces the CDK inhibitor p21, which leads to cell cycle arrest. Furthermore, 
Cdc2/cyclinE activity is essential for entry into mitosis, and this activity can be 
inhibited by p21, Gadd45, and 14-3-3-j, resulting in G2-M phase arrest.  
(D) Senescence is a potent tumour suppressor mechanism of p53. Telomere 
erosion, DNA damage, and oxidative stress or oncogenic stress can signal p53 
activation, triggering senescence response via the p21-Rb-E2F signaling pathway. 
Oncogenic Ras can activate MAP kinase pathway that phosphorylates and 
activates p53 and also induces the expression of ARF, which in turn binds to and 
inhibits Mdm2, leading to the up-regulation of p53 and the induction of senescence.  
(E) p53 can suppress angiogenesis through the down-regulation of proangiogenic 
proteins 
and up-regulation of antiangiogenic proteins. In addition, p53 can bind to HIF-1a, a 
promoter of angiogenesis during hypoxia, and target it for degradation by Mdm2. In 
a p53-independent manner, HIF-1a interacts with the p53-binding domain of Mdm2, 
and transcriptionally up-regulates the vascular endothelial growth factor (VEGF) 
promoting angiogenesis.  
(F) p53 plays a critical role in DNA damage repair. DNA damage and replication 
errors can activate ataxia telangiectasia mutated (ATM) and ataxia telangiectasia 
and Rad-related (ATR) kinases, which trigger several cellular responses, including 
DNA repair. ATM and ATR can phosphorylate DNA repair protein 53BP1 as well as 
induce the accumulation of p53 through phosphorylation directly or via CHK1and 
CHK2 kinases. p53 participates in DNA repair in a transactivation-dependent 
manner through the up-regulation of proteins such as p53R2 (p53-inducible small 
subunit of ribonucleotide reductase), p48 (gene product of DDB2 gene), and XPC 
(xeroderma pigmentosum group C protein), and in an independent manner through 
interaction with other DNA repair proteins, such as 53BP1. 
 
(Figure from [358])  
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4.2.3. The current role that bortezomib has in Multiple Myeloma and 
solid tumours 
The proteasome inhibitor bortezomib represents a significant advance in the 
therapeutic armamentarium against MM. However, resistance to bortezomib, de 
novo or acquired, is an important obstacle to achieving better clinical results. 
Furthermore, bortezomib has not been shown to be active against most solid 
tumours. Research is therefore trying to identify clinically applicable approaches 
that would allow us to extend bortezomib activity against a broader spectrum of 
tumours. In that context, we compared responses to bortezomib in MM versus solid 
tumour models to delineate mechanisms of differential bortezomib responsiveness.  
Bortezomib induces phosphorylation of p53 at serine 15 and induction of p53 
phosphorylation is associated with s increased p53 mRNA and protein levels [278]. 
It is unclear whether phosphorylation of p53 causes the dissociation of p53 from the 
p53/Mdm2 complex. Some studies have demonstrated that it does but others have 
shown that phosphorylated p53 is still associated with Mdm2 [278]. p53 and Mdm2 
interact with each other through an autoregulatory feedback loop. When p53 is 
activated, it transcribes the Mdm2 gene and in turn, the Mdm2 protein inhibits p53 
activity by binding to the p53 transactivation domain and inhibiting its transcriptional 
activity [165]. Mdm2 is also responsible for exporting p53 out of the nucleus, 
promoting its degradation via the ubiquitin/proteasome pathway [166] and rendering 
it inaccessible to the target genes. We hypothesized that inhibition of Mdm2, the E3 
ubiquitin ligase that ubiquitinates p53 and promotes its proteasomal degradation, 
could enhance p53 stabilization in bortezomib-treated MM cells, with a resultant 
synergistic effect on apoptosis induction. 
 
4.2.4. The role of single agent Nutlin-3 in Multiple Myeloma and 
epithelial carcinomas 
Many of the currently used cytotoxic drugs owe their antineoplastic effects to 
induction of apoptotic pathways. However, their therapeutic activity is a trade-off 
between efficacy and adverse effects, resulting in unspecific genotoxic collateral 
damage, which may induce genetic instability, selection of drug-resistant tumour 
subclones, and secondary malignancies. In contrast to the short-term side effects of 
genotoxic therapy, such as nausea, vomiting, mucositis, myelosuppression, and 
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infection, which are reversible and manageable, these long-term side effects are 
irreversible and cannot be managed clinically. Non-genotoxic activation of the p53 
pathway would therefore be an attractive therapeutic strategy for cancers with intact 
p53-dependent signalling. That was the basis of development of Mdm2 inhibitors 
such as nutlins. 
In our study, MM cell lines and epithelial tumours were sensitive to nutlin-3, 
although epithelial tumours were affected to a lesser extent than MM cells (Fig. 
3.2.2). This is in agreement with other studies in the literature [172, 179, 186, 188, 
359]. As an Mdm2 inhibitor, nutlin-3 is able to upregulate expression of several p53-
dependent targets including Bax, PUMA, Noxa, p21, and Mdm2 itself amongst 
others (Table 3.2.3). As in this thesis, the nutlin-3 used is a racemic mixture and not 
a pure solution of the active enantiomer, the doses used to affect cytotoxicity either 
as a single agent or in combination with bortezomib are in the mid-micromolar 
range rather than low micromolar range that would be common for small molecule 
inhibitors.   
The cellular response to genotoxic stress that damages DNA includes cell cycle 
arrest, activation of DNA repair, and in the event of irreparable damage, induction of 
apoptosis. When cells encounter genotoxic stress, certain sensors for DNA lesions 
eventually stabilize and activate p53. Caspase-3 cleavage was seen with nutlin-3 
treatment even though nutlins are a non-genotoxic drug. This is caused by p53 
activation of the apoptotic pathway (Fig. 3.2.3A). However, the pro-apoptotic effect 
of nutlin-3 was partially attenuated by the pan-caspase inhibitor, ZVAD-FMK (Fig. 
3.2.3B), suggesting that caspase activity is not the sole mechanism of nutlin-3 
induced cellular death. 
We have shown that nutlin-3 has anticancer activity on its own at low micromolar 
range for MM cells and at a mid micromolar range for epithelial tumours. We 
hypothesised that this activity and the potency of the drug could be increased by 
combination with bortezomib.  
 
4.2.5. The combined role of Mdm2 inhibitor and bortezomib 
We found that the combination of the Mdm2 inhibitor, nutlin-3, with bortezomib 
demonstrated lack of synergistic cytotoxicity against bortezomib-sensitive MM cell 
lines MM.1S, MM.1R, and NCI-H929 (Fig. 3.2.4.1). The calculated combination 
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index using Calcusyn software was >1. Of all the MM cell lines tested, KMS-11 was 
the only one that demonstrated synergistic cytotoxicity with the combination of 
nutlin-3 and bortezomib. It should be noted that KMS-11 is less sensitive to single 
agent nutlin-3 compared to the other MM cell lines tested. Its response to nutlin-3 
single agent was comparable to epithelial cancers. 
This combination however, demonstrated synergistic activity against epithelial 
cancer cell lines including thyroid, breast and prostate carcinomas (Fig. 3.2.4.2). 
The calculated combination index for all the epithelial cancer cell lines was <1. In 
the MM1.S and MM1.R cell lines, which were the most sensitive cell lines to nutlin-
3, the IC50 was 2µM. In the epithelial cancer cell lines, the IC50 was > 30µM. 
Direct inhibition of the E3 ubiquitin ligase, Mdm2, stabilizes p53 and activates the 
p53 apoptotic pathway in a non-genotoxic manner and, therefore, represents a 
promising approach for the treatment of cancer [177]. Treatment of MM cells with 
nutlin-3, which interrupts the p53-Mdm2 interaction, increases protein levels of p53, 
thereby inducing p53 targets and apoptotic cell death [179]. The differential 
response of MM versus epithelial malignancies to the combination of bortezomib 
with nutlin-3 sheds light on the role of p53 in bortezomib-induced apoptosis and 
suggests a complex, tissue-dependent, interaction between the MDM2/p53 and 
proteasome pathways. It is possible that p53 is more important for bortezomib-
induced apoptosis in epithelial malignancies than in MM. Mutations in p53 are very 
common in epithelial malignancies, whereas in MM, they have been historically 
considered to be present in only late stage disease (e.g., plasma cell 
leukaemia/extramedullary MM). However, their prevalence may increase in the 
future, because patients with advanced MM survive longer due to the therapeutic 
efficacy of novel agents including thalidomide, bortezomib, and lenalidomide. It is 
also possible that epithelial cancers that are bortezomib refractory may have more 
potential for sensitization upon Mdm2 inhibition than MM cells, which are more 
responsive to single-agent bortezomib and nutlin-3. We have also found that in 
KMS-11 MM cell line where the single agent nutlin-3 activity is more on par with 
epithelial cancer cell lines tested, the combination of nutlin-3 and bortezomib was 
synergistic (Fig. 3.2.4.1). Importantly, however, in advanced MM with p53 pathway 
lesions and bortezomib-resistance/refractoriness, concurrent Mdm2 inhibition may 
restore bortezomib sensitivity. 
Ubiquitinated p53, in particular Mdm2-ubiquitinated p53, is, in general, 
transcriptionally inactive [360]. Ubiquitination targets p53 not only for proteasomal 
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degradation, but also for nuclear export and cytosolic localization, thus eliminating 
the opportunity for binding to DNA [360]. Also, many of the same sites that are 
ubiquitinated by Mdm2 can also be acetylated by p300/CBP to promote p53 
activation. Acetylation of p53 is essential for the binding of p53 to p53-binding 
elements promoting transcription of various apoptosis or cell cycle arrest genes, 
including p21, PUMA, BAX, and Noxa [360]. However, when Mdm2 ubiquitinates 
p53, the latter cannot be acetylated by p300/CBP and becomes transcriptionally 
inactive, even in the absence of proteasome-mediated degradation [360]. This 
could explain why p53 does not seem to play a major role as a mediator of the 
effects of bortezomib monotherapy, because, although its total levels are increased 
in the presence of bortezomib [278], it is still ubiquitinated and functionally 
inactivated by Mdm2 [360]. Also, it provides another mechanism to explain the 
synergistic activity of bortezomib together with nutlin-3, which we describe in this 
study: the addition of Mdm2 inhibition to proteasome inhibition not only further 
stabilizes p53 and increases its protein levels, but also blocks its ubiquitination and 
transcriptional inactivation, thus making it more functional.  
 
4.2.6. The combination of Nutlin-3 and bortezomib enhances the 
activation of the p53 apoptotic pathway  
We next investigated the mechanism for the differential sensitivity of MM vs. 
epithelial cell lines to the combination of bortezomib with nutlin-3. Western blot 
analysis of MM cells treated with this combination demonstrated no evidence of 
synergistic activation of the p53 pathway and apoptosis mediators (Fig. 3.2.5), 
consistent with the lack of enhanced killing effect. In contrast, there was synergistic 
activation of the p53 pathway and apoptosis, associated with upregulation in p53, 
Mdm2, Noxa, and PUMA expression, as well as enhanced cleavage of PARP and 
caspase-3 (Fig. 3.2.5) when the epithelial carcinoma cell line was treated with this 
drug combination. These results were consistent with the lack of synergy seen in 
MM (Fig. 3.2.4.1) and synergistic activity seen in epithelial carcinoma (Fig. 3.2.4.2). 
This upregulation in p53 and its downstream markers explains the synergy seen 
when bortezomib is combined with nutlin-3. Enhanced cleavage of PARP and 
caspase-3 suggests that the p53 apoptotic pathway is activated. 
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4.2.7. Nutlin-3 may counteract molecular pathways associated with 
decreased responsiveness to bortezomib  
We had a hypothesis that cancers that are bortezomib refractory may have more 
potential for sensitization upon Mdm2 inhibition as outlined in Section 4.2.3... To 
probe this hypothesis, we next evaluated whether the transcriptional signature of 
tumour cell response to nutlin-3 treatment was enriched in genes which may 
correlate with clinical outcome.   
Bortezomib-treated MM patients enrolled in phase II SUMMIT and phase III APEX 
trials were divided into cohorts with high vs. low expression of nutlin-3-suppressed 
genes. A transcriptional index of tumour cell response to nutlin-3 was identified, 
based on previously published studies of transcripts selectively downregulated by 
nutlin-3 treatment [180]. Bortezomib-treated patients who had, at baseline, high 
expression of nutlin-3-suppressed genes had significantly shorter progression-free 
(panel A, p=0.001, log-rank test) and OS (panel B, p=0.002, log-rank test) 
compared to those with low expression levels (Fig 3.2.8). This observation suggests 
that if patients tumours responded to nutlin-3 in the same way as the cellular 
models employed, treatment with nutlin-3 might counteract molecular pathways 
associated with decreased responsiveness to bortezomib and thereby overcome 
clinical bortezomib resistance. 
 
4.2.8. Nutlin-3 activity in the presence of bone marrow stroma cells 
As mentioned, the BM microenvironment plays an important role in MM growth, 
proliferation, survival and drug resistance (Chapter 1.3). Interactions of MM cells 
with normal cells of the bone marrow milieu can attenuate the antitumour activity of 
conventional therapies, such as glucocorticoids, standard cytotoxic agents, such as 
alkylators, and novel targeted therapies, such as bortezomib [27]. In our opinion, all 
new treatments for MM and combination treatments should be tested in the 
presence of stroma to ensure that there is no attenuation of activity. 
In this study, we found that co-culture with BMSCs partially attenuated the response 
of MM cells to nutlin-3 (Fig.3.2.6.2). This is consistent with evidence that interaction 
with BMSCs suppresses p53 activity in highly bortezomib-responsive MM cells, 
MM1.S (Fig. 3.2.6.1). Quantitative RT-PCR of MM1S cells co-cultured with BMSCs 
demonstrated decreased expression of p53 and gene transcripts known to be 
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induced by p53 including Mdm2 [284], Bax [285], Noxa [286], PUMA [287], BTG1, 
DAPK1 [288], GADD45B, ID2, Jun, Plk1, and Plk2 [289]. These results suggest that 
co-culture with BMSCs triggers downregulation of the p53 pathway in MM cells, 
which can contribute to resistance to apoptosis, leading to attenuation of activity in 
the presence of BMSCs. We next wanted to assess if the downstream effectors of 
p53 would be upregulated upon nutlin-3 treatment in the presence of stroma, since 
its activity was attenuated. Importantly, however, treatment with nutlin-3 was able to 
induce the expression of Mdm2 (Fig. 3.2.6.3A), PUMA (Fig. 3.2.6.3B), Noxa, Bax 
and GADD45B, even in the presence of BMSCs. This implies that the drug is still 
having an effect although somewhat blunted by the presence of BMSCs. 
As noted above, the combination of nutlin-3 with bortezomib mediates additive 
cytotoxicity against MM cells, but triggers synergistic cytotoxicity against epithelial 
carcinoma cell lines. We investigated whether this latter effect persists in the 
presence of BMSC. This is important to evaluate as other cancer types also 
metastasise to the BM. We evaluated the impact of BSMCs on the effect of the 
combination of nutlin-3 with bortezomib on MDA-MB-231 met-luc-neo cells. This is 
a breast cancer cell line that was generated from bony metastasis, making this a 
relevant clinical model. We demonstrated that co-culture with BSMCs did not 
protect against the synergistic pro-apoptotic effect of the combination of nutlin-3 
with bortezomib in this epithelial carcinoma model (Fig. 3.2.7). These data suggest 
that the enhanced activity of nutlin-3 combined with bortezomib against epithelial 
models of cancer is unlikely to be inhibited by microenvironmental interactions.  
Thus, the combination of Mdm2 inhibitors and proteasome inhibitors promises to 
have good anticancer activity clinically.  
Clinically relevant preclinical models can help identify drug combinations with 
enhanced anticancer activity. We have previously reported that DNA-damaging 
chemotherapeutics including doxorubicin and melphalan induce synergistic MM 
cytotoxicity when combined with bortezomib [44]. This approach has been validated 
clinically [46, 190], and the combination of bortezomib with pegylated liposomal 
doxorubicin or with melphalan plus prednisone are now Food and Drug 
Administration–approved anti-MM combination regimens. We now report that non-
genotoxic activation of the p53 pathway using nutlin-3 can sensitize epithelial 
carcinoma cells to bortezomib in a manner that is not suppressed by 
microenvironmental interactions. These observations suggest that concurrent 
Mdm2 inhibition with nutlin-3 may extend the spectrum of bortezomib activity to 
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solid tumours, and also overcome bortezomib resistance in advanced MM. Our 
studies further provide the framework for derived combination clinical trials to 
improve outcome in patients with solid tumour and hematologic malignancies. 
 
 
4.2.9. Mdm2/p53 interaction independent of p53  
It is always thought that Mdm2 regulates tumourigenesis only when p53 is present. 
However, there is evidence that Mdm2 can mediate tumourigenesis independent of 
p53 [361]. For example, studies of human sarcomas and bladder cancers showed 
that a subset of these tumours overexpressed Mdm2 in addition to having mutated 
p53, and those patients whose tumours had both abnormalities had decreased 
survival compared with patients with tumours possessing either abnormality alone 
[362, 363]. Furthermore, one third of lymphomas that emerged in EA-myc 
transgenic mice that have mutated or deleted p53 also overexpressed Mdm2 [364]. 
For a tumour to overexpress Mdm2 and inactivate p53 would seem redundant, 
unless Mdm2 has other functions besides the regulation of p53. Alt et al.[365] have 
identified the Mre11/Rad50/Nbs1 (M/R/N) DNA repair complex in 
immunoprecipitations of endogenous Mdm2 from cells lacking functional p53. The 
M/R/N complex contributes to the preservation of genome stability by participating 
in DNA double-strand break repair, cell cycle check point control, and telomere 
maintenance [366]. The M/R/N complex functions in signalling the presence of DNA 
breaks, as well as the initial enzymatic processing of the broken DNA [366]. Mdm2 
was shown to associate with the M/R/N DNA repair complex by specifically binding 
to Nbs1, a protein critical for genome stability [365]. Maintaining genome integrity is 
essential for the prevention of transformation, and several reports provide evidence 
that altered Mdm2 levels affect genome stability. In vitro experiments showed that 
expression of Mdm2 at levels 2- to 4-fold higher than endogenous levels led to 
centrosome amplification and chromosome instability [367]. This increase in 
genomic instability caused by Mdm2 overexpression promoted the transformation of 
p53-null MEFs, and an intact Nbs1-binding domain in Mdm2 was required for the 
increased transformation potential of Mdm2 [368]. These studies showed that 
elevated levels of Mdm2 compromise genomic stability, leading to transformation 
independent of p53 and dependent on interaction with Nbs1. 
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Nutlins have been shown to have activity in p53-deleted or p53-mutated cells, 
Nutlins are able to activate alternative transcription factors, in particular E2F1 [181, 
182]. E2F1 can induce proliferation or apoptosis depending on the cell context and 
depending on the simultaneous activation of the Akt-prosurvival pathway [183]. 
Another study has demonstrated that Nutlins are able to induce apoptosis in p53-
null cells through activation of p73 [184]. p73 is a homolog of p53 and is able to 
transactivate proapoptotic genes and induce cell death. It is also regulated by 
Mdm2. These two targets make Nutlin a viable therapeutic option even when p53 is 
deleted or mutated. 
We hypothesised that we would continue to see synergy in p53 deleted/mutated 
cell lines with bortezomib and nutlin-3 combination. This investigation is important 
as most cancers are p53 mutated. Although MM in general, has little p53 mutation 
in early stage disease, there is mounting evidence that p53 deletion is a poor 
prognostic indicator [369]. There is also evidence that bortezomib therapy is unable 
to overcome the poor prognosis of chromosome 17p deletion [173].  
To demonstrate if the synergy between bortezomib and nutlin-3 persist in a p53 
independent situation, we utilised two p53 mutated cell lines; OPM2 and ANBL6. 
Fig. 3.2.9.1 showed that in both these cell lines, there was synergistic cytotoxicity in 
the combination. Synergy was calculated using Calcusyn (Table 3.2.9). Of note, 
these two cell lines are MM cell lines. In Fig. 3.2.4.1, we had shown that the 
combination of bortezomib and nutlin-3 did not yield synergy  All the cell lines used 
then are p53 wild type. The p53 mutated cell lines appear to be less sensitive to 
single agent nutlin-3, requiring higher doses compared to p53 intact cell lines. For 
example, MM1.S a sensitive p53 intact MM cell line had an IC50 of 2µM whereas 
ANBL6, a p53 mutated MM cell line had an IC50 of 30µM nutlin-3. However, the 
combination of nutlin-3 and bortezomib appears to be more potent as, in the p53 
mutated cell lines, we showed synergy when we did not demonstrate that in p53 
intact cell lines. As we had mentioned before (Section 4.2.5), the exquisite 
sensitivity of p53 intact MM cell lines to single agent nutlin-3 may render the 
combination less potent as there is major cytotoxicity with single agent alone. 
We then wanted to study if the activity of bortezomib and nutlin-3 would persist in a 
bortezomib resistant cell line. Using the subline of ANBL6 which developed 
bortezomib resistance in vitro with repeated exposure to bortezomib 5nM; ANBL6-
VR5 (courtesy of Dr Robert Orlowski, MD Anderson Cancer Center); we showed 
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that the combination of bortezomib and nutlin-3 continued to effect synergy (Fig. 
3.2.9.2A). 
Tabe et al recently reported that Nutlin-3 and bortezomib had synergistic anti-
proliferative effects in both p53 mutant- and p53 wild type-bearing mantle cell 
lymphoma cells .[359]. On a follow up to that study, it was demonstrated that the 
combination of nutlin-3 with bortezomib mainly induced synergistic cytotoxicity by 
apoptotic cell death [370]. The authors found that the nutlin-3 and bortezomib 
combination enhanced NOXA protein expression in p53 mutant-cells but not in wild 
type mantle cell lymphoma cells. They concluded that the combination of sublethal 
concentrations of nutlin-3 and bortezomib lead to an accumulation of NOXA protein 
by transcription-independent mechanisms as there was no increase of NOXA 
mRNA levels in the study. 
This result is different from our study which found that there the combination of the 
two drugs demonstrated an increase in NOXA protein expression in wild type p53 
cells that exhibited synergistic cytotoxicity i.e., the epithelial cancer cells. This 
difference between the two studies could be a cell specific effect or it is more likely 
related to the fact that NOXA upregulation is a result of bortezomib and nutlin-3 
combination. 
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4.3 Activation of AMP-kinase pathway as an alternative to overcome 
drug resistance in Multiple Myeloma 
 4.3.1. AMPK pathway in Multiple Myeloma 
AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase and 
serves as an energy sensor in all eukaryotic cells. AMPK is activated under 
conditions that deplete cellular ATP and elevate AMP levels such as glucose 
deprivation, hypoxia, ischaemia and heat shock which are associated with an 
increased AMP/ATP ratio [192]. As a result of the activation, AMP binds to the γ 
subunit causing phosphorylation of threonine 172 in the activation loop of the α 
catalytic subunit by upstream kinases such as LKB1 and CaMKK. 
LKB1 is a serine/threonine protein kinase and is the product of the gene lkb1. In 
patients with Peutz-Jeghers syndrome (PJS), this gene is mutated. Mutations in 
PJS patients were shown to be loss of function mutations of LKB1 ([193, 194]. PJS 
is characterized by mucocutaneous melanin pigmentation, gastrointestinal 
polyposis and markedly increased risk of cancer.  LKB1 mutants that are inactive 
failed to suppress cell growth indicating that LKB1 has antiproliferative function and 
hence anti-tumour effect. LKB1 also induced p53 and p21 upregulation resulting in 
cell cycle arrest in melanoma cells [195] providing further evidence that it can 
function as a tumour suppressor. Several studies from different groups have shown 
a clear connection between LKB1 and AMPK-induced cell cycle arrest [196, 197]. 
Several groups have reported that activation of AMPK suppresses mTOR signalling 
by growth factors and amino acids [198-200]. When AMPK is activated, TSC2 is 
phosphorylated at Thr-1227 and Ser-1345 and increases the activity of TSC1–
TSC2 complex to inhibit mTOR [201]. In addition, AMPK reportedly phosphorylates 
mTOR at Thr-2446 to reduce S6K1 phosphorylation by insulin, suggesting the 
inhibition of mTOR action [202]. Thus, AMPK directly and indirectly (via TSC2) 
suppresses mTOR activity to limit protein synthesis through the inhibition of 
translation elongation factor 2 (EF2). Therefore, AMPK activation regulates cellular 
proliferation in response to energy status or nutrient availability by limiting cell 
growth and proliferation when there is a lack thereof. 
The mammalian target of rapamycin (mTOR) is an evolutionarily conserved 
serine/threonine kinase and a key regulator of protein translation/synthesis and cell 
growth [203, 204]. The mTOR pathway is activated by amino acids and by growth 
factors (e.g. PDGF, epidermal growth factor (EGF) and insulin. This stimulates 
protein synthesis, cell growth and proliferation. mTOR increases translation 
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initiation of 5′-terminal oligopyrimidine tract-containing mRNAs, which encode 
components of the protein synthesis machinery. The downstream effectors of 
mTOR ribosomal protein S6 kinase 1 (p70S6K1 or S6K1) and the eukaryotic 
translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) stimulates the 
initiation step of translation [205].  
The PI3K-Akt-mTOR pathway is a crucial signalling pathway for cancer 
pathophysiology. Somatic activating mutations and/or gene amplification of the 
PIK3CA gene (which encodes the p110α catalytic subunit of PI3K), the PIK3R1 
gene (that encodes for the p85α subunit of PI3K), and the AKT genes or somatic 
inactivating mutations, deletions and gene silencing of the PTEN gene (that 
encodes for a phosphatidylinositol-3,4,5-trisphosphate 3'-phosphatase that turns off 
the PI3K pathway), as well as numerous upstream receptor tyrosine kinases can 
activate the PI3K-Akt-mTOR pathway in cancer cells [371, 372]. Targeting mTOR 
signalling with small molecule inhibitors, e.g. temsirolimus, have some positive 
response in the clinic for breast cancer, renal cell carcinoma and non-Hodgkin 
lymphoma [373-375]. 
AMPK activation is a feasible therapeutic strategy for these cancers since AMPK 
inhibits mTOR signalling downstream of Akt, and inhibition of mTOR pathway has 
been reported to inhibit tumour growth and metastasis in experimental animal 
models as well as in cultured cells. Activation of AMPK by metformin, AICAR or 
thiazolidinediones or expression of constitutively active mutants have been shown 
to cause apoptosis or cell cycle arrest of various cancer cells. On the other hand, 
activation of this pathway has been shown to be protective on non-neoplastic 
tissues such as injured cells in cardiac ischemia and reperfusion injury models [215, 
216]. AMPK activation protects human umbilical vein endothelial cells from 
hyperglycaemia by inhibition of caspase 3 and Akt activation [217] and by a similar 
mechanism in thymocytes [218].  These and other studies have suggested that 
AMPK activation confers protection against cell death. The underlying mechanism 
for these apparently opposing effects of AMPK activation is unknown at this time, 
but it can be postulated that in actively dividing cancer cells, the inhibition of ATP-
consuming processes by AMPK may be less compatible with their survival, 
whereas in non-dividing (non-neoplastic) cells, where the protective effects of 
AMPK have been observed under acute stress, the shutdown of ATP-consuming 
pathways may not alter the balance for survival and may be beneficial [219]. 
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It is known that a proportion of patients with MGUS and smouldering MM will 
progress on to full blown disease. There has been speculation that additional 
acquired genetic mutations are to blame for this progression, but no conclusive 
evidence. Thus far, there have been no therapies to prevent this transformation. 
Human epidemiologic evidence suggests that metformin, the most frequently used 
antidiabetic agent in the world, has anticancer activity [220, 221]. Both indirect 
effects of metformin on the endocrine and metabolic milieu, such as improvement of 
hyperinsulinemia, suppression of systemic IGF-I levels, and amelioration of the 
adipokine profile, and direct mechanisms [225-228, 230, 376-378] have been 
proposed to explain this effect. In the present study, we investigated the direct 
anticancer effects triggered by metformin and AICAR in multiple myeloma and solid 
tumour cell lines in vitro.  
 
4.3.2. Metformin and AICAR have activity in Multiple Myeloma cells 
We demonstrated that metformin is active in a panel of MM cell lines and solid 
tumour cell lines. The MM cells were generally more sensitive to metformin than 
solid tumour cell lines with an IC50 of 1-5mM in the MM cells and IC50 of ≥2mM in 
the solid tumour cell lines (Fig. 3.3.2.1). The doses used in our study was 
comparable to the other published studies in the literature  [227, 228, 377], In our 
study, as well as others [227, 228, 377], such a direct effect may be mediated via 
increased phosphorylation of AMPK and decreased mTOR downstream effectors 
such as p70S6K and S6 ribosomal as well as their phosphorylated proteins (Fig 
3.3.2.3). Decreased mTOR and p70S6K activation by metformin can suppress 
translation initiation and global protein synthesis [230, 376]. 
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) has similar metabolic 
effects as metformin and is a cell permeable activator of AMP-activated protein 
kinase (AMPK). Like metformin, AMPK activation by AICAR has also been recently 
reported to inhibit proliferation of various cancer cell lines in vitro and in vivo. 
AICAR has also been shown to have an anti-tumour role in myeloma, prostate 
cancer, gastric cancer, pancreatic cancer and liver cancer [235-239]. Similar to 
metformin, AICAR has anticancer activity in a panel of multiple myeloma cell lines 
as well as in epithelial carcinomas. Again as with metformin, the MM cell lines were 
more sensitive than for epithelial carcinomas. The IC50 of the most sensitive MM 
cell line, OCI-My5, was 20µM but the average IC50 was 200µM . This is in contrast 
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to the IC50 obtained for the solid tumour cell lines which averaged 1000µM (Fig. 
3.3.3.1). Our data on the activity of AICAR was comparable to the studies listed 
above. The molecular signalling after treatment with AICAR is similar to that seen in 
metformin. There was increased phosphorylation of AMPK and a decrease in 
downstream effectors of mTOR such as phosphorylated (Thr389) and total p70S6K 
and phosphorylated (Ser235/236) and total S6 ribosomal (Fig. 3.3.3.3). GSK3 α/β 
and phosphorylated GSK3 α/β (Ser21/9) was also downregulated by AICAR 
treatment (Fig. 3.3.3.3). 
Contrary to the direct AMPK-activating capacity of AICAR, metformin is an indirect 
AMPK activator [379]. The primary site of its action is currently considered to be a 
direct inhibitory effect on complex 1 of the respiratory chain 35. The resulting high 
cellular ratio of AMP:ATP functions as an allosteric signal that sensitizes AMPK to 
phosphorylation at Thr172 by LKB1 35. This raises the question whether the 
anticancer activity of metformin is mediated via AMPK. We found that the AMPK 
inhibitor Compound C could not attenuate the anticancer activity of metformin in 
myeloma or thyroid carcinoma cell lines, suggesting that the growth-suppressive 
effect of metformin in these cells is not exclusively dependent on AMPK (Fig. 
3.3.6.1). In agreement, in a prostate carcinoma model, metformin induced 
phosphorylation of AMPK, yet siRNA-mediated depletion of AMPK did not prevent 
the antiproliferative effect of metformin [225]. Similar results were recently reported 
in chronic lymphocytic leukemia (CLL) cells [380]. In another study, metformin was 
found to inhibit mTOR signalling in an AMPK-independent, rag GTPase-dependent 
manner [381]. On the contrary, the inhibitory effect of metformin on growth and 
translation initiation in breast carcinoma cells was attenuated by siRNA against 
AMPK and the AMPK inhibitor compound C [230, 376], suggesting that the effects 
of metformin in that particular model are AMPK-dependent. The difference between 
our findings and the findings in these other studies may be due to a cell specific 
effect. 
For both of these AMPK activators, studies have demonstrated their involvement in 
cell cycle inhibition at G0/G1 via a reduction in cyclin D1 [225, 232, 382, 383]. We 
have also demonstrated that AICAR and metformin affect cell cycle proteins in 
particular cyclin D1, cdk4 (or cdk6), cyclin B1 and cdc2 (Fig. 3.3.2.3 and Fig. 
3.3.3.3). There was a decrease noted in these cell cycle proteins with AICAR and 
metformin except for cyclin B1 where there was little change before a late increase 
was noted with AICAR treatment. Cyclin D1 and cdk4/6 is associated with G1 
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progression and cyclin B1 and cdc2 wtih G2-M progression. Most of the reported 
literature has associated metformin and AICAR with G0/G1 arrest. Our findings 
reflect this with an early reduction in cyclin D1 and cdk4/6 seen. Cyclin B1 and cdc2 
reduction was only seen much later in metformin. In AICAR treated cells, cdc2 
reduction was seen only after cyclin D1 was reduced. Cyclin B1 in AICAR treated 
cells increased at the late time points after a reduction in cyclin D1 and cdk6 was 
noted. This may be a rebound phenomenon to the G0/G1 cell cycle arrest.  
 
4.3.3. Metformin and AICAR are able to overcome the protective effect 
of the BM microenvironmental   
The BM milieu consists of two parts; organized cellular and non-cellular 
components which include the liquid component. The cellular component of the BM 
is composed BMSCs and OCs amongst other cellular components. The non-cellular 
component comprises extracellular matrix (ECM) proteins (fibronectin, collagen, 
laminin and osteopontin) and the liquid component consists of growth factors and 
cytokines. It is now well established that MM-induced disruption of the bone marrow 
(BM) homeostasis between the highly organized cellular and extracellular 
compartments supports MM cell proliferation, survival, migration and drug 
resistance through activation of various signalling pathways (as reviewed in [60, 
61]). For instance, it has been demonstrated that the response of MM to 
conventional therapies, such as glucocorticoids or cytotoxic chemotherapeutics is 
attenuated by the presence of bone marrow stromal cells (BMSCs) [27, 62-64]. This 
leads to decreased anticancer therapeutic activity, making the local 
microenvironment an important mechanism of treatment failure. As such, any new 
anticancer agent should be tested to see if its activity is attenuated in the presence 
of the local microenvironment.  
Using our CS-BLI assay, we studied the impact of stromal cells and osteoclasts on 
tumour cell sensitivity to metformin and AICAR. It is encouraging that the anticancer 
activity of both agents was not suppressed in the presence of stromal cells or 
osteoclasts (Fig 3.3.2.2 and Fig. 3.3.3.2). The fact that, in some cases, their anti-
tumour activity was enhanced in the presence of stromal cells or osteoclasts 
suggests that the signalling cascades [380] induced by these accessory cells 
interact in a synthetically lethal fashion with AMPK activation.  
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McMillin et al. [384] reported that the tumour stroma promotes in cancer cells a 
gene expression signature that is associated with stimulated Akt signalling (the 
upstream activator of mTOR signalling) and with self-renewal. In this study, we 
found that cells with constitutively active Akt (transfection of myristoylated Akt) are 
sensitized to acadesine, which may partially explain the sensitizing effect of the 
microenvironment (Fig 3.3.8.1). Collectively, these findings suggest that tumours 
with activated Akt/mTOR pathway (either constitutively due to somatic mutations in 
this pathway or due to tumour-stroma interactions in the context of the local 
microenvironment) may be even more sensitive to AMPK activators. Furthermore, 
there is emerging evidence that metformin suppresses self-renewal and 
proliferation of breast cancer stem/progenitor cell populations [385, 386]. 
 
 
4.3.4. AICAR has more antimyeloma activity compared to Metformin 
Although both metformin and AICAR suppressed mTOR signalling and growth in 
our study, their anticancer effects were not identical. Between the two agents 
studied, it was obvious that AICAR was the more effective antimyeloma agent 
compared to metformin. In the treatment of CD 138 MM cells purified from BM 
aspirates from MM patients, AICAR was able to demonstrate better activity 
compared to Metformin (Fig. 3.3.4).When these patient tumour cells were treated 
with AICAR, 3 / 4 MM patients responded to the drug with IC50 values <500 μM 
whereas only 1 / 3 MM patient showed a response to metformin, and then only at 
much higher drug concentrations.  
The anticancer activity of AICAR was further documented in a subcutaneous 
xenograft model (NOD.CB17 SCID mice). These mice are homozygous for the 
severe combined immune deficiency spontaneous mutation Prkdscid  and are 
characterised by an absence of functional T cells and B cells, lymphopaenia, 
hypogammaglobulinaemia but with a normal haematopoietic microenvironment. 
This characteristic of the NOD.CB17 SCID makes them an ideal model for cancer 
research as they will allow for the engraftment of xenograft cells. There were 7 mice 
in the control group and 8 mice in the treatment group. AICAR treatment 
significantly decreased tumour burden compared to controls (Fig. 3.3.9.1; P=0.005; 
unpaired one-tailed T-test). In addition, the survival of the treated mice was 
statistically significant compared to controls (Fig. 3.3.9.2; P=0.003; log-rank test) on 
Kaplan-Meier method. Furthermore, there was no significant change in the weights 
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of treated mice (Fig. 3.3.9.3) indicating that the mice tolerated the treatment well. 
There were also no potential toxicities observed during the course of treatment with 
AICAR. It is of interest that, in haematological malignancies, AICAR so far has 
demonstrated interesting preclinical activity against B-cell neoplasms (B-cell CLL 
[387] and B-cell lymphomas [388]), which is in agreement with our present results in 
MM. 
AICAR-treated mice responded to the treatment in a rapid fashion. Due to the rapid 
disappearance of the tumours, there was development of ulcers in the central 
portion of the tumour. These ulcers did not discomfort the mice and were showing 
signs of healing as treatment with AICAR progressed. Unfortunately, as per the 
protocol in the handling of mice in the Animal Care and Use Committee of the 
Dana-Farber Cancer Institute, any ulcer formation in the mice regardless of healing 
status or shrinking tumour load, required the mice to be sacrificed. As a result, we 
had to censor the groups to get an accurate Kaplan-Meier calculation.     
Although we showed that AICAR had more activity in MM patient cancer cells, the 
patient samples used when testing the activity of the two drugs were not the same. 
Differences in tumoural response may explain the difference in response seen 
between the two drugs. We are aware that the patient samples used in this study 
are small but there was difficulty in obtaining enough patient samples that had a 
high tumour load as most patients who attended Dana Farber Cancer Institute had 
been previously treated in their local institute. However, the finding that AICAR is 
more active an anti-MM agent is still valid as we have shown that AICAR has 
activity in a xenograft model and the mechanism of cell death is cytotoxic rather 
than cytostatic.   
Further examination of apoptosis-related activity, contrary to the findings with 
metformin, AICAR also induced mitochondrial membrane depolarisation and cell 
apoptosis (Fig 3.3.7.4 and Fig. 3.3.7.5). The mitochondria is an intrinsic part of cell 
death control that plays a role in apoptosis [389]. Apoptosis is finely regulated at the 
molecular level with formation of a proteinaceous pore at sites of contact between 
the inner and outer mitochondrial membranes [389]. This is accompanied by a 
decrease in mitochondrial membrane potential and heralds a transition in the 
permeability of the mitochondria. The phenomenon culminates in the release of 
sequestered molecules such as cytochrome c and apoptosis inducing factor (AIF) 
that are involved in downstream control and formation of the apoptotic phenomenon 
[390]. We have demonstrated that Metformin causes a calculated cell death of 54% 
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on MTT testing (Fig. 3.3.7.4) but little apoptosis or even necrosis seen in Annexin 
V/PI staining (26%) (Fig. 3.3.7.3). The MTT test primarily measures cell viability 
whereas Annexin V/PI measures cell death. Therefore, as there is a greater 
reduction in viability of RPMI-8226 cells after treatment with metformin using MTT 
compared to actual cell death as demonstrated by Annexin V/PI staining, we can 
postulate that the main mechanism of metformin’s antimyeloma activity is growth 
inhibition rather than apoptotic cell death. Thus, the fact that AICAR is able to 
induce apoptosis and growth inhibition rather than just growth inhibition as for 
metformin, makes AICAR a more attractive therapeutic option in treating MM cells. 
The pro-apoptotic activity of AICAR was attenuated by overexpression of Bcl-2, an 
anti-apoptotic molecule that stabilizes the mitochondrial membrane potential (Fig. 
3.3.8.1). Bcl-2 did not attenuate the anticancer activity of metformin, which is in 
agreement with the fact that metformin did not induce significant apoptosis in our 
models (Fig.3.3.8.1).  
 
4.3.5. AMPK activators synergise with glycolysis inhibitors 
Under aerobic conditions, mammalian cells can generate ATP through two 
metabolic pathways: glycolysis in the cytosol and oxidative phosphorylation in the 
mitochondria (aerobic respiration). ATP generation through mitochondrial 
respiration is more energy efficient (one glucose yields 36 ATP) than glycolysis 
(one glucose yields 2 ATP), and thus is a preferred pathway for the normal cells to 
generate energy supply. 
Plasma glucose is regulated by complex endocrine systems in mammals.  AMPK is 
activated in mammalian cells by a variety of physiological and pathological stresses 
that increase the intracellular AMP: ATP ratio, either by increasing ATP 
consumption (e.g. muscle contraction) or by decreasing ATP production (e.g., 
ischaemia or hypoxia). Once activated, AMPK acts to restore cellular energy 
homeostasis by promoting ATP generating pathways such as fatty acid oxidation, 
while simultaneously inhibiting ATP utilizing pathways, such as fatty acid synthesis 
and gluconeogenesis. By decreasing the amount of available glucose for cancer 
cells to utilise, the proliferation rate will be decreased. Otto Warburg first described 
that cancer cells have an increased rate of glucose uptake and glycolysis even 
under normoxic conditions (“Warburg effect”) , but moderate rates of mitochondrial 
respiration [391]. A recent review by Lopez-Lazaro [290] highlighted the importance 
of glycolysis in cancer cell development. Activation of glycolysis protects cells from 
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H2O2- induced cell death, causes hypoxia-inducible factor 1 (HIF-1) activation and 
provides carbon skeletons for biosynthesis. HIF-1 activation plays a key role in the 
transcription of genes that code for glucose transporters and glycolytic enzymes 
[290]. A reduction of the glycolytic capacity of tumour cells would restrict their ability 
to proliferate, invade adjacent tissues and migrate to distant organs. Because 
AICAR caused mitochondrial membrane potential depolarization, we hypothesized 
that concurrent activation of AMPK and inhibition of glycolysis could severely 
impact cancer cell energy metabolism and result in enhanced death of malignant 
cells, sparing normal cells that do not exhibit the Warburg effect. We found that the 
pyruvate analog 3-bromopyruvate (3-BrPA), which is a hexokinase inhibitor, and the 
glucose analog 2-deoxyglucose (2-DG), a competitive inhibitor of glucose 
metabolism, enhanced the anticancer activity of AICAR, suggesting that targeting 
AMPK may expose the cancer cell’s addiction to glycolysis [290]. 
 
Since the AMPK pathway plays an important role in promoting cellular nutrient 
uptake, cell growth and cell survival, a combination of AMPK activation and 
blockage of glycolysis seems to be a mechanism-based strategy to severely impact 
cancer cell energy metabolism and effectively kill the malignant cells. It was 
hypothesized that if glucose availability was reduced and the ability of cancer cells 
to generate ATP was inhibited by glycolysis inhibitors, that this combination would 
synergise and cause increased cancer cell death. There is also evidence that 
rapamycin, an mTOR inhibitor, can compromise the ability of cells to uptake 
glucose [392]. We demonstrated that the combination of AICAR and metformin with 
either 3-BrPA or 2-DG showed synergistic cytotoxicity even in cell lines such as 
MM1.S and FRO which are not very sensitive to single agent AICAR or metformin 
(Fig. 3.3.10.2 and Fig. 3.3.10.3). As far as we know, this is the first time that this 
combination has been examined for activity in MM and thyroid cancer cells. The 
mechanism of this synergy is not well understood. The combination would affect 
ATP generation and ATP depletion would certainly cause cell death. Pradelli et al. 
[393]. identified the signalling pathway initiated by glycolysis inhibition either by 
removal of glucose or the use of nonmetabolizable form of glucose (2-
deoxyglucose), that resulted in sensitisation to death receptor-induced apoptosis by 
Fas or tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). The 
authors reported that AMPK is activated upon glycolysis block. This study further 
supports the use of AMPK activators and glycolysis inhibitors in the treatment of 
human cancers. 
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4.3.6. The safety profile of metformin and AICAR 
With any new anticancer agents, the therapeutic index and its safety profile is a 
major concern. Metformin is a biguanide developed from galegine, a guanidine 
derivative found in Galega officinalis (French lilac). Metformin is an antidiabetic 
medicine that is commonly used in the treatment of non-insulin dependent diabetes 
mellitus (NIDDM) since 1957 in Europe and other countries, and in the US from 
1995. Metformin causes suppression of liver gluconeogenesis; decreased 
expression of lipogenic enzymes; increased fatty acid oxidation; and stimulation of 
glucose plasma membrane transport in skeletal muscle. Chemically, it is a 
hydrophilic base which exists at physiological pH as the cationic species (>99.9%). 
As a consequence, its passive diffusion through cell membranes is limited [394]. 
Studies with Caco-2 cells demonstrate a low rate of transport of metformin [395]. 
The oral bioavailability of metformin is 40-60% [394, 396]. It is absorbed 
predominately from the small intestine and gastrointestinal absorption is complete 
within 6 hours of ingestion. Metformin is rapidly distributed following absorption and 
does not bind to plasma proteins. No metabolites or conjugates of metformin have 
been identified. The absence of liver metabolism clearly differentiates the 
pharmacokinetics of metformin from that of other biguanides, such as phenformin. 
Metformin undergoes renal excretion and has a mean plasma elimination half-life 
after oral administration of between 4.0 and 8.7 hours. This elimination is prolonged 
in patients with renal impairment and correlates with creatinine clearance.  
It has an excellent safety profile when used as labelled [397]. The maximum 
dosage for adults is 2550mg/day. A study by Sambol et al. [398] showed no 
significant differences in metformin kinetics in patients with NIDDM and healthy 
subjects, in men compared with women, or during multiple-dose treatment versus 
single-dose treatment. In patients with NIDDM, single doses of 1,700-mg or higher 
of metformin significantly decreased postprandial, but not preprandial, glucose 
concentrations and did not influence insulin concentrations. With multiple doses, 
both preprandial and postprandial glucose concentrations and preprandial insulin 
concentrations were significantly lower than with placebo. In healthy subjects, 
single and multiple doses of metformin showed no effect on plasma glucose, but 
significantly attenuated the rise in immediate postprandial insulin levels. This study 
reassures us that metformin can likely be safely given to non-diabetic patients 
without undue worry about high rates of drug-induced hypoglycaemia. With the 
limited diffusion into cells and the lack of active transport into cells via plasma 
protein binding, dosing of metformin has to be of a high enough dose to ensure 
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enough therapeutic activity. That is the reason for the high dose levels used in the 
in vitro studies in this thesis and in other published studies.   
Nevertheless, our data should not be interpreted as support for the use of 
metformin in MM patients outside the context of a well-designed clinical trial. 
Physicians’ perception of the potential risks of metformin use is influenced by the 
withdrawal of the related biguanide phenformin from the US market in 1976 
because of probable association with lactic acidosis [397]. The latter is a much 
more lipophilic drug due to its phenyl and ethyl groups (N1,N1-
phenylethylbiguanide) which can permeate biological membranes readily, and is a 
more potent respiratory chain inhibitor, while metformin is positively charged and 
accumulates (~1000 fold) within the mitochondrial matrix in a slow, membrane-
potential driven fashion, that is also self-limiting because progressive inhibition of 
the respiratory chain leads to a drop in membrane potential, which will prevent 
further accumulation of the drug [399]. This may explain why lactic acidosis is 
extremely rare with metformin, in contrast to phenformin [397, 400, 401]. In a recent 
metaanalysis, pooled data from 347 comparative trials and cohort studies revealed 
no cases of fatal or non-fatal lactic acidosis in 70,490 patient-years of metformin 
use [402]. The upper limit for the true incidence of lactic acidosis per 100,000 
patient years was calculated as 4.3 cases in metformin users and 5.4 cases in non-
metformin users [402]. The authors concluded that there is no evidence from 
prospective comparative trials or from observational cohort studies that metformin is 
associated with an increased risk of lactic acidosis, compared to other anti-
hyperglycemic treatments [402]. Still, it would be prudent to limit metformin use to 
patients with adequate renal function, as metformin is renally cleared [403, 404]. 
Relevant guidelines have been proposed [405], including using metformin with 
caution if serum creatinine>130 micromol/l or eGFR <45 ml/minute/1.73 m2, and 
discontinuing metformin if serum creatinine >150 micromol/l or eGFR <30 
ml/minute/1.73 m2. For the same reason, the concurrent use of metformin and 
iodinated intravenous radiographic contrast or other nephrotoxins should be 
avoided.  
 
Existing MM treatment, such as glucocorticoids, can have the side effect of 
hyperglycaemia, concurrent metformin administration would have an added benefit 
of controlling their glucose levels whilst having anticancer properties. IGF-1R 
inhibitors have been shown in preclinical studies to have anti-myeloma properties 
[82]. When the trials for IGF-1R inhibitors were carried out, hyperglycaemia was an 
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unexpected complication that was not seen in mouse models [82]. Most studies 
[406-408] reported grade I-II toxicity with the exception of a trial reported by Hidalgo 
et al. [409] which reported grade III toxicity. Metformin was one of the agents used 
to normalise the patients’ blood glucose. It was demonstrated that IGF-1R inhibitor-
induced hyperglycaemia was treateable with metformin. 
More importantly, the clinical development of other AMPK activators, such as 
AICAR, holds promise of anticancer activity without concern, real or perceived, for 
lactic acidosis. AICAR was originally developed as an exercise mimicker by 
stimulating the uptake of glucose into skeletal muscle. The experimental doses of 
AICAR employed in this thesis may prompt some concern as to human 
extrapolations.  There is little data on the literature about the optimal dose and few 
studies on the pharmacokinetics of this drug. Dixon et al. [410] reported a study of 
AICAR on treatment of ischemic heart disease. In a placebo-controlled, double-
blind study in healthy men, the safety and kinetics of the drug after oral and IV 
administration of 10, 25, 50, and 100 mg/kg doses were evaluated. The authors 
reported that the drug was well tolerated at all dose levels. The post-infusion 
plasma concentrations of AICA-riboside declined rapidly in a biphasic fashion, and 
the terminal elimination phase had a harmonic mean t1/2 beta of 1.4 hours. The 
drug was not protein bound, and there was rapid uptake and phosphorylation in red 
blood cells to its 5'-monophosphate nucleotide. AICAR was renally cleared and and 
only 8% of the IV dose was excreted in the urine as intact AICAR. The highest 
intravenous dose of AICAR used, 100mg/kg converts to 267µM (see Appendix B for 
calculation). This dose level is within the doses used in the in vitro experiments in 
this thesis and in other studies. In the synergistic experiments with glycolysis 
inhibitors, we had utilised a higher dose (up to 600 µM) to exaggerate any potential 
synergistic action but we were assured that the lower dose of 200 µM also yielded a 
synergistic cytotoxicity with the glycolysis inhibitors. 
To futher research on AICAR’s therapeutic potential, we had undertaken several 
studies to examine the actions of this agent. We demonstrated that the majority of 
MM cell lines are much more sensitive than non-neoplastic tissues to the cytotoxic 
effects of AICAR. The BMSC line HS-5 and the immortalized hepatocyte cell line 
THLE-3 were shown to be insensitive to AICAR with calculated EC50 values 
>1000μM (Fig. 3.3.5.1).  Treatment of normal PBMCs, at doses of AICAR that 
induced killing of both MM cell lines and patient samples in vitro had minimal effect 
on these normal cells (Fig. 3.3.5.2). Our in vivo study also demonstrated that the 
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mice suffered no toxicities and had a steady weight throughout the study (Fig. 
3.3.9.3). This data suggest a favourable therapeutic index for AICAR. Recently, 
AICAR has received particular clinical attention as an agent that might prevent 
complications following coronary artery bypass graft surgery [411, 412]. As an 
anticancer agent, it is currently in Phase I testing in B-cell CLL using a dose of 
50mg/g [413] and the findings of this research may provide useful evidence for 
conducting MM-specific clinical research with the agent. 
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4.4 Proteomic analysis to examine bortezomib resistance 
4.4.1. Investigating bortezomib resistance mechanisms in Multiple 
Myeloma using proteomics 
Proteomics provide an advantage to genomics investigations of disease as it allows 
protein-protein interaction to be studied. Recent advances in the use of proteomic 
technologies (specifically the comparative proteomic approach) provide a robust 
approach to study multiple signalling pathways simultaneously and mechanisms of 
resistance to anticancer therapy. We are interested in the mechanisms of 
resistance developed by MM cells to bortezomib therapy. In this study, we used MM 
cell lines that are sensitive and of intermediate resistance, MM1.S and OPM2 
respectively, that were treated with bortezomib to IC50. As a resistant cell line to 
bortezomib is difficult to generate in MM cells, we had to use non-isogenic cell lines. 
We wanted to make the finding more robust by including a solid tumour cell line that 
has sensitive and resistant counterparts to bortezomib. We choose to use the 
thyroid carcinoma cell line, KAT18 (sensitive) and WRO (resistant). These cells 
lines were also treated to IC50 with bortezomib. The rationale for adding on a solid 
tumour counterpart was to account for any potential artefact that may arise due to 
differences in the cell lines themselves rather than due to bortezomib-induced 
changes. 
 
4.4.2. Generation of protein list  
Four lists of differentially expressed proteins were established. These compared 
control and treated MM1.S (list 1), control and treated KAT18 (list 2), control and 
treated OPM2 (list 3) and control and treated WRO (list 4). The generated protein 
list was analysed and the trend of change in the cell lines before (control) and after 
(24h) treatment with bortezomib was noted. Therefore, in order to further determine 
the significance of these differentially changed proteins, the design analysis was 
planned to specifically identify proteins that were altered in the same trend in both 
of the sensitive lines (MM1S, KAT18) vs. the resistant lines (OPM2, WRO), e.g. 
protein x upregulated in sensitive lines and downregulated or unchanged in 
resistant lines. The proteins of interest were determined (Table 3.4.2.1). 
 
 
 
 
251
 4.4.3. Identified proteins on proteomic analysis 
From the generated protein list, 50 spots containing proteins of interest were 
identified (Table 3.4.2.1) and 39 of those proteins were picked from the preparative-
scale gels which provided sufficient sample for identification studies on the mass 
spec. The other 11 spots contained proteins that were of too low abundance to be 
identified from the preparative gel. The picked spots were identified after trypsin 
digestion and mass spectrometry analysis. The MASCOT software was able to 
identify 14 of these 39 (Table 3.4.2). The reason that the other 25 spots containing 
proteins of interest were unable to be identified was because the low abundance of 
the proteins present even in a preparative-scale gel. In the case of these spots, too 
few peptides were identified in the post-trypsin digestion to generate a confident 
identification.  
Hsp70 and caspase-3 were two proteins that our proteomic analysis of bortezomib 
treatment in sensitive and resistant cells identified. This is an encouraging finding 
as these two proteins were already known in the literature as being associated with 
bortezomib treatment [278, 414]. As outlined below, the trend of the proteins seen 
in sensitive vs. resistant lines were consistent with what is known about them post 
bortezomib exposure. This finding validates the model and the technique that we 
used in this analysis. 
Proteasome 26S proteins were also identified in our analysis with a protein ID of 
675 (26S protease (S4) regulatory subunit), 914 (Proteasome 26S subunit, ATPase 
2) and 1088 (Proteasome 26S subunit, ATPase 2). It is not surprising to find these 
proteins as bortezomib is a proteasome inhibitor. Protein 675 and 914 were 
consistent with each other showing no change in the sensitive cell lines and an 
increase in the resistant cell lines. This can be explained by the fact that as the cells 
were exposed to bortezomib, the sensitive cells were rapidly killed whereas the 
resistant cells were able to mount a response to the bortezomib exposure by 
inducing proteasome synthesis. What is unclear is why protein 1088 did not behave 
as the others and had an opposite response (an increase in sensitive cells and a 
decrease in resistant cells). We would need to further investigate this phenomenon.  
The other proteins identified are discussed below with a review of what is known 
about their functions. 
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4.4.3.1. Heat shock protein 70kDa 
Our analysis showed that Hsp70 was upregulated in the sensitive cell lines vs. no 
change in the resistant cell lines (Fig. 3.4.3.1). This result was validated using Western 
blot and showed that Hsp70 was induced by bortezomib treatment in the sensitive cell 
line MM1.S resulting in an increase in Hsp70 levels (Fig. 3.4.3.3). 
Heat shock proteins (HSPs) or stress response proteins (SRPs) are synthesized in 
variety of environmental and pathophysiological stressful conditions. Many HSPs are 
involved in processes such as protein denaturation-renaturation, folding-unfolding, 
transport-translocation, activation-inactivation, and secretion. HSP70 has been shown 
to be involved in protective roles against thermal stress, cytotoxic drugs, and other 
damaging conditions leading to association with drug resistance.  
Hsp70 is known to be upregulated post bortezomib treatment [319, 415, 416]. NPI-0052 
have been shown to induce Hsp70 as well although to a lesser extent than bortezomib 
[415]. The presence of misfolded proteins in the cytosol may partially explain why 
proteasome inhibitors induce the expression of not only Hsp70 but also Hsp27 and 
Hsp90 [416]. In fact, there is evidence that inhibition of Hsp90 synergises with 
bortezomib [53] and there is currently a clinical trial investigating this combination. 
 
4.4.3.2. Caspase-3 
The caspase family of cysteine proteases play a key role in apoptosis. Caspase 3 (also 
known as CPP32, YAMA and apopain) is synthesized as an inactive pro enzyme that is 
processed in cells undergoing apoptosis by self proteolysis and/or cleavage by other 
upstream proteases (e.g. Caspases 8, 9 and 10). The cleaved form of Caspase 3 
consists of large (17kD) and small (12kD) subunits which associate to form an active 
enzyme. Caspase 3 is cleaved at Asp28 - Ser29 and Asp175 - Ser176. The active 
Caspase 3 proteolytically cleaves and activates other caspases (e.g. Caspases 6, 7 
and 9), as well as relevant targets in the cells (e.g. PARP).  
Our analysis showed that caspase-3 was downregulated in the sensitive cell lines vs. 
no change in the resistant cell lines (Fig. 3.4.3.2). This result was validated using 
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Western blot and showed that total caspase-3 was cleaved by bortezomib treatment in 
the sensitive cell line MM1.S resulting in a reduction in total caspase-3 (Fig. 3.4.3.3). 
Bortezomib has been shown to activate caspase-3 cleavage in several studies [278, 
415, 417]. Hideshima et al. [278] demonstrated that bortezomib activates caspase-3 
through caspase-8 activation as pan caspase inhibitors and caspase-8 inhibitors 
completely abrogate bortezomib–induced caspase-8/caspase-3 activation. The authors 
also showed that JNK inhibition was able to block bortezomib-induced cell death by the 
abrogation of caspase-3 cleavage. NPI-0052, another proteasome inhibitor is also able 
to activate caspse-3 cleavage [418] showing that this mechanism of apoptotic cell death 
is a class response and not specific to bortezomib.  
 
4.4.3.3. Far upstream element binding protein  
Overexpression of far upstream element binding protein 1 (FBP-1) and 2 (also known 
as KHSRP protein or FBP-2) has been shown to be associated with poor patient 
survival in >70% of human hepatocellular carcinoma [419]. In vitro, FBP-1 over 
expression predominantly induced tumour cell proliferation, while FBP-2 primarily 
supported migration in different HCC cell lines [419]. FBP-1, an activator of transcription 
of the proto-oncogene c-myc, demonstrated strong overexpression in human 
hepatocellular carcinoma (HCC) [420]. Rabenhorst et al., showed that knockdown of 
the protein in HCC cells resulted in increased sensitivity to apoptotic stimuli, reduced 
cell proliferation and impaired tumour formation in a mouse xenograft transplantation 
model [420]. The authors identified p21 as a direct target gene repressed by FBP1, and 
expression levels of the proapoptotic genes tumour necrosis factor alpha, tumour 
necrosis factor-related apoptosis- inducing ligand, Noxa and Bik were elevated in the 
absence of FBP1. Bortezomib treatment is known to cause induction of proapoptotic 
proteins such as Noxa [417].   
The two FBP proteins identified in our analysis were downregulated in the sensitive cell 
lines after bortezomib treatment. This suggests that bortezomib is able to overcome the 
c-myc activation and induce cytotoxicity. Deregulated or elevated expression of c-myc 
occurs in ~30% of human cancers, including breast, colon, cervical, small cell lung 
cancer, osteosarcoma, glioblastoma, melanoma, and myeloid leukemias.[421]. C-myc 
facilitates tumour cell growth via angiogenesis involving upregulation of HIF1 [421]. It 
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has been reported that bortezomib is able to downregulate HIF1 and inhibit 
angiogenesis and tumourigenesis [421]. 
 
4.4.3.4. Fascin 
Human fascin is a highly conserved actin-bundling protein and is thought to be involved 
in the formation of microfilament bundles. It is now thought that fascin is involved in 
filopodia assembly and cancer invasion and metastasis of multiple epithelial cancer 
types. Gastric cancer [422], prostate cancer [423] and colon cancer [424] have shown 
upregulation of fascin and an increase in cell invasiveness and metastasis. Li et al. 
[425] elegantly demonstrated that fascin is an integral component of invadopodia and is 
implicated in invasive migration into collagen I-Matrigel gels. It is unclear why fascin 
was found to be upregulated in the sensitive cell lines after bortezomib treatment. 
 
4.4.3.5. Heterogeneous nuclear ribonucleoprotein 
Heterogeneous nuclear ribonucleoprotein (hnRNP) family consists of several members 
including hnRNP A2/B1 isoform B1, hnRNP K, hnRNP D and hnRNP A1. The hnRNP 
family has several different cellular roles including transcription, mRNA shuttling, RNA 
editing and translation. Several reports implicate hnRNP K having a role in 
tumourigenesis, for instance hnRNP K increases transcription of the oncogene c-myc 
and hnRNP K expression is regulated by the p53/MDM 2 pathway [426]. In the mouse 
myeloma cell line, GS-NS0, there is an up-regulation of proteins triggered by a cellular 
response to external stress stimuli, revealing induction of different proteins including 
hnRNP K [427]. Recently, a loss of function screen done on a derivative pool of cells 
with loss of migration phenotype demonstrated the involvement of hnRNP K in 
metastasis [428]. HnRNP K was also implicated as being overexpressed in colon 
cancer and the authors showed that hnRNP K had an aberrant subcellular localisation 
in cancer cells [426].  Finally, overexpression of hnRNP K in breast cancer cells 
significantly increased target c-myc promoter activity and c-Myc protein and enhanced 
breast cancer cell proliferation and growth in an anchorage dependent manner. The 
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authors suggested that the activity of human EGF receptor family members regulates 
hnRNP K expression [429].  
There is less known about the other hnRNP family members. There is reports in the 
literature that HnRNP A2/B1 was shown to be upregulated in HepG2 [430], endometrial 
adenocarcinoma [431] and pancreatic epithelial cells (via EGF) [432]. Meanwhile, 
HnRNP D overexpression was shown in oral squamous cell cancer [433]. Thus far, the 
only member of this family to be reported to be involved in MM. HnRNP A1 was found 
to be a mediator of the IL-6 effect in MM. It does this by binding to the myc internal 
ribosome entry site (IRES) in vivo in myeloma cell lines as well as patient samples 
[434]. The authors then showed that knock down of hnRNP A1 prevented an IL-6 
increase in myc protein expression, myc IRES activity, and cell growth pointing to 
hnRNP A1 as a critical regulator of c-myc translation and a potential therapeutic target 
in MM [434]. 
In our analysis, all the members of the hnRNP protein family were downregulated after 
treatment with bortezomib in sensitive cells. This suggests that bortezomib treatment 
may be able to overcome this bad prognostic marker that has been found to be 
overexpressed in multiple cancer types. 
 
4.4.3.6. Annexin A2 
The Annexins are a family of structurally similar proteins. Annexins bind to 
phospholipids and may be involved in regulation of membrane transport, membrane 
channel activity, and interaction of the cell membrane with the extracellular matrix. 
Annexin II is a calcium-regulated membrane-binding protein whose affinity for calcium 
is greatly enhanced by anionic phospholipids. This protein functions as an autocrine 
factor which heightens osteoclast formation and bone resorption.  
2DE-based proteomic analysis of oesophageal squamous cell cancer compared to an 
immortal cell line, identified downregulation of annexin A2 and upregulation of heat 
shock 70 kDa protein amongst other proteins that are correlated to malignant 
transformation [435]. This result compares to our analysis where heat shock 70 kDa 
protein was upregulated by bortezomib treatment in sensitive cells. However, our result 
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showed an upregulation of annexin A2 in sensitive cells and was unchanged in the 
resistant cells. It is unclear how annexin interacts with bortezomib and this difference 
between our results and the what is known in the literature may be a drug related 
process. 
 
4.4.3.7. Endoplasmic reticulum protein 29  
Endoplasmic reticulum protein 29 (ERp29) is a novel endoplasmic reticulum (ER) 
secretion factor that facilitates the transport of secretory proteins in the early secretory 
pathway. Overexpression of ERp29 resulted in G0/G1 arrest leading to inhibition of cell 
proliferation in breast cancer cells, decreased cell migration/invasion and reduced cell 
transformation [436]. Unsurprisingly, we demonstrated that ERp29 is upregulated in the 
sensitive cell lines post bortezomib treatment. We know that bortezomib causes cell 
cycle arrest although in the reported literature the arrest was at G2/M [437-439] rather 
than at G0/G1. There may be others proteins involved in bortezomib treatment that can 
cause cell cycle arrest and ERp29 could be just one of the many proteins upregulated 
by bortezomib treatment.   
Conditions that disrupt protein folding in the ER, such as a chemical insult or nutrient 
deprivation, activate a stress signalling pathway known as the unfolded protein 
response (UPR) [416]. UPR induction results in both an initial decrease in general 
protein synthesis, to reduce the influx of nascent proteins into the ER and increased 
transcription of ER resident chaperones, folding enzymes and components of the 
protein degradative machinery to prevent the aggregation of the accumulating 
misfolded proteins. These misfolded proteins are recognized by ER quality control 
systems and retained in the ER, preventing them from proceeding further through the 
protein maturation process [416]. Proteins that cannot be properly refolded are then 
targeted for ER-associated protein degradation (ERAD), which involves the retrograde 
translocation or dislocation of the misfolded proteins out of the ER and subsequent 
degradation by cytosolic 26S proteasomes [416]. Therefore, bortezomib induces ER 
stress as it prevents degradation of misfolded proteins. This may explain the induction 
of ERp29. 
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4.4.3.8. Ferritin light chain 
Ferritin is a ubiquitous and highly conserved protein which plays a major role in iron 
homeostasis by sequestering and storing iron in a non-toxic and soluble form. It forms 
a holoenzyme of ~450 kDa, consisting of 24 subunits of two types, H (heavy; 21 kDa) 
and L (light; 19 kDa), and is capable of storing up to 4,500 atoms of ferric iron. 
Depending on the tissue type and physiological status of the cell, the ratio of H to L 
subunits in ferritin can vary widely. Ferritin is found in the liver, spleen, kidney and 
heart, with smaller amounts being found in blood. Serum ferritin levels serve as an 
indicator of the amount of iron stored in the body and is a sensitive test for anaemia. As 
ferritin is an acute-phase reactant, levels are often elevated during infection. Studies 
have shown the association of elevated serum ferritin and poor prognosis in MM [440, 
441] ,and lymphoma [442]. However, these studies looked at secreted ferritin and we 
are still unsure of the function of the light and heavy chain of the ferritin protein in 
tumourigenesis and drug resistance. A recent study found that cells transformed with 
oncogenic RAS have increased iron content relative to their normal cell counterparts 
through upregulation of transferrin receptor 1 and downregulation of ferritin heavy 
chain 1 and ferritin light chain [443]. Another study in breast cancer associated high 
levels of cytosolic ubiquitin and/or low levels of ferritin light chain were associated with 
a good prognosis in breast cancer [444]. In our proteomic analysis, the levels of ferritin 
light chain were upregulated by bortezomib treatment in both sensitive and resistant 
cell lines, although markedly in the sensitive cell lines. It is unclear why there should be 
an increase in the sensitive cell line to bortezomib treatment as upregulation of this 
protein is usually associated with poor prognosis. It could be that as ferritin is an acute 
phase reactant, it is a cellular inflammatory response to cell death caused by 
bortezomib.   
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Chapter 5 
Summary and Conclusion 
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5.1. MDR associated protein expression as a mechanism of resistance in 
Multiple Myeloma 
• Bortezomib was shown to likely be a P-gp substrate and a weak inhibitor. The 
combination of P-gp inhibitor, elacridar with bortezomib showed synergistic 
cytotoxicity. There was also cross resistance seen in P-gp expressing cell line 
DLKP-A. This suggests that P-gp overexpression could cause resistance to 
Bortezomib therapy. 
• Clinically, the combination of a P-gp inhibitor and bortezomib in P-gp positive 
myeloma patient should have a therapeutic effect. 
• Bortezomib was not shown to be a MRP-1 substrate. 
• Bortezomib was not demonstrated to be a BCRP substrate or inhibitor. There 
was no synergy when bortezomib was combined with a BCRP substrate (SN38) 
or inhibitor (elacridar). There was also no cross resistance seen in BCRP 
expressing cell line DLKP-SQ/Mitox. 
• P-gp expression levels correlated to bortezomib’s ability to function as a P-gp 
substrate. Cell lines that have a higher expression of P-gp were intrinsically 
more resistant to the actions of the drug and showed more synergy when 
bortezomib was combined with elacridar.  
• Bortezomib downregulated P-gp expression levels and function. 
• P-gp expression and function was downregulated when MM cells are co-
cultured with BMSCs. 
• There was transference of P-gp from the P-gp-positive MM cell line to the P-gp-
negative stromal cells when the two cell lines were co-cultured together. 
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5.2. Investigation of p53 signaling perturbations in Multiple Myeloma 
resistance 
• Nutlin-3, a Mdm2 inhibitor showed antimyeloma activity and anticancer activity. 
• Nutlin-3 upregulated the expression of p53-dependent targets such as Bak, 
Bax, PUMA, Noxa, p21, Hdm2, Hsp90 and VEGF. Nutlin-3 was also able to 
induce caspase-3 cleavage but this effect was only partially abrogated by a 
pan-caspase inhibitor suggesting that caspase activation was not the only 
mechanism of cell death. 
• Nutlin-3 combined with bortezomib was able to induce additive cytotoxicity in 
MM cells and synergistic activity in epithelial tumour cells. This is because MM 
cells were very sensitive to single agent bortezomib and nutlin-3, leaving little 
room for the synergistic action of when both drugs were combined. This effect 
was demonstrated by Western blot which demonstrated that the p53 apoptotic 
pathway was enhanced in the epithelial tumours but not in MM cells by the 
combination. 
• Nutlin-3 was not able to overcome the protective effect of BMSCs. However, 
the drug was still able to induce expression of p53 downstream effectors in the 
presence of BMSCs but to a lesser degree compared to in the absence of 
BMSCs. 
• The synergistic cytotoxicity seen with bortezomib in epithelial tumours was not 
affected by the presence of BMSCs. 
• The synergy between bortezomib and nutlin-3 was shown to be p53 
independent in certain cell lines. 
• Bortezomib-treated patients who had, at baseline, high expression of nutlin-3-
suppressed genes had significantly shorter progression-free survival (p=0.001, 
log-rank test) and OS (p=0.002, log-rank test) compared to those with low 
expression levels. 
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5.3. Activation of AMPK pathway as an alternative to overcome drug 
resistance in Multiple Myeloma 
• Metformin and AICAR were shown to have activity in MM cells and other 
epithelial cancer cell lines. 
• Both drugs were able to overcome the protective effect of BMSCs and OCs.  
• Both drugs activated AMPK and inhibited the downstream effectors of mTOR. 
The cell cycle proteins, cyclin D1 and cdk4/6 were also downregulated by 
metformin and AICAR. 
• As compound C, an AMPK inhibitor, did not reverse the antitumour activity of 
metformin completely, there is a suggestion that the anticancer activity of 
metformin also acts via an indirect AMPK pathway. 
• Both of the AMPK activators have a good safety profile. Metformin has been 
used as an antidiabetic agents for many years and AICAR was shown to have 
little effect on non-neoplastic cells. The mice also tolerated AICAR with no overt 
toxicity. 
• AICAR is the more potent of the two AMPK activators as it had more activity in 
the patient sample and was able to induce apoptosis and mitochondrial 
membrane depolarisation.  
• We were able to demonstrate a statistically significant results in a 
subcutaneous xenograft mouse model with reduction in tumour burden and 
statistically significant survival . 
• AICAR and Metformin synergised with glycolysis inhibitors, 2DG and 3BrPA 
and caused apoptosis with PARP and caspase 3 cleavage. 
• AMPK activation is promising as an anticancer pathway and there is a 
possibility that it can prevent cancer. 
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5.4. Proteomic analysis to examine bortezomib resistance 
• Proteomic comparative analysis of sensitive cell lines (MM1.S and KAT18) vs. 
resistant cell lines (OPM2 and WRO) pre- and post-bortezomib treatment for 
24hrs generated lists of differentially expressed proteins. 
• The distinctive design analysis of overlapping the four generated proteins lists 
to specifically identify proteins that had a trend of change that was unique to the 
sensitive cell lines vs. the resistant cell lines lead to the identification of these 
proteins:- 
o Heat shock protein 70kDa  
o Caspase-3 
o Far upstream element binding protein 
o Fascin 
o Heterogeneous nuclear ribonucleoprotein 
o Annexin A2 
o Endoplasmic reticulum protein 
o Ferritin, light polypeptide 
• Heat shock protein 70kDa and caspase-3 protein are known in the literature to 
be associated with bortezomib treatment. Our findings confirmed the data 
published and demonstrated the validity of using this technique to identify 
proteins that were affected by bortezomib treatment. 
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The focus of this thesis was to evaluate the mechanisms whereby myeloma cells 
develop intrinsic resistance with a focus on resistance in the context of bortezomib 
treatment. We believe that there is interplay between different mechanistic elements 
that gives rise to drug resistance and the most effective treatment regime will consist of 
well researched combinations of drugs individualised to the biology of the patient rather 
than a single super-agent. 
In our study, bortezomib cytotoxicity is reduced in P-gp overexpression, but the other 
MDR proteins; MRP-1 and BCRP are unlikely to contribute to the resistance seen to 
bortezomib. This makes bortezomib combination therapy with an P-gp modulator, i.e. 
elacridar, clinically relevant in surmounting bortezomib resistance caused by P-gp 
overexpression. We have further proved that this combination is clinically feasible as 
the combination activity is still synergistic even in the presence of the local tumour 
microenvironment. Bortezomib has a further role in modulating P-gp resistance by 
downregulating P-gp expression and function. We demonstrated that there is a 
transference of P-gp between MM cells and the local microenvironment that may 
contribute to the resistance seen to P-gp substrates such as doxorubicin and 
daunorubicin. 
We then tested the combination of bortezomib with an Mdm2 inhibitor, nutlin-3. In p53-
wild type (WT) cells, nutlin-3 affects the p53 apoptotic pathway. In p53-mutated cells, 
nutlin-3 also had activity but the dose levels used were much higher than for the p53 
wild type. Recent studies showed that nutlin-3’s cytotoxic activity in p53-negative and 
p53-mutant human tumour cells is via E2F1 binding to Mdm2 [181, 182]. In cell ines 
that require a higher dose of nutlin-3 as a single agent to have cytotoxic activity, the 
combination with bortezomib yielded synergy. This comprises p53-mutated MM cell 
lines and epithelial cell lines (p53-WT or p53-null or mutated). We postulate that the 
reason that the combination of bortezomib and nutlin-3 in p53-WT MM cells did not 
show synergy is because MM cells were very sensitive to single agent bortezomib and 
nutlin-3, leaving little room for the synergistic action of both drugs combined. Although 
nutlin-3 was not able to overcome the protective effect of BMSCs, it still has a clinical 
role as the drug was still able to induce expression of p53 downstream effectors in the 
presence of BMSCs but to a lesser degree compared to in the absence of BMSCs. The 
clinical relevance of the drug is further proven by the synergistic cytotoxicity seen with 
bortezomib in epithelial tumours in the presence of BMSCs. 
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The AMPK pathway is of interest in MM as activation of AMPK will inhibit mTOR, which 
is involved in cell proliferation and growth. Metformin and AICAR, both AMPK 
activators, were studied in the thesis and have clinical relevance as not only do they 
have anticancer activity in vitro but both of these drugs can overcome the protective 
(pro-cancer) effect of the local microenvironment.  Although the dose levels used in this 
study appears to be higher than the normal practice, it is consistent with the reported 
levels used in other studies. Metformin is positively charged and accumulates (~1000 
fold) within the mitochondrial matrix in a slow, membrane-potential-driven fashion, that 
is also self-limiting because progressive inhibition of the respiratory chain leads to a 
drop in membrane potential, which will prevent further accumulation of the drug [399]. 
Furthermore, as a hydrophilic base, metformin’s  passive diffusion through cell 
membranes is limited [394].  Clinically, metformin has been in use since the 1950s and 
has an excellent safety profile when used as labelled [397]. As with metformin, the 
AICAR doses used are higher than the normal practice. The thesis findings showed 
that AICAR is non-toxic to non-neoplastic cells at the cytotoxic doses used for cancer 
cells and the in vivo study showed no toxicity to the animals. Furthermore, a study by 
Dixon et al. [410] reported the pharmacokinetics of AICAR and the doses used in this 
study are within the range of doses used for our in vitro experiments. Between the two 
AMPK activators, AICAR has more antimyeloma activity and a clinical trial of this agent 
should be pursued.    
 
Proteomic comparative analysis of MM cells to mechanism of bortezomib resistance 
revealed novel proteins that are not known to be associated with MM. These proteins 
have been associated with other cancer types in the literature. This technique is a 
sensitive tool to examine bortezomib resistance.  
 
Recent studies published that both nutlin and metformin are P-gp substrates and they 
affect P-gp expression and function [445, 446]. Nutlin was shown to affect MRP-1 as 
well [446]. These two studies further connect the different anti-MM agents studied. 
  
  
 
265
Chapter 6 
Future Work 
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6.1. MDR protein resistance in Multiple Myeloma  
1. To confirm whether bortezomib is truly a P-gp substrate, we would like to look 
at the extrusion of bortezomib from a P-gp overexpressing cell, using either a 
radio-labelled or fluorescent-labelled bortezomib.   
2. We have showed that bortezomib is able to change the levels of P-gp protein 
expression and function, therefore investigation of the impacts of bortezomib 
treatment on other resistance proteins, i.e. BCRP and MRP-1 should be done. 
3. As recent studies have showed that nutlin-3 and metformin can affect P-gp 
function and expression, investigation into combination of these agents with 
bortezomib on the impact of P-gp expression is warranted. 
4. As it has been seen with other chemotherapeutic agents that are P-gp 
substrates, such as doxorubicin, we want to clinically correlate the P-gp 
expression in BM samples of bortezomib responsive and bortezomib refractory 
patients to see if exposure to bortezomib can select for P-gp expression. 
 
6.2. p53 signalling perturbations in Multiple Myeloma 
1. As p53-null or p53-mutated cell lines showed synergy with nutlin-3 and 
bortezomib, examination into the mechanism of cell death caused by this 
combination should be undertaken. 
 
6.3 APMK activation as an alternative pathway to overcome resistance to 
conventional treatment in Multiple Myeloma  
1. The combination of glycolysis inhibitors and AMPK activators yielded synergy 
and investigation into the mechanism of the combination should be undertaken. 
 
6.4. Proteomic analysis of bortezomib resistance in Multiple Myeloma 
1. The proteins identified in this thesis were novel proteins that are not known to 
be associated with MM or bortezomib treatment. Investigation of potential 
targets for resistance mechanism to bortezomib treatment by using siRNA to 
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generate a knockdown or upregulation of the target proteins. Alternatively, if 
there are small molecule inhibitors available, to use them to inhibit or activate 
the target proteins. 
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ABBREVIATIONS 
2-DE  - Two-dimensional gel electrophoresis 
2-DIGE - Two-dimensional differential in gel electrophoresis 
AICAR  - 5-aminoimidazole-4-carboxamide ribonucleoside   
AMPK  - AMP-activated protein kinase 
ASCT  - Autologous stem cell transplant 
BAFF  -  B-cell activating factor  
BCRP   - Breast cancer resistance protein 
BM  - Bone marrow 
BMECs - Bone marrow endothelial cells 
BMSCs - Bone marrow stromal cells 
DKK1  - Dickkopf 1 
ECM  - Extracellular matrix 
ERp  - Endoplasmic reticulum protein 
FBP  - Far upstream element binding protein (also known as FUSE binding 
protein) 
FGFs  - Fibroblast growth factors (FGFs) 
FISH   - Fluorescent in-situ hybridization 
FLC  - Free light chain 
HCC  - Hepatocellular carcinoma 
HDAC  - Histone deacytelase 
HGF  - Hepatocyte growth factor 
HIF-1  - Hypoxia-inducible factor 1 
HnRNP - Heterogeneous nuclear ribonucleoprotein 
HSP   - Heat shock protein  
HRD  - Hyperdiploid 
IGF-1  - Insulin-like growth factor-1 
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IGHR  - Immunoglobulin heavy chain variable region  
IL  - Interleukin 
MDR-1  - Multidrug resistance -1  
MGUS  - Monoclonal gammopathy of unknown significance 
MIP  - Macrophage inflammatory protein 
MM   - Multiple Myeloma 
MMP  - Matrix metalloproteinases  
MP  - Melphalan and Prednisolone 
MS  - Mass spectometry 
mTOR  - Mammalian target of rapamycin 
MVD  - Microvascular density 
NF-κB  - Nuclear factor-kappaB  
NHRD  - Nonhyperdiploid 
OB  - Osteoblasts 
OC  - Osteoclasts 
p38 MAPK  -  p38 mitogen-activated protein kinase  
P-gp  - P-glycoprotein 
PI3k  - Phosphotidylinositidol-3-phosphate-kinase 
PMF  - Peptide mass fingerprint 
RANKL - Receptor activator of NF-κB ligand   
SDF-1a - Stromal cell–derived factor –1a 
TGF  - Transforming growth factor 
TNF-α  - Tumour necrosis factor-α 
VAD  - Vincristine, doxorubicin, and dexamethasone  
VEGF  - Vascular endothelial growth factor 
 
  
 
271
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Knudson, A.G., Two genetic hits (more or less) to cancer. Nat Rev Cancer, 
2001. 1(2): p. 157-62. 
References
  
 
272
2. Landgren, O., et al., Monoclonal gammopathy of undetermined significance 
(MGUS) consistently precedes multiple myeloma: a prospective study. Blood, 
2009. 113(22): p. 5412-7. 
3. Rajkumar, S.V., et al., Serum free light chain ratio is an independent risk factor 
for progression in monoclonal gammopathy of undetermined significance. 
Blood, 2005. 106(3): p. 812-7. 
4. Kyle, R.A., et al., A long-term study of prognosis in monoclonal gammopathy of 
undetermined significance. N Engl J Med, 2002. 346(8): p. 564-9. 
5. Ries, L., et al., SEER Cancer Statistics Review, 1975-2001. 2004, Bethesda, 
MD, National Cancer Institute. 
6. Malpas, J., et al., Multiple myeloma: biology and management. . 1998, Oxford: 
Oxford University Press. 
7. Cohen, H., et al., Racial differences in the prevalence of monoclonal 
gammopathy in a community-based sample of the elderly. Am J Med, 
1998(104): p. 439–44. 
8. Munshi, N.C., Plasma cell disorders: an historical perspective. Hematology Am 
Soc Hematol Educ Program, 2008: p. 297. 
9. Laubach, J.P., et al., Novel therapies in the treatment of multiple myeloma. J 
Natl Compr Canc Netw, 2009. 7(9): p. 947-60. 
10. Avet-Loiseau, H., et al., Genetic abnormalities and survival in multiple 
myeloma: the experience of the Intergroupe Francophone du Myelome. Blood, 
2007. 109(8): p. 3489-95. 
11. Stewart, A.K., et al., Diagnostic evaluation of t(4;14) in multiple myeloma and 
evidence for clonal evolution. Leukemia, 2007. 21(11): p. 2358-9. 
12. Chng, W.J., et al., Genetic events in the pathogenesis of multiple myeloma. 
Best Pract Res Clin Haematol, 2007. 20(4): p. 571-96. 
13. Fonseca, R., et al., Genetics and cytogenetics of multiple myeloma: a workshop 
report. Cancer Res, 2004. 64(4): p. 1546-58. 
14. Bergsagel, D.E., et al., Evaluation of new chemotherapeutic agents in the 
treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). 
Cancer Chemother Rep, 1962. 21: p. 87-99. 
15. Mass, R.E., A comparison of the effect of prednisone and a placebo in the 
treatment of multiple myeloma. Cancer Chemother Rep, 1962. 16: p. 257-9. 
16. Alexanian, R., et al., Treatment for multiple myeloma. Combination 
chemotherapy with different melphalan dose regimens. JAMA, 1969. 208(9): p. 
1680-5. 
17. Alexanian, R., B. Barlogie, and S. Tucker, VAD-based regimens as primary 
treatment for multiple myeloma. Am J Hematol, 1990. 33(2): p. 86-9. 
18. Barlogie, B., L. Smith, and R. Alexanian, Effective treatment of advanced 
multiple myeloma refractory to alkylating agents. N Engl J Med, 1984. 310(21): 
p. 1353-6. 
19. Barlogie, B., et al., High-dose chemoradiotherapy and autologous bone marrow 
transplantation for resistant multiple myeloma. Blood, 1987. 70(3): p. 869-72. 
20. Attal, M., et al., A prospective, randomized trial of autologous bone marrow 
transplantation and chemotherapy in multiple myeloma. Intergroupe Francais 
du Myelome. N Engl J Med, 1996. 335(2): p. 91-7. 
21. Attal, M., et al., Single versus double autologous stem-cell transplantation for 
multiple myeloma. N Engl J Med, 2003. 349(26): p. 2495-502. 
22. Barlogie, B., et al., Total therapy with tandem transplants for newly diagnosed 
multiple myeloma. Blood, 1999. 93(1): p. 55-65. 
  
 
273
23. Tricot, G., et al., Graft-versus-myeloma effect: proof of principle. Blood, 1996. 
87(3): p. 1196-8. 
24. Verdonck, L.F., et al., Graft-versus-myeloma effect in two cases. Lancet, 1996. 
347(9004): p. 800-1. 
25. Aschan, J., et al., Graft-versus-myeloma effect. Lancet, 1996. 348(9023): p. 
346. 
26. Crawley, C., et al., Reduced-intensity conditioning for myeloma: lower 
nonrelapse mortality but higher relapse rates compared with myeloablative 
conditioning. Blood, 2007. 109(8): p. 3588-94. 
27. Hideshima, T., et al., The proteasome inhibitor PS-341 inhibits growth, induces 
apoptosis, and overcomes drug resistance in human multiple myeloma cells. 
Cancer Res, 2001. 61(7): p. 3071-6. 
28. Singhal, S., et al., Antitumor activity of thalidomide in refractory multiple 
myeloma. N Engl J Med, 1999. 341(21): p. 1565-71. 
29. Richardson, P.G., et al., Immunomodulatory drug CC-5013 overcomes drug 
resistance and is well tolerated in patients with relapsed multiple myeloma. 
Blood, 2002. 100(9): p. 3063-7. 
30. D'Amato, R.J., et al., Thalidomide is an inhibitor of angiogenesis. Proc Natl 
Acad Sci U S A, 1994. 91(9): p. 4082-5. 
31. Vacca, A., et al., Bone marrow angiogenesis and progression in multiple 
myeloma. Br J Haematol, 1994. 87(3): p. 503-8. 
32. Vacca, A., et al., Bone marrow of patients with active multiple myeloma: 
angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and 
CD44. Am J Hematol, 1995. 50(1): p. 9-14. 
33. Barlogie, B., et al., Extended survival in advanced and refractory multiple 
myeloma after single-agent thalidomide: identification of prognostic factors in a 
phase 2 study of 169 patients. Blood, 2001. 98(2): p. 492-4. 
34. van Rhee, F., et al., First thalidomide clinical trial in multiple myeloma: a 
decade. Blood, 2008. 112(4): p. 1035-8. 
35. Dimopoulos, M.A., et al., Thalidomide and dexamethasone combination for 
refractory multiple myeloma. Ann Oncol, 2001. 12(7): p. 991-5. 
36. Lee, C.K., et al., DTPACE: an effective, novel combination chemotherapy with 
thalidomide for previously treated patients with myeloma. J Clin Oncol, 2003. 
21(14): p. 2732-9. 
37. Offidani, M., et al., Low-dose thalidomide with pegylated liposomal doxorubicin 
and high-dose dexamethasone for relapsed/refractory multiple myeloma: a 
prospective, multicenter, phase II study. Haematologica, 2006. 91(1): p. 133-6. 
38. Adams, J., et al., Proteasome inhibitors: a novel class of potent and effective 
antitumor agents. Cancer Res, 1999. 59(11): p. 2615-22. 
39. Orlowski, R.Z., et al., Tumor growth inhibition induced in a murine model of 
human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res, 1998. 
58(19): p. 4342-8. 
40. Richardson, P.G., et al., A phase 2 study of bortezomib in relapsed, refractory 
myeloma. N Engl J Med, 2003. 348(26): p. 2609-17. 
41. Jagannath, S., et al., A phase 2 study of two doses of bortezomib in relapsed or 
refractory myeloma. Br J Haematol, 2004. 127(2): p. 165-72. 
42. Richardson, P.G., et al., Bortezomib or high-dose dexamethasone for relapsed 
multiple myeloma. N Engl J Med, 2005. 352(24): p. 2487-98. 
43. Richardson, P.G., et al., Extended follow-up of a phase 3 trial in relapsed 
multiple myeloma: final time-to-event results of the APEX trial. Blood, 2007. 
110(10): p. 3557-60. 
  
 
274
44. Mitsiades, N., et al., The proteasome inhibitor PS-341 potentiates sensitivity of 
multiple myeloma cells to conventional chemotherapeutic agents: therapeutic 
applications. Blood, 2003. 101(6): p. 2377-80. 
45. Orlowski, R.Z., et al., Phase 1 trial of the proteasome inhibitor bortezomib and 
pegylated liposomal doxorubicin in patients with advanced hematologic 
malignancies. Blood, 2005. 105(8): p. 3058-65. 
46. Orlowski, R.Z., et al., Randomized phase III study of pegylated liposomal 
doxorubicin plus bortezomib compared with bortezomib alone in relapsed or 
refractory multiple myeloma: combination therapy improves time to progression. 
J Clin Oncol, 2007. 25(25): p. 3892-901. 
47. Palumbo, A., et al., Bortezomib, doxorubicin and dexamethasone in advanced 
multiple myeloma. Ann Oncol, 2008. 19(6): p. 1160-5. 
48. Weber, D.M., et al., Lenalidomide plus dexamethasone for relapsed multiple 
myeloma in North America. N Engl J Med, 2007. 357(21): p. 2133-42. 
49. Dimopoulos, M., et al., Lenalidomide plus dexamethasone for relapsed or 
refractory multiple myeloma. N Engl J Med, 2007. 357(21): p. 2123-32. 
50. Knop, S., et al., Lenalidomide, adriamycin, and dexamethasone (RAD) in 
patients with relapsed and refractory multiple myeloma: a report from the 
German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples 
Myelom). Blood, 2009. 113(18): p. 4137-43. 
51. Hideshima, T., et al., Inhibition of Akt induces significant downregulation of 
survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol, 2007. 
138(6): p. 783-91. 
52. Mitsiades, C.S., et al., From the bench to the bedside: emerging new 
treatments in multiple myeloma. Best Pract Res Clin Haematol, 2007. 20(4): p. 
797-816. 
53. Mitsiades, C.S., et al., Antimyeloma activity of heat shock protein-90 inhibition. 
Blood, 2006. 107(3): p. 1092-100. 
54. Mitsiades, C.S., et al., Transcriptional signature of histone deacetylase 
inhibition in multiple myeloma: biological and clinical implications. Proc Natl 
Acad Sci U S A, 2004. 101(2): p. 540-5. 
55. Catley, L., et al., Aggresome induction by proteasome inhibitor bortezomib and 
alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 
are synergistic in myeloma cells. Blood, 2006. 108(10): p. 3441-9. 
56. Richardson, P., et al., Phase I trial of oral vorinostat (suberoylanilide 
hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk 
Lymphoma, 2008. 49(3): p. 502-7. 
57. Mitsiades, C.S. and M. Koutsilieris, Molecular biology and cellular physiology of 
refractoriness to androgen ablation therapy in advanced prostate cancer. 
Expert Opin Investig Drugs, 2001. 10(6): p. 1099-115. 
58. van Kempen, L.C., et al., The tumor microenvironment: a critical determinant of 
neoplastic evolution. Eur J Cell Biol, 2003. 82(11): p. 539-48. 
59. Zhou, J., et al., The role of the tumor microenvironment in hematological 
malignancies and implication for therapy. Front Biosci, 2005. 10: p. 1581-96. 
60. Mitsiades, C.S., et al., The role of the bone marrow microenvironment in the 
pathophysiology of myeloma and its significance in the development of more 
effective therapies. Hematol Oncol Clin North Am, 2007. 21(6): p. 1007-34, vii-
viii. 
61. Podar, K., D. Chauhan, and K.C. Anderson, Bone marrow microenvironment 
and the identification of new targets for myeloma therapy. Leukemia, 2009. 
23(1): p. 10-24. 
  
 
275
62. Chauhan, D., et al., Multiple myeloma cell adhesion-induced interleukin-6 
expression in bone marrow stromal cells involves activation of NF-kappa B. 
Blood, 1996. 87(3): p. 1104-12. 
63. Chauhan, D., et al., Regulation of interleukin 6 in multiple myeloma and bone 
marrow stromal cells. Stem Cells, 1995. 13 Suppl 2: p. 35-9. 
64. Uchiyama, H., et al., Adhesion of human myeloma-derived cell lines to bone 
marrow stromal cells stimulates interleukin-6 secretion. Blood, 1993. 82(12): p. 
3712-20. 
65. Giuliani, N., V. Rizzoli, and G.D. Roodman, Multiple myeloma bone disease: 
Pathophysiology of osteoblast inhibition. Blood, 2006. 108(13): p. 3992-6. 
66. Chauhan, D., et al., Identification of genes regulated by 2-methoxyestradiol 
(2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood, 2003. 
101(9): p. 3606-14. 
67. Reimold, A.M., et al., Plasma cell differentiation requires the transcription factor 
XBP-1. Nature, 2001. 412(6844): p. 300-7. 
68. Carrasco, D.R., et al., The differentiation and stress response factor XBP-1 
drives multiple myeloma pathogenesis. Cancer Cell, 2007. 11(4): p. 349-60. 
69. Le Gouill, S., et al., Mcl-1 regulation and its role in multiple myeloma. Cell 
Cycle, 2004. 3(10): p. 1259-62. 
70. Hideshima, T., et al., Biologic sequelae of interleukin-6 induced PI3-K/Akt 
signaling in multiple myeloma. Oncogene, 2001. 20(42): p. 5991-6000. 
71. Berger, L.C., et al., Tyrosine phosphorylation of JAK-TYK kinases in malignant 
plasma cell lines growth-stimulated by interleukins 6 and 11. Biochem Biophys 
Res Commun, 1994. 202(1): p. 596-605. 
72. Hideshima, T., et al., Characterization of signaling cascades triggered by 
human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded 
viral interleukin 6. Clin Cancer Res, 2000. 6(3): p. 1180-9. 
73. Lowik, C.W., et al., Parathyroid hormone (PTH) and PTH-like protein (PLP) 
stimulate interleukin-6 production by osteogenic cells: a possible role of 
interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun, 1989. 
162(3): p. 1546-52. 
74. Bataille, R., et al., Biologic effects of anti-interleukin-6 murine monoclonal 
antibody in advanced multiple myeloma. Blood, 1995. 86(2): p. 685-91. 
75. Klein, B., et al., Murine anti-interleukin-6 monoclonal antibody therapy for a 
patient with plasma cell leukemia. Blood, 1991. 78(5): p. 1198-204. 
76. Lu, Z.Y., et al., Measurement of whole body interleukin-6 (IL-6) production: 
prediction of the efficacy of anti-IL-6 treatments. Blood, 1995. 86(8): p. 3123-31. 
77. Montero-Julian, F.A., et al., Pharmacokinetic study of anti-interleukin-6 (IL-6) 
therapy with monoclonal antibodies: enhancement of IL-6 clearance by 
cocktails of anti-IL-6 antibodies. Blood, 1995. 85(4): p. 917-24. 
78. Hankinson, S.E., et al., Circulating concentrations of insulin-like growth factor-I 
and risk of breast cancer. Lancet, 1998. 351(9113): p. 1393-6. 
79. Chan, J.M., et al., Plasma insulin-like growth factor-I and prostate cancer risk: a 
prospective study. Science, 1998. 279(5350): p. 563-6. 
80. LeRoith, D. and C.T. Roberts, Jr., The insulin-like growth factor system and 
cancer. Cancer Lett, 2003. 195(2): p. 127-37. 
81. Mitsiades, C.S. and N. Mitsiades, Treatment of hematologic malignancies and 
solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther, 
2005. 5(3): p. 487-99. 
  
 
276
82. Garcia-Echeverria, C., et al., In vivo antitumor activity of NVP-AEW541-A novel, 
potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell, 2004. 5(3): p. 
231-9. 
83. Rajkumar, S.V. and R.A. Kyle, Angiogenesis in multiple myeloma. Semin 
Oncol, 2001. 28(6): p. 560-4. 
84. Podar, K. and K.C. Anderson, The pathophysiologic role of VEGF in 
hematologic malignancies: therapeutic implications. Blood, 2005. 105(4): p. 
1383-95. 
85. Jakob, C., et al., Angiogenesis in multiple myeloma. Eur J Cancer, 2006. 
42(11): p. 1581-90. 
86. Podar, K. and K.C. Anderson, Inhibition of VEGF signaling pathways in multiple 
myeloma and other malignancies. Cell Cycle, 2007. 6(5): p. 538-42. 
87. Tai, Y.T., et al., Human anti-CD40 antagonist antibody triggers significant 
antitumor activity against human multiple myeloma. Cancer Res, 2005. 65(13): 
p. 5898-906. 
88. Tai, Y.T., et al., Mechanisms by which SGN-40, a humanized anti-CD40 
antibody, induces cytotoxicity in human multiple myeloma cells: clinical 
implications. Cancer Res, 2004. 64(8): p. 2846-52. 
89. Tai, Y.T., et al., Immunomodulatory drug lenalidomide (CC-5013, IMiD3) 
augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: 
clinical implications. Cancer Res, 2005. 65(24): p. 11712-20. 
90. Silvestris, F., et al., Impaired osteoblastogenesis in myeloma bone disease: role 
of upregulated apoptosis by cytokines and malignant plasma cells. Br J 
Haematol, 2004. 126(4): p. 475-86. 
91. Hideshima, T., et al., The role of tumor necrosis factor alpha in the 
pathophysiology of human multiple myeloma: therapeutic applications. 
Oncogene, 2001. 20(33): p. 4519-27. 
92. Landowski, T.H., et al., Cell adhesion-mediated drug resistance (CAM-DR) is 
associated with activation of NF-kappa B (RelB/p50) in myeloma cells. 
Oncogene, 2003. 22(16): p. 2417-21. 
93. Moreaux, J., et al., BAFF and APRIL protect myeloma cells from apoptosis 
induced by interleukin 6 deprivation and dexamethasone. Blood, 2004. 103(8): 
p. 3148-57. 
94. Moreaux, J., et al., TACI expression is associated with a mature bone marrow 
plasma cell signature and C-MAF overexpression in human myeloma cell lines. 
Haematologica, 2007. 92(6): p. 803-11. 
95. Hideshima, T., et al., The biological sequelae of stromal cell-derived factor-
1alpha in multiple myeloma. Mol Cancer Ther, 2002. 1(7): p. 539-44. 
96. Podar, K., et al., GW654652, the pan-inhibitor of VEGF receptors, blocks the 
growth and migration of multiple myeloma cells in the bone marrow 
microenvironment. Blood, 2004. 103(9): p. 3474-9. 
97. Hov, H., et al., A selective c-met inhibitor blocks an autocrine hepatocyte 
growth factor growth loop in ANBL-6 cells and prevents migration and adhesion 
of myeloma cells. Clin Cancer Res, 2004. 10(19): p. 6686-94. 
98. Asosingh, K., et al., In vivo homing and differentiation characteristics of mature 
(CD45-) and immature (CD45+) 5T multiple myeloma cells. Exp Hematol, 2001. 
29(1): p. 77-84. 
99. Tai, Y.T., et al., Insulin-like growth factor-1 induces adhesion and migration in 
human multiple myeloma cells via activation of beta1-integrin and 
phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res, 2003. 63(18): p. 
5850-8. 
  
 
277
100. Hazlehurst, L.A., et al., Adhesion to fibronectin via beta1 integrins regulates 
p27kip1 levels and contributes to cell adhesion mediated drug resistance 
(CAM-DR). Oncogene, 2000. 19(38): p. 4319-27. 
101. Hazlehurst, L.A., et al., Genotypic and phenotypic comparisons of de novo and 
acquired melphalan resistance in an isogenic multiple myeloma cell line model. 
Cancer Res, 2003. 63(22): p. 7900-6. 
102. Barille, S., et al., Metalloproteinases in multiple myeloma: production of matrix 
metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 
by myeloma cells. Blood, 1997. 90(4): p. 1649-55. 
103. Flomenberg, N., J. DiPersio, and G. Calandra, Role of CXCR4 chemokine 
receptor blockade using AMD3100 for mobilization of autologous hematopoietic 
progenitor cells. Acta Haematol, 2005. 114(4): p. 198-205. 
104. Werts, E.D., et al., Characterization of marrow stromal (fibroblastoid) cells and 
their association with erythropoiesis. Exp Hematol, 1980. 8(4): p. 423-33. 
105. Urashima, M., et al., Transforming growth factor-beta1: differential effects on 
multiple myeloma versus normal B cells. Blood, 1996. 87(5): p. 1928-38. 
106. Urashima, M., et al., CD40 ligand triggered interleukin-6 secretion in multiple 
myeloma. Blood, 1995. 85(7): p. 1903-12. 
107. Nefedova, Y., et al., Involvement of Notch-1 signaling in bone marrow stroma-
mediated de novo drug resistance of myeloma and other malignant lymphoid 
cell lines. Blood, 2004. 103(9): p. 3503-10. 
108. Houde, C., et al., Overexpression of the NOTCH ligand JAG2 in malignant 
plasma cells from multiple myeloma patients and cell lines. Blood, 2004. 
104(12): p. 3697-704. 
109. Jundt, F., et al., Jagged1-induced Notch signaling drives proliferation of multiple 
myeloma cells. Blood, 2004. 103(9): p. 3511-5. 
110. Gan, Z.H. and Y. Chen, [Notch signaling pathway and multiple myeloma.]. 
Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2009. 17(5): p. 1380-3. 
111. Zdzisinska, B., A. Walter-Croneck, and M. Kandefer-Szerszen, Matrix 
metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 
production is abnormal in bone marrow stromal cells of multiple myeloma 
patients. Leuk Res, 2008. 32(11): p. 1763-9. 
112. Kline, M., et al., Cytokine and chemokine profiles in multiple myeloma; 
significance of stromal interaction and correlation of IL-8 production with 
disease progression. Leuk Res, 2007. 31(5): p. 591-8. 
113. Vacca, A., et al., Thalidomide downregulates angiogenic genes in bone marrow 
endothelial cells of patients with active multiple myeloma. J Clin Oncol, 2005. 
23(23): p. 5334-46. 
114. Roccaro, A.M., et al., Bortezomib mediates antiangiogenesis in multiple 
myeloma via direct and indirect effects on endothelial cells. Cancer Res, 2006. 
66(1): p. 184-91. 
115. Bataille, R., et al., Mechanisms of bone destruction in multiple myeloma: the 
importance of an unbalanced process in determining the severity of lytic bone 
disease. J Clin Oncol, 1989. 7(12): p. 1909-14. 
116. Esteve, F.R. and G.D. Roodman, Pathophysiology of myeloma bone disease. 
Best Pract Res Clin Haematol, 2007. 20(4): p. 613-24. 
117. Terpos, E., et al., Myeloma bone disease and proteasome inhibition therapies. 
Blood, 2007. 110(4): p. 1098-104. 
118. Hofbauer, L.C. and M. Schoppet, Clinical implications of the 
osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA, 
2004. 292(4): p. 490-5. 
  
 
278
119. Choi, S.J., et al., Antisense inhibition of macrophage inflammatory protein 1-
alpha blocks bone destruction in a model of myeloma bone disease. J Clin 
Invest, 2001. 108(12): p. 1833-41. 
120. Choi, S.J., et al., Macrophage inflammatory protein 1-alpha is a potential 
osteoclast stimulatory factor in multiple myeloma. Blood, 2000. 96(2): p. 671-5. 
121. Oba, Y., et al., MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast 
formation and increase adhesion of myeloma cells to marrow stromal cells. Exp 
Hematol, 2005. 33(3): p. 272-8. 
122. Franchimont, N., S. Rydziel, and E. Canalis, Transforming growth factor-beta 
increases interleukin-6 transcripts in osteoblasts. Bone, 2000. 26(3): p. 249-53. 
123. Nguyen, A.N., et al., Normalizing the bone marrow microenvironment with p38 
inhibitor reduces multiple myeloma cell proliferation and adhesion and 
suppresses osteoclast formation. Exp Cell Res, 2006. 312(10): p. 1909-23. 
124. Breitkreutz, I., et al., Lenalidomide inhibits osteoclastogenesis, survival factors 
and bone-remodeling markers in multiple myeloma. Leukemia, 2008. 22(10): p. 
1925-32. 
125. Breitkreutz, I., et al., Targeting MEK1/2 blocks osteoclast differentiation, 
function and cytokine secretion in multiple myeloma. Br J Haematol, 2007. 
139(1): p. 55-63. 
126. Vallet, S., et al., MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis 
and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood, 
2007. 110(10): p. 3744-52. 
127. Feng, R., et al., The histone deacetylase inhibitor, PXD101, potentiates 
bortezomib-induced anti-multiple myeloma effect by induction of oxidative 
stress and DNA damage. Br J Haematol, 2007. 139(3): p. 385-97. 
128. Boissy, P., et al., Resveratrol inhibits myeloma cell growth, prevents osteoclast 
formation, and promotes osteoblast differentiation. Cancer Res, 2005. 65(21): 
p. 9943-52. 
129. Feng, R., et al., SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-
kappaB activity, resulting in strong inhibition of osteoclast formation/activity and 
multiple myeloma cell growth. Blood, 2007. 109(5): p. 2130-8. 
130. Karsenty, G., et al., Cbfa1 as a regulator of osteoblast differentiation and 
function. Bone, 1999. 25(1): p. 107-8. 
131. Tian, E., et al., The role of the Wnt-signaling antagonist DKK1 in the 
development of osteolytic lesions in multiple myeloma. N Engl J Med, 2003. 
349(26): p. 2483-94. 
132. Oshima, T., et al., Myeloma cells suppress bone formation by secreting a 
soluble Wnt inhibitor, sFRP-2. Blood, 2005. 106(9): p. 3160-5. 
133. Fujita, K. and S. Janz, Attenuation of WNT signaling by DKK-1 and -2 regulates 
BMP2-induced osteoblast differentiation and expression of OPG, RANKL and 
M-CSF. Mol Cancer, 2007. 6: p. 71. 
134. Ehrlich, L.A., et al., IL-3 is a potential inhibitor of osteoblast differentiation in 
multiple myeloma. Blood, 2005. 106(4): p. 1407-14. 
135. Standal, T., et al., HGF inhibits BMP-induced osteoblastogenesis: possible 
implications for the bone disease of multiple myeloma. Blood, 2007. 109(7): p. 
3024-30. 
136. Yang, H.H., et al., Overcoming drug resistance in multiple myeloma: the 
emergence of therapeutic approaches to induce apoptosis. J Clin Oncol, 2003. 
21(22): p. 4239-47. 
137. Sharom, F.J., ABC multidrug transporters: structure, function and role in 
chemoresistance. Pharmacogenomics, 2008. 9(1): p. 105-27. 
  
 
279
138. Krishna, R. and L.D. Mayer, Multidrug resistance (MDR) in cancer. 
Mechanisms, reversal using modulators of MDR and the role of MDR 
modulators in influencing the pharmacokinetics of anticancer drugs. Eur J 
Pharm Sci, 2000. 11(4): p. 265-83. 
139. Hyafil, F., et al., In vitro and in vivo reversal of multidrug resistance by 
GF120918, an acridonecarboxamide derivative. Cancer Res, 1993. 53(19): p. 
4595-602. 
140. Dantzig, A.H., et al., Reversal of P-glycoprotein-mediated multidrug resistance 
by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res, 
1996. 56(18): p. 4171-9. 
141. Dale, I.L., et al., Reversal of P-glycoprotein-mediated multidrug resistance by 
XR9051, a novel diketopiperazine derivative. Br J Cancer, 1998. 78(7): p. 885-
92. 
142. Newman, M.J., et al., Discovery and characterization of OC144-093, a novel 
inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res, 2000. 
60(11): p. 2964-72. 
143. Pusztai, L., et al., Phase II study of tariquidar, a selective P-glycoprotein 
inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. 
Cancer, 2005. 104(4): p. 682-91. 
144. Fromm, M.F., Importance of P-glycoprotein at blood-tissue barriers. Trends 
Pharmacol Sci, 2004. 25(8): p. 423-9. 
145. van Tellingen, O., et al., P-glycoprotein and Mrp1 collectively protect the bone 
marrow from vincristine-induced toxicity in vivo. Br J Cancer, 2003. 89(9): p. 
1776-82. 
146. Grogan, T.M., et al., P-glycoprotein expression in human plasma cell myeloma: 
correlation with prior chemotherapy. Blood, 1993. 81(2): p. 490-5. 
147. Sonneveld, P., et al., Cyclosporin A combined with vincristine, doxorubicin and 
dexamethasone (VAD) compared with VAD alone in patients with advanced 
refractory multiple myeloma: an EORTC-HOVON randomized phase III study 
(06914). Br J Haematol, 2001. 115(4): p. 895-902. 
148. Dalton, W.S., et al., A phase III randomized study of oral verapamil as a 
chemosensitizer to reverse drug resistance in patients with refractory myeloma. 
A Southwest Oncology Group study. Cancer, 1995. 75(3): p. 815-20. 
149. Friedenberg, W.R., et al., Phase III study of PSC-833 (valspodar) in 
combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) 
versus VAD alone in patients with recurring or refractory multiple myeloma 
(E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer, 2006. 
106(4): p. 830-8. 
150. Rumpold, H., et al., Knockdown of PgP resensitizes leukemic cells to 
proteasome inhibitors. Biochem Biophys Res Commun, 2007. 361(2): p. 549-
54. 
151. Loo, T.W. and D.M. Clarke, The human multidrug resistance P-glycoprotein is 
inactive when its maturation is inhibited: potential for a role in cancer 
chemotherapy. FASEB J, 1999. 13(13): p. 1724-32. 
152. Fardel, O., et al., Physiological, pharmacological and clinical features of the 
multidrug resistance protein 2. Biomed Pharmacother, 2005. 59(3): p. 104-14. 
153. Leslie, E.M., R.G. Deeley, and S.P. Cole, Multidrug resistance proteins: role of 
P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol 
Appl Pharmacol, 2005. 204(3): p. 216-37. 
154. Hipfner, D.R., R.G. Deeley, and S.P. Cole, Structural, mechanistic and clinical 
aspects of MRP1. Biochim Biophys Acta, 1999. 1461(2): p. 359-76. 
  
 
280
155. Boumendjel, A., et al., Anticancer multidrug resistance mediated by MRP1: 
recent advances in the discovery of reversal agents. Med Res Rev, 2005. 
25(4): p. 453-72. 
156. Doyle, L.A., et al., A multidrug resistance transporter from human MCF-7 breast 
cancer cells. Proc Natl Acad Sci U S A, 1998. 95(26): p. 15665-70. 
157. Allikmets, R., et al., A human placenta-specific ATP-binding cassette gene 
(ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer 
Res, 1998. 58(23): p. 5337-9. 
158. Staud, F. and P. Pavek, Breast cancer resistance protein (BCRP/ABCG2). Int J 
Biochem Cell Biol, 2005. 37(4): p. 720-5. 
159. Diestra, J.E., et al., Frequent expression of the multi-drug resistance-associated 
protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 
monoclonal antibody in paraffin-embedded material. J Pathol, 2002. 198(2): p. 
213-9. 
160. Steinbach, D. and O. Legrand, ABC transporters and drug resistance in 
leukemia: was P-gp nothing but the first head of the Hydra? Leukemia, 2007. 
21(6): p. 1172-6. 
161. Sugimoto, Y., et al., Breast cancer resistance protein: molecular target for 
anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer 
Sci, 2005. 96(8): p. 457-65. 
162. Koshland, D.E., Jr., Molecule of the year. Science, 1993. 262(5142): p. 1953. 
163. Junttila, M.R. and G.I. Evan, p53--a Jack of all trades but master of none. Nat 
Rev Cancer, 2009. 9(11): p. 821-9. 
164. Iwakuma, T. and G. Lozano, MDM2, an introduction. Mol Cancer Res, 2003. 
1(14): p. 993-1000. 
165. Momand, J., et al., The mdm-2 oncogene product forms a complex with the p53 
protein and inhibits p53-mediated transactivation. Cell, 1992. 69(7): p. 1237-45. 
166. Vogelstein, B. and K.W. Kinzler, Cancer genes and the pathways they control. 
Nat Med, 2004. 10(8): p. 789-99. 
167. Jones, S.N., et al., Rescue of embryonic lethality in Mdm2-deficient mice by 
absence of p53. Nature, 1995. 378(6553): p. 206-8. 
168. Montes de Oca Luna, R., D.S. Wagner, and G. Lozano, Rescue of early 
embryonic lethality in mdm2-deficient mice by deletion of p53. Nature, 1995. 
378(6553): p. 203-6. 
169. Francoz, S., et al., Mdm4 and Mdm2 cooperate to inhibit p53 activity in 
proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A, 2006. 
103(9): p. 3232-7. 
170. Marine, J.C., et al., Keeping p53 in check: essential and synergistic functions of 
Mdm2 and Mdm4. Cell Death Differ, 2006. 13(6): p. 927-34. 
171. Hainaut, P. and M. Hollstein, p53 and human cancer: the first ten thousand 
mutations. Adv Cancer Res, 2000. 77: p. 81-137. 
172. Secchiero, P., et al., The MDM2 inhibitor Nutlins as an innovative therapeutic 
tool for the treatment of haematological malignancies. Curr Pharm Des, 2008. 
14(21): p. 2100-10. 
173. Loiseau, H.A., et al., Induction with Velcade®/Dexamethasone Partially 
Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young 
Patients with Multiple Myeloma. Blood, 2009. 114(22). 
174. Song, H., M. Hollstein, and Y. Xu, p53 gain-of-function cancer mutants induce 
genetic instability by inactivating ATM. Nat Cell Biol, 2007. 9(5): p. 573-80. 
175. Xu, Y., Induction of genetic instability by gain-of-function p53 cancer mutants. 
Oncogene, 2008. 27(25): p. 3501-7. 
  
 
281
176. Fakharzadeh, S.S., S.P. Trusko, and D.L. George, Tumorigenic potential 
associated with enhanced expression of a gene that is amplified in a mouse 
tumor cell line. EMBO J, 1991. 10(6): p. 1565-9. 
177. Vassilev, L.T., et al., In vivo activation of the p53 pathway by small-molecule 
antagonists of MDM2. Science, 2004. 303(5659): p. 844-8. 
178. Kojima, K., et al., Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by 
transcription-dependent and transcription-independent mechanisms and may 
overcome Atm-mediated resistance to fludarabine in chronic lymphocytic 
leukemia. Blood, 2006. 108(3): p. 993-1000. 
179. Stuhmer, T., et al., Nongenotoxic activation of the p53 pathway as a therapeutic 
strategy for multiple myeloma. Blood, 2005. 106(10): p. 3609-17. 
180. Tovar, C., et al., Small-molecule MDM2 antagonists reveal aberrant p53 
signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A, 2006. 
103(6): p. 1888-93. 
181. Ambrosini, G., et al., Mouse double minute antagonist Nutlin-3a enhances 
chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating 
E2F1. Oncogene, 2007. 26(24): p. 3473-81. 
182. Secchiero, P., et al., The MDM-2 antagonist nutlin-3 promotes the maturation of 
acute myeloid leukemic blasts. Neoplasia, 2007. 9(10): p. 853-61. 
183. Hallstrom, T.C., S. Mori, and J.R. Nevins, An E2F1-dependent gene expression 
program that determines the balance between proliferation and cell death. 
Cancer Cell, 2008. 13(1): p. 11-22. 
184. Lau, L.M., et al., HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and 
enhances p73 function. Oncogene, 2008. 27(7): p. 997-1003. 
185. Secchiero, P., et al., Functional integrity of the p53-mediated apoptotic pathway 
induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic 
leukemia (B-CLL). Blood, 2006. 107(10): p. 4122-9. 
186. Coll-Mulet, L., et al., MDM2 antagonists activate p53 and synergize with 
genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood, 2006. 
107(10): p. 4109-14. 
187. Secchiero, P., et al., Synergistic cytotoxic activity of recombinant TRAIL plus 
the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid 
leukemia cells. Curr Drug Metab, 2007. 8(4): p. 395-403. 
188. Kojima, K., et al., MDM2 antagonists induce p53-dependent apoptosis in AML: 
implications for leukemia therapy. Blood, 2005. 106(9): p. 3150-9. 
189. Drakos, E., et al., Inhibition of p53-murine double minute 2 interaction by nutlin-
3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin 
lymphoma. Clin Cancer Res, 2007. 13(11): p. 3380-7. 
190. San Miguel, J.F., et al., Bortezomib plus melphalan and prednisone for initial 
treatment of multiple myeloma. N Engl J Med, 2008. 359(9): p. 906-17. 
191. Hardie, D.G., Minireview: the AMP-activated protein kinase cascade: the key 
sensor of cellular energy status. Endocrinology, 2003. 144(12): p. 5179-83. 
192. Kemp, B.E., et al., AMP-activated protein kinase, super metabolic regulator. 
Biochem Soc Trans, 2003. 31(Pt 1): p. 162-8. 
193. Mehenni, H., et al., Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, 
and evidence for allelic and locus heterogeneity. Am J Hum Genet, 1998. 63(6): 
p. 1641-50. 
194. Ylikorkala, A., et al., Mutations and impaired function of LKB1 in familial and 
non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum 
Mol Genet, 1999. 8(1): p. 45-51. 
  
 
282
195. Tiainen, M., et al., Growth arrest by the LKB1 tumor suppressor: induction of 
p21(WAF1/CIP1). Hum Mol Genet, 2002. 11(13): p. 1497-504. 
196. Kyriakis, J.M., At the crossroads: AMP-activated kinase and the LKB1 tumor 
suppressor link cell proliferation to metabolic regulation. J Biol, 2003. 2(4): p. 
26. 
197. Hardie, D.G., The AMP-activated protein kinase pathway--new players 
upstream and downstream. J Cell Sci, 2004. 117(Pt 23): p. 5479-87. 
198. Bolster, D.R., et al., AMP-activated protein kinase suppresses protein synthesis 
in rat skeletal muscle through down-regulated mammalian target of rapamycin 
(mTOR) signaling. J Biol Chem, 2002. 277(27): p. 23977-80. 
199. Kimura, N., et al., A possible linkage between AMP-activated protein kinase 
(AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. 
Genes Cells, 2003. 8(1): p. 65-79. 
200. Krause, U., L. Bertrand, and L. Hue, Control of p70 ribosomal protein S6 kinase 
and acetyl-CoA carboxylase by AMP-activated protein kinase and protein 
phosphatases in isolated hepatocytes. Eur J Biochem, 2002. 269(15): p. 3751-
9. 
201. Inoki, K., T. Zhu, and K.L. Guan, TSC2 mediates cellular energy response to 
control cell growth and survival. Cell, 2003. 115(5): p. 577-90. 
202. Cheng, S.W., et al., Thr2446 is a novel mammalian target of rapamycin 
(mTOR) phosphorylation site regulated by nutrient status. J Biol Chem, 2004. 
279(16): p. 15719-22. 
203. Fingar, D.C., et al., Mammalian cell size is controlled by mTOR and its 
downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev, 2002. 16(12): p. 
1472-87. 
204. Schmelzle, T. and M.N. Hall, TOR, a central controller of cell growth. Cell, 
2000. 103(2): p. 253-62. 
205. Carrera, A.C., TOR signaling in mammals. J Cell Sci, 2004. 117(Pt 20): p. 
4615-6. 
206. Hideshima, T., et al., Cytokines and signal transduction. Best Pract Res Clin 
Haematol, 2005. 18(4): p. 509-24. 
207. Descamps, G., et al., The magnitude of Akt/phosphatidylinositol 3'-kinase 
proliferating signaling is related to CD45 expression in human myeloma cells. J 
Immunol, 2004. 173(8): p. 4953-9. 
208. Lu, Y., H. Wang, and G.B. Mills, Targeting PI3K-AKT pathway for cancer 
therapy. Rev Clin Exp Hematol, 2003. 7(2): p. 205-28. 
209. Toker, A. and M. Yoeli-Lerner, Akt signaling and cancer: surviving but not 
moving on. Cancer Res, 2006. 66(8): p. 3963-6. 
210. Martelli, A.M., et al., Phosphoinositide 3-kinase/Akt signaling pathway and its 
therapeutical implications for human acute myeloid leukemia. Leukemia, 2006. 
20(6): p. 911-28. 
211. Hideshima, T., et al., Perifosine, an oral bioactive novel alkylphospholipid, 
inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple 
myeloma cells. Blood, 2006. 107(10): p. 4053-62. 
212. McMillin, D.W., et al., Antimyeloma activity of the orally bioavailable dual 
phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-
BEZ235. Cancer Res, 2009. 69(14): p. 5835-42. 
213. Baumann, P., et al., The novel orally bioavailable inhibitor of phosphoinositol-3-
kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and 
proliferation in multiple myeloma. Exp Cell Res, 2009. 315(3): p. 485-97. 
  
 
283
214. Pene, F., et al., Role of the phosphatidylinositol 3-kinase/Akt and 
mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple 
myeloma. Oncogene, 2002. 21(43): p. 6587-97. 
215. Kristiansen, S.B., et al., 5-Aminoimidazole-4-carboxamide-1-beta-D-
ribofuranoside increases myocardial glucose uptake during reperfusion and 
induces late pre-conditioning: potential role of AMP-activated protein kinase. 
Basic Clin Pharmacol Toxicol, 2009. 105(1): p. 10-6. 
216. Russell, R.R., 3rd, et al., AMP-activated protein kinase mediates ischemic 
glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and 
injury. J Clin Invest, 2004. 114(4): p. 495-503. 
217. Ido, Y., D. Carling, and N. Ruderman, Hyperglycemia-induced apoptosis in 
human umbilical vein endothelial cells: inhibition by the AMP-activated protein 
kinase activation. Diabetes, 2002. 51(1): p. 159-67. 
218. Stefanelli, C., et al., Inhibition of glucocorticoid-induced apoptosis with 5-
aminoimidazole-4-carboxamide ribonucleoside, a cell-permeable activator of 
AMP-activated protein kinase. Biochem Biophys Res Commun, 1998. 243(3): p. 
821-6. 
219. Rattan, R., et al., 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside 
inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein 
kinase. J Biol Chem, 2005. 280(47): p. 39582-93. 
220. Evans, J.M., et al., Metformin and reduced risk of cancer in diabetic patients. 
BMJ, 2005. 330(7503): p. 1304-5. 
221. Bowker, S.L., et al., Increased cancer-related mortality for patients with type 2 
diabetes who use sulfonylureas or insulin. Diabetes Care, 2006. 29(2): p. 254-
8. 
222. Wright, J.L. and J.L. Stanford, Metformin use and prostate cancer in Caucasian 
men: results from a population-based case-control study. Cancer Causes 
Control, 2009. 20(9): p. 1617-22. 
223. Bodmer, M., et al., Long-term metformin use is associated with decreased risk 
of breast cancer. Diabetes Care. 33(6): p. 1304-8. 
224. Jiralerspong, S., et al., Metformin and pathologic complete responses to 
neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol, 
2009. 27(20): p. 3297-302. 
225. Ben Sahra, I., et al., The antidiabetic drug metformin exerts an antitumoral 
effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 
2008. 27(25): p. 3576-86. 
226. Buzzai, M., et al., Systemic treatment with the antidiabetic drug metformin 
selectively impairs p53-deficient tumor cell growth. Cancer Res, 2007. 67(14): 
p. 6745-52. 
227. Cantrell, L.A., et al., Metformin is a potent inhibitor of endometrial cancer cell 
proliferation-implications for a novel treatment strategy. Gynecol Oncol, 2009. 
228. Rattan, R., et al., Metformin attenuates ovarian cancer cell growth in an AMP- 
kinase dispensable manner. J Cell Mol Med, 2009. 
229. Wang, L.W., et al., Metformin induces apoptosis of pancreatic cancer cells. 
World J Gastroenterol, 2008. 14(47): p. 7192-8. 
230. Zakikhani, M., et al., Metformin is an AMP kinase-dependent growth inhibitor for 
breast cancer cells. Cancer Res, 2006. 66(21): p. 10269-73. 
231. Corton, J.M., et al., 5-aminoimidazole-4-carboxamide ribonucleoside. A specific 
method for activating AMP-activated protein kinase in intact cells? Eur J 
Biochem, 1995. 229(2): p. 558-65. 
  
 
284
232. Imamura, K., et al., Cell cycle regulation via p53 phosphorylation by a 5'-AMP 
activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-
ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys 
Res Commun, 2001. 287(2): p. 562-7. 
233. Jones, R.G., et al., AMP-activated protein kinase induces a p53-dependent 
metabolic checkpoint. Mol Cell, 2005. 18(3): p. 283-93. 
234. Igata, M., et al., Adenosine monophosphate-activated protein kinase 
suppresses vascular smooth muscle cell proliferation through the inhibition of 
cell cycle progression. Circ Res, 2005. 97(8): p. 837-44. 
235. Baumann, P., et al., Activation of adenosine monophosphate activated protein 
kinase inhibits growth of multiple myeloma cells. Exp Cell Res, 2007. 313(16): 
p. 3592-603. 
236. Xiang, X., et al., AMP-activated protein kinase activators can inhibit the growth 
of prostate cancer cells by multiple mechanisms. Biochem Biophys Res 
Commun, 2004. 321(1): p. 161-7. 
237. Saitoh, M., et al., Adenosine induces apoptosis in the human gastric cancer 
cells via an intrinsic pathway relevant to activation of AMP-activated protein 
kinase. Biochem Pharmacol, 2004. 67(10): p. 2005-11. 
238. Kefas, B.A., et al., AICA-riboside induces apoptosis of pancreatic beta cells 
through stimulation of AMP-activated protein kinase. Diabetologia, 2003. 46(2): 
p. 250-4. 
239. Meisse, D., et al., Sustained activation of AMP-activated protein kinase induces 
c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett, 2002. 
526(1-3): p. 38-42. 
240. Jung, J.E., et al., 5-Aminoimidazole-4-carboxamide-ribonucleoside enhances 
oxidative stress-induced apoptosis through activation of nuclear factor-kappaB 
in mouse Neuro 2a neuroblastoma cells. Neurosci Lett, 2004. 354(3): p. 197-
200. 
241. Meri, S. and M. Baumann, Proteomics: posttranslational modifications, immune 
responses and current analytical tools. Biomol Eng, 2001. 18(5): p. 213-20. 
242. Poly, W.J., Nongenetic variation, genetic-environmental interactions and altered 
gene expression. III. Posttranslational modifications. Comp Biochem Physiol A 
Physiol, 1997. 118(3): p. 551-72. 
243. Graves, P.R. and T.A. Haystead, Molecular biologist's guide to proteomics. 
Microbiol Mol Biol Rev, 2002. 66(1): p. 39-63; table of contents. 
244. Yates, J.R., 3rd, Mass spectrometry. From genomics to proteomics. Trends 
Genet, 2000. 16(1): p. 5-8. 
245. Blackstock, W.P. and M.P. Weir, Proteomics: quantitative and physical mapping 
of cellular proteins. Trends Biotechnol, 1999. 17(3): p. 121-7. 
246. Deng, M., et al., Mapping Gene Ontology to proteins based on protein-protein 
interaction data. Bioinformatics, 2004. 20(6): p. 895-902. 
247. Shen, D.W., et al., Multiple drug-resistant human KB carcinoma cells 
independently selected for high-level resistance to colchicine, adriamycin, or 
vinblastine show changes in expression of specific proteins. J Biol Chem, 1986. 
261(17): p. 7762-70. 
248. Sinha, P., et al., Increased expression of annexin I and thioredoxin detected by 
two-dimensional gel electrophoresis of drug resistant human stomach cancer 
cells. J Biochem Biophys Methods, 1998. 37(3): p. 105-16. 
249. Wang, Y., et al., Proteomic approach to study the cytotoxicity of dioscin 
(saponin). Proteomics, 2006. 6(8): p. 2422-32. 
  
 
285
250. Wang, Y., J.F. Chiu, and Q.Y. He, Proteomics approach to illustrate drug action 
mechanisms. Curr Drug Discov Technol, 2006. 3(3): p. 199-209. 
251. Wang, Y., et al., Modulation of gold(III) porphyrin 1a-induced apoptosis by 
mitogen-activated protein kinase signaling pathways. Biochem Pharmacol, 
2008. 75(6): p. 1282-91. 
252. Ge, F., et al., Proteomic and functional analyses reveal a dual molecular 
mechanism underlying arsenic-induced apoptosis in human multiple myeloma 
cells. J Proteome Res, 2009. 8(6): p. 3006-19. 
253. Rees-Unwin, K.S., et al., Proteomic evaluation of pathways associated with 
dexamethasone-mediated apoptosis and resistance in multiple myeloma. Br J 
Haematol, 2007. 139(4): p. 559-67. 
254. Pratt, W.B. and D.O. Toft, Steroid receptor interactions with heat shock protein 
and immunophilin chaperones. Endocr Rev, 1997. 18(3): p. 306-60. 
255. Weinkauf, M., et al., 2-D PAGE-based comparison of proteasome inhibitor 
bortezomib in sensitive and resistant mantle cell lymphoma. Electrophoresis, 
2009. 30(6): p. 974-86. 
256. Loeffler-Ragg, J., et al., Proteomic identification of aldo-keto reductase 
AKR1B10 induction after treatment of colorectal cancer cells with the 
proteasome inhibitor bortezomib. Mol Cancer Ther, 2009. 8(7): p. 1995-2006. 
257. Sinha, P., et al., Increased expression of epidermal fatty acid binding protein, 
cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel 
electrophoresis, mass spectrometry and microsequencing of drug-resistant 
human adenocarcinoma of the pancreas. Electrophoresis, 1999. 20(14): p. 
2952-60. 
258. Sinha, P., et al., Search for novel proteins involved in the development of 
chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-
dimensional electrophoresis, mass spectrometry and microsequencing. 
Electrophoresis, 1999. 20(14): p. 2961-9. 
259. Yoo, B.C., et al., Metabotropic glutamate receptor 4-mediated 5-Fluorouracil 
resistance in a human colon cancer cell line. Clin Cancer Res, 2004. 10(12 Pt 
1): p. 4176-84. 
260. Shin, Y.K., et al., Down-regulation of mitochondrial F1F0-ATP synthase in 
human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res, 
2005. 65(8): p. 3162-70. 
261. Sinha, P., et al., Identification of novel proteins associated with the 
development of chemoresistance in malignant melanoma using two-
dimensional electrophoresis. Electrophoresis, 2000. 21(14): p. 3048-57. 
262. Urbani, A., et al., A proteomic investigation into etoposide chemo-resistance of 
neuroblastoma cell lines. Proteomics, 2005. 5(3): p. 796-804. 
263. Yoo, B.C., et al., Decreased pyruvate kinase M2 activity linked to cisplatin 
resistance in human gastric carcinoma cell lines. Int J Cancer, 2004. 108(4): p. 
532-9. 
264. Hathout, Y., et al., Differential protein expression in the cytosol fraction of an 
MCF-7 breast cancer cell line selected for resistance toward melphalan. J 
Proteome Res, 2002. 1(5): p. 435-42. 
265. Gehrmann, M.L., C. Fenselau, and Y. Hathout, Highly altered protein 
expression profile in the adriamycin resistant MCF-7 cell line. J Proteome Res, 
2004. 3(3): p. 403-9. 
266. Smith, L., et al., Cancer proteomics and its application to discovery of therapy 
response markers in human cancer. Cancer, 2006. 107(2): p. 232-41. 
  
 
286
267. Martin, A. and M. Clynes, Acid phosphatase: endpoint for in vitro toxicity tests. 
In Vitro Cell Dev Biol, 1991. 27A(3 Pt 1): p. 183-4. 
268. Jakubikova, J., Y. Bao, and J. Sedlak, Isothiocyanates induce cell cycle arrest, 
apoptosis and mitochondrial potential depolarization in HL-60 and multidrug-
resistant cell lines. Anticancer Res, 2005. 25(5): p. 3375-86. 
269. Mulligan, G., et al., Gene expression profiling and correlation with outcome in 
clinical trials of the proteasome inhibitor bortezomib. Blood, 2007. 109(8): p. 
3177-88. 
270. Chou, T.C. and P. Talalay, Trends in Pharmacological Sciences. Vol. 4. 1983. 
271. Chou, T.C. and P. Talalay, Quantitative analysis of dose-effect relationships: 
the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme 
Regul, 1984. 22: p. 27-55. 
272. Duffy, C.P., et al., Enhancement of chemotherapeutic drug toxicity to human 
tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs 
(NSAIDs). Eur J Cancer, 1998. 34(8): p. 1250-9. 
273. Clynes, M., et al., Multiple drug-resistance in variant of a human non-small cell 
lung carcinoma cell line, DLKP-A. Cytotechnology, 1992. 10(1): p. 75-89. 
274. Imai, Y., et al., C421A polymorphism in the human breast cancer resistance 
protein gene is associated with low expression of Q141K protein and low-level 
drug resistance. Mol Cancer Ther, 2002. 1(8): p. 611-6. 
275. Collins, D.M., et al., Tyrosine kinase inhibitors potentiate the cytotoxicity of 
MDR-substrate anticancer agents independent of growth factor receptor status 
in lung cancer cell lines. Invest New Drugs, 2009. 
276. Roovers, D.J., et al., Idarubicin overcomes P-glycoprotein-related multidrug 
resistance: comparison with doxorubicin and daunorubicin in human multiple 
myeloma cell lines. Leuk Res, 1999. 23(6): p. 539-48. 
277. Sarver, J.G., et al., Microplate screening of the differential effects of test agents 
on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast 
cancer cells that overexpress P-glycoprotein. J Biomol Screen, 2002. 7(1): p. 
29-34. 
278. Hideshima, T., et al., Molecular mechanisms mediating antimyeloma activity of 
proteasome inhibitor PS-341. Blood, 2003. 101(4): p. 1530-4. 
279. Liang, Y., et al., Enhanced in vitro invasiveness and drug resistance with 
altered gene expression patterns in a human lung carcinoma cell line after 
pulse selection with anticancer drugs. Int J Cancer, 2004. 111(4): p. 484-93. 
280. Hideshima, T., et al., Understanding multiple myeloma pathogenesis in the 
bone marrow to identify new therapeutic targets. Nat Rev Cancer, 2007. 7(8): p. 
585-98. 
281. Levchenko, A., et al., Intercellular transfer of P-glycoprotein mediates acquired 
multidrug resistance in tumor cells. Proc Natl Acad Sci U S A, 2005. 102(6): p. 
1933-8. 
282. Brown, C.J., et al., Awakening guardian angels: drugging the p53 pathway. Nat 
Rev Cancer, 2009. 9(12): p. 862-73. 
283. Mitsiades, N., et al., Molecular sequelae of proteasome inhibition in human 
multiple myeloma cells. Proc Natl Acad Sci U S A, 2002. 99(22): p. 14374-9. 
284. Wu, X., et al., The p53-mdm-2 autoregulatory feedback loop. Genes Dev, 1993. 
7(7A): p. 1126-32. 
285. Miyashita, T. and J.C. Reed, Tumor suppressor p53 is a direct transcriptional 
activator of the human bax gene. Cell, 1995. 80(2): p. 293-9. 
  
 
287
286. Tai, Y.T., et al., Ku86 variant expression and function in multiple myeloma cells 
is associated with increased sensitivity to DNA damage. J Immunol, 2000. 
165(11): p. 6347-55. 
287. Yu, J., et al., PUMA induces the rapid apoptosis of colorectal cancer cells. Mol 
Cell, 2001. 7(3): p. 673-82. 
288. Martoriati, A., et al., dapk1, encoding an activator of a p19ARF-p53-mediated 
apoptotic checkpoint, is a transcription target of p53. Oncogene, 2005. 24(8): p. 
1461-6. 
289. Burns, T.F., et al., Silencing of the novel p53 target gene Snk/Plk2 leads to 
mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol, 2003. 
23(16): p. 5556-71. 
290. Lopez-Lazaro, M., The warburg effect: why and how do cancer cells activate 
glycolysis in the presence of oxygen? Anticancer Agents Med Chem, 2008. 
8(3): p. 305-12. 
291. Ralser, M., et al., A catabolic block does not sufficiently explain how 2-deoxy-D-
glucose inhibits cell growth. Proc Natl Acad Sci U S A, 2008. 105(46): p. 17807-
11. 
292. Schwarzenbach, H., Expression of MDR1/P-glycoprotein, the multidrug 
resistance protein MRP, and the lung-resistance protein LRP in multiple 
myeloma. Med Oncol, 2002. 19(2): p. 87-104. 
293. Cornelissen, J.J., et al., MDR-1 expression and response to vincristine, 
doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory 
to alkylating agents. J Clin Oncol, 1994. 12(1): p. 115-9. 
294. Turner, J.G., et al., ABCG2 expression, function, and promoter methylation in 
human multiple myeloma. Blood, 2006. 108(12): p. 3881-9. 
295. Ross, D.D., et al., Atypical multidrug resistance: breast cancer resistance 
protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl 
Cancer Inst, 1999. 91(5): p. 429-33. 
296. Ross, D.D., Novel mechanisms of drug resistance in leukemia. Leukemia, 
2000. 14(3): p. 467-73. 
297. Sauerbrey, A., et al., Expression of the BCRP gene (ABCG2/MXR/ABCP) in 
childhood acute lymphoblastic leukaemia. Br J Haematol, 2002. 118(1): p. 147-
50. 
298. Fisher, G.A., et al., Pharmacological considerations in the modulation of 
multidrug resistance. Eur J Cancer, 1996. 32A(6): p. 1082-8. 
299. Berenson, J.R., et al., Maintenance therapy with alternate-day prednisone 
improves survival in multiple myeloma patients. Blood, 2002. 99(9): p. 3163-8. 
300. Boote, D.J., et al., Phase I study of etoposide with SDZ PSC 833 as a 
modulator of multidrug resistance in patients with cancer. J Clin Oncol, 1996. 
14(2): p. 610-8. 
301. Advani, R., et al., Treatment of refractory and relapsed acute myelogenous 
leukemia with combination chemotherapy plus the multidrug resistance 
modulator PSC 833 (Valspodar). Blood, 1999. 93(3): p. 787-95. 
302. Baer, M.R., et al., Phase 3 study of the multidrug resistance modulator PSC-
833 in previously untreated patients 60 years of age and older with acute 
myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood, 2002. 
100(4): p. 1224-32. 
303. Traunecker, H.C., et al., The acridonecarboxamide GF120918 potently 
reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 
cells. Br J Cancer, 1999. 81(6): p. 942-51. 
  
 
288
304. den Ouden, D., et al., In vitro effect of GF120918, a novel reversal agent of 
multidrug resistance, on acute leukemia and multiple myeloma cells. Leukemia, 
1996. 10(12): p. 1930-6. 
305. Allen, J.D., et al., The mouse Bcrp1/Mxr/Abcp gene: amplification and 
overexpression in cell lines selected for resistance to topotecan, mitoxantrone, 
or doxorubicin. Cancer Res, 1999. 59(17): p. 4237-41. 
306. de Bruin, M., et al., Reversal of resistance by GF120918 in cell lines expressing 
the ABC half-transporter, MXR. Cancer Lett, 1999. 146(2): p. 117-26. 
307. Sparreboom, A., et al., Clinical pharmacokinetics of doxorubicin in combination 
with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs, 
1999. 10(8): p. 719-28. 
308. Planting, A.S., et al., A phase I and pharmacologic study of the MDR converter 
GF120918 in combination with doxorubicin in patients with advanced solid 
tumors. Cancer Chemother Pharmacol, 2005. 55(1): p. 91-9. 
309. Fracasso, P.M., et al., Phase I study of docetaxel in combination with the P-
glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res, 
2004. 10(21): p. 7220-8. 
310. Ruff, P., et al., A randomized, placebo-controlled, double-blind phase 2 study of 
docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with 
metastatic or locally recurrent breast cancer who have received one prior 
chemotherapy regimen. Cancer Chemother Pharmacol, 2009. 64(4): p. 763-8. 
311. Sandler, A., et al., A Phase I trial of a potent P-glycoprotein inhibitor, 
zosuquidar trihydrochloride (LY335979), administered intravenously in 
combination with doxorubicin in patients with advanced malignancy. Clin 
Cancer Res, 2004. 10(10): p. 3265-72. 
312. Morschhauser, F., et al., Phase I/II trial of a P-glycoprotein inhibitor, 
Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with 
the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma, 
2007. 48(4): p. 708-15. 
313. Le, L.H., et al., Phase I study of the multidrug resistance inhibitor zosuquidar 
administered in combination with vinorelbine in patients with advanced solid 
tumours. Cancer Chemother Pharmacol, 2005. 56(2): p. 154-60. 
314. Germann, U.A., et al., Chemosensitization and drug accumulation effects of 
VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant 
HL60/ADR cells expressing the multidrug resistance-associated protein MRP. 
Anticancer Drugs, 1997. 8(2): p. 141-55. 
315. Rowinsky, E.K., et al., Phase I and pharmacokinetic study of paclitaxel in 
combination with biricodar, a novel agent that reverses multidrug resistance 
conferred by overexpression of both MDR1 and MRP. J Clin Oncol, 1998. 
16(9): p. 2964-76. 
316. Cripe, L.D., et al., Zosuquidar, a novel modulator of P-glycoprotein, does not 
improve the outcome of older patients with newly diagnosed acute myeloid 
leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative 
Oncology Group 3999. Blood. 116(20): p. 4077-85. 
317. Orlowski, M. and S. Wilk, Catalytic activities of the 20 S proteasome, a 
multicatalytic proteinase complex. Arch Biochem Biophys, 2000. 383(1): p. 1-
16. 
318. Rechsteiner, M.C., Ubiquitin-mediated proteolysis: an ideal pathway for 
systems biology analysis. Adv Exp Med Biol, 2004. 547: p. 49-59. 
319. Fribley, A., Q. Zeng, and C.Y. Wang, Proteasome inhibitor PS-341 induces 
apoptosis through induction of endoplasmic reticulum stress-reactive oxygen 
  
 
289
species in head and neck squamous cell carcinoma cells. Mol Cell Biol, 2004. 
24(22): p. 9695-704. 
320. LeBlanc, R., et al., Proteasome inhibitor PS-341 inhibits human myeloma cell 
growth in vivo and prolongs survival in a murine model. Cancer Res, 2002. 
62(17): p. 4996-5000. 
321. Adams, J. and P.J. Elliott, New agents in cancer clinical trials. Oncogene, 2000. 
19(56): p. 6687-92. 
322. Nakamura, T., et al., The mechanism of cross-resistance to proteasome 
inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. 
Int J Oncol, 2007. 31(4): p. 803-11. 
323. Iijima, M., I. Momose, and D. Ikeda, Increased ABCB1 expression in TP-110-
resistant RPMI-8226 cells. Biosci Biotechnol Biochem. 74(9): p. 1913-9. 
324. Fujita, T., et al., Proteasome inhibitors can alter the signaling pathways and 
attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer, 2005. 
117(4): p. 670-82. 
325. Styczynski, J., et al., Activity of bortezomib in glioblastoma. Anticancer Res, 
2006. 26(6B): p. 4499-503. 
326. Wiberg, K., et al., In vitro activity of bortezomib in cultures of patient tumour 
cells--potential utility in haematological malignancies. Med Oncol, 2009. 26(2): 
p. 193-201. 
327. Lu, S., et al., The effects of proteasome inhibitor bortezomib on a P-gp positive 
leukemia cell line K562/A02. Int J Lab Hematol, 2009. 
328. Minderman, H., et al., Bortezomib activity and in vitro interactions with 
anthracyclines and cytarabine in acute myeloid leukemia cells are independent 
of multidrug resistance mechanisms and p53 status. Cancer Chemother 
Pharmacol, 2007. 60(2): p. 245-55. 
329. Sonneveld, P., Multidrug resistance in haematological malignancies. J Intern 
Med, 2000. 247(5): p. 521-34. 
330. Kuo, M.T., et al., Induction of human MDR1 gene expression by 2-
acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase 
pathway that activate NF-kappaB signaling. Oncogene, 2002. 21(13): p. 1945-
54. 
331. Thevenod, F., et al., Up-regulation of multidrug resistance P-glycoprotein via 
nuclear factor-kappaB activation protects kidney proximal tubule cells from 
cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem, 2000. 
275(3): p. 1887-96. 
332. Ros, J.E., et al., Induction of Mdr1b expression by tumor necrosis factor-alpha 
in rat liver cells is independent of p53 but requires NF-kappaB signaling. 
Hepatology, 2001. 33(6): p. 1425-31. 
333. Zhang, Y., et al., Proteasome inhibitor MG132 reverses multidrug resistance of 
gastric cancer through enhancing apoptosis and inhibiting P-gp. Cancer Biol 
Ther, 2008. 7(4): p. 540-6. 
334. Mayo, M.W. and A.S. Baldwin, The transcription factor NF-kappaB: control of 
oncogenesis and cancer therapy resistance. Biochim Biophys Acta, 2000. 
1470(2): p. M55-62. 
335. Bentires-Alj, M., et al., NF-kappaB transcription factor induces drug resistance 
through MDR1 expression in cancer cells. Oncogene, 2003. 22(1): p. 90-7. 
336. Zhang, Z., et al., Regulation of the stability of P-glycoprotein by ubiquitination. 
Mol Pharmacol, 2004. 66(3): p. 395-403. 
  
 
290
337. Loo, T.W. and D.M. Clarke, Functional consequences of glycine mutations in 
the predicted cytoplasmic loops of P-glycoprotein. J Biol Chem, 1994. 269(10): 
p. 7243-8. 
338. Schinkel, A.H., et al., N-glycosylation and deletion mutants of the human MDR1 
P-glycoprotein. J Biol Chem, 1993. 268(10): p. 7474-81. 
339. Kramer, R., et al., Inhibition of N-linked glycosylation of P-glycoprotein by 
tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer, 
1995. 71(4): p. 670-5. 
340. Perez, L.E., et al., Bortezomib restores stroma-mediated APO2L/TRAIL 
apoptosis resistance in multiple myeloma. Eur J Haematol, 2009. 
341. Garcia, M.G., et al., PI3K/Akt inhibition modulates multidrug resistance and 
activates NF-kappaB in murine lymphoma cell lines. Leuk Res, 2009. 33(2): p. 
288-96. 
342. Petrylak, D.P., et al., P-glycoprotein expression in primary and metastatic 
transitional cell carcinoma of the bladder. Ann Oncol, 1994. 5(9): p. 835-40. 
343. Zhou, X., et al., Nitric oxide induces thymocyte apoptosis via a caspase-1-
dependent mechanism. J Immunol, 2000. 165(3): p. 1252-8. 
344. Fuchs, S.Y., et al., Mdm2 association with p53 targets its ubiquitination. 
Oncogene, 1998. 17(19): p. 2543-7. 
345. Inoue, T., et al., Downregulation of MDM2 stabilizes p53 by inhibiting p53 
ubiquitination in response to specific alkylating agents. FEBS Lett, 2001. 
490(3): p. 196-201. 
346. Maki, C.G., Oligomerization is required for p53 to be efficiently ubiquitinated by 
MDM2. J Biol Chem, 1999. 274(23): p. 16531-5. 
347. Li, M., et al., Mono- versus polyubiquitination: differential control of p53 fate by 
Mdm2. Science, 2003. 302(5652): p. 1972-5. 
348. Di Stefano, V., et al., HIPK2 neutralizes MDM2 inhibition rescuing p53 
transcriptional activity and apoptotic function. Oncogene, 2004. 23(30): p. 5185-
92. 
349. Ofir-Rosenfeld, Y., et al., Mdm2 regulates p53 mRNA translation through 
inhibitory interactions with ribosomal protein L26. Mol Cell, 2008. 32(2): p. 180-
9. 
350. Hoffman, W.H., et al., Transcriptional repression of the anti-apoptotic survivin 
gene by wild type p53. J Biol Chem, 2002. 277(5): p. 3247-57. 
351. Bennett, M., et al., Cell surface trafficking of Fas: a rapid mechanism of p53-
mediated apoptosis. Science, 1998. 282(5387): p. 290-3. 
352. Wu, G.S., et al., KILLER/DR5 is a DNA damage-inducible p53-regulated death 
receptor gene. Nat Genet, 1997. 17(2): p. 141-3. 
353. Moroni, M.C., et al., Apaf-1 is a transcriptional target for E2F and p53. Nat Cell 
Biol, 2001. 3(6): p. 552-8. 
354. Schuler, M., et al., p53 induces apoptosis by caspase activation through 
mitochondrial cytochrome c release. J Biol Chem, 2000. 275(10): p. 7337-42. 
355. Wolff, S., et al., p53's mitochondrial translocation and MOMP action is 
independent of Puma and Bax and severely disrupts mitochondrial membrane 
integrity. Cell Res, 2008. 18(7): p. 733-44. 
356. Chipuk, J.E. and D.R. Green, Cytoplasmic p53: bax and forward. Cell Cycle, 
2004. 3(4): p. 429-31. 
357. Tasdemir, E., et al., p53 represses autophagy in a cell cycle-dependent fashion. 
Cell Cycle, 2008. 7(19): p. 3006-11. 
358. Shangary, S. and S. Wang, Targeting the MDM2-p53 interaction for cancer 
therapy. Clin Cancer Res, 2008. 14(17): p. 5318-24. 
  
 
291
359. Tabe, Y., et al., MDM2 antagonist nutlin-3 displays antiproliferative and 
proapoptotic activity in mantle cell lymphoma. Clin Cancer Res, 2009. 15(3): p. 
933-42. 
360. Lee, J.T. and W. Gu, The multiple levels of regulation by p53 ubiquitination. Cell 
Death Differ. 17(1): p. 86-92. 
361. Ganguli, G. and B. Wasylyk, p53-independent functions of MDM2. Mol Cancer 
Res, 2003. 1(14): p. 1027-35. 
362. Cordon-Cardo, C., et al., Molecular abnormalities of mdm2 and p53 genes in 
adult soft tissue sarcomas. Cancer Res, 1994. 54(3): p. 794-9. 
363. Lu, M.L., et al., Impact of alterations affecting the p53 pathway in bladder 
cancer on clinical outcome, assessed by conventional and array-based 
methods. Clin Cancer Res, 2002. 8(1): p. 171-9. 
364. Alt, J.R., et al., Mdm2 haplo-insufficiency profoundly inhibits Myc-induced 
lymphomagenesis. EMBO J, 2003. 22(6): p. 1442-50. 
365. Alt, J.R., et al., Mdm2 binds to Nbs1 at sites of DNA damage and regulates 
double strand break repair. J Biol Chem, 2005. 280(19): p. 18771-81. 
366. Stracker, T.H., et al., The Mre11 complex and the metabolism of chromosome 
breaks: the importance of communicating and holding things together. DNA 
Repair (Amst), 2004. 3(8-9): p. 845-54. 
367. Carroll, P.E., et al., Centrosome hyperamplification in human cancer: 
chromosome instability induced by p53 mutation and/or Mdm2 overexpression. 
Oncogene, 1999. 18(11): p. 1935-44. 
368. Bouska, A., et al., Mdm2 promotes genetic instability and transformation 
independent of p53. Mol Cell Biol, 2008. 28(15): p. 4862-74. 
369. Drach, J., et al., Presence of a p53 gene deletion in patients with multiple 
myeloma predicts for short survival after conventional-dose chemotherapy. 
Blood, 1998. 92(3): p. 802-9. 
370. Jin, L., et al., MDM2 antagonist Nutlin-3 enhances bortezomib-mediated 
mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 
299(2): p. 161-70. 
371. Engelman, J.A., Targeting PI3K signalling in cancer: opportunities, challenges 
and limitations. Nat Rev Cancer, 2009. 9(8): p. 550-62. 
372. Engelman, J.A., J. Luo, and L.C. Cantley, The evolution of phosphatidylinositol 
3-kinases as regulators of growth and metabolism. Nat Rev Genet, 2006. 7(8): 
p. 606-19. 
373. Hess, G., et al., Phase III study to evaluate temsirolimus compared with 
investigator's choice therapy for the treatment of relapsed or refractory mantle 
cell lymphoma. J Clin Oncol, 2009. 27(23): p. 3822-9. 
374. Chan, S., et al., Phase II study of temsirolimus (CCI-779), a novel inhibitor of 
mTOR, in heavily pretreated patients with locally advanced or metastatic breast 
cancer. J Clin Oncol, 2005. 23(23): p. 5314-22. 
375. Kapoor, A. and R.A. Figlin, Targeted inhibition of mammalian target of 
rapamycin for the treatment of advanced renal cell carcinoma. Cancer, 2009. 
115(16): p. 3618-30. 
376. Dowling, R.J., et al., Metformin inhibits mammalian target of rapamycin-
dependent translation initiation in breast cancer cells. Cancer Res, 2007. 
67(22): p. 10804-12. 
377. Gotlieb, W.H., et al., In vitro metformin anti-neoplastic activity in epithelial 
ovarian cancer. Gynecol Oncol, 2008. 110(2): p. 246-50. 
378. Pu, X.Y., et al., Insulin-like growth factor-1 restores erectile function in aged 
rats: modulation the integrity of smooth muscle and nitric oxide-cyclic 
  
 
292
guanosine monophosphate signaling activity. J Sex Med, 2008. 5(6): p. 1345-
54. 
379. Ben Sahra, I., et al., Metformin in cancer therapy: a new perspective for an old 
antidiabetic drug? Mol Cancer Ther, 2010. 9(5): p. 1092-9. 
380. Santidrian, A.F., et al., AICAR induces apoptosis independently of AMPK and 
p53 through upregulation of the BH3-only proteins BIM and NOXA in chronic 
lymphocytic leukemia cells. Blood, 2010: p. blood-2010-05-283960. 
381. Kalender, A., et al., Metformin, independent of AMPK, inhibits mTORC1 in a rag 
GTPase-dependent manner. Cell Metab, 2010. 11(5): p. 390-401. 
382. Zhuang, Y. and W.K. Miskimins, Cell cycle arrest in Metformin treated breast 
cancer cells involves activation of AMPK, downregulation of cyclin D1, and 
requires p27Kip1 or p21Cip1. J Mol Signal, 2008. 3: p. 18. 
383. Alimova, I.N., et al., Metformin inhibits breast cancer cell growth, colony 
formation and induces cell cycle arrest in vitro. Cell Cycle, 2009. 8(6): p. 909-
15. 
384. McMillin, D.W., et al., Tumor cell-specific bioluminescence platform to identify 
stroma-induced changes to anticancer drug activity. Nat Med. 16(4): p. 483-9. 
385. Hirsch, H.A., et al., Metformin selectively targets cancer stem cells, and acts 
together with chemotherapy to block tumor growth and prolong remission. 
Cancer Res, 2009. 69(19): p. 7507-11. 
386. Vazquez-Martin, A., et al., The anti-diabetic drug metformin suppresses self-
renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer 
stem cells. Breast Cancer Res Treat, 2010. 
387. Campas, C., et al., Acadesine activates AMPK and induces apoptosis in B-cell 
chronic lymphocytic leukemia cells but not in T lymphocytes. Blood, 2003. 
101(9): p. 3674-80. 
388. Campas, C., et al., Acadesine induces apoptosis in B cells from mantle cell 
lymphoma and splenic marginal zone lymphoma. Leukemia, 2005. 19(2): p. 
292-4. 
389. Green, D.R. and G.P. Amarante-Mendes, The point of no return: mitochondria, 
caspases, and the commitment to cell death. Results Probl Cell Differ, 1998. 
24: p. 45-61. 
390. Susin, S.A., N. Zamzami, and G. Kroemer, Mitochondria as regulators of 
apoptosis: doubt no more. Biochim Biophys Acta, 1998. 1366(1-2): p. 151-65. 
391. Warburg, O., On the origin of cancer cells. Science, 1956. 123(3191): p. 309-
14. 
392. Xu, R.H., et al., Synergistic effect of targeting mTOR by rapamycin and 
depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. 
Leukemia, 2005. 19(12): p. 2153-8. 
393. Pradelli, L.A., et al., Glycolysis inhibition sensitizes tumor cells to death 
receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in 
translation. Oncogene, 2009. 
394. Graham, G.G., et al., Clinical pharmacokinetics of metformin. Clin 
Pharmacokinet. 50(2): p. 81-98. 
395. Dimitrijevic, D., A.J. Shaw, and A.T. Florence, Effects of some non-ionic 
surfactants on transepithelial permeability in Caco-2 cells. J Pharm Pharmacol, 
2000. 52(2): p. 157-62. 
396. Scheen, A.J., Clinical pharmacokinetics of metformin. Clin Pharmacokinet, 
1996. 30(5): p. 359-71. 
397. Misbin, R.I., The phantom of lactic acidosis due to metformin in patients with 
diabetes. Diabetes Care, 2004. 27(7): p. 1791-3. 
  
 
293
398. Sambol, N.C., et al., Pharmacokinetics and pharmacodynamics of metformin in 
healthy subjects and patients with noninsulin-dependent diabetes mellitus. J 
Clin Pharmacol, 1996. 36(11): p. 1012-21. 
399. Owen, M.R., E. Doran, and A.P. Halestrap, Evidence that metformin exerts its 
anti-diabetic effects through inhibition of complex 1 of the mitochondrial 
respiratory chain. Biochem J, 2000. 348 Pt 3: p. 607-14. 
400. Bailey, C.J. and R.C. Turner, Metformin. N Engl J Med, 1996. 334(9): p. 574-9. 
401. Gan, S.C., et al., Biguanide-associated lactic acidosis. Case report and review 
of the literature. Arch Intern Med, 1992. 152(11): p. 2333-6. 
402. Salpeter, S.R., et al., Risk of fatal and nonfatal lactic acidosis with metformin 
use in type 2 diabetes mellitus. Cochrane Database Syst Rev, 2010(1): p. 
CD002967. 
403. Bailey, C.J., Biguanides and NIDDM. Diabetes Care, 1992. 15(6): p. 755-72. 
404. Hermann, L.S., Metformin: a review of its pharmacological properties and 
therapeutic use. Diabete Metab, 1979. 5(3): p. 233-45. 
405. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national 
clinical guideline for management in primary and secondary care (update). 
London: Royal College of Physicians, 2008. 
406. Atzori, F., A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study 
of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) 
monoclonal antibody (MAb) in patients (pts) with advanced solid tumors ASCO 
Meeting Abstracts 2008. 26: p. 3519. 
407. Lacy, M.Q., et al., Phase I, pharmacokinetic and pharmacodynamic study of the 
anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 
in patients with multiple myeloma. J Clin Oncol, 2008. 26(19): p. 3196-203. 
408. Sarantopoulos, J. A phase IB study of AMG 479, a type 1 insulin-like growth 
factor receptor (IGF1R) antibody, in combination with panitumumab (P) or 
gemcitabine (G). in ASCO. 2008. 
409. Hidalgo, M., A phase I study of MK-0646, a humanized monoclonal antibody 
against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid 
tumor patients in a q2 wk schedule. ASCO Meeting Abstracts 2008. 26: p. 
3520. 
410. Dixon, R., et al., AICA-riboside: safety, tolerance, and pharmacokinetics of a 
novel adenosine-regulating agent. J Clin Pharmacol, 1991. 31(4): p. 342-7. 
411. Mangano, D.T., et al., Post-reperfusion myocardial infarction: long-term survival 
improvement using adenosine regulation with acadesine. J Am Coll Cardiol, 
2006. 48(1): p. 206-14. 
412. Mangano, D.T., Effects of acadesine on myocardial infarction, stroke, and death 
following surgery. A meta-analysis of the 5 international randomized trials. The 
Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA, 
1997. 277(4): p. 325-32. 
413. Van Den Neste, E., G. Van den Berghe, and F. Bontemps, AICA-riboside 
(acadesine), an activator of AMP-activated protein kinase with potential for 
application in hematologic malignancies. Expert Opin Investig Drugs, 2010. 
19(4): p. 571-8. 
414. Spisek, R., et al., Bortezomib enhances dendritic cell (DC)-mediated induction 
of immunity to human myeloma via exposure of cell surface heat shock protein 
90 on dying tumor cells: therapeutic implications. Blood, 2007. 109(11): p. 
4839-45. 
  
 
294
415. Chauhan, D., et al., Combination of proteasome inhibitors bortezomib and NPI-
0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 2008. 
111(3): p. 1654-64. 
416. Obeng, E.A., et al., Proteasome inhibitors induce a terminal unfolded protein 
response in multiple myeloma cells. Blood, 2006. 107(12): p. 4907-16. 
417. Ooi, M.G., et al., Interactions of the Hdm2/p53 and Proteasome Pathways May 
Enhance the Antitumor Activity of Bortezomib. Clin Cancer Res, 2009. 
418. Chauhan, D., T. Hideshima, and K.C. Anderson, A novel proteasome inhibitor 
NPI-0052 as an anticancer therapy. Br J Cancer, 2006. 95(8): p. 961-5. 
419. Malz, M., et al., Overexpression of far upstream element binding proteins: a 
mechanism regulating proliferation and migration in liver cancer cells. 
Hepatology, 2009. 50(4): p. 1130-9. 
420. Rabenhorst, U., et al., Overexpression of the far upstream element binding 
protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology, 
2009. 50(4): p. 1121-9. 
421. Zhang, J., et al., Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-
1alpha-dependent pathway in multiple myeloma. Cancer Res, 2009. 69(12): p. 
5082-90. 
422. Kim, S.J., et al., Galectin-3 Increases Gastric Cancer Cell Motility by Up-
Regulating Fascin-1 Expression. Gastroenterology, 2009. 
423. Darnel, A.D., et al., Fascin regulates prostate cancer cell invasion and is 
associated with metastasis and biochemical failure in prostate cancer. Clin 
Cancer Res, 2009. 15(4): p. 1376-83. 
424. Qualtrough, D., et al., The actin-bundling protein fascin is overexpressed in 
colorectal adenomas and promotes motility in adenoma cells in vitro. Br J 
Cancer, 2009. 101(7): p. 1124-9. 
425. Li, A., et al., The Actin-Bundling Protein Fascin Stabilizes Actin in Invadopodia 
and Potentiates Protrusive Invasion. Curr Biol. 
426. Carpenter, B., et al., Heterogeneous nuclear ribonucleoprotein K is over 
expressed, aberrantly localised and is associated with poor prognosis in 
colorectal cancer. Br J Cancer, 2006. 95(7): p. 921-7. 
427. Krampe, B., H. Swiderek, and M. Al-Rubeai, Transcriptome and proteome 
analysis of antibody-producing mouse myeloma NS0 cells cultivated at different 
cell densities in perfusion culture. Biotechnol Appl Biochem, 2008. 50(Pt 3): p. 
133-41. 
428. Inoue, A., et al., Loss-of-function screening by randomized intracellular 
antibodies: identification of hnRNP-K as a potential target for metastasis. Proc 
Natl Acad Sci U S A, 2007. 104(21): p. 8983-8. 
429. Mandal, M., et al., Growth factors regulate heterogeneous nuclear 
ribonucleoprotein K expression and function. J Biol Chem, 2001. 276(13): p. 
9699-704. 
430. Ma, K.W., S.W. Au, and M.M. Waye, Over-expression of SUMO-1 induces the 
up-regulation of heterogeneous nuclear ribonucleoprotein A2/B1 isoform B1 
(hnRNP A2/B1 isoform B1) and uracil DNA glycosylase (UDG) in hepG2 cells. 
Cell Biochem Funct, 2009. 27(4): p. 228-37. 
431. Byrjalsen, I., et al., Two-dimensional gel analysis of human endometrial 
proteins: characterization of proteins with increased expression in hyperplasia 
and adenocarcinoma. Mol Hum Reprod, 1999. 5(8): p. 748-56. 
432. Hong, O.K., et al., Proteomic analysis of differential protein expression in 
response to epidermal growth factor in neonatal porcine pancreatic cell 
monolayers. J Cell Biochem, 2005. 95(4): p. 769-81. 
  
 
295
433. Kang, X., et al., Regulation of the hTERT promoter activity by MSH2, the 
hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells. 
Oncogene, 2009. 28(4): p. 565-74. 
434. Shi, Y., et al., IL-6-induced stimulation of c-myc translation in multiple myeloma 
cells is mediated by myc internal ribosome entry site function and the RNA-
binding protein, hnRNP A1. Cancer Res, 2008. 68(24): p. 10215-22. 
435. Qi, Y.J., et al., Proteomic identification of malignant transformation-related 
proteins in esophageal squamous cell carcinoma. J Cell Biochem, 2008. 
104(5): p. 1625-35. 
436. Bambang, I.F., et al., Overexpression of endoplasmic reticulum protein 29 
regulates mesenchymal-epithelial transition and suppresses xenograft tumor 
growth of invasive breast cancer cells. Lab Invest, 2009. 89(11): p. 1229-42. 
437. Russo, A., et al., Bortezomib: A New Pro-apoptotic Agent in Cancer Treatment. 
Curr Cancer Drug Targets. 
438. Wang, Y., et al., Targeted proteasome inhibition by Velcade induces apoptosis 
in human mesothelioma and breast cancer cell lines. Cancer Chemother 
Pharmacol, 2009. 
439. Pitts, T.M., et al., Vorinostat and bortezomib exert synergistic antiproliferative 
and proapoptotic effects in colon cancer cell models. Mol Cancer Ther, 2009. 
8(2): p. 342-9. 
440. Song, M.K., et al., Elevation of serum ferritin is associated with the outcome of 
patients with newly diagnosed multiple myeloma. Korean J Intern Med, 2009. 
24(4): p. 368-73. 
441. Linkesch, W. and H. Ludwig, Serum ferritin and beta 2-microglobulin in patients 
with multiple myeloma. Cancer Detect Prev, 1983. 6(1-2): p. 297-301. 
442. Ohnishi, K., et al., Quantification of ferritin-secreting cells in patients with non-
Hodgkin's lymphoma. Acta Haematol, 1985. 73(3): p. 145-9. 
443. Yang, W.S. and B.R. Stockwell, Synthetic lethal screening identifies 
compounds activating iron-dependent, nonapoptotic cell death in oncogenic-
RAS-harboring cancer cells. Chem Biol, 2008. 15(3): p. 234-45. 
444. Ricolleau, G., et al., Surface-enhanced laser desorption/ionization time of flight 
mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as 
prognostic biomarkers in node-negative breast cancer tumors. Proteomics, 
2006. 6(6): p. 1963-75. 
445. Kim, H.G., et al., Metformin inhibits P-glycoprotein expression via the NF-
kappaB pathway and CRE transcriptional activity through AMPK activation. Br J 
Pharmacol. 162(5): p. 1096-108. 
446. Michaelis, M., et al., Reversal of P-glycoprotein-mediated multidrug resistance 
by the murine double minute 2 antagonist nutlin-3. Cancer Res, 2009. 69(2): p. 
416-21. 
 
 
 
 
 
 
 
 
 
  
 
296
 
 
 
 
 
 
 
 
 
 
 
  
 
A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
  
 
B
 
 
APPENDIX A 
Details of the Mascot software identification  
(a) KHSRP protein 
Ascension  - gi|54648253  
Mass   - 73307 
Mascot score - 149 
Expect  - 1.6e-010 
Peptide match - 22 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 26% 
Matched peptides shown in Bold Red 
  
1 MSDYSTGGPP PGPPPPAGGG GGAGGAGGGP PPGPPGAGDR GGGPGGGGP  
51 GGGSAGGPSQ PPGGGGPGIR KDAFADAVQR ARQIAAKIGG DAATTVNNST  
101 PDFGFGGQKR QLEDGDQPES KKLASQGDSI SSQLGPIHPP PRTSMTEEYR  
151 VPDGMVGLII GRGGEQINKI QQDSGCKVQI SPDSGGLPER SVSLTGAPES  
201 VQKAKMMLDD IVSRGRGGPP GQFHDNANGG QNGTVQEIMI PAGKAGLVIG  
251 KGGETIKQLQ ERAGVKMILI QDGSQNTNVD KPLRIIGDPY KVQQACEMVM  
301 DILRERDQGG FGDRNEYGSR IGGGIDVPVP RHSVGVVIGR SGEMIKKIQN  
351 DAGVRIQFKQ DDGTGPEKIA HIMGPPDRCE HAARIINDLL QSLRSGPPGP  
401 PGGPGMPPGG RGRGRGQGNW GPPGGEMTFS IPTHKCGLVI GRGGENVKAI  
451 NQQTGAFVEI SRQLPPNGDP NFKLFIIRGS PQQIDHAKQL IEEKIEGPLC  
501 PVGPGPGGPG PAGPMGPFNP GPFNQGPPGA PPHAGGPPPH YPPQGWGNT  
551 YPQWQPPAPH DPSKAAAAAA DPNAAWAAYY SHYYQQPPGP VPGPAPAPAA  
601 PPAQGEPPQP PPTGQSDYTK AWEEYYKKIG QQPQQPGAPP QQDYTKAWEE  
651 YYKKQAQVAT GGGPGAPPGF LAPPTVFQPL LSSALAQLPR PRPSPLPGLV  
701 CCLFICSRGD  
 
 
  
 
C
Observed   Mr(expt)  Mr(calc)   Delta Start End  Miss Ions Peptide 
805.4341   804.4268  804.4381  -0.0113 285 291  0  ---  R.IIGDPYK.V 
851.3661   850.3588  850.3569  0.0019 307 314  0  ---  R.DQGGFGDR.N 
872.4899   871.4826  871.4511  0.0315 348 355  0  ---  K.IQNDAGVR.I 
923.5353   922.5280  922.5348  -0.0068 332 340  0  ---  R.HSVGVVIGR.S 
988.4399   987.4326  987.4338  -0.0011 621 627  0  28  K.AWEEYYK.K 
988.4399   987.4326  987.4338  -0.0011 647 653  0  ---  K.AWEEYYK.K 
992.4481   991.4408  991.4723  -0.0315 72 80  0  ---  K.DAFADAVQR.A 
1000.5678   999.5605  999.5461  0.0144 347 355  1  ---  K.KIQNDAGVR.I 
1016.4730   1015.4657  1015.4280  0.0377 143 150  0  ---  R.TSMTEEYR.V 
1079.6150   1078.6077  1078.6134  -0.0057 321 331  0  17  R.IGGGIDVPVPR.H 
1079.6150   1078.6077  1078.6134  -0.0057 321 331  0  ---  R.IGGGIDVPVPR.H 
1122.5692   1121.5619  1121.5651  -0.0032 369 378  0  ---  K.IAHIMGPPDR.C + Oxidation (M) 
1122.5692   1121.5619  1121.5651  -0.0032 369 378  0  ---  K.IAHIMGPPDR.C + Oxidation (M) 
1136.5399   1135.5326  1135.5006  0.0320 305 314  1  ---  R.ERDQGGFGDR.N 
1184.6915   1183.6842  1183.6924  -0.0082 385 394  0  ---  R.IINDLLQSLR.S 
1242.6794   1241.6721  1241.6801  -0.0080 151 162  0  ---  R.VPDGMVGLIIGR.G + Oxidation (M) 
1354.6958   1353.6885  1353.6888  -0.0003 178 190  0  ---  K.VQISPDSGGLPER.S 
1501.7175   1500.7102  1500.8147  -0.1045 191 205  1  ---  R.SVSLTGAPESVQKAK.M 
1533.8008   1532.7935  1532.7946  -0.0011 449 462  0  5  K.AINQQTGAFVEISR.Q 
1533.8008   1532.7935  1532.7946  -0.0011 449 462  0  ---  K.AINQQTGAFVEISR.Q 
1980.9694   1979.9621  1979.9701  -0.0080 629 646  0  ---  K.IGQQPQQPGAPPQQDYTK.A 
2058.0652   2057.0579  2057.0575  0.0004 267 284  0  ---  
K.MILIQDGSQNTNVDKPLR.I + 
Oxidation (M) 
Table 1A   Peptides matched to KHSRP protein 
 
 
 
 
 
  
Fig. 1A
 
Monoi
Fixed 
Ions S
Match
 
 
 
  
# Im
1 44
2 15
3 10
4 10
5 13
6 13
7 10
Table 1
      Ion match t
sotopic mass o
Modifications : Ca
core: 28  Expect:
es (Bold Red): 7
 
mon. A
.0495 44.0
9.0917 230.1
2.055 359.1
2.055 488.
6.0757 651.2
6.0757 814.3
1.1073 
B Ions m
o peptide AWEE
f neutral peptide
rbamidomethyl 
 0.17   
/60 fragment ion
 
 a0
495  
288  
714 341.16
214 470.20
773 633.26
406 796.33
 
atch
YYK 
 Mr(calc): 987.4
(C) 
s using 12 most 
b 
72.0444
258.1237
08 387.1663
34 516.2089
67 679.2722
01 842.3355
 
D
338 
intense peaks 
 
b0 
  
  
 369.1557 
 498.1983 
 661.2616 
 824.325 
 
Seq. y
A 
W 917.
E 731.3
E 602.2
Y 473.2
Y 310.1
K 147.1
 
 y*
 
404 900.37
246 714.29
821 585.25
395 456.21
761 293.14
128 130.08
 
 
y0 
 
74 899.3934
81 713.3141
55 584.2715
29  
96  
63  
 
 
 
 
 
#
7
6
5
4
3
2
1
  
  
  
 
  
  
 
E
(b) Heterogeneous nuclear ribonucleoprotein A2/B1 isoform B 
Ascension - gi|14043072  
Mass   - 37464 
Mascot score - 370 
Expect  - 1.3e-032 
Peptide match - 24 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 50% 
 
Matched peptides shown in Bold Red 
  
   1 MEKTLETVPL ERKKREKEQF RKLFIGGLSF ETTEESLRNY YEQWGKLTDC  
  51 VVMRDPASKR SRGFGFVTFS SMAEVDAAMA ARPHSIDGRV VEPKRAVARE  
 101 ESGKPGAHVT VKKLFVGGIK EDTEEHHLRD YFEEYGKIDT IEIITDRQSG  
 151 KKRGFGFVTF DDHDPVDKIV LQKYHTINGH NAEVRKALSR QEMQEVQSSR  
 201 SGRGGNFGFG DSRGGGGNFG PGPGSNFRGG SDGYGSGRGF GDGYNGYGGG  
 251 PGGGNFGGSP GYGGGRGGYG GGGPGYGNQG GGYGGGYDNY GGGNYGSGNY  
 301 NDFGNYNQQP SNYGPMKSGN FGGSRNMGGP YGGGNYGPGG SGGSGGYGGR  
 351 SRY 
 
  
  
 
F
Table 2A   Peptides matched to HnRNP A2/B1 isoform B protein
Observed   Mr(expt)   Mr(calc)    Delta  Start    End  Miss  Ions  Peptide 
836.4279   835.4206   835.4188   0.0018  16  -  21  1   14   R.EKEQFR.K 
836.4279   835.4206   835.4188   0.0018  16  -  21  1   ---   R.EKEQFR.K 
861.5499   860.5426   860.5483   -0.0057  113  -  120  1   ---   K.KLFVGGIK.E 
912.3812   911.3739   911.3733   0.0007  229  -  238  0   ---   R.GGSDGYGSGR.G 
1009.4787   1008.4714   1008.4732   -0.0018  47  -  54  0   ---   K.LTDCVVMR.D + Oxidation (M) 
1013.4435   1012.4362   1012.4362   0.0000  204  -  213  0   29   R.GGNFGFGDSR.G 
1013.4435   1012.4362   1012.4362   0.0000  204  -  213  0   ---   R.GGNFGFGDSR.G 
1050.4384   1049.4311   1049.4341   -0.0030  130  -  137  0   30   R.DYFEEYGK.I 
1050.4384   1049.4311   1049.4341   -0.0030  130  -  137  0   ---   R.DYFEEYGK.I 
1057.5878   1056.5805   1056.5815   -0.0010  4  -  12  0   ---   K.TLETVPLER.K 
1087.4813   1086.4740   1086.4770   -0.0030  39  -  46  0   53   R.NYYEQWGK.L 
1087.4813   1086.4740   1086.4770   -0.0030  39  -  46  0   ---   R.NYYEQWGK.L 
1165.5220   1164.5147   1164.5159   -0.0012  121  -  129  0   4   K.EDTEEHHLR.D 
1165.5220   1164.5147   1164.5159   -0.0012  121  -  129  0   ---   K.EDTEEHHLR.D 
1188.6450   1187.6377   1187.6398   -0.0020  138  -  147  0   56   K.IDTIEIITDR.Q 
1188.6450   1187.6377   1187.6398   -0.0020  138  -  147  0   ---   K.IDTIEIITDR.Q 
1237.5436   1236.5363   1236.5404   -0.0041  191  -  200  0   ---   R.QEMQEVQSSR.S + Oxidation (M) 
1377.6301   1376.6228   1376.6221   0.0008  214  -  228  0   42   R.GGGGNFGPGPGSNFR.G 
1377.6301   1376.6228   1376.6221   0.0008  214  -  228  0   ---   R.GGGGNFGPGPGSNFR.G 
1538.7664   1537.7591   1537.7749   -0.0158  174  -  186  1   ---   K.YHTINGHNAEVRK.A 
1695.7605   1694.7532   1694.7576   -0.0044  154  -  168  0   49   R.GFGFVTFDDHDPVDK.I 
1695.7605   1694.7532   1694.7576   -0.0044  154  -  168  0   ---   R.GFGFVTFDDHDPVDK.I 
1798.9182   1797.9109   1797.9148   -0.0039  23  -  38  0   ---   K.LFIGGLSFETTEESLR.N 
2205.9026   2204.8953   2204.8928   0.0025  326  -  350  0   ---   
R.NMGGPYGGGNYGPGGSGGSGGYGGR.S + Oxidation 
(M) 
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APPENDIX B 
Calculation of AICAR dose  
 
100mg/kg of AICAR in 200ml of normal saline administered to a 70kg 
man. The molecular weight of AICAR is 258.2. The Cmax of AICAR of this 
administered dose was 68.9 µg/mL.  
 
 
Using the formula, 
 
Molecular weight = g/moles and Molar = moles/L 
 
1 M = 258.2 mg/mL 
 
1mM = 258.2 µg/mL 
 
1 µg/mL = 1/258.2 mM 
   = 0.003873 mM 
   = 3.873 µM 
 
68.9 µg/mL = 266.8497 µM  
 
 
 
 
 
 
  
 
I
APPENDIX C 
Scientific work published or presented  
Manuscript 
1. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, 
Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman 
P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N. Interactions of the 
Hdm2/p53 and proteasome pathways may enhance the antitumor activity of 
bortezomib. Clin Cancer Res. 2009 Dec 1;15(23):7153-60. Epub 2009 Nov 24. 
Presentations to Learned Societies 
1. Ooi MG, O’Connor R, Jakubikova J, Meiller, J, Klippel S, Delmore J, Kastritis E, 
McMillin DW, Clynes M, Richardson PG, Mitsiades CS, O’Gorman P, Anderson 
KC. The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug 
Transporters: Implications for Therapeutic Applications of Bortezomib in 
Advanced Multiple Myeloma and Other Neoplasias. Poster Presentation, 
American Society of Haematology, Dec 2009 
2. Ooi MG, Dowling P, Richardson PG, Mitsiades CS, Clynes M, Anderson KC, 
O’Gorman P. Proteomics as a Functional Tool in Evaluating Bortezomib 
Treatment and Drug Resistance Mechanism. Poster Presentation, American 
Society of Haematology, Dec 2009 
3. Ooi M, , Kotoula V, Charalambous E, Daskalaki E, Mitsiades CS, Mitsiades N. 
The Antidiabetic Biguanide Metformin Induces Growth Arrest in Thyroid 
Carcinoma Cells In Vitro. Poster Presentation, The Endocrine Society’s Annual 
Meeting, June 2009 
4. Ooi MG, Hayden PJ, McMillin DW, Negri JM, Delmore J, Raje NS, Munshi NC, 
Chauhan D, Hideshima T, Richardson PG, Mitsiades CS, Anderson KC, 
Mitsiades N. Interactions of the Mdm2/p53 and Proteasome Pathways: 
Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of 
Bortezomib. Poster Presentation, American Society of Haematology, Dec 2008 
5. Ooi MG, McMillin DW, Negri JM, Delmore J, Munshi NC, Chauhan D, 
Hideshima T, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N. The 
Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma 
Cells in Vitro, overcoming the Effect of Stromal Cells. Poster Presentation, 
American Society of Haematology, Dec 2008 
